NATIONAL QUALITY FORUM

+ + + + +

MEASURE APPLICATION PARTNERSHIP MEDICAID CHILD TASK FORCE

+ + + + +

THURSDAY MAY 25, 2017

+ + + + +

The Task Force met at the National Quality Forum, 9th Floor Conference Room, 1030 15th Street, N.W., Washington, D.C., at 9:00 a.m., Richard Antonelli, Chair, presiding.

MEMBERS PRESENT:

RICHARD ANTONELLI, MD, Chair TERRY ADIRIM, MD, MPH, Office of the Assistant Secretary of Defense for Health Affairs ANDREA BENIN, MD, Children's Hospital Association KATHRYN BEATTIE, MD, St. Luke's Children's Hospital ANN GREINER, MUP, Patient-Centered Primary Care Collaborative DEBORAH KILSTEIN, RN, MBA, JD, Association for Community Affiliated Plans RACHEL LA CROIX, PhD, PMP, Florida Agency for Health Care Administration ROANNE OSBORNE-GASKIN, MD, MBA, FAAFP, MDwise, Inc. AMY POOLE-YAEGER, MD, Centene Corporation AMY RICHARDSON, MD, MBA, Aetna Medical CAROL SAKALA, PhD, MSPH, National Partnership

for Women and Families

KIM ELLIOTT, PhD, CPHQ, Health Services Advisory Group

FEDERAL GOVERNMENT MEMBERS PRESENT (NON-VOTING):

SUMA NAIR, MS, RD, Office of Quality Improvement MARSHA SMITH, MD, MPH, FAAP, Centers for

Medicare and Medicaid Services*

NQF STAFF:

HELEN BURSTIN, MD, Chief Scientific Officer ELISA MUNTHALI, Vice President, Quality

Measurement

SHACONNA GORHAM, MS, PMP, Senior Project Manager MIRANDA KUWAHARA, Policy Analyst DEBJANI MUKHERJEE, MPH, Senior Director MAY NACION, MPH, Project Manager ALSO PRESENT:

SEPHEEN BYRON, MHS, National Committee for Quality Assurance LINDSAY COGAN, Bureau of Quality Measurement and Evaluation, New York State Department of Health RENEE FOX, MD, Division of Quality and Health Outcomes, Centers for Medicare and Medicaid Services KAREN MATSUOKA, PhD, Division of Quality and Health Outcomes, Centers for Medicare and Medicaid Services LAURIE NORRIS, JD, Division of Quality and Health Outcomes, Centers for Medicare and Medicaid Services LAYLA PARAST, RAND Corporation* KIMBERLY PERRAULT, Centers for Medicare and Medicaid Services GIGI RANEY, LCSW, Centers for Medicare and Medicaid Services SHIVANI SHAH, Children's Hospital of Philadelphia* JEFF SILBER, MD, Children's Hospital of Philadelphia* ANDREA STEWART, New Hampshire Department of Health and Human Services*

* present by teleconference

CONTENTS

Call to Order	•	•	•	•	. 5
Opening Remarks	•	•	•	•	. 7
Overview of Meeting Materials and Key Points form Staff Review of Core Set	•	•	•	•	.10
CMS/State Perspective Panel	•	•	•	•	.34
CMS/State Perspective Panel Lindsay Cogan	•	•	•	•	.57
Measure-Specific Recommendations on Strengthening the Child Core Set	•	•	•	•	104
Opportunity for Public Comment	•	•	•	•	200
Update on the Pediatric Quality Measures Program measures	•	•	•	•	201
Opportunity for Public Comment	•	•	•	•	307
Prioritizing Measures	•	•	•	•	307
Prioritizing Remaining Measure Gap Areas	•	•	•	•	309
Opportunity for Public Comment	•	•	•	•	318
Summarize Next Steps	•	•	•	•	334
Adjourn	•	•	•	•	338

1 P-R-O-C-E-E-D-I-N-G-S 2 9:08 a.m. Hi, everybody. 3 MS. MUKHERJEE: 4 Welcome back. Good morning. My name is Debjani again, but, by now, 5 you all probably know me. 6 And so, without ado, we will get 7 8 started on our third and last day of the Medicaid 9 Adult and Child Task Forces, and today we are Child Task Force only. So, hopefully, we'll 10 11 power on and we will get done early again. With that, I will turn it over to our 12 13 Chair, Rich. 14 CHAIR ANTONELLI: Good morning, 15 everybody. 16 Thank you for the engagement yesterday, and I'm really looking forward to the 17 18 work that is before us today. 19 We want to talk a little bit about 20 what is going to happen today, the structure of 21 the day, and then, we will review a little bit of 22 what we decided yesterday jointly with our Adult

1

Task Force partners.

2	In the morning we are going to review
3	the materials that we have received in
4	preparation coming to the Task Force. CMS is
5	going to weigh-in with their perspective. Our
6	colleague who joined us from New York State is
7	going to give us the view from the trenches, if
8	you will. And they are going to set the context
9	for an approach to strengthening the child core
10	set and prioritizing the gap areas.
11	In the afternoon, we are going to work
12	through these gap areas, make recommendations on
13	measures for consideration to add to the child
14	core set.
15	You should have all received the
16	discussion guide materials.
17	A word about parsimony. So, people
18	heard a lot of themes yesterday. I had the
19	privilege of actually acknowledging the CEO, and
20	Dr. Agrawal opened us yesterday. At the Annual
21	Meeting of the NQF, he actually called out that
22	the Standing Committee on Care Coordination

actually removed measures, and this notion of
 let's not just promote measures because there are
 measures.

I guess I want to channel Mary 4 5 Applegate yesterday. You know, there are measures that she needs. And so, there's lot of 6 7 opportunity in that space. So, parsimony should 8 be top of mind for our work today. In the 9 strategic conversation this afternoon, Debjani is going to talk specifically about moving forward 10 with additional pruning opportunities. And some 11 12 measures may actually be brought out today.

13 So, the highlights from day two: we 14 reviewed maternal and perinatal measures, the recommendations for removal; 1391, frequency of 15 16 ongoing prenatal care, timeliness of prenatal 17 care, conditional support to remove, and the 18 behavioral risk assessment for pregnant women. 19 I'm just going to take the Chair's 20 prerogative and spend 30 seconds to talk about 21 why I think this was really important. The idea

that, yes, we're measuring. We heard some really

Neal R. Gross and Co., Inc. Washington DC

important things from the frontlines. Rachel, in particular, your comment about a lot of work is being done already in this space, resources have been invested, we have to be respectful of that.

5 But, to where we need to get, some 6 decisions were made. And the optics, if you 7 will, the messaging that comes out of this Task 8 Force is really, really important. There isn't 9 anybody in this room that doesn't think that timeliness of prenatal care isn't important or 10 11 frequency of prenatal care isn't important.

12 So, as Karen has assured us, and our 13 CMS colleagues have assured us, the commentary 14 that comes out of this body is going to be 15 critically important for advancement.

16 Carol, I particularly want to thank 17 you for bringing the Behavioral Health Risk 18 Assessments. What was really, for me, kind of 19 affirming was that it went back to 2012. It 20 initially was intended to an eMeasure and wasn't 21 gaining traction for whatever reason, some of 22 which has to do with were the EMRs capturing that

1

2

3

4

1 So, there's not a sense that asking those data. 2 questions of pregnant is not important; it is vitally important, but was the measure able to 3 deliver, and I think coming up with that 4 5 recommendation. Next, the contraceptive care with the 6 7 most moderately effective methods with the 8 conditional supports, we moved forward, and the 9 AMR as well. I am going to hand it over to 10 Okav. 11 May who is going to talk a little bit about staff 12 review experience of the core set. By the way, 13 do we have any Task Force members on the phone 14 today? 15 Hi. This is Marsha Smith. DR. SMITH: 16 CHAIR ANTONELLI: Who is that? 17 Marsha? Okay, good. 18 Good morning, Marsha. 19 And is it just Marsha on the phone 20 because I see Dr. Benin. Is here today. Yes, 21 good. Okay. 22 May?

1	DR. NACION: Hello. Okay? Okay.
2	So, here I will just do a quick
3	overview of CMS' goals for the child and adult
4	core set, again, which are to increase state
5	reporting, increase the number of measures
6	reported, and increase the number of states using
7	the core set measures.
8	This was also previously discussed
9	yesterday and gives us an idea of how CMS uses
10	their core set data. So, I won't really go over
11	this.
12	Here again is an overview of the
13	measure selection criteria, as presented in the
14	previous days. So, I will just go to the next
15	slide.
16	For 2016, the Task Force members
17	supported all but two of the 2016 child core set
18	measures and recommended five measures for phased
19	addition to the 2017 child core set.
20	Presented are the five measures for
21	phased addition. The measures outlined in red
22	
22	were adopted in the 2017 core set. As an update,

the measures conditionally supported last year 1 2 actually have received NQF endorsement. Here are the 2016 Task Force 3 recommended measures for removal. So, it was 4 frequency of ongoing prenatal care and, and was 5 voted on yesterday, it was also recommended for 6 removal by this Task Force, as well as the child 7 and adolescents access to primary care 8 9 practitioners. Last year's Task Force noted that 10 performance on this measure was very high overall and with little opportunity for improvement. 11 12 For the 2017 core set, again, two

measures were added, but no recommended measures for removal were removed. Do note that the contraceptive care postpartum measure was also added to the adult core set into an alignment of these measures.

18 CMS did remove one measure, the HPV 19 vaccination for female adolescents measure. This 20 was retired by the measure steward and added to 21 the immunizations for adolescence measure, No. 22 1407, which is already in the child core set.

1	Again, the HPV measure was retired and
2	combined with the immunizations for adolescents
3	measure. These two measures will be combined to
4	reflect the Advisory Committee on Immunization
5	Practices recommendation that males and females,
6	starting at age 11 or 12, should receive routine
7	meningococcal, Tdap, and HPV vaccination. This
8	new specification has not submitted for NQF
9	endorsement yet. NCQA, which is the measure
10	steward, expects to make these updates during the
11	next annual update or endorsement maintenance
12	phase.
13	Here are the next few slides. We'll
14	just show the 2017 child core set measures
15	categorized by their topic areas. The measure
16	here outlined in red was the 2016 recommendation
17	that was added to the 2017 child core set. Here,
18	another 2016 recommendation added to the core
19	set.
20	And on this slide, again, to note the
21	endorsement for medication management for people
22	with asthma, No. 1799, has been removed, as

1

discussed yesterday.

2	Here's a breakdown of the measures in
3	the core set by endorsement status, measure type,
4	data collection method, and federal program
5	alignment. We have 17 endorsed measures. The
6	majority of measures are process measures and are
7	primarily administrative claims data. Here the
8	characteristics are not mutually-exclusive.
9	Here, I am just going to go give a
10	brief update on any endorsement updates. So,
11	three measures lost endorsements, so No. 1391,
12	1517, and 1799, and the reasons have been
13	outlined during the maternal, perinatal, and
14	asthma discussions yesterday.
15	This is an overview of the federal
16	fiscal year 2015 reporting. The 2015 child core
17	set includes 24 measures. Fiscal year 2015 is
18	the first year reporting of two new measures,
19	which are the dental sealants for 6- to 9-year-
20	old children at elevated Caries risk, as well as
21	the child and adolescent major depressive
22	disorder suicide risk assessment. One measure

was retired, the percentage of eligibles that 1 2 receive dental treatment services. This slide illustrates the number of 3 4 states reporting on each measure in the core set 5 for fiscal year 2015. The central-lineassociated bloodstream infection measure is not 6 7 reflected in the data because, beginning in 8 fiscal year 2012, data for the CLABSI measure was 9 obtained from CDC's National Healthcare Safety 10 Network. 11 The measures most frequently reported 12 by states for fiscal year 2015: assess 13 children's access to primary care; percentage 14 with well-child visits; use of dental services; receipt of childhood immunizations, and 15 satisfaction with care received. 16 17 Here, this slide illustrates the 18 number of states reporting on each measure in the 19 core set and changes in reporting from fiscal 20 vear 2013 to 2015. The measure above the red 21 horizontal line highlights the measures that are 22 publicly reported by 25 or more states in 2015.

1	And for the purposes of illustration,
2	we bucketed the measures into high, medium, and
3	low. So, a closer look at the measures with high
4	levels of reporting, this graph shows measures
5	reported by greater than 40 states in fiscal year
6	2015. These tend to be claims-based measures and
7	primarily reflective of primary care encounters.
8	Here, these are measures that were
9	reported more frequently in 2015, which are
10	between 26 to 40 states reporting. All of the
11	measures experienced an increase in fiscal year
12	2015 except for the live births weighing less
13	than 2500 grams. This decreased from 29 states
14	in 2014 to 28 states in 2015.
15	Here, these four measures reflect the
16	number of recording by the fewest number of
17	states. So, this is between 1 to 22 states
18	reporting in fiscal year 2015. Reasons for low
19	reporting will be discussed later in the day.
20	Not surprisingly, the child and
21	adolescent major depressive disorder measure is
22	the lowest reported because it was new to the

1 2015 core set, with one state reporting this 2 measure. The next few slides just present more 3 detailed information on which states reported 4 5 which measures. So, you should have a handout in your seats, so you can see the information a 6 little bit better. 7 8 I'm just going to go quickly Okay. 9 through these. So, again, just another page of the states and specific measures reported. 10 11 So, here, in conclusion, there is 12 always room for improvement, but, overall, the 13 child core set, participation is guite strong, 14 with 19 of the 24 core measures are reported by 15 25 or more of the states. 16 Okay. 17 CHAIR ANTONELLI: Thank you, May. 18 So, we have some time to open this up for questions and comments from Task Force 19 20 members. Just a reminder to use your tent cards to get into the queue. 21 22 Ann?

1	MEMBER GREINER: I'm wondering if the
2	staff has done any analysis to look at the most
3	frequently-reported measures and the performance
4	and how states fare.
5	MS. RANEY: Can you tell us if you're
6	asking a question about a specific measure or
7	just a general question about reporting?
8	MEMBER GREINER: Well, I recognize
9	that, given the number of measures, you couldn't
10	do it for all. So, the question was, has there
11	been any attempt to look at the most frequently-
12	reported measures and look across states to see
13	how they compare to each other?
14	MS. RANEY: We have recently just
15	received the 2015 chart pack, which you guys
16	received, and we are still actually in the
17	process of putting that up on medicaid.gov. So,
18	you guys have a little advanced preview of that.
19	So, we are in the process of doing that right
20	now.
21	MEMBER GREINER: Sure. Because I
22	don't know, but from my years at NQF, I know that

Neal R. Gross and Co., Inc. Washington DC

policymakers are very interested, as you know, in
 how the states perform and they always want to
 see how they perform vis-a-vis their neighbors
 and other benchmark states.

5 MS. RANEY: Yes. So, we are in the 6 process of getting that information out there, 7 and I'm sure we will hear back where some of the 8 priorities are, for us to take a deeper dive with 9 the limited resources that we have to do so. 10 Sure.

MEMBER GREINER: Thank you.

12 DR. FOX: In the past we have looked 13 at sort of best-performing states and published 14 briefs about them. So, on our website there is It's a little dated now, but that 15 information. 16 is the kind of thing we do. But the maps will 17 tell you how states are doing in the chart packs. 18 MEMBER POOLE-YAEGER: I think they 19 asked this yesterday about the adult set, but could you give us a little color on some of the 20 21 ones that you decided not to include or take off? 22 MS. RANEY: Sure. Any specific one

> Neal R. Gross and Co., Inc. Washington DC

that you would like us to focus on? 1 2 MEMBER POOLE-YAEGER: Essentially, the dental screening one. That one was removed? 3 Is 4 that what I read, or no? That was actually, we 5 DR. FOX: replaced that one with the sealant. 6 MEMBER POOLE-YAEGER: Okay. 7 MS. RANEY: We are going to bring our 8 9 dental expert up to address your question. DR. FOX: Who will be speaking later. 10 11 MS. NORRIS: So, last year we took the 12 dental treatment measure off and we replaced it 13 with a sealant measure. And the reason why we 14 did that -- and you guys recommended it, I think -- is because the dental treatment measure was 15 16 problematic. We could track utilization of 17 dental treatment, but we didn't know what that 18 You know, are we doing a good job of meant. 19 finding more kids who need care and addressing 20 their needs? Or are we doing a poor job with 21 prevention and more kids are -- we didn't know 22 whether it should be going up or down, because we

had no way of knowing what the need for dental 1 2 treatment was. So, that measure didn't feel 3 4 productive to us; whereas, the sealant measure, 5 we know sealants is the most evidence-based 6 intervention that can happen for kids in the 7 dentist office. And so, we were thrilled to have 8 that measure on instead of the dental treatment 9 measure. 10 MEMBER POOLE-YAEGER: Great. Thank 11 you. 12 And I'm only asking because the 13 sealant, I agree, is a great measure, but it is 14 only the 3-, 4-, 5-, 6-year-olds, right? So, it 15 doesn't --16 MS. NORRIS: It's 6 to 9. 17 MEMBER POOLE-YAEGER: Or 6 to 9, yes. 18 And just from, again, our experience, access to 19 dental care is a huge issue. For Medicaid patients finding dentists that will take Medicaid 20 21 patients is a struggle. From a perspective of 22 getting an all-encompassing look at whether

Medicaid kids are getting dental care, I just was 1 2 interested. 3 MS. NORRIS: So, we have another 4 measure, our most reported measure, and I will 5 not give you the whole thing because I am presenting in a few minutes about it. 6 7 MEMBER POOLE-YAEGER: Yes. 8 But you'll see that we MS. NORRIS: 9 still have PDENT, which is preventive dental services. 10 11 MEMBER POOLE-YAEGER: Got it. Got it. 12 MS. NORRIS: With that, we are 13 tracking, and that gives us a picture of all ages and levels of access. 14 15 MEMBER POOLE-YAEGER: Okay. 16 MS. NORRIS: So, I will give you the 17 results on that. 18 MEMBER POOLE-YAEGER: That's awesome. 19 Perfect. Thank you. And I think some of those 20 MS. RANEY: thoughts or one of the other measures that had 21 22 been recommended for removal last year was the

child and adolescents access to primary care 1 2 practitioners. And there was lively discussion last year about this. We actually decided to 3 4 keep that as part of our measure set for several 5 reasons, one being that there was some variability and there were some states that had a 6 7 lot of room for improvement on that measure, 8 particularly in regard to adolescents. And 9 another reason was we wanted to maintain it for potential use with states' new access monitoring 10 11 review plans, and just kind of keeping it on 12 So, it lines up similar with what Laurie there. 13 was saying about the dental care and access. 14 MEMBER POOLE-YAEGER: Yes, and I'm sorry to keep asking those questions. 15 I'm sort 16 of new. I wasn't at the last ones. I'm just curious about --17 18 CHAIR ANTONELLI: As long as it's not 19 about dental because --20 MEMBER POOLE-YAEGER: As long as it's 21 not about dental? CHAIR ANTONELLI: -- because the next 22

item is dental. 1 2 (Laughter.) MEMBER POOLE-YAEGER: 3 No, this is about well-child visits now. 4 So, I'm just 5 curious of your thought about EPSDT versus reporting on the well-child visits, which are 6 7 just several -- you know, looking at those separate age groups and how you look at that. 8 9 DR. FOX: Well, they are really separate. There are overlapping things, but, of 10 11 course, EPSDT is what happens in the office, and physicians are --- people are required to report 12 that for Medicaid. Some of the other, this is 13 14 not mandatory. So, it gives us a way to compare 15 and contrast what is happening. There are gaps 16 in both. Neither is perfect. 17 MEMBER POOLE-YAEGER: And I'm just 18 asking, you know, with the discussion about 19 reporting burden, it is two sets of reporting 20 that has to go on to get the similar measures 21 with slightly different specs, and sort of, kind of telling you sort of the same thing, but not 22

1	exactly. And I would love to have some ability
2	to say, okay, can we come up with something that
3	is going to address all of it?
4	CHAIR ANTONELLI: So, actually, since
5	you made that statement we would, too can
6	we talk a little bit about that, thinking from
7	the perspective of data flows and performance.
8	So, those of us that care for patients with
9	Medicaid, we know EPSDT. It has limitations.
10	But, then, we are looking at some of the other
11	measures.
12	And I was actually going to bring this
13	up later on today when we talk about the
14	sunsetting of the measure on developmental
15	screening, which nobody in this room at its heart
16	says that's not important, similar to prenatal
17	care.
18	But talk a little bit about what are
19	the opportunities. Renee, you mentioned that
20	there is a little bit of overlap. But is that
21	overlap leverageable or are they disparate enough
22	so that the ability to squeeze some parsimony out

would actually be worth pursuing going forward? 1 2 DR. FOX: We're going to invite our This is Kimberly Perrault. 3 colleague to come up. MS. PERRAULT: Just to address some of 4 5 the questions in terms of data, we do have various sources that we use to try to paint the 6 7 picture of what we're seeing in terms of core set 8 measure reporting, and specifically looking at, 9 let's say, comparing EPSDT data. We have a longstanding process for that. And states are 10 11 very familiar with the technical assistance that 12 we can provide to try to iron out some of the 13 data. 14 One of our focuses, I think, going forward is definitely trying to streamline the data that we are receiving and working with states to make sure that, you know, across the

15 forward is definitely trying to streamline the 16 data that we are receiving and working with 17 states to make sure that, you know, across the 18 board we're looking at apples to apples for each 19 of the measures. We are recognizing that states 20 are unique and all have individual challenges. 21 So, going forward, I think the 22 questions, as we provide technical assistance,

are just kind of asking what are the types of 1 2 databases that you're using; what are the data sources; where can we find that overlap. 3 And 4 those discussions can vary from state to state. But we do recognize that, where we can 5 make contributions and use data and move towards 6 7 other data sources that are more conformed, it is helpful, and we do tend to get better reporting. 8 9 We are also recognizing that, if we can do things like develop stats codes that work with a state's 10 11 database system and to provide TA, that we are 12 also having some uniformity there, as well as, 13 ideally, looking internally at our own CMS 14 systems where we are receiving data to see how we can improve that and have a more robust and 15 16 better look at what is being presented. 17 CHAIR ANTONELLI: So, to get really 18 tactical about this, if we decide let's take 19 developmental screening from zero to 3 out of the 20 core set, does that mean that we will know the 21 performance based on the EPSDT data? 22 DR. FOX: Yes, we have really

struggled this year about the developmental 1 2 screening. We got close last year in the 2015 data, and we knew that the endorsement had been 3 4 withdrawn or was withdrawing. And we decided it 5 was just like access. It was something that we did not want to take off because we didn't want a 6 7 signal to anybody that that wasn't important. 8 We would love -- and I know Lindsay 9 and I had a conversation a couple of months ago about developmental screening -- we would love a 10 11 better measure. We would love somebody to 12 develop a better measure. There just aren't any 13 measures out there, and this side of CMS does not 14 develop measures. Did you say that 15 MEMBER POOLE-YAEGER: the endorsement status was removed from the 16 17 screening measure? And if that's true, can you 18 say why? 19 DR. FOX: I can explain why. It was 20 given provisional or conditional endorsement 21 based on further data, and the measure developer 22 was unable -- you know, the cycle this year, we

1	had another pediatric measure committee and we
2	encouraged so, the measure developer was
3	unable to give us any more data. So, wasn't able
4	to submit for re-endorsement. And so, that makes
5	it, by NQF rules, no longer endorsed.
6	MEMBER POOLE-YAEGER: It's a
7	challenging measure.
8	CHAIR ANTONELLI: Microphone, please.
9	MEMBER ADIRIM: What I'm saying is, it
10	wasn't because now we have found it to be a bad
11	measure. It is just that there wasn't any
12	further research or evidence or data to
13	support
14	DR. FOX: Right.
15	MEMBER POOLE-YAEGER: Okay.
16	DR. FOX: They were unable to perform
17	the data analysis that they needed to submit it.
18	MS. RANEY: And just a key reminder,
19	CMS is not required to have measures that are
20	NQF-endorsed on our core set. So, if you'll
21	notice the slide that May had earlier, I believe
22	there are 10 measures that are currently on the

child core set that are not NQF-endorsed for one reason or another. So, losing endorsement is not reason itself for removing a measure or measure not having it, period. You know, there are other things to take into consideration. MEMBER ADIRIM: Thanks for that clarification. I think both points are important. Thanks. DR. FOX: And that's different, those of you who cross over into like adult world, that's different from Medicare, where the MAP actually can direct what they adopt on the Medicare side. The Medicare, CMS has to accept the MAP recommendations. MEMBER POOLE-YAEGER: Sorry to keep asking questions. I'm trying to get it to pull up, but the slide that you showed where you don't have it on the core set where it was recommended by MAP, I think the sickle cell measure was on there. Yes. Can you talk a little bit why you didn't DR. FOX: Well, the word		
 reason itself for removing a measure or measure not having it, period. You know, there are other things to take into consideration. MEMBER ADIRIM: Thanks for that clarification. I think both points are important. Thanks. DR. FOX: And that's different, those of you who cross over into like adult world, that's different from Medicare, where the MAP actually can direct what they adopt on the Medicare side. The Medicare, CMS has to accept the MAP recommendations. MEMBER POOLE-YAEGER: Sorry to keep asking questions. I'm trying to get it to pull up, but the slide that you showed where you don't have it on the core set where it was recommended by MAP, I think the sickle cell measure was on there. Yes. Can you talk a little bit why you didn't 	1	child core set that are not NQF-endorsed for one
 not having it, period. You know, there are other things to take into consideration. MEMBER ADIRIM: Thanks for that clarification. I think both points are important. Thanks. DR. FOX: And that's different, those of you who cross over into like adult world, that's different from Medicare, where the MAP actually can direct what they adopt on the Medicare side. The Medicare, CMS has to accept the MAP recommendations. MEMBER POOLE-YAEGER: Sorry to keep asking questions. I'm trying to get it to pull up, but the slide that you showed where you don't have it on the core set where it was recommended by MAP, I think the sickle cell measure was on there. Yes. Can you talk a little bit why you didn't 	2	reason or another. So, losing endorsement is not
 things to take into consideration. MEMBER ADIRIM: Thanks for that clarification. I think both points are important. Thanks. DR. FOX: And that's different, those of you who cross over into like adult world, that's different from Medicare, where the MAP actually can direct what they adopt on the Medicare side. The Medicare, CMS has to accept the MAP recommendations. MEMBER POOLE-YAEGER: Sorry to keep asking questions. I'm trying to get it to pull up, but the slide that you showed where you don't have it on the core set where it was recommended by MAP, I think the sickle cell measure was on there. Yes. Can you talk a little bit why you didn't 	3	reason itself for removing a measure or measure
 MEMBER ADIRIM: Thanks for that clarification. I think both points are important. Thanks. DR. FOX: And that's different, those of you who cross over into like adult world, that's different from Medicare, where the MAP actually can direct what they adopt on the Medicare side. The Medicare, CMS has to accept the MAP recommendations. MEMBER POOLE-YAEGER: Sorry to keep asking questions. I'm trying to get it to pull up, but the slide that you showed where you don't have it on the core set where it was recommended by MAP, I think the sickle cell measure was on there. Yes. Can you talk a little bit why you didn't 	4	not having it, period. You know, there are other
<pre>7 clarification. I think both points are 8 important. Thanks. 9 DR. FOX: And that's different, those 10 of you who cross over into like adult world, 11 that's different from Medicare, where the MAP 12 actually can direct what they adopt on the 13 Medicare side. The Medicare, CMS has to accept 14 the MAP recommendations. 15 MEMBER POOLE-YAEGER: Sorry to keep 16 asking questions. I'm trying to get it to pull 17 up, but the slide that you showed where you don't 18 have it on the core set where it was recommended 19 by MAP, I think the sickle cell measure was on 20 there. Yes. Can you talk a little bit why you 21 didn't</pre>	5	things to take into consideration.
 important. Thanks. DR. FOX: And that's different, those of you who cross over into like adult world, that's different from Medicare, where the MAP actually can direct what they adopt on the Medicare side. The Medicare, CMS has to accept the MAP recommendations. MEMBER POOLE-YAEGER: Sorry to keep asking questions. I'm trying to get it to pull up, but the slide that you showed where you don't have it on the core set where it was recommended by MAP, I think the sickle cell measure was on there. Yes. Can you talk a little bit why you didn't 	6	MEMBER ADIRIM: Thanks for that
9 DR. FOX: And that's different, those 10 of you who cross over into like adult world, 11 that's different from Medicare, where the MAP 12 actually can direct what they adopt on the 13 Medicare side. The Medicare, CMS has to accept 14 the MAP recommendations. 15 MEMBER POOLE-YAEGER: Sorry to keep 16 asking questions. I'm trying to get it to pull 17 up, but the slide that you showed where you don't 18 have it on the core set where it was recommended 19 by MAP, I think the sickle cell measure was on 20 there. Yes. Can you talk a little bit why you 21 didn't	7	clarification. I think both points are
10 of you who cross over into like adult world, 11 that's different from Medicare, where the MAP 12 actually can direct what they adopt on the 13 Medicare side. The Medicare, CMS has to accept 14 the MAP recommendations. 15 MEMBER POOLE-YAEGER: Sorry to keep 16 asking questions. I'm trying to get it to pull 17 up, but the slide that you showed where you don't 18 have it on the core set where it was recommended 19 by MAP, I think the sickle cell measure was on 10 there. Yes. Can you talk a little bit why you 21 didn't	8	important. Thanks.
11 that's different from Medicare, where the MAP 12 actually can direct what they adopt on the 13 Medicare side. The Medicare, CMS has to accept 14 the MAP recommendations. 15 MEMBER POOLE-YAEGER: Sorry to keep 16 asking questions. I'm trying to get it to pull 17 up, but the slide that you showed where you don't 18 have it on the core set where it was recommended 19 by MAP, I think the sickle cell measure was on 10 there. Yes. Can you talk a little bit why you 21 didn't	9	DR. FOX: And that's different, those
12 actually can direct what they adopt on the 13 Medicare side. The Medicare, CMS has to accept 14 the MAP recommendations. 15 MEMBER POOLE-YAEGER: Sorry to keep 16 asking questions. I'm trying to get it to pull 17 up, but the slide that you showed where you don't 18 have it on the core set where it was recommended 19 by MAP, I think the sickle cell measure was on 10 there. Yes. Can you talk a little bit why you 21 didn't	10	of you who cross over into like adult world,
Medicare side. The Medicare, CMS has to accept the MAP recommendations. MEMBER POOLE-YAEGER: Sorry to keep asking questions. I'm trying to get it to pull up, but the slide that you showed where you don't have it on the core set where it was recommended by MAP, I think the sickle cell measure was on there. Yes. Can you talk a little bit why you didn't	11	that's different from Medicare, where the MAP
14 the MAP recommendations. 15 MEMBER POOLE-YAEGER: Sorry to keep 16 asking questions. I'm trying to get it to pull 17 up, but the slide that you showed where you don't 18 have it on the core set where it was recommended 19 by MAP, I think the sickle cell measure was on 20 there. Yes. Can you talk a little bit why you 21 didn't	12	actually can direct what they adopt on the
MEMBER POOLE-YAEGER: Sorry to keep asking questions. I'm trying to get it to pull up, but the slide that you showed where you don't have it on the core set where it was recommended by MAP, I think the sickle cell measure was on there. Yes. Can you talk a little bit why you didn't	13	Medicare side. The Medicare, CMS has to accept
16 asking questions. I'm trying to get it to pull 17 up, but the slide that you showed where you don't 18 have it on the core set where it was recommended 19 by MAP, I think the sickle cell measure was on 20 there. Yes. Can you talk a little bit why you 21 didn't	14	the MAP recommendations.
17 up, but the slide that you showed where you don't 18 have it on the core set where it was recommended 19 by MAP, I think the sickle cell measure was on 20 there. Yes. Can you talk a little bit why you 21 didn't	15	MEMBER POOLE-YAEGER: Sorry to keep
18 have it on the core set where it was recommended 19 by MAP, I think the sickle cell measure was on 20 there. Yes. Can you talk a little bit why you 21 didn't	16	asking questions. I'm trying to get it to pull
19 by MAP, I think the sickle cell measure was on 20 there. Yes. Can you talk a little bit why you 21 didn't	17	up, but the slide that you showed where you don't
20 there. Yes. Can you talk a little bit why you 21 didn't	18	have it on the core set where it was recommended
21 didn't	19	by MAP, I think the sickle cell measure was on
	20	there. Yes. Can you talk a little bit why you
22 DR. FOX: Well, the word	21	didn't
	22	DR. FOX: Well, the word
п		

"parsimony" --

2	MEMBER POOLE-YAEGER: Yes.
3	DR. FOX: comes up again. We
4	recognize that, clearly, sickle cell disease is
5	disproportionately represented in the Medicaid
6	population, just by who's covered in Medicaid.
7	We just really thought that many of our other
8	measures also addressed disparities, just by the
9	basis of measuring access.
10	CHAIR ANTONELLI: Roanne?
11	MEMBER OSBORNE-GASKIN: Hi. I just
12	had a quick question about and I don't know if
13	this is the time to ask about it about the
14	childhood immunization status measure. Do you
15	have just the specs on that? Is there an age
16	range for that one, specific one? Okay. I was
17	trying to look for it, and I couldn't find it.
18	DR. FOX: There's two
19	MEMBER OSBORNE-GASKIN: Yes, up to a
20	specific age?
21	DR. FOX: It's 0038.
22	Yes, it's getting all of your
I	•

organizations. There's several sets of COBL 1, 1 2 2, 3, 4, 5 which have different sets of immunizations, but it is also that childhood 3 4 immunization schedule, but by age 2. So, you 5 know, whether you get your three DTPs and your Idaps, yes, those also. But you have to get them 6 all by the age of 2 to meet that measure. 7 8 MEMBER POOLE-YAEGER: Right, it's 9 assessed at age 2. 10 DR. FOX: Yes. 11 MEMBER POOLE-YAEGER: Can I just give 12 a comment on that one, since I know this measure 13 very well? The other spec problem, in my mind, 14 the spec -- and again, this is managed care kind of talk here. So, we pulled this measure, and 15 16 the specs say that you have to have a continuous 17 eligibility for at least one year. 18 And for pediatricians in the room, you 19 know that most of your immunizations are given in 20 the first year of life, not in the second. This 21 is a two-year measure, right? So, we have people 22 that get eligible when they turn 1 to 2, and they

1 all look non-compliant because we don't have the 2 data from when they were born to when they were 1. 3 4 And so, unless there is a good 5 immunization registry in the market, which is not -- you know, I've got 23 states and varying, 6 7 varying degrees of good immunization registry 8 So, it will look to me like none of my data. 9 kids are vaccinated, even though a lot of them 10 are. 11 So, when you're trying to do an 12 intervention to say, "Hey, you're behind," it's virtually impossible to do if we don't have the 13 14 So, I'm just kind of bringing that up as a data. 15 barrier in the real world. I think 16 CHAIR ANTONELLI: All right. 17 we'll call up Laurie Norris, make up some time 18 here on the schedule. Are you ready? 19 MS. NORRIS: I'm ready. 20 CHAIR ANTONELLI: Yes. We are going 21 to talk a little bit --- Laurie, if you could introduce yourself? And we're going to dive into 22

1 the Oral Health Initiative, please. 2 MS. NORRIS: So, thank you, and good 3 morning. 4 And I want to say a special hi to 5 Rachel. I don't think -- have we ever met 6 We've been talking on the phone for before? 7 three years. 8 MEMBER LA CROIX: Thank you. It's 9 great to be here in person. 10 MS. NORRIS: Thank you. What a nice 11 surprise. 12 CHAIR ANTONELLI: Let's really get to 13 your slides, right? Yes. 14 (Laughter.) 15 MS. NORRIS: Yes. Okay, here we go. 16 So, I'm here to talk about, I guess 17 I'm supposed to give the perspective on how CMS 18 uses the measures and maybe a little bit on how 19 we observe states using the measures. And I'm 20 going to do that in the context of the oral 21 health measures in the child core set. 22 So, how does CMS use the measures to

begin with? We use it to understand how states are doing in the first instance. We do religiously compare across states to track who's going up, who's going down, who's at the head of the line, who's at the tail of the line, that kind of thing.

And then, we also use the measures to 7 8 support states to improve. And I know that is 9 the ultimate goal. That is a sort of selective effort. We don't have the resources to work with 10 11 every single state. We hope that our publication 12 of who's at the head of the line and who's at the tail of the line will, like, self-motivate states 13 14 to do their own improvement efforts. And it 15 does in some instances. But we also work sort of 16 hands-on with a small number of states to support 17 their improvement.

So, how do states use the measures?
They use it to monitor their plans --- their
health plans. So, they use the measures at the
next level down and, also, to encourage
improvement. So, it is a similar sort of

1	parallel process, and I'll tell you in a little
2	bit more in detail about what we've observed
3	states doing with the oral health measures in a
4	few slides.
5	I'm also going to end today with a
6	little bit of, like, the next steps of what we
7	see in the oral health measures, where we would
8	like to go next if we have the opportunity to do
9	that.
10	Next slide.
11	All right. So, I think I shared this
12	slide with you last year, and we now have one
13	more data point. It remains my good news/bad
14	news slide. The good news is that the line is
15	continuing to slope upward for any dental
16	service.
17	And this goes to the original point.
18	You know, we do track whether a child between the
19	ages of 1 to 20 got a dental service, and that is
20	the blue line at the top. That is any kind of
21	they were at the dentist's office, regardless of
22	what happened there.

It is sort of a milestone for us that 1 2 in 2015 we reached the 50-percent mark. So, half of our kids are using the benefit, which is 3 terrific. But the bad news is the other half 4 5 aren't, right? So, we still have a long way to 6 qo. 7 The red line is our preventive dental 8 services measure specifically. And that is very 9 narrowly-defined. There are really only three things that are in that line: a cleaning, a 10 11 fluoride treatment, or a sealant. That's it. We 12 don't count exams or x-rays or, you know, just 13 your checkup stuff that you might think would be 14 in there. We only check if there was an actual intervention that has a preventive effect. 15 16 And then, that bottom line, the green 17 one is the treatment services. We do track that. 18 It's not in the core set, but it comes in through 19 our EPSDT data. 20 Like I said earlier, we have no idea 21 whether we are happy this line is staying steady 22 or whether we wish it was going up or whether we
1	wish it was going down, because we don't have a
2	way of measuring what the need for dental
3	treatment is. So, that measure is kind of a
4	mystery to us.
5	Okay, next slide.
6	So, these are all the measures in the
7	core set. You've seen this slide a million
8	times. But what we are showing here are the two
9	oral health measures by rate of report by states.
10	So, the most frequently reported
11	measure is the preventive dental services
12	measure. And there is no mystery behind why that
13	is the most frequently reported measure. It is
14	because all states are required by law to send us
15	their dental data through EPSDT reporting
16	process, and we just take the data and number-
17	crunch it and dump it into the core set. So, the
18	states aren't actually reporting this into the
19	core set. They're reporting it elsewhere, and we
20	do the transfer. So, we win every year, but, you
21	know, there is really no magic to it. And that
22	measure has been in the core set since the

I

1

2	Way further down is that sealant
3	measure for children 6 to 9 at risk of caries.
4	That measure was added last year. But we are
5	super proud that we got 26 states to report the
6	very first year, which means that we can report
7	it out publicly right away. So, we now have our
8	baseline and it can become public.
9	We are not using it for improvement
10	yet because it is just our baseline. But, unlike
11	the other new measure that was added last year
12	that I think had one or two states report, we are
13	really, really pleased with this reporting.
14	Next slide.
15	So, the PDENT measure is the one that
16	we most actively and have been using since before
17	it was even PDENT, through the EPSDT reporting.
18	It is the core measure that we use in our Oral
19	Health Initiative.
20	And I previewed this for you last
21	year. Our aim is to increase by 10 percentage
22	points the proportion of children who receive a

1

preventive dental service.

2	We set our baseline in 2011.
3	Nationally, we were at 42 percent in 2011. So,
4	our goal is to get it to 52 percent. We had
5	improved by 4 percentage points as of 2015. That
6	was our original deadline for ourselves. We
7	didn't quite make it. So, we have given
8	ourselves a three year extension out to 2018 to
9	continue to make progress.
10	Of course, we have the national goal,
11	but every single state has their own baseline and
12	their own 10-percentage-point improvement goal.
13	And I get to call out Florida here, is one of the
14	four states that made their 10-percentage-point
15	improvement goal by 2015. So, we had a few that
16	made it. Florida was very motivated. I will
17	show you the graph in a minute. So, we are still
18	working on this.
19	Next slide.
20	So, here's our, you know, who's at the
21	head of the line, who's at the tail of the line
22	slide. As of 2015, we had a new winner in 2015.

Texas moved to the head of the line for the first 1 2 time. So, they are really, really up there. Connecticut, Washington, New 3 4 Hampshire, Vermont have been good performers, 5 really strong performers, and continue to be strong performers. Those little New England 6 7 states seem to have a handle on how to address 8 dental access for kids. 9 But, then, sadly, down at the tail of the line, on the righthand side, Florida is no 10 longer the lowest-performing state in the nation. 11 12 (Laughter.) 13 They held that place of honor for many 14 years, but now they have moved up to the third 15 from the bottom, and Wisconsin is now our lowest-16 performing state, and North Dakota, South Dakota, 17 and Ohio also hanging out there in the bottom. 18 I mentioned earlier that we are 19 focusing on a small number of states in our 20 improvement efforts, our sort of hands-on 21 improvement efforts. We are focusing on those 22 low-performing states to try to engage them in

www.nealrgross.com

improvement efforts. 1 2 Next slide. All right. So, that's how CMS uses 3 4 the measures. So, I wanted to just spend a 5 little bit more time on how states use the oral 6 health quality measures. Some states have started using SEAL. So, that is not just about 7 8 It is also about SEAL. PDENT. 9 The sealant measure has been out in the world before we put it into our core set. 10 11 So, states, you know, some states got a headstart 12 on adopting its use. 13 So, states with managed care use it in 14 their health plan contracting. This is a super 15 strong way to motivate health plans to pay 16 attention to oral health services. They set 17 improvement goals. They set specific improvement 18 qoals. Florida did that. They tie incentives or 19 penalties to the achievement of those improvement 20 qoals. So, that is probably the most frequently 21 used way. 22 And we have about 36 states now, I

think, that use managed care for dental services. 1 2 So, this is a really good tool for states. Also, as you may be aware, states with 3 managed care are required to do performance 4 5 improvement projects with their plans, or their plans are required to do performance improvement 6 7 projects. That is another way that states can use these measures, as building them in, building 8 9 a performance improvement project around the They also include the measures as part 10 measures. 11 of their quality strategies. 12 We have also seen some states and some 13 managed care plans, depending on what level is 14 actively working on improvement, use the measures to motivate provider improvement, so one level 15 16 down, paying providers incentives for reaching

17 certain goals or just improving the number of 18 services they provide; using some kind of a pay-19 for-performance approach. Or we have one state, 20 Oregon, that is actually starting to experiment 21 with a shared savings approach, and they are 22 using SEAL, maybe with a slight modification in

1

the measure specification, to do that.

2 There's also at least one state, Tennessee, that is really effectively using the 3 measures for provider motivation. There's no 4 5 money attached to it, but every quarter they send out these beautiful dashboards to all their 6 7 providers and they tell the providers how they 8 are performing relative to the last quarter 9 themselves and relative to their peers in the 10 state on a variety of measures, including our measures. And it just sort of juices up the 11 12 competitive sense of the dentists and it helps 13 them improve that way. So, we are seeing some 14 pretty robust use of the measures by states. Next slide. 15 16 So, this is another sort of good news 17 slide. As we've seen coverage and enrollment 18 increase over the last few years, we've seen 19 access to care increase. And this, the 20 information that is displayed on this slide, on 21 the lefthand side it is broken down by racial and ethnic groups. We're seeing improvements across 22

Neal R. Gross and Co., Inc. Washington DC 43

www.nealrgross.com

1	all racial and ethnic groups. We are seeing the
2	gaps in access between racial and ethnic groups
3	actually shrink almost to closing. So, this is
4	just really super good news. You can see the
5	2014 numbers are very close to being the same.
6	The same is true by source of
7	insurance. Whether a kid has commercial
8	insurance, employer-based insurance, or Medicaid
9	or CHIP, we're seeing that use of dental
10	services, at least in one study, showed that
11	there was essentially no difference between the
12	two, based on parent-report, after adjusting for
13	certain demographic and parent characteristics.
14	So, we are doing a good job at closing some of
15	those gaps.
16	However next slide what we're
17	not necessarily seeing is that more access to
18	care is leading to better care. And here, we are
19	sort of moving from the utilization and access
20	space to the outcome space, right? And these
21	are, what I'm showing you on this slide are just
22	some sort of scattered studies that looked at

various aspects of the care we're delivering and what we're spending on it and what we're getting for it.

4 And so, I'm just going to call your 5 attention to the third bullet on the slide just We looked at our preventive, our 6 as one example. 7 PDENT measure compared to our sealant measure in 8 2015 and the 6-to-9 age group. And what we saw 9 was that 57 percent of children in the 6-to-9 age group had a preventive dental service. 10 That's not bad, you know. And as I said before, that is 11 12 either a cleaning or a sealant or a fluoride 13 treatment.

14 Only 16 percent of those kids got a So, almost all of those kids needed a 15 sealant. 16 sealant. And we know they were in the dentist's 17 chair. So, we're not talking about the heavier 18 lift of getting the kid into the office. These 19 kids were in the office, but they didn't get the 20 most evidence-based intervention while they were 21 in the office. So, that is just an example of 22 how we are doing a good job of driving more care,

> Neal R. Gross and Co., Inc. Washington DC

1

2

1	but we are not necessarily doing a good job of
2	driving the best care.
3	Next slide.
4	So, to begin to address that issue, we
5	have launched a value-based payment project in
6	collaboration with our Innovation Accelerator
7	Program. We have designed a project to work with
8	states to just do very small pilot projects, to
9	look at driving value and outcomes through a
10	different way of paying for care.
11	And I'll just say that this project is
12	designed in a kind of unusual way for a reason.
13	We have observed that there are dental clinicians
14	out there who were self-motivated to figure out
15	how to get better outcomes for their kids. And
16	so, they have turned on its head the normal way
17	of thinking about dental care for kids. They're
18	doing intensive prevention. They're doing
19	evidence-based prevention. They're doing more
20	frequent visits. They're doing more family
21	engagement. They're doing some sort of new
22	treatment interventions, something called interim

therapeutic restorations, something called silver diamine fluoride. These are all very low-cost, low-impact, no-surgery ways of dealing with the disease and halting the progress of the disease in a child's mouth. And they're getting some really good results.

7 So, what we have asked for in this 8 project is that states that want to experiment in 9 this space partner with a clinical site that has already figured out how to get better outcomes 10 11 and, then, work with the state Medicaid agency to 12 figure out how to develop a value-based payment 13 approach that will make that clinical approach 14 sustainable.

What we are finding is that the clinicians who have revised and reformed the way they deliver care, dental care, to kids are having to -- you know, they are just not getting reimbursed for a lot of stuff and they are having to go to foundations to backfill. It just seemed logical to us, if they

It just seemed logical to us, if they
are producing the health outcomes that we want,

Neal R. Gross and Co., Inc. Washington DC

1

2

3

4

5

we should be paying for it in a way that makes it feasible for them to continue to provide care that way and, then, ultimately, to spread those models beyond those initial sites.

5 So, that is the theory. That is our 6 theory of change. We are pleased to be able to 7 test it with just a few states over the next two 8 years to select, design, and test a value-based 9 payment approach in partnership with their 10 clinical site to see whether we can figure out 11 how to sustain those outcomes.

A challenge, getting back to the 12 13 measures space, a challenge we expect to face in this work is the dearth of outcomes measures in 14 15 the children's oral health space, to be able to 16 measure whether the value is being produced or 17 So, that is something that we will just not. 18 have to tackle in the context of this project, 19 but we see that as really a next step in measure 20 development in this area.

I think that's my last slide. Yes.Thank you.

1

2

3

4

1	CHAIR ANTONELLI: Thank you, Laurie.
2	And while people are getting ready to
3	put their cards up, I have a question. Can you
4	speak a little bit about the reporting at the
5	state level? So, for either the sealant and/or
6	PDENT, those are dental codes, obviously. But
7	are there states that are using non-dental
8	personnel for any of those services, but bundled
9	into a primary care service, for example?
10	MS. NORRIS: Yes. Yes. Every state
11	in the country now Indiana was the last one to
12	join us last year but every state in the
13	country now does reimburse medical providers,
14	primary care providers, for providing the oral
15	health interventions for kids that are within
16	their scope of practice.
17	We do collect that data as well. It
18	is part of our EPSDT reporting. It is not in the
19	core set. So, we do track that.
20	The numbers are not encouraging. I
21	would say the latest numbers are hovering around
22	10 percent. That is of children ages 1 to 5.

And I think that is the best-performing age group 1 2 for interventions in the primary care office. So, we are tracking it, but it is a 3 4 definitely a place where there are huge opportunities for improvement. 5 MEMBER BENIN: Hi. Thanks. 6 That was really interesting. 7 8 Is there a data that looks at what is 9 covered by state, like what folks get reimbursed 10 for by the performance on the metrics? That has 11 always been the urban myth, anyway --12 MS. NORRIS: Yes. 13 MEMBER BENIN: -- that the reason why 14 you can't get anybody into a dentist is because the dentists don't get paid for it, so they won't 15 16 take the patients. 17 MS. NORRIS: Well, I'm going to 18 interpret your question as having two dimensions. 19 One dimension is it's covered, but how much does 20 a provider get paid, right? So, what are the 21 reimbursement rates? And that is a challenge. 22 We do, thanks to the American Dental

> Neal R. Gross and Co., Inc. Washington DC

www.nealrgross.com

Association's Health Policy Institute, we do have 1 2 data on that. So, we know what states pay, at least in their fee-for-service fee schedules. 3 4 And there is a wide range from something like 26 5 percent of the usual and customary all the way up to 80 percent of usual and customary, depending 6 7 on the state. So, we do keep track of that. CMS 8 doesn't track it, but we have access to it and we 9 do pay attention to that. And when we engage with states about their performance, we talk 10 about that if it is an issue. 11 12 In terms of what is covered -- so you 13 have to give a service away -- children's oral 14 health services are mandatory and it is part of So, theoretically, all services that a 15 EPSDT. 16 child needs are supposed to be covered, right? 17 And that tends to be the case, like sort of no 18 questions asked in the treatment space. If 19 somebody says, "This kid needs a root canal," the 20 kid is going to get a root canal. He needs an 21 extraction; no problem.

22

Where it is more challenging is in the

prevention space, which is where we are trying to 1 2 focus more attention. There is a periodicity schedule for dental care. And unlike maybe how 3 it operates in the primary care space -- I'm not 4 5 really as familiar with that -- but, you know, it's sort of the recommended frequencies for 6 7 checkups. But how it tends to be implemented by states is the ceiling of frequencies and not the 8 9 floor of frequencies.

10 So, what a typical periodicity is, is 11 two dental checkups a year with two cleanings a 12 year and two fluoride treatments a year, et 13 cetera. And some states have implemented that as 14 you can't get any more than that; you can't get 15 paid for any more than that.

And so, there becomes a challenge that, well, hypothetically, you could if you submitted a justification as to why this child needs to come four times a year, why they need more fluoride treatments, et cetera. But that becomes a big burden on the provider to do that for every single kid that they need more frequent

(202) 234-4433

care.

2	Some states are beginning to and
3	Texas is an example to allow kids at high risk
4	or even kids below the age of 5, or some kind of
5	a limiter like that, to allow they pay four
6	times a year. So, it is starting to loosen up,
7	as I think states are learning that the higher
8	frequencies can be impactful on children's oral
9	health, but it is not the standard yet.
10	And so, that is where people run into
11	it. Like there is no reimbursement for oral
12	health education. And so, providers are
13	reluctant to do the family engagement piece. Or
14	there is no reimbursement for silver diamine
15	fluoride. So, they can't do that simple
16	intervention that will halt the disease. So,
17	those things are starting to get traction, but
18	they are not in every state yet.
19	MEMBER BENIN: It just does seem to me
20	that, as we are potentially in a situation where
21	those states will have less money for Medicaid,
22	that these things will get more complicated and

these kinds of programs will be at risk. 1 It will 2 be interesting to see that --MS. NORRIS: Yes. 3 MEMBER BENIN: -- in each of the 4 5 states and how that impacts the metrics and how we think about the need for the metrics. 6 To me, 7 that ties together. 8 CHAIR ANTONELLI: Yes. Thank you. 9 MS. NORRIS: Yes, and I think, also, one of the --10 11 CHAIR ANTONELLI: Actually, Laurie, I am going to cut that off because I want to do 12 13 this. 14 Deborah, Kim, and, then, Lindsay. And then, we're going to move into Lindsay's 15 16 presentation. So, we can do that later, but I 17 want to make sure that we have enough time for 18 the New York presentation. 19 Okay. So, Deborah? 20 MEMBER KILSTEIN: Question: when you 21 talked about 36 states with managed care for dental, I assume that includes states where it is 22

carved out of the health plan and is part of DPO? 1 2 And do you see any issues in terms of the carveout where a physician service might be 3 4 covered under the managed care plan, but the 5 dental service, when it is done by the dentist, is done by the DPO? 6 7 MS. NORRIS: Yes. Yes, we are -- I am 8 including carveouts in that number, but only for 9 carveouts that are managed care dental carveouts. Some states carve it out to like an 10 11 administrative services organization. So, it is 12 fee-for-service. So, yes, and it does complicate 13 the tracking of expenses and potential 14 motivations for savings when you separate the 15 dental from the medical, because on the medical 16 side is where you are still paying for the 17 operatory -- like if kids have to go to the 18 operating room. But where you are going to 19 impact that is by doing a better job over on the 20 dental side. So, yes, it complicates it. 21 DR. ELLIOTT: Have you found a way now 22 to capture all of the other provider types in the

CMS 416 for doing the preventative services, like 1 2 the PCP and other providers in the PCP's office? Yes, we have a line in 3 MS. NORRIS: 4 our EPSDT reporting that is not by a dentist and 5 not under the supervision of a dentist. So, you know, the typical, the dentist and under the 6 7 supervision of, that gets you all the dental 8 hygiene and dentist services. And then, we have 9 this other line which is the primary care folks, and that's the one I was talking at the 10 11 beginning, where we are around 10 percent of kids 12 in ages 1 to 5 that are getting those services. 13 DR. ELLIOTT: And then, that rolls up 14 into the actual reported rates, so like the 50-15 some percent? 16 MS. NORRIS: Actually, it doesn't. 17 DR. ELLIOTT: Okay. So, I think that 18 has been some of the challenges that states have 19 had. 20 MS. NORRIS: Yes. In our PDENT 21 measure we are not counting the contribution of 22 the primary care folks because of denominator

issues.

1

Ŧ	issues.
2	CHAIR ANTONELLI: Lindsay?
3	MS. COGAN: So, I'm pretty sure Rachel
4	just walked out.
5	My question was and maybe it could
6	be more of just a global statement was, so
7	what did Florida do to bring up their rates? And
8	that's something I think that, as other states, I
9	think it is great when you highlight briefs where
10	there's high-performers, but I think it would be
11	just as interesting to highlight states that are
12	maybe low-performers that are managing to pull
13	themselves up a little bit. So, what are they
14	doing? What's working for them and how can we
15	spread that to other states?
16	MS. NORRIS: So, I had a slide on
17	Florida which didn't make it into this deck. So,
18	very quickly, Florida put a requirement of a 10-
19	percentage-point improvement in well, to meet
20	the 10-percentage-point improvement rate for each
21	of their health plans in the contract, and they
22	had a disincentive attached to it. And all but

1

one plan met the goal.

2	They also mandated an oral health PIP
3	across all their health plans, which I suppose
4	the plans used to help them meet their goal.
5	They also really ratched-up their stakeholder
6	engagement, and through that process, they did a
7	statewide they designed and deployed a
8	statewide oral health education campaign that
9	involved community-based organizations and
10	started to do a much better job of getting the
11	message to families that this benefit was
12	available and they should use it. So, those are
13	the top three things they did.
14	CHAIR ANTONELLI: Thank you very much,
15	and thank you for a strengths-based approach to
16	reporting that data.
17	All right. We are going to invite
18	Lindsay Cogan to come and present the New York
19	State perspective with respect to the child core
20	set.
21	Lindsay, if you could just take 30
22	seconds to introduce yourself, your role, and

I	
1	then, launch into the discussion?
2	MS. COGAN: Sure. Thank you very much
3	for having me today.
4	My name is Lindsay Cogan. I'm with
5	the New York State Department of Health, and I
6	work in the space of quality measurement. I'm
7	the Director of the Division of Quality
8	Measurement, and our area handles quality
9	measurement across multiple levels.
10	So, we look at quality measurement
11	across payers. We look at it specifically for
12	Medicaid. And my area handles a lot of the
13	reporting for both the adult and child core set
14	to CMS.
15	As of late, we have been doing quality
16	measurement in all different kinds of spaces as
17	well. As part of our 1115 waiver, we have been
18	looking at more health systems. And as part of
19	our work with our SIM grant, we have even been
20	getting down to more provider practice-based
21	quality measurement.
22	So, I'm excited to be here. I'm

excited to talk about the child core set. 1 2 Usually, I talk about the adult core set. So, this is a great opportunity to move into this 3 4 space, which I think is exciting and a little bit 5 more challenging. So, next slide. 6 7 So, here is just a brief overview of 8 what I am going to talk about. I'm going to say 9 that I aimed high. You know, go big or go home. I've got some aspirational goals in here, and not 10 11 always a clear path on how to get there. So, I 12 just want to acknowledge that right upfront, 13 that, you know, some of the asks are things that 14 we would want as a state may be unobtainable for 15 now, but I want us to really think about stretch 16 goals here. 17 And so, I'm going to give you an 18 overview and, then, some recommendations and, 19 then, sort of where we would like to see the 20 future of the core set go. 21 Next slide. 22 So, here's just a brief snapshot of

New York State Medicaid and children, right? 1 So, 2 children account for about 43 percent of all Medicaid enrollees. You can see I've given you 3 4 some distributions by age and by race. So, about 5 60 percent of our population is in New York City, which is an extremely diverse population. 6 7 In this space, most of our children 8 are enrolled in managed care. You can see about 9 a 90/10 split fee-for-service. 10 We have a small proportion of children 11 in the State who are SSI. It's about 5 percent 12 in 2015. 13 And if you go to the next slide, I 14 have given sort of complement to the population 15 now and shifted over to cost. So, our colleagues 16 at the United Hospital Fund did a great study in 17 2014 looking at continuously-enrolled children, 18 and I have given a link at the bottom, if you are 19 interested in looking more at this. 20 You can see that average cost per 21 child is about a third, maybe 37 percent, of what we spend on adults. Children are mostly healthy 22

There is a small proportion of 1 and low-cost. 2 children, however, that are very costly. And you can see down in the bottom slides there some of 3 4 our cost per child enrollee for the year for a 5 child, say, with SSI compared to not. And even within SSI, there are certain populations that 6 7 are those drivers of high cost, high need. And again, I don't think that this is 8 9 a story really that differs much on the national picture as well, but I kind of wanted to give 10 11 some relevance here. We do see that children 12 with one or more chronic conditions is guite a 13 bit higher in New York State than we see on the 14 national front. It could speak to more of our benefit package waivers where we cover more 15 16 children perhaps than other states, but I just 17 thought it worth noting. 18 Next slide. 19 So, here's a little bit about the 20 history of the Medicaid managed care program in 21 New York State. As I said, we are a managedcare-for-all state and have been since our first 22

Medicaid waiver, known as the Partnership Plan in 1 2 the nineties. And each year since, we have really been looking to expand and bring in those 3 4 excluded populations into managed care, keeping a 5 close eye on the quality. But we have continued to roll out managed care in more and more of our 6 population. We are a Medicaid expansion state as 7 8 well.

9

Next slide.

So, with that background, this gets 10 11 into really the meat of what I want to talk about 12 here today. So, in New York we've been reporting on the child core set since 2013. In the most 13 14 recent reporting cycle, we were able to report on 15 23 of the 26 measures. We didn't report on the 16 following three measures that I have listed here. No surprise; these are ones that sort of showed 17 18 up in the slides earlier as being sort of low-19 reporters from other states as well. 20 Next slide.

21 And so, one of the main reasons as a 22 state we're able to report all that we are able

to report to is because we leverage our strong 1 2 outpatient reporting system that's largely comprised of HEDIS measures collected through our 3 4 managed care plans. And I think this is a 5 similar story for other states that you have 6 heard before. 7 We are able to report some information 8 to both the child and adult core set from 9 existing projects, one of which I've listed here. And I'll get into that a little bit later. 10 11 And then, I have given you a flavor of 12 some of the types of measures that are difficult 13 at a state level to report. Since we are managed 14 care for all state, anything non-HEDIS gets tricky. Anything provider-based or coming from 15 16 electronic data sources is also really challenging. 17 18 We are looking for a statewide 19 solution for electronic data collection. We are 20 just not there yet. 21 And we really weigh the additional cost versus the new information that we would be 22

able to yield before deciding to add resources to 1 2 really collect a measure for one of these core 3 sets. Next slide. 4 5 So, now that I have told you what we report and how we do it, let's talk a little bit 6 7 about the uses of quality measures. I don't need 8 to tell you all sort of the three main uses of 9 quality measures. We do all three in some capacity. We publicly report all of our data. 10 11 We feel very strongly about data transparency. 12 We offer financial incentives to our Medicaid 13 managed care plans that tie back to a lot of the 14 quality measures in the core set. 15 I get asked a lot -- in fact, in 16 preparation for this presentation -- how we use 17 this data in the core set for quality 18 improvement. So, since we are a managed care 19 state, a lot of our quality improvement work goes 20 through the managed care plans in either a 21 performance improvement project or a targeted 22 study.

1	And then, we talked a little bit about
2	stratification yesterday. So, I'm not going to
3	get too much into it other than to really hammer
4	home how important we think stratifying our
5	measures not only by age, gender, or race, but by
6	looking at some of these other conditions, other
7	vulnerable populations. We call them priority
8	populations.
9	And we do this regularly because we
10	want to understand the quality of care for these
11	populations, and we want to best use the
12	information that we have available.
13	So, we use this in our quality
14	improvement space to sort of drill in and help
15	people understand where best to target some
16	populations, as well as to understand perhaps
17	where other gaps are. And we would put that
18	under research as well. So, sort of understanding
19	the need, evaluating different programs and
20	populations, and tying process to outcomes, we
21	think is incredible important.
22	Next slide.

(202) 234-4433

1	So, I mentions this, and I apologize
2	for not a good transition, but I put this in here
3	because I wanted to mention this. This is one
4	example where we are working directly with
5	providers on quality improvement as it relates to
6	our prenatal care standards that were updated in
7	2009.
8	So, what we have done is we are
9	working with high-volume providers. We are going
10	in; we are having them take a sample of medical
11	records from those who had a live birth, and we
12	are asking them to go through the entire medical
13	record and answer some questions.
14	And we've had to develop this portal
15	for providers to actually extract information
16	from the medical record and bring it to us. So,
17	we have a portal.
18	And I'm sorry, I missed Mary's
19	presentation yesterday. I'm guessing she
20	probably got into this, too. So, a lot of the
21	information that we want to gather is in the
22	notes section of an electronic health record,

1 right? So, there's no standardized way for us to 2 get that information. So, it is incredibly 3 labor-intensive. It is on a small sample of 4 records because of that.

5 It has really been a rich project 6 where we have gotten a lot of great information, 7 but it has also been rich in the sense that it is 8 incredibly costly. We have gone way, way over 9 budget. So, the sustainability of this project 10 is really coming into question.

And I bring that up because -- next slide -- this is one place where we were able to gather some information to put into our core set reporting. So, we are able to report on this behavioral health risk assessment for pregnant women measure using the small sample of records.

And if we didn't have this project, we would never have been able to put the resources into collecting it. So, we are able to use it, and it is expected in our prenatal care centers that women receive the psychosocial risk assessment screening, counseling, and referral

1 for care.

2	We do adapt this measure a little bit
3	in how we report it. We don't report it the way
4	the specs do. So, we do not on the first visit,
5	but we count anything over the initial two
6	visits.
7	And the reason why we do that is
8	because we've found that in the medical record
9	reviews it is common for the risk assessment to
10	be conducted by a social worker or other non-
11	physician provider and, then, followed up with a
12	provider in the next subsequent visit.
13	So, we're not going to go back and
14	say, "Don't do that. That's not compliant,"
15	because that is the reality of the care and how
16	it is being delivered. And it is a good thing.
17	So, we do adapt that measure a little
18	bit. And we don't stop with just the screen,
19	right? So, the screen, we are doing all of it.
20	We are at 81 percent. You know, we don't just
21	like, good, we're good to go. We don't, because
22	you can see that the counseling and referral from

those people who are identified as positive 1 2 ranges quite a bit. It goes down to 69 and, then, up to 100 and, then again, even those who 3 were referred, asking if they followed up and 4 5 actually either went to another appointment or got the service, or something else. You see it 6 7 drops even lower. We get down to like the 8 fifties.

9 So, we just really wanted to make the 10 point that it is highly labor-intensive to 11 collect this information. I don't know that you 12 need every state in the country to invest the 13 resources to know that we fall down on followup. 14 And I think we fall down on followup not just 15 here, but in other spaces as well.

16 So, the next slide I want to talk 17 about is really kind of what brought me here 18 today and really what motivated me to come and 19 speak to you. Getting back to counting what 20 counts, and I apologize for not being here for 21 the whole meeting, but I'm assuming that this has 22 been brought up in some way or another.

1	And I took this line from the Vital
2	Signs Core Metrics for Health and Healthcare
3	Progress Report that I am sure some of you wrote.
4	I know Helen was the Chair. Many of you probably
5	participated or put forth this information.
6	But I think this paper is incredibly
7	relevant to the main points of developing a core
8	set. And it has become my guiding principle as I
9	come out of my first tenure in the field of
10	quality measurement. I'm not here to talk about
11	gaps in measures. In fact, I think we have a lot
12	of measures; sometimes we have too many measures.
13	The gap comes in how we're using and
14	applying these measures. So, that is really what
15	I kind of want to hammer home here today. What
16	we have done is we have taken measures that were
17	never intended to be used to describe a
18	healthcare system, a state, the care of children
19	in Medicaid, and we are applying them in this way
20	and putting it into a core set.
21	If you are not familiar with this
22	report, they outline sort of domains and key

www.nealrgross.com

elements and core measure focus. And then, they
 say, you know, "And here's the best measures we
 have that are selected that are the most
 representative and could fit into these
 particular areas."

And I did this mapping of your core set measures into these domains. This didn't come necessarily out of the report. This was just me, in preparation for this presentation, to kind of demonstrate that, for the most part, your core set seems to follow the same framework.

12 And I have, again, backed in the best 13 current measures you have in the core set to 14 these measure-focused areas like preventive services, access to care, patient safety. 15 I have 16 sort of called out a challenge. You don't have a 17 preventable hospitalization rate in your core 18 I am not necessarily advocating that you set. 19 need to include something like the PDIs. Oh, you 20 recommend it? Okay. I am not necessarily going 21 out on that limb and saying that you need to put 22 one in there. I am just calling out that I think
this particular area is a real challenge for
ensuring that we have measures that address
evidence-based care.

4 And in the next slide, you know, the 5 phase 1 of your core set really was taking these measures and kind of backing in what we have 6 7 currently available to us. And I think the theme 8 I have gotten from just the little that I have 9 been here is that we want more outcome measures, less process. And this is children. 10 Most are 11 healthy; most are low-cost. That is a challenge 12 in the child space; whereas, I think you get more 13 traction in the adult space. We've got really 14 small numbers.

Outcomes in children may not be known for many, many years. And so, while I totally agree that outcome measures are great, we support outcome measures. You just heard a dental presentation where you want to move towards outcome. It is important not to abandon

22 evidence-based process-of-care measures. If you

1	do, and you only look at the outcome, you won't
2	know what's not working along that path. You
3	won't know until it's too late to go back and do
4	something.
5	So, just proceed with caution. As you
6	look to sort of throw out process and replace
7	with outcome, just don't throw them all out. We
8	think it is important to have some in there.
9	And again, just to get back to most of
10	these measures were developed for very specific
11	purposes. As we get through this first phase of
12	the core measurement set, is using the best
13	measures available, is that really good enough?
14	And so, on the next slide, I have
15	given you sort of a flavor of some of the
16	measures that were designed to do something
17	really specific, right? And I agree with all of
18	these measures. I agree with measures for
19	specific populations. I agree with it is
20	important for us to know that adolescent women
21	were screened for chlamydia. It is important to
22	know that we screen women for all kinds of

1	things. I'm not saying that, but is that really
2	driving us towards where we need to go?
3	And if you just hit down once, there
4	is an animation in the slide. So, are you really
5	ready today to give us additional screening
6	measures to track when it is the followup that we
7	seem to fall down on time and time again?
8	Caveat: I didn't look ahead at the measures that
9	you propose today.
10	But, again, are the best measures we
11	have the best we can do? Are we really counting
12	what counts or just measuring something for the
13	sake of measuring something. Time and time
14	again, I think this has really started to come up
15	and percolate in our State.
16	And the next slide, this isn't
17	something I hear a lot about at the measures I
18	attend. It is often getting to measures that are
19	designed to measure system performance, and this
20	is really where we need to go. After all, we're
21	here today because you want to say something
22	about the quality of care of children in

Medicaid, right? You want to say something about
the Medicaid system as a whole.

Instead, when we stick with these 3 4 individual fragmented measures, none of which 5 were actually designed to be put together, and come up with a patchwork of care, we may miss the 6 bigger picture. And I struggle with some of the 7 8 data that comes out on the core set because it is 9 up and down; it is all over the place. I do good on access. I'm not good on this. I'm good at 10 11 followup for ADHD. I'm not good at behavioral 12 risk assessment screening. It's kind of up/down, 13 all over.

14 And I think what we really want is 15 either some intelligence to those measures, put 16 them together and tell me something, add 17 something on top of just pushing out the results, 18 or -- and this is like the huge aspirational ask 19 -- do we need to change how we think about 20 measurement, so that we're thinking more at this 21 whole spectrum of care?

22

Are people getting to the care? Do

1	they have the access to care they need? When
2	they get there, are they getting the evidence-
3	based care that is required or needed? And then,
4	if they need something additional, are they able
5	to follow up, right?
6	And so, that is the big picture. I
7	think that is all where we want to go. And I do
8	acknowledge that that is a huge ask.
9	And Vital Signs really stopped just
10	short of taking this next step. They said, you
11	know, "We're not going to go to that composite
12	level. We're not going to go to that next
13	level." And I'm here today to tell you the time
14	is now. We really need to take that next step.
15	And this is why, in the next slide.
16	So, we are changing the way we pay for care. And
17	New York, we have big goals and in short order.
18	By 2020, we are pushing to have 80 percent of all
19	payments be value-based arrangements.
20	So, the way we are doing this is
21	through a couple of different initiatives. We
22	have so many. These are just the big ones,

1	right?
2	So, we are looking to advance primary
3	care as well as our Medicaid 1115 waiver, our
4	disparate program. And this is where I, as
5	quality is the gateway to the shared savings, I
6	spend almost all of my time now talking about
7	quality measures and their application in value-
8	based payment.
9	And while I appreciate the core set
10	has not been designed to be used for payment, I
11	will tell you that we are trying to align, align,
12	align. So, those measures that you signal that
13	are important in the core set, we are trying to
14	say that is a starting place for sort of
15	alignment as we move down and across payers.
16	So, while you didn't intend for these
17	measures to be used for payment, they are being
18	used for payment, and because we do want that
19	alignment, that parsimony across sets.
20	And a few years ago, where it seemed
21	like we were looking hard at cutting back on the
22	number and type of measures, this introduction of

EBP has created a mania. It's mania. It's manic 1 2 around measures again. It has exploded all over. And for ours, in our State, we are 3 4 taking an incremental phased-in guality 5 measurement approach, not unlike what I described in phase 1 of the core measurement set. 6 We are 7 leveraging in 16 measures to get off the ground. 8 We are looking to sort of come to a core set of 9 measures. We're doing our best to push for 10 alignment across sets, like the core set, and 11 then, across payers, too. So, let's not forget 12 that, right? 13 So, providers don't just provide care 14 to Medicaid enrollees. We do have some safetynet providers that may provide the bulk of their 15 16 care to Medicaid, but that is few and far in 17 between in a state as large as New York. We want 18 all providers and payers to come to some sort of

19 quality measurement alignment.

20 And we're trying to reduce duplicative 21 effort, measurement burden, and cost, but, 22 eventually, we need to get to the measures we

1	really need. And I ask you, when are we going to
2	the measures we really need? We don't want to
3	be, as a state, going at it alone and going off
4	on a tangent.
5	I constantly say that to people who
6	are within our State's interest groups that come
7	in and say, "You don't need NQF endorsement. We
8	need to just do it our self." And I say, "Whoa,
9	whoa. Bring it back. Like let's think about
10	that and the implications of us sort of going off
11	on our own."
12	But I do feel the challenges. We're
13	really pushing providers to take on risk. And in
14	some of these measurement spaces, I'm losing it,
15	getting up there and saying, "Well, we can just
16	use what we have. It will be fine."
17	Because we are talking about keeping
18	the lights on and closing providers. They are
19	taking on huge risk here. So, I'm losing that
20	ability to say what we have is good enough
21	anymore.
22	And that's tricky. I have been doing
21	anymore.

that for a long time. I was the one they sent 1 2 out to say, "No, we don't need anything new. Just use what we have. It will be fine." 3 And 4 so, for me to lose that really has sort of pushed 5 us to look further. So, next slide. 6 I'm not sure if this measure is what 7 8 we are really looking for. And I don't know if 9 it is necessarily an example of what we are thinking, but I did want to pull in a very real 10 example of where we are launching a small pilot, 11 leveraging a healthcare value-based payment model 12 13 to engage the healthcare sector in school 14 readiness. So, I caveat that with the fact that 15 16 school readiness is hard to measure. There is 17 not currently a uniform way to do it. But we 18 feel very strongly that the healthcare sectors 19 plays a critical role in ensuring school 20 readiness. So, we're going to give it a shot. 21 Next slide. 22 We're fostering a cross-sector

1	collaboration between several managed care plans,
2	some high-volume pediatric providers in the city
3	of Albany, early intervention, schools and
4	parents. And we're incentivizing things like
5	developmental screening in the first three years
6	of life, referrals, positive identification
7	services, and eventually kindergarten readiness.
8	More to come on this, as we continue
9	to build up this project. But the point being
10	here that we are looking towards the whole
11	spectrum of care for children and not just paying
12	for the individual pieces.
13	And I know anyone who has talked to me
14	about sort of developmental screening in the
15	first three years of life, when I put on my data,
16	my measurement hat, that is an incredibly hard
17	measure to gather and collect and report out on.
18	But, when I put on my policy hat, it is a really
19	important measure. It's population-based. It's
20	sort of a way to get children the services they
21	may need.
22	So, I struggle, constantly going back

and forth on this particular measure. And we don't have a statewide solution for it, and we're pushed. Every day I get more and more questions about, when are we going to have a statewide solution for this measure?

6 So, we are going to look at, through 7 this pilot, trying to see if maybe kindergarten 8 readiness is not the right outcome to be pushing. 9 Maybe it is the screening that we do want to 10 push. So, hopefully, I will be able to come back 11 to you and talk to you a little bit more about 12 what we learn there.

The last slide is really 13 But, next. 14 what I leave you with here today. It is that 15 more is not better. Continuing to propagate a 16 core set made up of fragmented measures that 17 represent our fragmented system of care or 18 feeding the beast, as I like to call it, you 19 know, looking for more measures for specialized 20 populations, of which you will never have enough. 21 You will never reach all the populations that you 22 need to.

	ε Ι
1	Will that really get us any closer to
2	measuring system performance? Are you ready to
3	count what counts or just measure something for
4	the sake of measuring something?
5	So, with that, I will take all kinds
6	of questions, and you can feel free to hit me
7	with them. I love questions.
8	And I have left my contact information
9	here, too. So, please do feel free to follow up
10	with me at any point if we don't get to all of
11	the questions today.
12	CHAIR ANTONELLI: Bravo, and thank you
13	so much.
14	Can we advance to the group discussion
15	thing? So, again, for the sake of time
16	management, I would appreciate it if the
17	questions and comments from the Task Force for
18	Lindsay and the New York experience can anchor to
19	these themes.
20	So, most significant challenges and
21	how changes to the core set help facilitate that,
22	I think you did a marvelous job of articulating

your frustrations, where your successes may lie, and your needs going forward.

Any of the points of feedback for the 3 states to influence the decision process around 4 5 our recommendation of either removing or putting forward specific measurements. And most notable 6 successes related to quality measurement. 7 8 And so, again, try to keep our 9 comments and questions anchored to these themes. 10 So, I think we had Deborah first and, 11 then, Terry.

12 MEMBER KILSTEIN: Question for you. 13 Besides this kindergarten readiness, are you 14 doing anything where you are looking at multiple measures for an individual child and looking 15 16 across all kids? Like how many kids are getting 17 their EPSDT, their dental screening, their 18 developmental screening, and looking for the 19 child and looking at all these measures, rather 20 than looking at the service across all kids? 21 MS. COGAN: So, we have done a lot of work in that space, trying to take what we do at 22

1

a sort of health plan quality rating. We do a 1 2 five-star rating for health plans, taking these measures and rolling them up into like domains or 3 4 families. So, we are starting to look in that 5 space to say, you know, what if we look at this as more of a domain approach? But, then, you get 6 7 into all kinds of questions about what weighs 8 heavier than others. Do they all equally weight-9 in? So, we are playing around with that a 10 11 little bit and trying to think about more of So, if you get all of the above or 12 composites. none of the above, we are kind of looking at that 13 14 does response. If you get some of it, but not all of it, and then, again, trying to tie that to 15 16 outcome. So, we are dabbling in that space a 17 little bit. Again, I don't have all the answers, 18 but it is something to start with at least. 19 MEMBER ADIRIM: Great presentation. 20 I think it is really helpful to hear from states 21 how they are really using the measures and what you talk about with regard to how you are trying 22

to achieve improvement around some of those measures.

3	I have a brief comment and, then, a
4	question. The comment is around the kindergarten
5	pilot that you are going to do. Are you working
6	with your home visiting program? Because I know
7	that the home visiting programs have measures
8	around certain domains. And we don't have
9	quality measures for kindergarten readiness that
10	I know of and that kind of education domain, but
11	there may be, if you work with your home visiting
12	program. So, that was just a comment.
13	The second, the question is with
14	regard at the beginning of your presentation
15	you talked about your higher-cost populations.
16	Do you find that there's a gap in measurement
17	around that particular population? And if you
18	could speak a little bit about what your needs
19	may be around that?
20	MS. COGAN: So, the issue with getting
21	at measuring that population is it is so small.
22	So, you lose power very quickly.

Neal R. Gross and Co., Inc. Washington DC

1

1	So, we do a lot with stratification
2	and we try to really hone-in on, like I
3	mentioned, you know, children with special
4	healthcare needs, but that is an incredibly wide
5	and diverse group of children.
6	So, then, diving a little bit deeper,
7	who is it in that group that really needs
8	something? So, we haven't gone as far as to say
9	we know we need a measure for I don't know;
10	I'm going to make it up this one segment of
11	the population. We have looked a little bit at
12	sickle cell, and I do work with Michigan who I
13	think is the recipient of a grant that is looking
14	at sickle cell a little bit. One of our medical
15	directors is very interested in sickle cell. So,
16	we are trying to dive a little bit deeper into
17	sickle cell.
18	And then, again, look at, is it that
19	it is a gap do we need a gap? Is there a gap
20	because we need a new measure or do we need a way
21	to measure if children get what they get? So,

22

I

Neal R. Gross and Co., Inc. Washington DC

that has kind of been our struggle going back and

2	MEMBER BEATTIE: Hi. So, I am an
3	administrator for a children's hospital and a
4	pediatrician working as a hospitalist, but I am
5	here representing America's Essential Hospitals.
6	And one of the things that I didn't
7	see you talk about, but I am going to link to
8	your request for prevental hospitalizations, is
9	the issue of psychiatric care for kids. And even
10	in looking at like we currently have in the
11	core set, it addresses more of the after-the-fact
12	as opposed to preventative and the continuum of
13	care.
14	And I'm not sure what the situation is
15	in New York, but we really don't have continuum
16	of care to even offer to kids in my State, in
17	many states, where you have got outpatient with
18	poor access and you have got inpatient with not
19	enough beds, and nothing in between.
20	So, is that something that we should
21	be looking at to help drive for states to be
22	supporting development of continuity of care to

prevent the incorrect hospitalizations? Because what happens is these kids end up in our medical hospitals because there's no place for them in psych beds.

5 And when I was at the CHA conference 6 last year, I noted that something like 30 percent 7 of the presentations were all about this 8 challenge that all of our children's hospitals 9 are having. And I know it is true in the 10 community hospitals as well.

11 So, can you talk a little bit about 12 what Medicaid in your State is doing and how we 13 might be to even begin to address that in some 14 sort of an element within our quality core sets? 15 MS. COGAN: Absolutely. So, that is 16 a huge challenge. And I think we have started in 17 the adult space with our Health Home Initiative 18 and sort of carving our behavioral health 19 services back into managed care. So, I think we 20 have started with adults.

21 Children's health homes, in looking at 22 more complex conditions for children, is sort of

1

2

3

1 just coming up to the forefront for us. So, I 2 will be pulled into those conversations next about, you know, what is the right measure? 3 How do we want to look at kids? 4 5 And I agree with you, that is a huge 6 There's that integrating physical and issue. behavioral health. So, it is something we are 7 8 starting to try and tackle, and kids are ending 9 up in the emergency room, right? So, that is how they are getting into the hospital, because they 10 11 can't get any outpatient care. So, they are 12 showing up in crisis in the emergency room, and we hear that often a lot in New York. 13 14 So, it is an area that I think is ripe, and we would welcome some more work in that 15 16 space. And I agree, again, if we can keep the measure that looks sort of across -- what you've 17 18 given us in this space in the core set is a very 19 specific measure on screening for suicide assessment for children diagnosed with 20 21 depression. So, you've gone way down. And so, if we could just sort of back up a little bit and 22

1	talk more about accessing mental health care or
2	take a step back. And that is, I think, where
3	we would welcome some health and support.
4	MEMBER BEATTIE: So, the AAP, of
5	course, has a recommendation of depression
6	screening for all from 12 and older. And we
7	don't really have anything like that in here.
8	So, I'm just thinking, as I'm listening to her,
9	that that might be something.
10	And I know in the adult core set there
11	is some generalized use of the depression
12	screening and, then, follow up if you are scoring
13	over a 6. So, that might be something to
14	consider for the future.
15	MS. COGAN: Are you going to talk
16	about that measure today? Because it does go
17	down to age 12. So, they've cut it at adults for
18	the adult core set, but the actual measure was
19	endorsed for 12 and above. So, I didn't know if
20	that was on the docket for today. No? Okay.
21	CHAIR ANTONELLI: We don't think so,
22	but if you can confirm that while we continue the

conversation? 1 2 So, you're making eye contact, but I'm looking at her name. Okay. It is hard enough 3 4 being middle-aged. 5 (Laughter.) All right, go ahead, Kim. 6 7 DR. ELLIOTT: You were talking a 8 little bit about not throwing away the process 9 measures because we are moving more and more I would like to hear 10 towards outcomes measures. you talk a little bit more about that, because I 11 12 see outcomes measures as being driven by 13 processes. So, if you are measuring the outcomes 14 and you are having some issues or concerns with the rates you are receiving, you would go back 15 16 and look at the processes that drive that 17 outcome. So, I'm a little curious as to your 18 thoughts on that. 19 MS. COGAN: Yes. So, you will always 20 have the process measures, right? So, we are not 21 going to get rid of the process measures. 22 Sometimes we don't have good outcomes. So, I

1	don't know that I can measure kindergarten
2	readiness. You know, we have something. We have
3	a tool. We are going to use it. We are going to
4	try. I may never be able to accurately and
5	consistently report something for kindergarten
6	readiness, but I may have really strong evidence
7	that something else, a process measure, really
8	ties very closely to that outcome.
9	So, I may want to keep and hang onto
10	that process measure because it really does
11	correlate very closely with an outcome. So, it
12	gives us the best opportunity to measure what we
13	are trying to get to. So, I think that is more
14	of what I am talking about.
15	I am all about for shrinking. So,
16	don't keep it all in for me. You know, I am
17	about sort of limiting your set. And we will
18	always have those individual measures to go back
19	to and sort of drill in deeper at a state level,
20	and understand where the gaps are. But I think
21	sometimes with children, I think outcomes are a
22	challenge.

1	MS. GORHAM: So, just to answer your
2	question, we do have a slide already prepared for
3	discussion for the child and adolescent major
4	depressant disorder, suicide risk assessment.
5	So, we do have that slated for discussion.
6	CHAIR ANTONELLI: Terry, are you in
7	the queue again or is that an artifact? All
8	right. Do you have a new one?
9	MEMBER BEATTIE: Yes. Just I think
10	what we are referring to is to add the depression
11	screening for all adolescents. It is not about
12	suicide screening for adolescents who were
13	previously identified and known to have a
14	depressive disorder. It is, are you screening in
15	primary care for a psychiatric condition?
16	CHAIR ANTONELLI: So, where you are
17	going will actually be for later today. So,
18	absolutely keep that. I asked the staff to
19	comment specific to this question. If you would
20	like to raise that later on, we could absolutely
21	take it on. But I guess I will charge you with
22	doing that. Okay? Okay.

1 Andrea? 2 MEMBER BENIN: Lindsay, I think given the fact that you expanded a little bit on how 3 4 these metrics do get used for payment purposes, 5 which is something I think we all know, although there is always sort of this discussion as though 6 7 that is not true, but we know that it is. Could 8 you expand a little bit on the concepts that were 9 discussed a little bit yesterday around how, when you have metrics where the ideal performance 10 11 isn't known, how that plays out in your world 12 where you are using them for pay, and sort of how 13 we think about including metrics that may or may 14 not -- you know, that aren't 100 percent or zero percent goal target, easily set. Everybody needs 15 16 PDENT, or whatever, but some of these other 17 metrics where we've said, "Oh, it's okay to hit" 18 X -- fill in the blank; choose your target. If 19 you could speak a little bit about how that plays 20 out, I think it would be helpful. 21 MS. COGAN: So, what we do in a lot of those situations is we have sort of a pay-for-22

performance and, then, a pay-for-reporting. 1 And 2 that has been kind of a recommendation we have delineated. In particular, with the 3 contraception care measure, I have been pretty 4 5 close to that measure. I work very closely with Lucretia. We are a recipient of a grant to help 6 7 develop that measure. 8 So, I have been very close to that. 9 So, I have been able to bring back to my State the recommendation that we don't use that for 10

pay-for-performance; that really it not been 12 endorsed that way; it has not been put forth that 13 You know, the conditional requirement. way.

14 So, I am able to make those types of 15 policy recommendations. I don't know that every 16 state sort of has that closeness to either CMS or 17 a measure developer or NQF, to even know enough 18 that, when you look at a measure endorsement, 19 that you have provided recommendations about what it should be used for. 20

21 And I do get some pushback when I say, 22 "Hey, you know, this measure wasn't really

> Neal R. Gross and Co., Inc. Washington DC

intended to be used for payment." And I 1 2 sometimes get overrided and they say, "I don't really care. We're using it for payment." 3 4 So, it is a struggle that we face time 5 and time again. But one of our strategies is we will do sort of a recommendation that this be a 6 7 pay-for-performance because it is clear that we 8 want to get to higher is better, as close to 100 9 percent as we can. And then, for those that we are not as certain about, we will maybe put in a 10 pay-for-reporting. So, we just want you to keep 11 12 an eye on it. It is important enough that we 13 want you to report on it, but we are not going to 14 include that in any kind of shared savings 15 arrangement. 16 CHAIR ANTONELLI: Amy, I will let you 17 ask the last question for this segment. 18 MEMBER RICHARDSON: Your slide about fortune is in the followup, to make sure I 19 20 understand, are you arguing for sort of fewer 21 domains. But, for example, you have chlamydia 22 screening. We can screen a zillion things and

they are good, but if the screening wasn't 1 2 followed by treatment and a followup visit, right, the screening isn't worth much. 3 So, are you arguing for fewer 4 5 measures, but that include the screening and the What is the argument here? 6 outcome? 7 MS. COGAN: So, I am kind of posing 8 that as a real question. So, I think you're 9 right on, right? We can screen, and as a part of my dissertation work, I looked at whether or not 10 women in Medicaid were actually screened, not 11 12 only screened for chlamydia, but those who tested 13 positive were treated. And I've got to tell you, 14 it wasn't good. And I am sure it is not good in the commercial space, either. 15 16 So, I am throwing that out there as a 17 possibility. I think, ideally, we would want to 18 look at the whole picture, right? So, you don't 19 want to just stop with the screening. You want 20 to know that not only was someone screened, but 21 if they needed followup care, did they get that 22

followup care? And then, what happened after,

1

2	But I know I am asking something
3	really big here and sort of changing the way that
4	we are thinking about measurement. I am also
5	saying, "Don't give me something about screening
6	for chlamydia and, then, suicide assessment and,
7	then, something else."
8	Just we are getting to this realm of
9	I don't need to know necessarily it would be
10	nice to have this, all the underneath and, then,
11	the specifics, again, to be able to dig into it
12	deeper if we don't know. But, at a state level
13	or at that higher level, just: did you get in?
14	Were you screened for what you needed to be
15	screened for, whether it be depression,
16	chlamydia, counseling on your weight, nutrition,
17	physical activity? And then, if you were found
18	to be positive, did you have the necessary
19	followup care?
20	And I realize that is a big
21	aspirational ask, right? Because that is not how
22	we think about measurement. Right now, we look

I

at chlamydia screening; we look at weight 1 2 counseling; we look at physical counseling; we look at counseling for nutrition. But we are not 3 4 putting it all together and saying, for children, 5 I don't care what age you're at, were you able to get in; were you able to get what you need, and 6 7 did you have followup if you needed it? So, I do realize it is a huge ask. 8 9 CHAIR ANTONELLI: So, there are some 10 measures that actually look at -- sort of the jargon and care coordination measurement is with 11 12 closing the loop, which includes some of the remission measures for behavioral health 13 14 But it is early. diagnoses. 15 All right. So, we have two minutes 16 until the break. I would be happy to let you 17 now, assuming that Kim didn't usurp your card 18 again, go ahead, Roanne. 19 MEMBER OSBORNE-GASKIN: Yes, so I just 20 had an observation point. I noticed that you 21 said that New York did not report on the 22 developmental screening in the first few years of

But in your pilot that you are talking 1 life. 2 about for kindergarten readiness, it is part of what they are going to be using. 3 4 So, is it that you are going to move 5 to what is reporting on it because you are going to actually have that as a way to sort of 6 7 standardize how you assess for kindergarten 8 readiness in New York? 9 MS. COGAN: Well, it is such a small pilot. We could provide you some results. 10 We 11 also did another sort of -- we cracked open some 12 medical records, about 400, a couple of years ago and looked at whether or not we could come up 13 14 with a statewide solution for this measure, and it wasn't good. 15 16 It just wasn't something we 17 could implement that we felt actually reflected 18 the care that was happening in the State because 19 of just the measure, how it is built, and how you extract that information with the instructions 20 21 that is given in the specs. It is tough. It is 22 tricky.

1	The interpretation varied, and that is
2	what worried us about putting forward results for
3	something when we are not clear about what we are
4	measuring and if we are actually capturing the
5	right thing. So, we were trying to do it
6	administratively. The code was picking up oxygen
7	screening. It doesn't count. If you read the
8	measure, it doesn't count, but the code is there.
9	So, we just got into all kinds of
10	implementation issues. We are going to try to
11	figure it out, though. In this very small pilot
12	we are going to try to figure out, you know, how
13	can we measure this in a very small, controlled
14	situation with just a couple of thousand
15	children. And then, hopefully, we will be able
16	to build that out and come up with a statewide
17	solution that would allow us to measure that.
18	Because I don't care if you unendorse
19	it or don't put it in the core set. I have got a
20	whole State full of people that say, "You need to
21	measure this for me and I want results at a
22	statewide level." So, I do have to answer to

them as well. So, we are going to be coming up 1 2 with a statewide solution for this measure, more than likely, and we will report it if we can. 3 4 CHAIR ANTONELLI: So, thank you so 5 What you contributed yesterday and today much. was wonderful. 6 7 So, we are going to take a break. We 8 will start promptly at the top of the hour. We 9 have got a lot of work ahead of us. But thanks to CMS and thanks to the 10 State of New York. 11 12 (Whereupon, the foregoing matter went off the record at 10:46 a.m. and went back on the 13 14 record at 11:02 a.m.) CHAIR ANTONELLI: All right, let's get 15 16 started on the next section. 17 Can you move us to the next slide, 18 May, please? 19 All right. So, measure-by-measure 20 review of the child core set. Shaconna is going 21 to step in to do a presentation for us. 22 I just want to make sure we still have

1	Dr. Smith on the phone.
2	DR. SMITH: Yes, I'm on the phone.
3	CHAIR ANTONELLI: Great. Okay, thank
4	you.
5	(Pause.)
6	We're solving a technical issue.
7	MS. GORHAM: Okay. We are going to
8	get started in the room. We realize that, if you
9	are streaming, you are having a bit of difficult.
10	Our screen is frozen. So, we do acknowledge that
11	you may not be able to follow along as we advance
12	through the slides because we cannot advance, but
13	we are working. But, for the sake of time, we
14	want to stay on time. So, we are going to
15	continue in the room. So, please listen to the
16	conversation. Thank you.
17	So, please move to the next slide.
18	So, right now, we're on slide 307.
19	And I won't spend a lot of time on
20	this. Some of the slides, we actually reviewed
21	yesterday. We stuck them in the slide deck for
22	sake of organization.

1	But this, again, is our measure-to-
2	measure review, and the measures reported in
3	FY2015 appear to be functioning pretty well.
4	Over the next few slides, we will discuss the
5	four measures that 22 or fewer states reported
6	on.
7	So, we can go to the next slide.
8	This slide shows the potential reasons
9	for removal from the core set. And again, we
10	discussed that yesterday. So, unless we have
11	questions, I will move on. Okay.
12	This shows exactly what is on your
13	handout and what we discussed yesterday as far as
14	the decision categories. So, you have support,
15	conditional support, and do not support. And
16	again, if we decide to support a measure
17	conditionally, we just need to state the reason
18	for that condition.
19	Okay. Slide 310.
20	So, these are the four measures with
21	low levels or the lowest levels of reporting in
22	the child core set for FY2015.

I

	لـ ۱
1	Next slide.
2	So, we talked a little bit about 1448
3	earlier, and that is the developmental screening
4	in the first three years of life. This measure
5	is no longer endorsed and, as stated earlier, the
6	developer didn't have the resources to test or
7	maintain this measure. The endorsed or the
8	previously endorsed, the measure you have in
9	front of you, the specs you have in front of you
10	did not the current standards have been
11	updated, and this measure does not reflect that.
12	This measure, on the 2015 core set 22
13	states reported the measure, which is an increase
14	from the 20 states that reported the measure in
15	both 2013 and 2014. Twenty-seven states did not
16	report this measure in FY2015, for a number of
17	reasons. Again, I refer you back to the resource
18	that CMS provided and that we sent before the
19	meeting.
20	So, some of those reasons include
21	and again, I won't read all of them but,
22	again, some of the reasons, the same as we have

discussed so far: budget constraints. 1 Data 2 elements necessary for calculation are only available via medical records review. Providers 3 are using the CPT code for this measure. 4 5 However, guidance has not been provided yet to providers to ensure the tools used for the screen 6 are consistent with the specification. 7 The tate 8 does not calculate this measure, nor require our 9 health plans to calculate it. So, those are a Inconsistencies made the data unavailable, 10 few. 11 and so forth. 12 The next measure, 0471, is a PC-02 Caesarian birth measure. The number of states 13 14 reporting the measure increased from 12 states in FY2012 to 17 states in FY2013 and, then, 15 16 decreased to 16 states in 2014, and 15 states in 17 2015. 18 So, 34 states did not report this 19 Reasons include data requires measure. information from the Division of Public Health 20 Vital Statistics Office. The state has not been 21 22 able to validate the rates yet with hospitals.
Birth certificate data have been not to 1 2 specification logic. However, states would like to verify the data with some hospitals. 3 MCOs are 4 not required to submit this HEDIS measure, and so 5 Again, you have a comprehensive list in forth. your reference material. 6 7 We voted on this measure yesterday. 8 You all voted not to have the measure continue in 9 the core set, so to have the measure removed. 10 So, I won't go into this measure, as it was 11 discussed yesterday. 12 If we advance the slide, please? 13 Thank you. 14 So, the behavioral health risk assessment is the one that you all voted to 15 remove from the core set. So, I won't go into 16 the particulars about this measure. 17 18 Next slide. Okay. 19 And then, the child and adolescent 20 major depressive disorder, the suicide risk 21 assessment, we had a little discussion about this 22 earlier today. Forty-eight states did not report

this measure. I will say that the measure was 1 2 just added in FY2015. So, that could also be a reason for low reporting. 3 4 Some of the reasons stated state: it 5 is focusing on trying to improve the quality of reporting all measures that have been reported 6 7 consistently over the last few years, and prefer 8 to work on quality over quantity. Data element from electronic health 9 10 records are necessary for calculation, but are 11 not available. MCOs are not required to submit 12 this measure, and so forth. 13 Next measure, next slide. 14 So, I'll turn it over to Rich. Okay. But, again, as we do all of the days, we just 15 16 highlight some of those measures that have low 17 reporting by the states. You all definitely can 18 discuss again. You have already discussed the 19 behavioral health risk assessment and decided to 20 remove that measure. 21 Rich? 22 CHAIR ANTONELLI: Okay. Thank you.

I	
1	So, we want to think about the process
2	of consideration for removal from the set. I
3	really liked the interaction there at the end of
4	the last session where Lindsay said, "It's a
5	heavy lift, but we're going to do the behavioral
6	health screening inside our Albany demonstration
7	project because it's important." And that wasn't
8	because it's in the core set. And so, I think we
9	need to be mindful of that, as we deliberate
10	keeping measures in or putting them forward for
11	inclusion. You know, are they meeting criteria
12	around parsimony and is it moving us
13	directionally where we want to go?
14	So, the reason, we have already talked
15	about 1448. So, I won't spend any more time with
16	that.
17	And I think, in general, why don't we
18	just go ahead and proceed to open up to the Task
19	Force, if anybody would like to raise any
20	Karen, do you want to add something at this
21	point?
22	DR. MATSUOKA: Yes. I just wanted to

note that a measure does not have to be a low-1 2 reported measure in order to be a candidate for So, I know this was a point of 3 removal. 4 confusion that Roanne asked about yesterday. So, 5 I just want to clarify. That is certainly one of the reasons 6 7 why you might consider removing a measure, is 8 because states aren't reporting it, but that 9 doesn't have to be the reason why. 10 CHAIR ANTONELLI: Really important. 11 Thank you very much. 12 Okay. So, we have Roanne and, then, 13 Rachel. Go ahead. 14 MEMBER OSBORNE-GASKIN: So, I just wanted to refer to slide 252. Is that one of the 15 16 ones that is also being recommended for removal, 17 the child and adolescence access to primary care practitioners? Or is that also -- slide 252. 18 19 Are we considering that one as well? Or that's 20 not for discussion right now? 21 MS. GORHAM: So, that measure was 22 recommended last year, but you certainly can

recommend that measure, have discussion, and if 1 2 it is seconded, someone motions to second, you definitely can recommend it again. Just because 3 4 it was recommended last year does not mean you cannot recommend it again. 5 So, Karen made a really good point, 6 that we, as staff, just organized our deck where 7 we have like the low-reported measures. 8 But you 9 can look at any measure from the core set. And if you want to have discussion about removal and 10 11 recommend to CMS, you can. 12 So, again, that was a recommendation 13 made last year, and you can, again, have 14 discussion and make the recommendations to CMS. 15 MEMBER OSBORNE-GASKIN: So, it was 16 recommended last year, but it was cut? It did 17 not --18 MS. GORHAM: Exactly. 19 MEMBER OSBORNE-GASKIN: Okay. 20 MS. GORHAM: It was recommended by the 21 Task Force last year, but CMS did not elect to 22 have that measure removed. And now, Karen may

1

want to speak about the reason, but --

2 DR. MATSUOKA: Yes. So, I think the main reason that we wanted to keep this in here, 3 because, first, we thought it was an important 4 complement to well child visit. I know that a 5 lot of the discussion last year -- I'm trying to 6 7 jog my memory -- was around, you know, if we have 8 a well child visit, do we really need this one. 9 And I think part of the answer that we heard from our interaction with states, but also internally 10 at CMS, was that having a measure of access to 11 12 any kind of care at all is measuring something 13 slightly different than well child visit, which 14 is measuring some of the content at what you're 15 getting at the PCP visit. So, for that reason, 16 we thought we wouldn't want to remove it just 17 because we had well child visit in there. 18 The other main reason why we decided 19 to keep it in was because, although, by and

large, in the aggregate we are doing very well, states are doing very well on that measure, we saw a noticeable gap with regard to adolescents.

> Neal R. Gross and Co., Inc. Washington DC

20

21

And we didn't want to -- I don't know that we thought about just kind of keeping the adolescent piece of it in the core set and getting rid of the other age groupings. But, in order to be able to keep tabs on how we are doing with adolescent care, we decided to keep the whole measure in.

8 MEMBER OSBORNE-GASKIN: So, I guess my 9 other question to that would be that, even with adolescent well care visit and the immunizations 10 11 for adolescents, you have two other measures 12 there that look at adolescents, you know, if 13 that's a population that you want to look at 14 specifically. So, maybe I should just look at it, but where there are significant differences 15 16 between, so you kind of capture the well car and the immunizations for adolescents. Was there 17 18 some difference that was seen that made you still 19 want to keep that there?

20 DR. MATSUOKA: So, you bring up an 21 interesting point, which is that some of these 22 measures become very interesting when they are

> Neal R. Gross and Co., Inc. Washington DC

1

2

3

4

5

6

looked at in conjunction with each other. 1 So, 2 this is a good example of, you know, if you have a state who has a relatively good access to care 3 measure, but is slightly doing less well on well 4 5 child visits for adolescents, and doing slightly less well in terms of immunizations for 6 adolescents, each of those measures taken 7 8 together tell you a slightly different story 9 about what a state might think about as an intervention point with regard to the delivery of 10 care for adolescents in their state overall. 11 12 So, they are very related and they are 13 all getting to access to and quality of 14 preventive care, but measuring a slightly different dimension of it. 15 16 Another example would be asthma. So, 17 we have an asthma measure that we talked about 18 yesterday. That is looking at sort of medical 19 adherence and the extent to which the clinical 20 side of delivery of care for kids with asthma are 21 evidence-based. 22 But we also have the PQI-15 measure

for the extent to which there are avoidable 1 2 admissions to the hospital for asthma. And you could say, well, those are both kind of looking 3 at quality of care for asthma, but they are 4 5 measuring something slightly different. And they become very interesting in states where maybe 6 medication adherence is actually doing quite 7 well, but you are, nevertheless, seeing a fairly 8 9 elevated level of admissions to the hospital for 10 avoidable asthma care. It tells you something 11 slightly different. And so, I don't know that we 12 13 necessarily think of all asthma measures as being 14 one and the same, and so, as long as we have one, we're okay. So, I don't know if that answers 15

your question, but we do kind of, at least at the federal level, we do, then, take that information to think about, you know, what kind of affinity groups do we want to offer.

20 So, we know that the HPV adolescent 21 vaccination rate was quite low. So, looking at 22 that, if we didn't have that apart from

(202) 234-4433

information about the well child visits for 1 2 adolescents, we wouldn't know that there might be a need for having some targeted technical 3 assistance to states on how to boost immunization 4 rates for adolescents. 5 So, I think a long answer, but I will 6 stop there and see if that answered your 7 8 question. Okay. 9 CHAIR ANTONELLI: And so, I want to ask another question. Was that sufficient for 10 11 you or do you want to entertain proposing it for 12 consideration? Because we kind of moved into the 13 consideration phase, but because it was CMS 14 leadership speaking, I didn't want to cut it off. But I don't mind burning clock time, but I want 15 16 to make sure that we are burning clock time for things that rise to the level of a motion that 17 18 gets seconded. 19 So, would you like to proceed or was that sufficient and you don't want to consider 20 21 raising a motion? 22 MS. GORHAM: I can also, Roanne, if it

would help, just tell you some of the reasoning
behind the recommendation last year, as far as
the Task Force is concerned, if that would at all
help you.
MEMBER KILSTEIN: Yes. And I just
want to kind of leave I just wanted to bring
it back to the floor. I don't know if anybody
else has any strong feelings about it. And then,
I know we have to leave the time for discussion
for the others. So, I mean, it is fine to swing
back and, you know, if it comes up again, then
CHAIR ANTONELLI: Okay. Okay. Thank
you. Thank you.
Amy?
MEMBER RICHARDSON: Thank you.
I think there's one on this list that
sort of falls pretty quickly into some of the
discussion we had yesterday and here today. And
that is the Caesarian birth one that is on slide
312, yes, the Joint Commission.
So, I have no doubt that our Medicaid
moms are having higher rates of unnecessary

C-sections for term babies. But I'm not sure --1 2 if we think about the downstream of measure intervention, that the Joint Commission is in far 3 4 better position to (a) measure this and (b) do 5 something about it through their management of 6 quality at the hospital level. 7 So, I would like to move that this be 8 removed. 9 MEMBER BENIN: Second. 10 CHAIR ANTONELLI: Okay. And guidance 11 do we want anything to finish from the staff: 12 the conversation ending in a vote? Or do we want 13 to collect the measures and, then, adjudicate 14 them? Okay. 15 So, if it is up to me, what I would 16 like to do is let's note that, with a seconded 17 motion. Let's spend the time seeing if there are 18 other measures that people would like to bring 19 forward. And then, we will do the discussion 20 with a group of the measures or the measure. 21 Okay. 22 Rachel?

1	MEMBER LA CROIX: I have comments on
2	just a couple of the measures. First, I agree
3	with the recommendation for the Caesarian birth.
4	That is a measure we think is really important,
5	but, again, those data are often housed with our
6	vital statistics data, which sometimes has a lag
7	and is sometimes hard to match up with our
8	Medicaid data, and it is difficult to look at at
9	a health plan level sometimes.
10	I think there have been some
11	improvements with ICD-10 of being able to pick up
12	some of these other information and codes that
13	you might have in claims and encounters, but
14	maybe that would be a new measure down the line
15	that someone could come up with using some of
16	those codes.
17	My other comment was related to the
18	developmental screening measure. We do think
19	that is a really important measure, but, like New
20	York, we have had difficulties pulling data for
21	that measure. And we did have a couple of plans
22	try to use the administrative method for that,

1	
1	but the code that is available for that is not a
2	valid code to use for the instruments required
3	for that measure. And so, we found that to not
4	be meaningful to pull it that way.
5	And we did report it this past year,
6	but it did require medical record review and
7	looking at just a sample of records. So, it is a
8	harder one for us to look at as well.
9	CHAIR ANTONELLI: Thank you.
10	Task Force Members, are there any
11	other measures that you would like to consider
12	suggesting for removal?
13	Terry?
14	MEMBER ADIRIM: No, I just wanted to
15	follow up on your comment about the developmental
16	screening. I think where feasibility for
17	implementation should be a consideration, this is
18	a really critical measure domain. So, I would
19	not recommend taking it off the core set, but I
20	think we should maybe think about, you know, how
21	we can facilitate its implementation in the
22	states.

	-
1	CHAIR ANTONELLI: Go ahead.
2	MS. GORHAM: So, I usually don't ask
3	these questions of staff. But, just for my
4	curiosity, the note that I have for this
5	particular measure is that the developer didn't
6	have the resources to test or maintain. And so,
7	the current standards, the measure as it stands,
8	the current standards, they don't have the
9	ability to test. So, they withdrew from
10	consideration.
11	So, if the developer is saying that
12	they aren't maintaining this measure, but
13	guidelines and standards, and so forth, are
14	changing, how do you, then, know that this is
15	still a good measure?
16	MEMBER ADIRIM: Well, obviously, we
17	don't because it hasn't been tested. But, you
18	know, if there isn't another measure that
19	measures development in the first three years,
20	this is such a critical piece to this population,
21	then I think we need to look at how we can
22	implement and maybe hint, hint CMS might

pay for some field testing or something to help 1 2 support this measure and states' implementation of the measure. 3 4 MS. GORHAM: Do you keep the measure 5 up, not knowing that it is like a valid measure? CHAIR ANTONELLI: Well, the issue, 6 7 though, that it is going to lose its NQF 8 endorsement. 9 DR. MATSUOKA: That doesn't mean it is not a valid --10 11 CHAIR ANTONELLI: Exactly. So, I 12 guess I just sort of want to define the issue 13 here. So, we are not going to argue that, you 14 know, NQF, please find it in your heart to break That's not the issue. 15 your rules. 16 I think it actually gets down to the 17 dynamic, and Karen's point before rings true yet 18 again. There are other reasons to think about 19 removal, but, also, they don't have to have NQF 20 endorsement to keep measures in. 21 So, I think what you're saying -- and I'm not going to make a motion for you -- but 22

1	what I think you are saying is you want to talk
2	about the value of this measure and maintaining
3	it in the core set, in spite of the fact that,
4	for technical reasons, it lost its NQF
5	endorsement. Is that correct?
6	MS. GORHAM: Yes.
7	CHAIR ANTONELLI: Okay. But, again,
8	I'm not making a motion for you, yes.
9	Karen, did you want to weigh-in?
10	DR. MATSUOKA: Not to necessarily
11	weigh-in, but to just ask and kind of repeat what
12	we said for the first two days. But just to
13	underscore here, too, that beyond the actual
14	yes/no vote, it is this discussion that is
15	actually the most helpful for CMS in terms of
16	deliberating ultimately what makes it in or out.
17	And so, as we are discussing these
18	measures, if we could be very clear about when
19	you are advocating for removal or addition, I
20	think we definitely want to hear about the
21	feasibility issues, but if we can just note that.
22	So, just as an example for Caesarian

section, definitely heard that it is hard to 1 2 measure because it is a hospital measure and requires some linkage to vital records. 3 But, then, to Terry's point, it would be helpful for 4 5 us to know whether, beyond feasibility, you know, if there were some way that we could think about 6 7 finding a way to slice data and report it at a 8 Medicaid-specific number for the states, would it 9 be important?

10 So, in your discussions, just kind of 11 carefully teasing out, you know, and separating 12 feasibility from importance. We want to know 13 about both. But, if we can just kind of make 14 sure we differentiate in the discussion?

MEMBER POOLE-YAEGER: 15 Thanks. I'm 16 going to just speak with the managed care hat 17 here and say, you know, when I read a lot of the 18 comments about why states weren't reporting, it 19 was because the MCOs aren't reporting it and 20 don't report it. And we are held to NCQA 21 accreditation standards. There is a set of NCQA 22 accreditation measures, HEDIS. Every

administrative company has software and auditing and hybrid specifications, and all the things to do that in managed care.

4 So, as much as we could align this set 5 with those or get that set to align with these, it would really help all of us, I think, to say, 6 7 okay, we can all, then, roll in the same 8 direction. Because what happens is we have some 9 states that say, okay, we want to measure this, so we are going to do some offline HEDIS admin, 10 you know, hybrid chase, versus the ones that are 11 12 in HEDIS, and it gets really kind of complicated. 13 So, I just bring that up as a point. 14 CHAIR ANTONELLI: Amy? Then, Carol 15 and, then, Terry, you just raised again, yes? 16 MEMBER ADIRIM: Yes. 17 CHAIR ANTONELLI: Okay. 18 MEMBER RICHARDSON: Thank you. 19 So, with my pediatric hat on, I 20 completely agree with the AAP's guidelines about 21 developmental screening. 22 CHAIR ANTONELLI: Could you lean into

1

2

1	the microphone, please?
2	MEMBER RICHARDSON: Sorry.
3	I completely agree with the AAP's
4	recommendation for developmental screening.
5	Now I am going to take off that hat
6	and put on my hat as a certified coder and a
7	managed care executive, which is these two codes
8	that drive the measurement are amuck and a mess.
9	So, they are adjacent. They are 96110 and 96111.
10	Primary care providers haven't got a
11	clue what distinguishes those two, which one is
12	appropriate, who should be doing it, what
13	documentation is required. I can't tell you how
14	many potential fraud cases have been sent to me
15	to review, and it wasn't fraud. It was somebody
16	in the doctor's billing office who didn't know
17	which code to use.
18	And so, until we educate the provider
19	community about the guidelines, about how to code
20	and bill for them correctly, the data that
21	underlies your measure isn't reliable.
22	So, I agree that it is important. I

don't think we are at a place where it is being 1 2 properly done or properly documented or properly And so, do we want to make state-level 3 coded. 4 decisions about where we are going to spend our 5 money, promoting quality on something whose foundation is not yet solid? 6 CHAIR ANTONELLI: 7 Carol? 8 MEMBER SAKALA: So, you will not be 9 surprised that I strongly feel that we should 10 keep the Caesarian measure. There are three 11 different kind of Caesarian-related -- well, one 12 woman in three is having a Caesarian. We stopped 13 the steep rise, but it has plateaued. 14 When Pacific Business Group did a 15 pilot tying it to payment reform, boy, did it 16 drop really fast and, also, the VDAC rose, even 17 though that wasn't even a part of it. And it 18 rose across all covered women, even though some 19 of them fell under the contracts that led to the 20 changes. 21 So, I think there is a lot we can do 22 with improvement, and I think the value-based

world is coming. And this is widely recognized 1 2 as a huge issue around cost and outcomes for mothers and for babies. 3 This rate is viewed as the fairest 4 5 rate in comparison with the total Caesarian or primary Caesarian. So, I think that is really 6 7 important for our service providers. You know, the early elective delivery 8 9 was kind of our test case in maternity care. We came a little late to QI, but now everybody knows 10 11 we can do better. And to a great extent, this is 12 the new kind of focus now in the field. 13 So, we have had the AIM project of Alliance for Innovation in Maternal Health that 14 has a bundle for intended vaginal birth that is 15 16 being implemented by all the leading national clinical professional societies that are behind 17 18 this. The ACOG and the Society for Maternal-

19 Fetal Medicine, after being silent since 2000, on 20 what's going on with Caesarians, said this is 21 overused; we need to do something about it. They 22 issued a lot of recommendations in 2014 and have

1 reaffirmed that.

2	There is a Committee Opinion this year
3	from ACOG suddenly really getting with the
4	program around evidence-based practices that are
5	highly related to this. So, the field is really
6	going in this direction.
7	It is a part of the Joint Commission
8	measure set, and they are developing an eMeasure
9	to have multiple ways of collecting it. It is in
10	the CMS-AHIP Core Set.
11	And I feel that we also first, I
12	was like, why is this in the child and not the
13	adult? But, since then, I feel it is really
14	important for the child because we don't go by
15	individual studies, but we really want to see a
16	well-conducted, systematic review of the best
17	available studies.
18	And there are now systematic reviews
19	showing about a 20-percent increase in the
20	likelihood of Caesarian-born children developing
21	a whole series of chronic conditions. And that
22	includes asthma, allergy, Type 1 diabetes,

Crohn's disease, autism spectrum disorder. 1 And 2 the theory is that this is related to the human microbiome. And so, it is very foundational for 3 lifelong health. 4 5 And there is broad variation as well. And we have real high-performers. 6 So, I think 7 that the core set should be aligning with these 8 other programs that are focusing on this as a 9 huge opportunity for improvement in health and 10 cost. 11 CHAIR ANTONELLI: So, I am going to 12 pause us for a second. 13 So, 0471, there is a motion. Because, 14 remember, my goal was let's get the measures out that people want to be considered for removal. 15 16 Then, we will sequentially bring conversation. 17 And then, we will actually vote. We would like 18 to get that done before the midday break. 19 So, do we want to put any other motions on the floor for other measures? 20 Ι 21 promise we will come back to the one that has already had a motion in a second. 22

1	Deborah?
2	MEMBER KILSTEIN: Yes, I am concerned
3	about the developmental screening. While I think
4	it is a very important measure, the fact that the
5	measure is not being supported anymore, it is not
6	NQF-endorsed, you know, I think it calls it into
7	question.
8	And in terms of removal, I mean, at
9	best, I could support this being on conditionally
10	until something else is developed. But to just
11	say we should go continue with this without
12	calling it into question I think is an issue.
13	CHAIR ANTONELLI: Okay. So, is there
14	a motion embedded in what you just said?
15	MEMBER KILSTEIN: Yes, I'll make a
16	motion that this one should be either removed or
17	you know, I don't know of that yes, I would
18	make a motion it should be removed.
19	CHAIR ANTONELLI: 1448.
20	MEMBER KILSTEIN: Yes.
21	CHAIR ANTONELLI: The motion on the
22	floor is to remove 1448. Is there a second?

1	L
1	DR. ELLIOTT: I'll second that.
2	CHAIR ANTONELLI: There's a second.
3	Okay. Okay.
4	So, we have two measures to consider,
5	and we will get there next. Are there any other
6	measures that people would like to bring out to
7	discuss besides the two that have motions on the
8	floor?
9	Terry? If it is related to the two
10	motions on the floor, I want you to hold it,
11	please. I want to do the housekeeping. If you
12	could put your card down, please?
13	All right. People be thoughtful. Any
14	other potential measures for consideration for
15	removal?
16	I would err on the side of sharing
17	your ideas. Go ahead.
18	MEMBER OSBORNE-GASKIN: So, back to my
19	original question on child and adolescent access
20	to primary care practitioners, I think I would
21	make a motion to remove. And my rationale is
22	that it talks about access, but coming from the

managed care world, true access is something that health plans do. And I am just curious about how this is measuring quality, and I am not quite sure how it is measuring quality.

And I understand what you said, Karen, 5 about the fact that you do see variations between 6 7 not so much a child, but the adolescent well child visit and adolescent immunizations, but 8 9 this is something that is tracked by health plans, that there are certain standards that the 10 11 health plans have to use to make sure that 12 there's a primary care provider within a certain 13 number of miles for the population that they 14 serve. And I am just having a little difficulty trying to figure out how that -- if there needs 15 16 to be an additional measure to track that and how 17 that will actually affect quality.

So, that would be my motion.
CHAIR ANTONELLI: Okay. So, could you
maybe more succinctly state the motion, please?
MEMBER OSBORNE-GASKIN: The child and
adolescent access to primary care practitioners,

Neal R. Gross and Co., Inc. Washington DC

1

2

3

I don't see a number here. Oh, okay, it is not. 1 2 Okay. But it is part of the child care. Okay. So, just a motion to remove the child 3 4 and adolescent access to primary care 5 practitioners from the core set. CHAIR ANTONELLI: Okay. 6 Okay. Thank 7 you. 8 Any seconds? 9 MEMBER POOLE-YAEGER: I'll second 10 that. 11 CHAIR ANTONELLI: Okay. So, we have 12 three measures to consider, and I will give folks 13 another minute or so. We are not talking about 14 these three measures. We are just collecting candidates right now. 15 16 Any other measures that people would like to put forward for consideration of removal? 17 18 (No response.) 19 So, what order should we go in? Okay. 20 MEMBER OSBORNE-GASKIN: So, I have a 21 quick question. I'm sorry. The one, 1365, are we not removing? It is on the list of low-22

reporting measures, but we are not going to --1 2 you are not making a motion to remove that one, that child and adolescent measure, major 3 4 depressive disorder, suicide risk assessment? 5 So, again, just because MS. GORHAM: 6 it is on the list of low-reported measures does 7 not necessarily mean that you have to remove it or make a motion to remove it. It is up to you 8 9 whether or not you think the measure should 10 remain in the core set. If not, then why would 11 you want it removed? 12 We simply, when we did our bucketing 13 of measures, we just put high-reported, medium-14 reported, and low-reporting. And so, these four measures are the measures that are least reported 15 16 by the states, but we are in no way suggesting --17 it is definitely up to the Task Force and your 18 expertise and your work with the core set 19 measures, if you think they should be removed. 20 That is just a way to guide the discussion. 21 CHAIR ANTONELLI: Okay. You have a 22 motion? Okay. Put your microphone on, please.

ĺ	
1	MEMBER POOLE-YAEGER: I'm going to
2	move for this child and adolescent major
3	depressive disorder, suicide risk assessment
4	measure to be removed, with the thought of
5	replacing it with the one that we were talking
6	about that is overall depression screening in
7	adolescents down to the age of 12.
8	CHAIR ANTONELLI: So, that sounds like
9	a conditional motion.
10	Is there a second for 1365?
11	MEMBER OSBORNE-GASKIN: Second.
12	CHAIR ANTONELLI: Second. Okay. All
13	right.
14	So, May, why don't you move us to the
15	first one? So, we have four to consider for
16	removal. I am very respectful that we have had
17	conversations tied to each of these things, and I
18	am very comfortable revisiting that, so that we
19	can actually surround each of these big decisions
20	with the appropriate content and context.
21	Okay. Terry?
22	MEMBER ADIRIM: Thank you.

1	I have just a general comment with
2	regard to removal of measures and, then, a
3	specific one about the developmental screening.
4	I think we need to be really careful
5	with regard to the measures that we want to add
6	or take off, in not allowing the technical or
7	necessarily the implementation pieces to drive
8	the whole conversation. Because I think what
9	happens is we have a lot of managed care people
10	here, and they may not want to add something
11	because it may cost too much, be hard, or
12	whatever.
13	We are supposed to be leading the
14	country in what we think should be measured. It
15	shouldn't be what the end-users want to be
16	measured. So, I think we need to be really
17	careful in teasing out those particular issues.
18	And so, with regard to the
19	developmental screening, I hear you. It may need
20	some work. I may need some technical assistance
21	for implementation, which I think that's what it
22	is.

	ц И
1	It sounds to me, from what the NQF
2	staff have said, that the NQF endorsement is
3	being removed, not because it is a bad measure,
4	but because the measure steward or developer
5	didn't have the resources, or whatever it was, to
6	do further testing. That is not the same as
7	saying it is a bad measure. So, I think we need
8	to be really, really careful here because we
9	don't have another measure to supplant this.
10	And in childhood I'm an emergency
11	physician; I am not a general pediatrician
12	but, in childhood, developmental screening is
13	critical. It is not being done. And I think we
14	need to, as the guiding light for quality
15	improvement, send out that message that this is
16	an important measure, an important concept. So,
17	that is my little piece on that.
18	CHAIR ANTONELLI: Okay. Thank you.
19	Deborah?
20	MEMBER KILSTEIN: Is the vote to
21	remove, does it have to be a yes or no? There
22	can't be a conditional like

I	
1	MS. MUKHERJEE: So, that would be in
2	the discussion. So, when we put in the measure
3	in the report, we will say, Measure So-and-So was
4	voted to remove. And then, we will say the
5	discussion included, you know, these caveats or
6	sort of considerations. So, it will be in there
7	and we also have CMS
8	CHAIR ANTONELLI: And my intention was
9	to follow the paradigm we did yesterday, which
10	is, prior to going to the dichotomous yes/no, was
11	to give the Task Force a chance to actually
12	suggest a condition, which, then, makes it a
13	three-way vote selection, right?
14	MEMBER KILSTEIN: Okay. Thank you.
15	CHAIR ANTONELLI: So, I will do that
16	for each one of these measures. Okay?
17	MEMBER KILSTEIN: Thank you.
18	CHAIR ANTONELLI: All right. So,
19	focusing on 1448.
20	Yes?
21	MEMBER POOLE-YAEGER: So, I totally
22	agree that this is an important one. I am not

1 sure that we have got the coding stuff worked out 2 in order to do it. So, it would be a medical 3 record review.

I think my main concern with that is not always effort, but, you know, what are the specs for that? How do we make sure that is done well? This is not a typical HEDIS measure. This is a now not-endorsed NQF measure.

9 So, maybe I would propose some, you know, a removal conditional on it becoming a more 10 11 standard, if it is going to have to be a medical 12 record review for the short-term until we get the 13 coding worked out. That is a long-winded way of 14 saying that, but, you know, conditional on work 15 toward getting some better specs on how to get to 16 that measure.

17 CHAIR ANTONELLI: Okay. Thank you.
18 It doesn't seem there is any more
19 discussion on 1448. So, let me actually come and
20 build off that.
21 So, would you like to -- I don't know,

and forgive me if this is reading something that

Neal R. Gross and Co., Inc. Washington DC

1	you didn't intend. Are you formulating a
2	condition that we would want to attach to a vote
3	for 1448? And if so, would you like to
4	articulate it?
5	MEMBER POOLE-YAEGER: Correct. Yes,
6	I would probably say we would move to
7	conditionally approve it with the condition that,
8	knowing that it is no longer NQF-endorsed, we do
9	need to work toward getting a standardization and
10	a way to measure it in short order.
11	CHAIR ANTONELLI: Okay. So, I am
12	allowed to take that as a motion and, then, to
13	solicit a second one and, then, combine them into
14	a vote. Yes.
15	So, Amy just formulated a condition
16	for 1448. I am mindful, because I would rather
17	not vote the other down. I would rather just
18	append this one to that. Is that okay if I do
19	that?
20	Could you restate the condition,
21	please?
22	MEMBER POOLE-YAEGER: Oh, sure. That

there would be -- again, it is conditional 1 2 because of the pending NQF endorsement or at least a specification of a measure steward who is 3 4 going to take it on as somebody that is going to 5 keep the specs up-to-date and will be allowing us to know how best to capture it. 6 7 CHAIR ANTONELLI: Yes. I hope we 8 don't have to vote up/down and, then, come back. 9 Can we just do this one as an amendment to the vote on 1448? 10 11 MS. GORHAM: I actually need to check 12 with my leadership. But the measure is already 13 -- the endorsement has been removed. So, whether 14 the measure will ever be submitted again, we have 15 no control; we don't know that. So, that 16 condition, just I need to check because the 17 measure has been submitted. It has been, the 18 endorsement has been removed. The developer has 19 already said he cannot maintain it. 20 Whether or not another developer picks 21 this measure up, and whether or not it is submitted to NQF, I can't see the future. 22 So,
for that to be a condition --

2	MEMBER KILSTEIN: But couldn't the
3	condition, because, again, going back to the
4	chart with the three potentials, couldn't the
5	condition be for CMS to support that activity in
6	terms of coming up with the specifications that
7	take into account everything that was said here,
8	regardless of whether it gets NQF endorsed?
9	MS. MUKHERJEE: So, just to talk a
10	little bit about this conditional voting, the way
11	it is going to happen, I mean, at this point this
12	measure is an orphan measure. It doesn't have a
13	steward. I mean, it truly is an orphan measure.
14	And it is already in the core set.
15	So, what we can do is we can do an
16	up/down vote. And then, it is not necessarily
17	voting on a condition, but it is saying we are
18	doing a remove because this is our condition.
19	And the condition is more like a thought process
20	and our suggestion to CMS. And I think calling
21	it like a condition almost makes it sound more
22	constructive than it is. It is basically we are

voting up or down, so, yes, remove, or, no, 1 2 remove. And then, our condition, our sort of thought around this vote is, you know, the intent 3 4 is great; it is not feasible to implement, and we 5 are looking for a better, newer measure. 6 So, the way our reports are sort of structured is that it is not as if you are voting 7 8 with a condition, but you are voting yes or no. 9 And your gestalt, your sort of thought process is that this is sort of what your thinking is around 10 this measure. 11 12 I just want to clarify that because I feel like a lot of removals are conditional 13 14 removals. I mean, they are already in the core, so it is not a conditional removal. 15 Either you 16 are removing it or not. But your thought process 17 around that is you are removing it with a caution 18 or with a suggestion or with a recommendation. 19 CHAIR ANTONELLI: Has the issue been 20 framed for the esteemed Dr. Burstin? All right. 21 So, we are calling you in as our line of support 22 with your white cavalry hat.

	L.
1	DR. BURSTIN: I don't know what kind
2	of hat that is, but that's okay.
3	So, this is an interesting measure.
4	These are a set of questions, essentially, that
5	come out of a national survey of children's
6	health.
7	So, the developer here moved from
8	Oregon, now at Johns Hopkins, developed the
9	survey for HRSA as part of this HRSA survey. It
10	is administered, I think, every four years.
11	Correct me if I'm wrong.
12	And so, these questions came in to us,
13	but it was never very clear what the actual path
14	was to collect the data, particularly at the
15	state level for Medicaid. Have you guys figured
16	out a different pathway?
17	DR. FOX: I don't believe that is
18	another measure that came to the pediatric that
19	wasn't renewed. That is through the I'm
20	forgetting her name who moved from Oregon. No,
21	this is the measure that comes from coding for
22	developmental screening. And then, it is hybrid

i	1 1
1	measure. So, you either measure the 96110, or it
2	is done by chart review. And it was originally,
3	it is Oregon but a different group at Oregon. It
4	is not CAMI.
5	DR. BURSTIN: Oh, okay.
6	DR. FOX: The CAMI measures, yes.
7	DR. BURSTIN: Most of those measures
8	that came in through CAMI were all parent self-
9	report as part of a special survey. This one is
10	not?
11	DR. FOX: This one is not.
12	DR. BURSTIN: And it is still owned by
13	Oregon, and they just Elisa probably could
14	finish the story, then, of what happened.
15	DR. FOX: So, they did not submit it
16	in the pediatric measures for measure re-
17	endorsement because they didn't have the required
18	testing. They weren't able to do the required
19	testing.
20	MS. GORHAM: So, the note that I have
21	for this is the measure lost endorsement because
22	the developer did not have the resources to test

and maintain it. The previously-endorsed version
 isn't up to current standards, and they did not
 have the ability to test it right now, so
 withdrew it from consideration.

5 MS. MUNTHALI: Yes, and just to add a 6 little bit of context to that, this measure was 7 reviewed in our Health and Well-Being Project in 8 2016, so just last year. And we did try to work 9 with the developer. And as Shaconna said, they 10 don't have the resources right now to maintain 11 it.

12 And what we do typically in this 13 situation is we will put the measure out there to 14 see if any other developers that we work with --15 we work with hundreds of developers to see if any 16 of them would like to pick it up. And we didn't 17 hear from anyone.

So, I think that was part of the conversation when Helen and I were out of the room, is, you know, perhaps somebody else would be interested in maintaining this measure, but we haven't heard yet. It has been almost, I think,

about a year since it has lost endorsement. 1 2 DR. FOX: Yes, and then, we encouraged the developer to submit to the Pediatric Measures 3 4 Committee that met in the fall, and that was the 5 other followup, yes. And so, what we could 6 MS. MUNTHALI: do, even though they are not maintaining NQF 7 8 endorsement, it does not mean that they are not 9 maintaining their measure for their own needs. 10 And so, we may be able to find that out. And I 11 know there is a strong preference for NQF 12 endorsement, endorsed measures in the core sets, 13 but we could find that out for the group, if that 14 would work as well. So, I think, to 15 CHAIR ANTONELLI: 16 clarify, I am trying to process what you were 17 saying before. You are suggesting that we do an 18 up/down and the commentary serve as the condition 19 itself, yes? Yes, okay. 20 I can't remember, Amy, if somebody 21 seconded your -- okay. All right. So, then, I don't know if the Chair is allowed to make a 22

1

2

3

4

5

motion. Yes.

So, basically, then, I am going to follow Debjani's lead suggestion which is that we vote up/down on this, but that the commentary serve as the condition.

And I do want to remind people, to the 6 7 degree that the commentary would say it needs to 8 be NQF-endorsed, that's not really the end-game 9 here, right? The loss of stewardship implies 10 maintenance, et cetera, et cetera, those are 11 highly aligned, but they are not the same thing. 12 In fact, I would make an editorial comment. The 13 fact that such an important measure doesn't have 14 resources attached to it says more about the 15 country's ethos than it does necessarily about 16 the underlying science. So, that is the elephant 17 in the room. So, nobody has to check their souls 18 at the door. This is a big deal. So, let's make 19 sure the commentary gets done well and gets done 20 right.

21 And I will end my comment by coming 22 back to what Karen said. CMS does not need to

> Neal R. Gross and Co., Inc. Washington DC

www.nealrgross.com

1 have NQF-endorsed measures to have measures in 2 the core set. So, would somebody like to second the 3 motion that I just made? 4 5 Andrea seconds? MEMBER BENIN: I'll second it. 6 CHAIR ANTONELLI: Okay. All right. 7 8 So, do we need to ask about coffee? 9 (Laughter.) 10 MS. KUWAHARA: Because we used the 11 clickers yesterday, I think we can skip over that 12 question. 13 (Laughter.) 14 And we can move straight into Measure 15 No. 1448. This is developmental screening for 16 the first three years of life. If you would like to see this measure 17 18 removed, please select 1, yes, or 2, no. 19 CHAIR ANTONELLI: And somebody with a 20 vote left. 21 MS. KUWAHARA: Yes. 22 CHAIR ANTONELLI: Do we have her vote?

1	
1	MS. KUWAHARA: Yes. Ann Greiner
2	stepped out of the room, but she gave us all of
3	her votes
4	CHAIR ANTONELLI: She did?
5	MS. KUWAHARA: and staff will be
6	submitting them via the system.
7	CHAIR ANTONELLI: Okay. Thank you.
8	Okay.
9	MS. KUWAHARA: Yes.
10	(Vote.)
11	CHAIR ANTONELLI: Mine went
12	flatlining, too.
13	(Laughter.)
14	Do you guys have any Epi?
15	(Laughter.)
16	MS. KUWAHARA: Maybe we should have
17	done that coffee question.
18	All right. So, it looks like a number
19	of us are flatlining over here. So, why don't we
20	move to a hand vote?
21	CHAIR ANTONELLI: May I have the Chair
22	privilege of taking a vote to see if people are

1 comfortable with a hand vote? 2 MS. KUWAHARA: Sure. CHAIR ANTONELLI: Is that okay? 3 **All** 4 right. 5 And Dr. Smith is not a voting member, right, because she is federal? 6 7 MS. KUWAHARA: Yes. 8 CHAIR ANTONELLI: Okay. So, for 9 people in the room, this is not a vote on the This is a vote on whether we're 10 measure. comfortable, given the fact that all of our 11 12 clickers are flatlined, are we comfortable with a 13 hand vote? All that are comfortable with hand 14 15 vote show your hand. 16 (Show of hands.) 17 We need to count? Okay. 18 MS. KUWAHARA: And to answer you 19 question, we need 9 for a quorum. 20 So, I will be voting on Ann's behalf. All of those who would like to see 21 22 this measure removed for 1448 please raise your

hand. 1 2 I don't believe that there is a condition with this measure. 3 4 DR. BURSTIN: With the comment. 5 CHAIR ANTONELLI: Yes. (Show of hands.) 6 7 MS. KUWAHARA: And those who vote no? 8 (Show of hands.) 9 So, what's the final? 10 So, 7 yes and 6 no. 11 DR. BURSTIN: It sounds like to 12 reflects your conversation, I think. CMS has 13 heard the discussion. I don't know that it 14 reaching 60 percent or not is going to 15 necessarily change. 16 And again, we would be happy to work with Karen and her team to see if we might be 17 18 able to find somebody. Particularly, I don't 19 know if there are any available dollars even to help them do the minimum amount of testing it 20 21 sounds like they would need to do to bring it back in. 22

1	Seven to 6 is kind of split. It is
2	pretty obvious it is not 60 percent.
3	CHAIR ANTONELLI: Could staff tell the
4	Task Force what the outcome is, please?
5	MS. KUWAHARA: Yes. So, it was 7
6	voted to remove and 5 I'm sorry 6 voted not
7	to remove. Therefore, 54 percent voted to
8	remove.
9	CHAIR ANTONELLI: But it has to
10	achieve 60 percent?
11	MS. GORHAM: So, therefore, the Task
12	Force will not be recommending to remove this
13	measure because you had to have greater than 60
14	percent.
15	DR. BURSTIN: But, again, the
16	commentary here is the most important piece of
17	it, and I think it has been heard loud and clear.
18	CHAIR ANTONELLI: Yes.
19	Helen, thank you for coming in.
20	And, Debjani, thank you for the
21	suggestion. And thanks to the Task Force.
22	Okay. One down and three to go.

1	What's next, May?
2	DR. NACION: 0471.
3	CHAIR ANTONELLI: 0471. We're not
4	moving to a vote. We're in a discussion for
5	this.
6	Actually, let's start with Amy. Then,
7	we will go to Carol.
8	MEMBER POOLE-YAEGER: So, I just
9	wanted to ask a question. Again, since the Joint
10	Commission reports on this on a hospital level, I
11	just don't know the logistics of getting it, you
12	know, in the short-term getting it collected.
13	Because I agree that it is a good measure to
14	have. It is probably the best C-section measure
15	that we have.
16	You know, we do try to work with
17	providers with high C-section rates, but, overall
18	C-section rate is really not a useful measure.
19	So, this at least gets to first-time moms, term,
20	head-down, probably shouldn't have a C-section,
21	you know, in many cases. And the numbers are
22	really high in that group, and you would think,

1	well, why is this happening?
2	So, personally, I like the measure,
3	but I just was wondering if, you know, again,
4	from the discussion perspective, recognizing that
5	it is difficult to obtain, hopefully, somebody
6	will hear that we would like a way to get it a
7	little more easily than it is now.
8	CHAIR ANTONELLI: Thanks.
9	MEMBER SAKALA: So, just three more
10	points that I would like to share with you.
11	First of all, we do have a national
12	benchmark for this measure. I think that is
13	really important, that Healthy People 2020 has a
14	benchmark, and that is being used in California
15	by I can't think of the Exchange name now.
16	And they have set some standards for that, and
17	100 hospitals in California are using this
18	measure as a QI effort and there is a toolkit to
19	do that.
20	Second, it is first births and women
21	who have a Caesarian; 9 out of 10 will go on to
22	have another Caesarian. So, another child health

issue is the hazards of intrauterine development in a scarred, damaged uterus. And we have increased rates of stillbirth, and the children in future pregnancies face some pretty severe hazards, especially as those scars accumulate. So, that is another relationship to us.

7 And then, finally, our proven health 8 analytics, we Commissioned a report a few years 9 ago that was adjusted to national costs, and the 10 payments made on behalf of all maternal/newborn 11 care are about 50-percent higher, whether it is 12 Medicaid or commercial, with a Caesarian birth 13 relative to a vaginal birth.

14 So that, when we look at our valuebased care opportunities, that is where we can 15 16 pick up resources to do the good things, to do 17 care coordination and better referrals, and all 18 kinds of things that are not getting done now 19 because that intrapartum phase of care with its 20 high Caesarians and other technology-intensive 21 stuff that many women don't need is sucking up so 22 many resources. So, it really has a role in

> Neal R. Gross and Co., Inc. Washington DC

1

2

3

4

5

	1
1	where we need our maternity care system and
2	healthcare system to go.
3	Thank you.
4	CHAIR ANTONELLI: Thanks, Carol.
5	Amy? And then, Kathryn.
6	MEMBER RICHARDSON: So, agree with all
7	of the bad stuff from unnecessary Caesarians. My
8	question is, from the state perspective, what can
9	you do about it at the state level versus what
10	the Joint Commission can actually do to move the
11	needle?
12	There is a reason that the states
13	aren't collecting it. And so, that link between
14	the measure and what you can do with the outcomes
15	of the measure, that is what I am searching for.
16	It seems to me the locus of control is with the
17	Joint Commission.
18	CHAIR ANTONELLI: Helen?
19	DR. BURSTIN: I did reach out to David
20	Baker yesterday he is the Executive Vice
21	President of the Joint Commission just to see
22	if there was a possibility of bringing these data

in. They don't get patient-level data at the
 Joint Commission. So, they couldn't actually
 help here.

4 So, I think it is back to what CMS 5 might be able to do internally, because this is 6 on the IQR, right, possible IQR? So, it is 7 already a measure submitted through the Inpatient 8 Quality Reporting Program. And one question 9 might be, internally, can you try to pull statelevel data from that, if we can be helpful here? 10 11 DR. MATSUOKA: Yes, we're looking into 12 that. Yes. 13 DR. SMITH: Yes, I just sent an 14 inquiry and I'm waiting back to hear -- this is 15 Marsha -- to see if that is possible. 16 CHAIR ANTONELLI: So, Karen, can you 17 say a little bit more detail on that? Because I 18 think that what you and Helen and the voice from 19 above just said something very important for us 20 to hear, and I would like the group to hear it. So, the Joint 21 DR. MATSUOKA: 22 Commission measures are a good example of -- and

I think to an earlier speaker's point -- it's the 1 2 rare setting where you are only seeing Medicare patients or Medicaid patients, commercial 3 patients. In many settings of care, not just 4 5 hospitals, but, you know, school nursing facilities, home healthcare providers, they are 6 7 seeing a broad array of patients from many 8 different payer sources.

9 And it turns out that different parts 10 of CMS are collecting information, and it is 11 possible that we are collecting information and 12 discarding things that aren't relevant to the 13 given center within Medicare. So, this is what 14 we are exploring. We don't know whether there is 15 truth to that or not.

But, just as an example, we know that because this measure and all the PC measures are on the hospital and patient quality reporting activities; that the information is being submitted to CMS in some form or fashion. So, our next step is to work internally with CCSQ to see, is there some mechanism by which we can

start to attach a flag for payer source, to come 1 2 at a state and payer level number on this kind of measure? 3 4 But you can imagine the same thing could be said for skilled nursing facilities. 5 Oftentimes, bennies come in starting out as a 6 Medicare patient, but they become a long-term 7 8 patient; they become Medicaid. 9 So, a lot of the kind of reporting is 10 the same for the patients at the nursing facility. It's just that we only report on a 11 12 subset of that. So, this is what we are just 13 now, literally starting yesterday, looking into. 14 So, hopefully, coming back next year, we will have something to report about that. 15 16 CHAIR ANTONELLI: Thank you. 17 Kathryn? And then, Rachel, I thought 18 I saw you come up and, then, you went down? 19 Okay. All right. Kathryn? 20 MEMBER BEATTIE: Just in response to 21 what the state level can do, I know --CHAIR ANTONELLI: Lean in a little 22

www.nealrgross.com

closer.

2	MEMBER BEATTIE: I know, for
3	example, at the State level in Washington, it is
4	part of the pay-for-performance program within
5	the Medicaid system. And that had a big impact
6	on how that measure was picked up by commercial
7	networks in their pay-for-performance, because it
8	was an expectation.
9	With reference to the relevance to the
10	child core set, I did look up some data and,
11	actually, it was about the increase in NICU
12	admission rates, the higher use of oxygen
13	supplementation, and extended length of stay.
14	And some of those metrics were almost double for
15	kids who had had C-section versus a VBAC. So, it
16	really does have a big impact on our children,
17	both their healthcare and their newborn period,
18	as well as outcomes and, then, of course, the
19	efficiency of care we deliver.
20	MEMBER LA CROIX: We also have
21	included for some of our provider-level
22	incentives that our health plans are offering to

providers in their network, we do have looking at 1 2 reduced C-section rates, especially for OB/GYNs, as a possible pay-for-performance or incentive 3 payment measure. But, also, at a state level 4 5 there is the possibility of not just for C-sections in general, but look at not paying for 6 7 elective C-section deliveries and making some of 8 those policy changes to support health plans in 9 having those policies and not reimbursing for those elective non-medically-indicated 10 11 C-sections. So, there are some policy things 12 states can do around that. 13 CHAIR ANTONELLI: Lindsay? 14 MS. COGAN: So, that is a tool that we have employed for early elective delivery that 15 16 you could think about for C-section. 17 Just a caveat. So, I have been asked 18 a lot about this measure lately, especially in 19 the value-based payment space. And I acknowledge the risks of sort of the child health as a 20 21 result. But I also want to put some context that 22 this measure is relatively low in the Medicaid

population in New York. 1 So, we're looking at 2 statewide rates of about 13 or 14 percent. So, it is getting pretty low. 3 We've done a lot in this space. 4 It 5 used to be double in commercial what it is in Medicaid. So, there has been a lot of work in 6 7 the commercial space as of late. So, when people come to me with this 8 9 measure, my first inclination is it's not really a Medicaid problem; it is really it used to be a 10 commercial problem. 11 12 So, I just want to kind of provide 13 that level of context around the measure, that is 14 it getting really lower and lower every year. So, just from that state-side perspective. 15 16 (Question asked off-microphone.) 17 MS. COGAN: I don't know that I could 18 answer that question with certainty, but it is 19 costly. And so, costs often can drive changes in 20 behavior. So, I think the attention that has 21 gone to things like early elective delivery and 22 this move of states just not to pay for things

anymore could be an alarming trend that people 1 2 not want to change their behavior. But I don't know the -- I can't answer that question. 3 4 CHAIR ANTONELLI: So, at the risk of 5 putting you on the spot, I will. (Laughter.) 6 7 If this was pulled from the core set, 8 what would happen to 13 percent? North? South? 9 No difference? Or are you making the case that there are other things being tracked that would 10 11 actually continue to maintain or drive that 12 trend? Whether or not this 13 MS. COGAN: 14 measure is in the core set hasn't influenced us as a State on where we think the movement is. Of 15 16 course, we want parsimony in sets. So, I don't 17 know where else this is in other sets. I don't 18 know if anybody can answer that. Besides the 19 child core set, is it in your maternity set? So, 20 you have a maternity core set, too, correct, at 21 the federal level? 22 DR. MATSUOKA: Yes.

1	MS. COGAN: Yes?
2	DR. MATSUOKA: It is the maternity
3	core set and, to Carol's point, we have developed
4	those to the public/private alignment issues. We
5	have been working with CCSQ. They have an AHIP
6	collaborative to do some public/private
7	alignment. So, internally, we have been doing
8	Medicaid/Medicare alignment, and this measure is
9	on the OB/GYN list. So, it is in several
10	different federal reporting programs.
11	CHAIR ANTONELLI: Thanks.
12	Kim? And then, Carol.
13	DR. ELLIOTT: My only comment is that
14	I think that most states would report it, but
15	there are very similar things like the elective
16	delivery, which gets to a lot of the root of what
17	they're trying to address. And then, there's the
18	cost factor. It is really an expensive measure
19	to collect at the state or the health plan level
20	because it is chart review.
21	MEMBER SAKALA: Nobody in maternity
22	care would say this measure is topping out.

Twenty-three point nine is the benchmark for 1 2 Healthy People 2020. And there is a huge variation and lots of states and facilities above 3 4 that rate. 5 As far as fully elective Caesarians, we have looked at that in our National Listening 6 7 to Mothers Surveys, and that was initially the 8 People are clamoring for this and it's idea. 9 People are giving a code for it that casual. 10 they believe, with very rare exception, it needs 11 to happen. 12 Now the elective delivery really was 13 about waiting to 39 weeks and, then, it is a 14 green light and there is almost a stampede in 15 many settings. Okay? So, that helped people 16 wait, but didn't deal with the inductions and

17 Caesarians that are happening in many contexts.
18 So, that would be really a new measure to say
19 wait to a certain point beyond 39 weeks, for
20 example. So, I just want to share that.
21 CHAIR ANTONELLI: Let's do Terry, then
22 Amy.

	ц И
1	MEMBER ADIRIM: No, I just wanted to
2	emphasize, I mean, I hear from our state
3	colleagues that this is an expensive
4	intervention. And so, avoiding it, C-sections,
5	is very important for that basis and, also, for
6	the health of the mother and the child.
7	But it still strikes me that this
8	would be better on the adult core set, since it
9	directly affects health care of the woman. So, I
10	think that is what I am sort of stuck on, the
11	fact that it is on our core set and not on the
12	adult core set. I am having a little trouble
13	with that.
14	MEMBER RICHARDSON: So, I would
15	actually like to ask for a clarification and,
16	then, may modify my motion. Did I just hear that
17	this actually sits in another CMS core set, so
18	that it is redundant?
19	DR. MATSUOKA: Being a core set means
20	that, for that given program, it is being
21	collected. So, in this particular case, let's
22	say we are talking about the Medicare inpatient

They have all the Joint Commission, the 1 program. 2 PC series in there, but they are reporting it on the Medicare providers, the patients who get 3 4 their care through Medicare providers. There is 5 just a small number. But, nevertheless, that is 6 what they are measuring. 7 So, what this measure would be is this 8 measure but for the Medicaid population at the 9 state level. So, the fact that a measure sits on 10 different core sets is more a signal of alignment 11 as opposed to duplication of effort. 12 MEMBER RICHARDSON: So, may I modify 13 my motion? Is that permissible? 14 So, my modification would be that it is taken out of the core child set after a 15 16 recommendation is adopted to move it to the adult 17 No? We can't, conditional on moving it to set. 18 -- conditional on its being considered for -- no? 19 Who's going to act on it? What's the right 20 context for it? So, again, I'm not 21 CHAIR ANTONELLI: 22 going to make your motion, but what you're

looking for is, if it is not in the child core 1 2 set, what is the line of sight, so that it is somewhere that is meaningful? 3 4 MEMBER RICHARDSON: In the right place. 5 6 CHAIR ANTONELLI: Yes. Okay. 7 Karen, would you like to comment, 8 please? 9 DR. MATSUOKA: So, this is another one 10 of those strange things about the history of these core sets. And it alludes to how the two 11 12 different core sets had a different origin point. 13 So, initially, we only had the child core set. 14 ACA added the adult core set. That sometimes describes why measures sort of landed in one set 15 16 or the other. 17 I think Lucretia is on the phone and 18 can say more about the history of why this 19 particular measure landed on the child core set. 20 It could be as simple as this is recognized as 21 being very important from the very beginning. We only had a child core set to begin with and it 22

1

landed there.

2 It is not to say that, in terms of implementation and use -- I mean, I think we 3 4 should hear from the state perspectives. But, 5 certainly at the federal level when we are looking at this measure, we are not saying, you 6 7 know, it's on the adult core set. And so, 8 therefore, we're targeting like adult healthcare providers. 9 That's not it at all. It is, is it 10 an important measure to measure? If it is in the 11 child core set, is there some link to child's 12 care outcomes, which there are? So, is there a link that we can at least make to the fact that 13 14 it is important for child health care. And if it is, typically, we will use it, looking at that 15 16 lifespan perspective that Lucretia talked about 17 yesterday. 18 So, here, too, I would say, you know,

18 I would say, you know,
19 I would worry less about where the measure has
20 landed. I think we will in the future look
21 towards rationalizing where measures land. I
22 don't think that should necessarily affect the

way you vote on the measure. So, know that if 1 2 you vote for this measure, it will be used to reduce the rate, knowing that it is important for 3 both the mother's health, but also for the 4 5 child's health. Certainly at the federal level we don't think about -- you know, we think about 6 the entire lifespan. 7 So, reformulation or 8 CHAIR ANTONELLI: 9 are you good where we are? MEMBER RICHARDSON: Well, actually, 10 11 what I'm thinking is probably withdraw my motion. 12 CHAIR ANTONELLI: Withdraw the motion 13 for removal? 14 MEMBER RICHARDSON: Removal. 15 CHAIR ANTONELLI: Okay. I don't think 16 we have to vote on that because it was her 17 motion. Okay. 18 Other Amy? 19 MEMBER POOLE-YAEGER: I was just going 20 to make a comment about what you can do around 21 it. I think some of the things that we're looking at are some payment reform. 22 I'm a

pediatrician, right; I'm not an OB. But, from 1 2 what I hear from my OB colleagues, trying to take -- how should I say this? -- the convenience of 3 4 doing a C-section versus sitting in a hospital 5 and waiting for somebody to labor through sometimes will win over. You know, again, nobody 6 7 dies from a C-section. So, like there are some 8 outcomes that happen when you do that. Right, 9 right. So, the idea of not paying hospitals 10 11 or physicians more for a C-section than a 12 vaginal, if you're making bundle payments, that 13 is basically the same whether it is a vaginal or 14 a C-section. Just for the delivery is something 15 we are tossing around. I think probably the 16 states could toss around something. I mean, we 17 would be interested in the states tossing around 18 something like that. I think that might be 19 something that would be effective at driving that 20 down. So, Rachel, I see 21 CHAIR ANTONELLI:

22

Neal R. Gross and Co., Inc. Washington DC

that your card is up, but I just want to make an

-- it's not up? Okay.

2	All right. Since Amy has withdrawn
3	the motion to consider removal of 0471, I am
4	going to ask, does anybody want to make that
5	motion? Otherwise, I want to stop the
6	conversation and move on to the next measure.
7	(No response.)
8	Okay. Next
9	DR. BURSTIN: Just one general comment
10	I think would be helpful for us, as we think
11	about the overall report. In both the child and
12	the adult set, having sat through several of
13	these days, this issue of what to do with
14	hospital-based measures is something I think
15	oftentimes people get tripped up, not because the
16	measure isn't important, but how incredibly
17	difficult it is to get provider-level data
18	stratified by payer.
19	CHAIR ANTONELLI: Yes.
20	DR. BURSTIN: And so, it just feels
21	like that is an opportunity for us to think about
22	it's not so much the measure; it is the

mechanism to gather the data, and that seems like a place where I hope the report from this Task Force would be pretty clear; that is an issue we need to resolve -- and Karen is clearly shaking her head, for those on the phone -- as being a really important piece of this.

7 Because the data are being routinely 8 collected. It is a core measure of the Joint 9 Commission. It is in the IQR, although, oddly, only for Medicare, which is strange. But it's 10 11 being collected at every hospital in America, as 12 Carol knows. So, how hard could it truly be to 13 have payer-level data to bring it up at the state 14 level, is something I think needs to be explored.

CHAIR ANTONELLI: Yes. 15 You are so 16 much more eloquent than I, but if the staff could 17 be sure to include that, even though we removed 18 the motion to remove this measure, I think this 19 is really a critical statement for the Child 20 Health Task Force. This is really important. 21 Figure it out, CMS. You have our full blessing. 22 (Laughter.)

> Neal R. Gross and Co., Inc. Washington DC

1

2

3

4

5

1	ц — Ц
1	And we don't want to burn real estate
2	in the child core set if somebody else is doing
3	it. So, I mean, that is parsimony. That is
4	alignment. It's synergy. It is using us to
5	affirm the value of this. But that spirit is so
6	critically important.
7	DR. BURSTIN: Right. And I don't want
8	to put all the emphasis here on CMS, either,
9	right? So, the Joint Commission, the American
10	Hospital Association; as she pointed out, AHIP
11	and CMS have this measure on the core set; ACOG.
12	So, there is an opportunity here for a
13	meeting of the minds.
14	CHAIR ANTONELLI: Right.
15	DR. BURSTIN: And you can say we live
16	in a consensus world. There should be a solution
17	for these hospital-based measures of import to
18	Medicaid that could make this work.
19	CHAIR ANTONELLI: Right. Walking the
20	talk of alignment, I love it. Thank you.
21	Okay, 1365, we have a motion on the
22	floor to remove. Open for comments, questions.

1	You should just leave your card up.
2	(Laughter.)
3	MEMBER POOLE-YAEGER: I had to say the
4	condition to replace, right? So, can we add that
5	in there.
6	CHAIR ANTONELLI: Yes.
7	MEMBER POOLE-YAEGER: Yes.
8	CHAIR ANTONELLI: Absolutely. Now is
9	the time.
10	MEMBER POOLE-YAEGER: Right. Okay.
11	So, yes, I do want to make sure we replace with
12	the other more encompassing measure.
13	CHAIR ANTONELLI: Yes. And can we
14	actually have a number? Or can the staff provide
15	the number that Amy has got in mind?
16	Okay. So, for the sake of due
17	diligence, would we put 0418 up, so that people
18	see what we're removing and we're potentially
19	promoting?
20	MS. GORHAM: So, this measure was
21	discussed on day one by the Adult Task Force. It
22	is currently on the Adult Task Force. But the

Neal R. Gross and Co., Inc. Washington DC

facts for the measure, it includes patients age 12 and older.

3 CHAIR ANTONELLI: So, in fact, this is 4 a clarifying question. I'm not going to make 5 your motion. So, your motion was to pull the 6 existing measure and replace it with this one.

7 My question is for the staff. Rather 8 than having that be a condition, can we vote one 9 down and potentially promote inclusion of another 10 one? So, in other words, uncouple the 11 conditionality and just do it separate votes? Is 12 that acceptable? Okay.

So, back to you, Amy. Would you like
to potentially reformulate your motion? Yes,
essentially, remove the conditionality --

MEMBER POOLE-YAEGER: Okay.

17 CHAIR ANTONELLI: -- and you could 18 actually make -- you know, then this would be a 19 second motion. And if you're afraid that, you 20 know, if we vote one down and nothing gets -- you 21 can go in either order. So, I will give you the 22 prerogative.

1

2
MEMBER POOLE-YAEGER: Yes. Okay. So,
I move that we add the NQF 0418 measure to the
child set. Down to the age of 12 is already in
the adult set. And we are going to remove my
condition from
CHAIR ANTONELLI: Actually, let's
leave that there.
MEMBER POOLE-YAEGER: Okay, yes.
CHAIR ANTONELLI: Let's leave it as
that motion.
MEMBER POOLE-YAEGER: Okay, yes.
CHAIR ANTONELLI: Is there a second to
include 0418 in the child core set? I'm looking
for a second.
MEMBER BEATTIE: Second.
CHAIR ANTONELLI: Is that a second?
MEMBER BEATTIE: Yes.
CHAIR ANTONELLI: It is? Okay. So,
the motion has been seconded. We'll come back to
the other one. Let's start with this. So, open
for discussion for promoting 0418 into the child
core set.

I	
1	Kathryn, you didn't have a comment?
2	That was just flagging? Because you were ahead
3	of Deb if you had a comment.
4	MEMBER BEATTIE: I was seconding, but
5	I can comment as well.
6	CHAIR ANTONELLI: All right. So,
7	let's let Deb go first. And then, you are next.
8	Go ahead.
9	MEMBER KILSTEIN: Just a question. If
10	staff could just kind of go back and confirm what
11	the conversation was at the adult core measure
12	meeting, because this did get discussed?
13	DR. BURSTIN: While they are looking,
14	a lot of discussion was around the fact that the
15	U.S. Preventive Services Task Force requires not
16	just depression screening, but depression
17	screening with a referral for followup or some
18	action. And that was the logic of this measure.
19	And I believe it stayed in the adult core set.
20	Yes, it did.
21	MS. MUKHERJEE: Yes, and they said
22	that followup should technically be beyond the

initial followup. It just shouldn't be one. It should be six months, one year, things like that. And USPTF, they talked about that and about how they only endorse measures that screen and, then, follow up.

And they said that PHQ-9 is not 6 collected in claims. That was one of the other 7 8 discussions in keeping it. And for now, they 9 said this is sufficient as a core set measure, 10 but, technically, they would like to see 11 something that has a lot more followup. And it was one of those, you know, this is good for now, 12 13 not necessarily the perfect. That was the 14 decision.

DR. BURSTIN: Now that Debjani said it, there was also discussion of whether you could move to a measure of actually depression remission as opposed to looking at patientreported outcome and seeing improvement, but, for now, left this in place with an eye toward the future of looking more at remission.

22

(202) 234-4433

1

2

3

4

5

CHAIR ANTONELLI: Yes.

Neal R. Gross and Co., Inc. Washington DC 183

www.nealrgross.com

1	MEMBER KILSTEIN: And that was my
2	recollection, but there was a lot of commentary
3	to CMS around this measure. So, I just wanted to
4	make sure everyone understood that.
5	MEMBER BEATTIE: So, I'm really
6	thrilled to have this added as it is an AP
7	recommendation down to the age of 12. Some of
8	the nuances for inclusion for consideration with
9	CMS is how we define the standardized test;
10	what's appropriate. PHQ-9; for adolescents, the
11	PHQA versus the PHQ-2, is that enough? How do we
12	identify what adequate followup is and when
13	followup is indicated?
14	At my own organization, there was
15	extensive discussion, well, on the PHQ-9, do you
16	need a score of 6 or a score of 9 to count as
17	positive? I think some of those details need to
18	actually be included in the specifications, so
19	that we can drive consistency and make sure that
20	it really makes a difference. So, is a 6
21	important or just 9 out of 30 on a PHQ-9? Those
22	are things that aren't currently in the

specifications. It would be useful moving 1 2 forward. Thanks. 3 4 CHAIR ANTONELLI: So, at the risk of 5 recognizing you're opening a can of worms, we are 6 not in a position to tweak specifications. So, 7 are you arguing against the motion that you 8 already seconded? 9 MEMBER BEATTIE: No. No, I'm in 10 support of the motion that I'm seconding. 11 However, it has repeatedly been stated that the 12 commentary is taken into consideration. CHAIR ANTONELLI: 13 Yes. 14 So, I just wanted to MEMBER BEATTIE: 15 state that for the record. Thanks. 16 DR. BURSTIN: And we can certainly take that back to the Behavioral Health 17 18 Committee. 19 CHAIR ANTONELLI: Yes. DR. BURSTIN: Harold Pincus co-chairs 20 that, as a matter of fact. So, we can certainly 21 22 bring that and --

1	CHAIR ANTONELLI: Yes.
2	DR. BURSTIN: see whether there is
3	additional work to be done. That's a good
4	suggestion.
5	CHAIR ANTONELLI: Good. Good. Okay.
6	So, for the sake of time management, I
7	don't have a sense that there's very much
8	negative energy in the room on this measure. So,
9	would you like to tee it up for the motion on the
10	oh, we're still using our hands, aren't we?
11	That's right.
12	So, 0418 being recommended for
13	inclusion for the child core set.
14	MS. KUWAHARA: So, those who would
15	like is there a question? Those who would
16	like to support inclusion of 0418, screening for
17	clinical depression and followup, please raise
18	your hand.
19	(Show of hands.)
20	So, 100 percent of the 12 voting
21	members in the room voted to support 0418 into
22	the child core set.

I	۲۲ ۲۲
1	CHAIR ANTONELLI: Thank you.
2	And then, Amy, do you want to come
3	back to
4	MEMBER POOLE-YAEGER: I will repeat my
5	motion to remove I forget the number
6	CHAIR ANTONELLI: 1365.
7	MEMBER POOLE-YAEGER: 1365, which
8	was just more of a subset of this measure to kind
9	of reduce the duplications.
10	CHAIR ANTONELLI: Does anybody feel
11	the need for discussion on 1365? Otherwise, I'm
12	going to move us to a vote. Was that an "Um"?
13	(Laughter.)
14	MEMBER ADIRIM: So, I was just going
15	to say, just because we added this one doesn't
16	mean that you have to remove the other, right?
17	So, it's uncoupled? I just want okay.
18	CHAIR ANTONELLI: Oh, yes. That's why
19	I split them. These are two separate votes.
20	MEMBER ADIRIM: Right, right. No, but
21	I don't want people to think, just because we
22	voted that one in, that you necessarily have to

Neal R. Gross and Co., Inc. Washington DC

1 the suicide risk assessment, right? Okay, 2 suicide --3 CHAIR ANTONELLI: No. As I said, 4 these are two separate votes, period, hard stop. 5 Now we're on to 1365. Motion on the floor is to remove this. 6 7 We do have two people that want to make comments. And I apologize, I didn't see 8 9 whose card went up. So, honor system, whoever 10 was first, jump in. 11 So, I was just going MEMBER BEATTIE: to comment that this specific 1365 is for a very 12 13 small subset of the population, and that was, I 14 believe, the reason behind considering removal of it from the subset, because of the small impact 15 16 it would have, where you truly have to have 17 already had the major depressive disorder 18 diagnosis for you to be in the denominator. And 19 presumably, the majority of those children are 20 now identified and receiving care. Because it's, did you assess them when they were in your 21 encounter for care? So, it just is a lower 22

1 impact overall. 2 CHAIR ANTONELLI: Andrea? MEMBER BENIN: Did you want discussion 3 about gaps around these kinds of things now? 4 Or do you want to save that for later? 5 6 CHAIR ANTONELLI: No, I want comments specifically --7 Just specifically? 8 MEMBER BENIN: 9 CHAIR ANTONELLI: -- on the motion to remove 1365. 10 11 MEMBER ADIRIM: I just have a 12 question. So, just because somebody is being 13 assessed for having a depression doesn't 14 necessarily mean they're being assessed for risk 15 of suicide. So, I just want to make that clear. 16 So that they are not the same measure. There may 17 be some overlap. But this is a subset, as was 18 just said, but that suicide is a high-impact 19 thing. I mean, this is people dying. Maybe I 20 come from the ER perspective, but I see a lot of 21 suicide ideations, suicide attempts, and so on, 22 in teenagers. So, I just want to throw that out

1	there.
2	MEMBER BEATTIE: May I ask a
3	clarification, so I understand exactly what the
4	measure is? Is it that you are assessing at
5	every single encounter?
6	So, I have a 15-year-old that on their
7	record they have that diagnosis code. Does that
8	mean that, when they break their arm and they go
9	to the orthopedist, the orthopedist is supposed
10	to complete a suicide what specifically are
11	the encounters? Because I want to make sure that
12	I am understanding exactly what the request is
13	here.
14	CHAIR ANTONELLI: Can you pull the
15	specs up, please?
16	MS. MUKHERJEE: So, the measure
17	description was up there, and it is the same.
18	Percentage of patient visits of those patients
19	age 6 through 17 years with a diagnosis of major
20	depressive disorder or an assessment for suicide
21	risk.
22	The numerator is patient visits with

an assessment for suicide rate, and the 1 2 denominator is all patients for those patients age 6 through 17 years with a diagnosis of major 3 depressive disorder, and there are no exclusions. 4 CHAIR ANTONELLI: So, I would like to 5 call the question? 6 7 Or, Terry, are you --MEMBER ADIRIM: Is there a timeframe 8 9 for this or no? CHAIR ANTONELLI: This is it. 10 Yes. 11 Yes. 12 So, I'm going to ask Miranda to set us 13 up for a vote on 1365, please. 14 MS. KUWAHARA: Sure. So, this is a vote to remove NQF No. 1365, child and adolescent 15 16 major depressive disorder, suicide risk 17 assessment. 18 If you would like to see this measure 19 removed please raise your hand. 20 (Show of hands.) 21 And if you would like to see this measure remain on the core set please raise your 22

1	ц —
1	hand.
2	(Show of hand.)
3	Eight were in favor of removing and 5
4	were in favor of keeping it. So, therefore, we
5	achieved the 60-percent threshold. This measure
6	will be removed from the child core set.
7	DR. BURSTIN: Recommended
8	MS. KUWAHARA: I'm sorry. Recommended
9	for removal.
10	DR. BURSTIN: One state is currently
11	reporting it. That is what that says at the
12	bottom there. It must be pretty hard, huh?
13	CHAIR ANTONELLI: So, plow through,
14	because we are going to do a working lunch in
15	case anybody is doubting that. But I think we
16	have one more measure, the access to primary care
17	measure. I'm going to exercise the prerogative;
18	we are just going to finish out and, then, we'll
19	grab some lunch. Okay?
20	So, can we put it's not an NQF-
21	endorsed measure. So, it doesn't have a number.
22	Can we put the measure up on the screen, please?

1	And I will open for conversation on
2	this measure.
3	Would you like to restate or remind
4	people what your motion was? And then, if you
5	would like to open up the commentary?
6	MEMBER OSBORNE-GASKIN: So, child and
7	adolescent access to primary care practitioners,
8	my motion was to remove it from the child core
9	set. And I think part of my rationale was that
10	the access does not necessarily mean that these
11	patients or these children are visiting the
12	primary care practitioners. There is also geo-
13	access that is done by health plans, and they
14	have to make sure that there are primary care
15	providers within a certain distance or mileage
16	from their populations that they serve.
17	And so, I just had some difficulties
18	sort of crosswalking this to the quality. If we
19	want to look at the quality of care or whether
20	the kids are getting their well childcare visits,
21	that is also addressed in the immunizations for
22	adolescents and adolescent well care, as opposed

to just looking at access, which just kind of 1 2 gives you how many primary care providers, not necessarily how many patients are being seen by 3 4 the providers. 5 CHAIR ANTONELLI: Other questions or comments? 6 7 Amy? 8 MEMBER POOLE-YAEGER: Yes, I would 9 like to see the specs. I don't know this measure perfectly well, but my recollection about how it 10 works is that, you know, it is any visit to a 11 PCP, right, but not a primary care visit? And 12 13 maybe the reason the teenagers -- you know, 14 they're just not sick, right? So, that's why they are not going in and that's why they look --15 16 it is not that they don't have access or have a 17 place to go, to kind of highlight on that. But I 18 am not sure if we can see the --19 MS. MUKHERJEE: So, I have the specs 20 It is the percentage of members 12 months up. 21 and 19 years of age who had a visit with a PCP. 22 The organization reports four separate

percentages for each product line, and the two 1 2 product lines are commercial and Medicaid, and they are reported separately. And it is children 3 12 to 24 months and 25 months to 6 years who had 4 5 a PCP visit during the measurement year. And then, the second is children 7 to 11 years and 6 7 adolescents 12 to 19 years who had a visit with a PCP during the measurement year or the year prior 8 9 to the measurement year. They have continuous enrollment 10 11 requirements in this measure. They have 12 allowable gaps in this measure. And, yes. 13 MEMBER POOLE-YAEGER: Yes. And again, 14 you know, could it be access -- I guess it could 15 be access, but, more or less, if you are not 16 going in for -- you know, teenagers just maybe 17 don't go in for their -- you know, they're not 18 sick very often. So, they are not going in. So, that's why it looks less often. That would be my 19 20 hypothesis, but I'm not sure. 21 MEMBER ADIRIM: Yes, the way I read 22 this measure, it's not necessarily access to

1 primary care; it's access to the primary care 2 practitioner. So, you would still want the chi 3 or the adolescent to have access to a primary 4 care practitioner even when they are sick, for 5 sick visits. I mean, that is the way I read it 6 MEMBER POOLE-YAEGER: Yes, and I 7 agree. But I think what Roanne was saying was 8 that we have the adolescent well care visit 9 measure already, and we know that they don't go 10 in for their well visits. So, are we getting 11 much more from this measure? Then, that would is 12 my question. 13 CHAIR ANTONELLI: Andrea, Amy, and	
 or the adolescent to have access to a primary care practitioner even when they are sick, for sick visits. I mean, that is the way I read it MEMBER POOLE-YAEGER: Yes, and I agree. But I think what Roanne was saying was that we have the adolescent well care visit measure already, and we know that they don't go in for their well visits. So, are we getting much more from this measure? Then, that would implementation. CHAIR ANTONELLI: Andrea, Amy, and 	
 4 care practitioner even when they are sick, for 5 sick visits. I mean, that is the way I read it 6 MEMBER POOLE-YAEGER: Yes, and I 7 agree. But I think what Roanne was saying was 8 that we have the adolescent well care visit 9 measure already, and we know that they don't go 10 in for their well visits. So, are we getting 11 much more from this measure? Then, that would is 12 my question. 13 CHAIR ANTONELLI: Andrea, Amy, and 	
5 sick visits. I mean, that is the way I read it 6 MEMBER POOLE-YAEGER: Yes, and I 7 agree. But I think what Roanne was saying was 8 that we have the adolescent well care visit 9 measure already, and we know that they don't go 10 in for their well visits. So, are we getting 11 much more from this measure? Then, that would 12 12 my question. 13 CHAIR ANTONELLI: Andrea, Amy, and	
6 MEMBER POOLE-YAEGER: Yes, and I 7 agree. But I think what Roanne was saying was 8 that we have the adolescent well care visit 9 measure already, and we know that they don't go 10 in for their well visits. So, are we getting 11 much more from this measure? Then, that would 1 12 my question. 13 CHAIR ANTONELLI: Andrea, Amy, and	
7 agree. But I think what Roanne was saying was 8 that we have the adolescent well care visit 9 measure already, and we know that they don't go 10 in for their well visits. So, are we getting 11 much more from this measure? Then, that would 12 12 my question. 13 CHAIR ANTONELLI: Andrea, Amy, and	
8 that we have the adolescent well care visit 9 measure already, and we know that they don't go 10 in for their well visits. So, are we getting 11 much more from this measure? Then, that would 1 12 my question. 13 CHAIR ANTONELLI: Andrea, Amy, and	
9 measure already, and we know that they don't go in for their well visits. So, are we getting much more from this measure? Then, that would in my question. 13 CHAIR ANTONELLI: Andrea, Amy, and	
10 in for their well visits. So, are we getting 11 much more from this measure? Then, that would i 12 my question. 13 CHAIR ANTONELLI: Andrea, Amy, and	
11 much more from this measure? Then, that would in 12 my question. 13 CHAIR ANTONELLI: Andrea, Amy, and	
<pre>12 my question. 13 CHAIR ANTONELLI: Andrea, Amy, and</pre>	
13 CHAIR ANTONELLI: Andrea, Amy, and	e
14 Deborah?	
15 MEMBER BENIN: As previously	
16 discussed, we have very few good metrics for	
17 truly understanding access, and we are in an	
18 environment where access to services for folks	
19 with Medicaid may become even more compromised	
20 than it already is.	
21 And the only way that we can really	
22 understand access, I think, is probably by	

Neal R. Gross and Co., Inc. Washington DC

www.nealrgross.com

triangulating a number of different metrics around the problem and understanding it by kind of fleshing out the whole circle of the issues. I don't know that there's any one perfect isometric out there that we are going to be able to find.

7 So, I would strongly advocate for us 8 at this point not removing metrics that give us 9 any hope of understanding access, and especially if following a metric over time that may benefit 10 11 that and give us the ability to watch and see 12 what happens. As the environment around us changes, it is critical that we understand what 13 14 is going on, and we are not going to be able to understand that with one little slice of the pie. 15 16 And the pie is multidimensional.

So, I strongly advocate for leavingthis metric in the set.

MS. MUKHERJEE: So, I'm just going to
quickly read out all the different areas where
you could sort of code for this measure, and it
has CPT codes for: office or other outpatient

Neal R. Gross and Co., Inc. Washington DC

1

2

3

4

5

services, home services, preventive medicine, and 1 2 general medicine examinations. So, all of that falls under this measure. 3 4 CHAIR ANTONELLI: Amy? MEMBER RICHARDSON: I just have a 5 I can't tell from this 6 question, please. 7 spreadsheet here. What is the source of these 8 Is this claims data? data? Okay. Thank you. 9 CHAIR ANTONELLI: Okay. Deborah? 10 MEMBER KILSTEIN: I'm just not sure that this measure measures access. 11 I mean, what 12 it does is it tells you, for example, 13 adolescents, they are not getting well care 14 visits. Are they getting sick visits? And then, you will see how many kids are being seen, but it 15 16 doesn't mean that there is an access problem or 17 not an access problem. It just means they 18 weren't sick; they didn't need to go in. 19 But, I mean, I have no problems with 20 the measure as it is. I'm just not sure it 21 actually measures access. 22 CHAIR ANTONELLI: Are you ready for a

1	vote, although I did now maintain the paradigm
2	from yesterday and the conditions, so we know
3	whether this is a dichotomous or trichotomous
4	vote? No conditions.
5	Okay, Miranda. So, we're looking at
6	an up/down.
7	MS. KUWAHARA: So, we are voting to
8	remove the measure child and adolescents' access
9	to primary care practitioners.
10	If you would like to see this measure
11	removed from the core set, please raise your
12	hand.
13	(Show of hands.)
14	If you would like to see this measure
15	remain on the core set please raise your hand.
16	(Show of hands.)
17	Yes, this vote is to remain on the
18	core set.
19	Okay, perfect.
20	So, 1 voting member voted to remove
21	this measure; 12 voted to include this measure.
22	So, the measure will be recommended to remain on

1 the core set. 2 CHAIR ANTONELLI: Thank you, everybody. Operator, can you open the line to see 3 if there's any public comment, please? 4 Ladies and gentlemen, if 5 OPERATOR: you would like to make a public comment, please 6 7 press *, then 1, on your telephone keypad. Again, *1 to make a public comment. 8 9 (Pause.) And currently, we have no public 10 comments at this time. 11 12 CHAIR ANTONELLI: Thank you. 13 Miranda, any in the chat to you? 14 MS. KUWAHARA: No. 15 CHAIR ANTONELLI: Okay. Anybody in 16 the room, public comment? 17 (No response.) 18 All right. So, if the staff can give 19 us directions for the lunch break? I think the 20 food is here. Yes. Okay. 21 Debjani, do you want to tell us? 22 MS. MUKHERJEE: So, let's take a 10, a

	2
1	15-minute. Well, let's take a 15-minute break.
2	And then, we'll do a working lunch back here.
3	So, when it's 1:00, we will be back and do a
4	working lunch for the rest of the afternoon.
5	(Whereupon, the foregoing matter went
6	off the record for lunch at 12:45 p.m. and went
7	back on the record at 1:10 p.m.)
8	CHAIR ANTONELLI: Welcome back,
9	everybody.
10	So, we are going to pivot from pruning
11	to planting, or in this case nominating measures
12	for the child core set. I know the staff is
13	working on teeing things up. So, it will just
14	take another minute or so.
15	(Pause.)
16	Ready? Okay.
17	So, May is going to give us an update
18	on the Pediatric Quality Measures Program
19	measures. Then, we will proceed into a
20	discussion about measures that folks suggested a
21	few weeks back. The staff has done some work to
22	tee them up for discussion.

I	4
1	All right. So, May, if you can
2	proceed, please?
3	DR. NACION: Okay. So, I will just
4	briefly review what PQMP is and measures that
5	have been developed under PQMP.
6	So, the Pediatric Quality Measures
7	Program, PQMP, was established under CHIPRA and
8	intended to improve and strengthen this core set
9	of measures, to generally expand the availability
10	of pediatric quality measures for use by public
11	and private healthcare purchasers, to advance
12	development and innovation around new and
13	emerging quality measures, and to increase the
14	portfolio of evidence-based, consensus-driven
15	pediatric quality measures available to the
16	field.
17	In terms of a breakdown of what has
18	been endorsed and what has not, to date, this is
19	a moving target. So, currently, we have 16 NQF-
20	endorsed PQMP measures. Four are behavioral
21	health, mental health, substance-abuse-type
22	measures. Two are readmission measures, one

patient-reported outcome measure, and one sickle cell measure, as well as eight family experiences with coordination of care measures. So, many of these measures will be discussed today, as Task Force members have recommended them for addition to the core set.

Not listed on this slide, but
development of the child HCAHPS tool also took
place under PQMP. But, since MAP already has the
standing recommendation that this measure be part
of the child core set, it's not listed here.

12 In addition, there are six PMQP 13 measures currently undergoing endorsement review 14 and fall under topics such as appropriate use of 15 antibiotics, asthma, and insurance coverage.

There are a total of 90 PMQP measures available, including perinatal care, child clinical preventative services, management of acute conditions and chronic conditions, patientreported outcomes, duration of enrollment and coverage, availability of services, and medication reconciliation.

1

2

3

4

5

1	As of 2015, 24 measures are under
2	development. I believe later Dr. Mistry can
3	elaborate on any others in development or any
4	other current priorities.
5	MS. GORHAM: So, we actually have
6	Renee here.
7	So, Renee, if you would like to add
8	anything else?
9	DR. FOX: Thank you. And Karen is
10	here as well.
11	And, yes, there are measures that were
12	developed in phase 1. I just wanted to let
13	everybody know that AHRQ, with funding from CMS,
14	has begun phase 2 with Centers of Excellence to
15	look at taking the measures developed by the COEs
16	and testing them, implementing them at the state
17	health plan and provider level, so to look at how
18	useful the measures are, with two key goals of
19	assessing both the feasibility and the usability
20	of some of these measures within the Medicaid and
21	CHIP patient populations, and as well as to
22	support performance monitoring and quality

improvement through both field testing, 1 2 refinement, data collection, reporting on new measures, and use of performance data to define 3 4 QI goals and test multilevel improvement 5 strategies. So, we were hoping to take these 6 7 measures and the work that was done previously, 8 as well as the ongoing work, to sort of bring it 9 to the next level of not just having a measure, but having a measure that is useful at various 10 11 levels. 12 I don't know if people have specific

13 questions about that. The HCAHPS measure, which 14 is the measure that is on our core set, but we don't currently report, one of our grantees --15 16 thank you; I'm sorry, I should have a lavalier 17 mic -- one of our grantees is going to explore 18 that measure and how we can look at it, take it 19 from the hospital measure to a state-reporting 20 measure.

21 MS. GORHAM: Okay. So now we will 22 look at measure review, and these are measures

for potential addition to the core set. 1 2 Next slide. This is a review from yesterday, and 3 4 just a general overview of how the measure is 5 submitted and analyzed. So, as we did yesterday, for those folks who recommended a measure, you 6 7 will be the lead discussant for that measure or 8 measures that you recommended. 9 Again, we discussed the measure selection criteria earlier. We heard feedback 10 11 from the state. And so that, we ask that you 12 take all of that into consideration and, also, 13 whether or not the measure addresses a gap area. 14 Next slide. 15 We discussed the preliminary analysis 16 algorithm yesterday, some of those points, and 17 how the staff used the algorithm in order to 18 assess the measure. 19 Okay, move forward. 20 This is just the specific subcriteria 21 we used for Medicaid. You can move forward. 22

1	Again, discussing vote, but after day
2	two, you all are pros at voting. So, we do not
3	need to discuss that.
4	Again, decision categories you have in
5	front of you, but, again, you are familiar with
6	them by now: support, conditional support, and
7	do not support.
8	Next slide.
9	So, the next several slides, the next
10	three slides to be exact, are the gap areas
11	identified in 2015 and 2016. The asterisk
12	denotes new gaps, newly-identified gaps. And
13	later on in the day, we will really have a good
14	gaps discussion. So, I won't go into detail
15	about the gaps now.
16	But, if we go to slide 333, okay, so
17	this slide, not including the maternal measures
18	and not including the measures that MAP
19	recommended for removal, these are the
20	recommendations, 2015 and 2016, that this Task
21	Force recommended to CMS that were not added to
22	the core set.

I

	а И	21
1	So, 2393, pediatric oral condition	
2	readmission measure and, also, 2797, the sickle	
3	cell anemia measure.	
4	Next slide.	
5	This slide and the next are a list of	
6	measures that were recommended by your peers.	
7	So, the first measure and we will go over each	
8	in detail a little later but the first	
9	measure, 1659, influenza immunization; 2800,	
10	metabolic monitoring for children and adolescents	
11	on antipsychotics; 1354, informed coverage; 3166,	
12	antibiotic prophylaxis among children with sickle	
13	cell anemia, and then, the last, emergency	
14	department visits potentially treatable in	
15	primary care.	
16	Let me just say the two measures with	
17	the asterisk are pending endorsement. So, they	
18	are currently in a project right now.	
19	And then, the next slide, we have the	
20	FECC measures that were recommended.	
21	So, this is a good spot, before we go	
22	into each individual discussion of the measures,	

if you open your discussion guide, there we have
 the specs and, also, the results of the
 algorithm.

4 So, the first measure that we are 5 going to discuss is the 1659. If you click on 6 that measure, it's best if you are in your 7 discussion guide. If you go to your gray tab, 8 you have a button for measure. That is the 9 easiest way to find the measures, I believe, and 1659 is the first measure under care 10 coordination. So, we will give you a little 11 12 while to get there.

(Pause.)

Okay. Andrea suggested this measure.
And so, I will turn it over to her, as the lead
discussant.

17 MEMBER BENIN: This metric is the 18 metric of inpatients who get screened for needing 19 a flu vaccine and receiving a flu vaccine before 20 the time of discharge. This is a metric that is 21 used in other federal reporting areas, and I 22 think in at least one it looks like it is used --

implicit here, it has been used in two other
 federal reporting programs.

It is an opportunity to round out the 3 panel around immunizations as well as providing a 4 5 metric that can address truly preventable admissions down the line and preventable harm to 6 patients. And so, it is an important access 7 point, when children are in the hospital, for 8 them to have their flu shots evaluated and taken 9 a look at. And so, having this on the set would 10 11 round out that process and add this in. It also 12 is, like the other immunization metrics, 13 something of a proxy for access. You know, the downside of it are the issues that have 14 previously been discussed about how it is 15 16 involved in other programs, and people may be 17 getting at this in different ways. I do not know 18 about the feasibility of reporting. 19 I also do know that, in general, the performance on this metric in adult hospitals is 20

22

21

Neal R. Gross and Co., Inc. Washington DC

fairly high, and there has been a lot of work

done in adult facilities to make this metric

pretty high. But there is little to no insight into what this looks like across the board in children's hospitals. And so, there is not a way to really benchmark this metric for children's hospitals. And so, whether this would be a mechanism for that would be interesting.

CHAIR ANTONELLI: 7 I'll open this up, 8 but I actually want to seize the prerogative of a 9 The exclusion about the vaccine question. production gap and distribution gap is intriguing 10 11 to me because I am sort of thinking of this as a 12 population measure. And so, are you familiar 13 enough with the measure to speak to -- and just 14 to be clear, I'm not saying the hospital is responsible for having vaccines that are not 15 16 available, but I am trying to think of this at 17 the level of a population that merits vaccine, 18 and if they don't get it, you know, I am not sure 19 that that is a patient-centered type of a metric. 20 So, comment, please.

21 MEMBER BENIN: Yes. I mean, there may 22 be somebody who knows the idiosyncracies of the

> Neal R. Gross and Co., Inc. Washington DC

1

2

3

4

5

development of this particular metric better than 1 2 I do. I do believe that this stems from the years when there were those pretty massive 3 4 shortages, when you remember everyone was waiting 5 in line. And it has only been in the past few 6 7 years that the recommendation has been expanded 8 to really be everybody six months and older. So, 9 I suspect that that was sort of the legacy from those years, which hasn't happened in a few 10 years, but certainly could again. I think every 11 year the supply is at risk. 12 13 And then, combining in now, we are 14 also recommending it to everybody. So, if there 15 is no vaccine to be had, who are you holding 16 accountable for that? I don't know the answer, 17 but there may be some who actually was involved 18 more in the development. I don't know. 19 CHAIR ANTONELLI: Yes, because I just 20 think if hospital A doesn't have vaccine, 21 hospital B likely wouldn't. And so, that would affect everybody's performance. And it just 22

seems to me that, if your central supply person 1 2 forgot to put the order in on time, that that's not a good reason against that measure. 3 So, I 4 just step back into my share. 5 Terry? Yes, I have one really 6 MEMBER ADIRIM: 7 naive question. Implement of vaccine is not 8 included in any of the other measures, right? 9 MEMBER POOLE-YAEGER: It's in the 10 combo for the first two years of life. 11 MEMBER ADIRIM: Okay. 12 MEMBER POOLE-YAEGER: One of the 13 combos for that. 14 MEMBER ADIRIM: Right. So, yes, I thought so. 15 16 CHAIR ANTONELLI: So, none of us heard 17 that. 18 MEMBER POOLE-YAEGER: Sorry. 19 Immunization is in the CIS measure, the Combo Immunization Series for the infants. 20 There's 21 Combo 1, 2, 3, 4, all the way up to 10. In one of those combos -- I don't remember which --22

influenza vaccine is in there.

1

2	MEMBER ADIRIM: Right. So, I was just
3	kind of curious about the additional benefit to
4	I know this gets at it a different way,
5	vaccination a different way, but about the
6	additional benefit to this measure.
7	As you were talking, the first thought
8	that went into my head is, yes, I would like to
9	have a measure for healthcare providers at
10	children's hospitals. But I was just kind of
11	curious about what your thinking is with regard
12	to the additional benefit to this measure with
13	the other measure that's measuring, that includes
14	influenza vaccines.
15	MEMBER BENIN: Maybe I am not
16	remembering the details of these other metrics
17	well enough, but my understanding is they are
18	truly around your childhood immunization. So,
19	you are up to about age 5-ish between those two
20	metrics and, then, the adolescents.
21	But if you take your chronic who is
22	in our hospitals, right? There is a little bit

of that and, then, there is a lot of your chronic players. And those are your players who are on Medicaid often, and those children may not be captured entirely by your routine vaccination schedules, just because everybody should get one every year, right? So, it is more than just what is in your routine schedule.

8 But I would have to go back through, 9 to your point, Terry, just to confirm that 0038 10 -- I mean, I thought 0038 was the infant one, but 11 I'm not remembering.

12 MEMBER POOLE-YAEGER: So, we have done 13 -- again, you know, I have 23 Medicaid health 14 plans -- we have done a lot of work around flu vaccination rates in our population. And we have 15 16 looked at claims for flu vaccinations. And then, 17 there is also a question in the CAHPS survey 18 about, did your child get a flu vaccine? 19 I can tell you that the rates are 20 vastly different. So, probably half of what is 21 reported in the CAHPS survey is what we get in

claims. So, I struggled with this for a long

Neal R. Gross and Co., Inc. Washington DC

1 Like how do we judge the flu vaccination time. 2 rate of our population? The only thing what I worry about this one is I think it is going to be 3 4 really hard. I don't know that the hospital --5 you know, you're going to have to get into the 6 hospital record to see if they offered flu 7 vaccination. If somebody got a flu vaccine from 8 their provider office report, they won't need one 9 when they are discharged from the hospital. So, I just have a little concern about this. 10 I think flu vaccination is an 11 important one. I'm not sure that that's the best 12 13 one to pick out of all of them from my 14 perspective. But CAHPS, I don't know, CAHPS survey 15 16 results could be one, right? Is that on the --17 DR. MATSUOKA: So, CAHPS, the health 18 plan CAHPS is on both the adult and child core 19 set, but not all --20 MEMBER POOLE-YAEGER: Not all 21 questions --22 Not all plans are DR. MATSUOKA:
reporting those to the states, and if a state is 1 2 a fee-for-service state, they may not be administering it at all. 3 MEMBER POOLE-YAEGER: Yes, got it. 4 5 Okay. Further discussion? CHAIR ANTONELLI: 6 7 Should we vote sometime --8 I just wanted to MS. GORHAM: Sure. 9 highlight, if you just scroll down a little bit more, some of your questions about feasibility 10 11 and that type of thing, we did attempt to answer 12 some of those questions, so highlighted in your 13 discussion guide, and May just highlighted the 14 bullet point. I think it is maybe one, two, three, four down, we talk about feasibility. 15 16 This measure was reviewed in our 17 Health and Well-Being Project. So, we have a 18 little bit of information from the Health and 19 Well-Being Project and from those experts that sat on that standing committee. 20 21 And so, I know that this measure, the evidence for the measure is based on 22

recommendations from ACIP on routine vaccinations.

1

2

I would say that, just as you are thinking and deliberating, this measure did not fall into a gap identified in 2016, but that definitely doesn't mean that you can't consider it.

As far as the Health and Well-Being Committee, this measure was endorsed with reserve status, just because the performance is rather high. And so, kind of narrowing the performance gap was clinically significant, but they did not allow and they did not believe that narrowing the performance gaps was clinically significant.

But, again, we outlined for you just where the measure is currently used because it is in use now. So, that is on your screen.

18 MEMBER BENIN: Do you know, Shaconna, 19 if they were able to identify that this was a 20 problem, that the performance was high for 21 children? Because my understanding is that, 22 while the performance is high overall for

hospitals in the CMS IQR, I don't know that we know the answer for what that always looks like for children; that that in children may be 4 different. I don't know.

1

2

3

5 DR. BURSTIN: We could check the 6 actual submission form and see if they stratify by populations. I don't recall. I think they 7 8 have tended to do race and ethnicity, but it is 9 an easy enough question to try to get answered.

MEMBER BENIN: And the children's 10 11 hospitals would not be submitting to that program 12 So, you wouldn't have that data there. anyway. 13 So, the only mechanism right now where you get this data is through U.S. News and World Report. 14 This is where people put it. 15

16 So, I think we just have to think 17 about what are our sources of how -- for 18 children's hospitals, it is an ORYX metric, but 19 the one place that it gets gathered and sort of 20 looked at globally, if you will, is in U.S. News 21 and World Report. There is not a real context for it in the other discussion. This may provide 22

(202) 234-4433

such a context, the Medicaid side. 1 2 CHAIR ANTONELLI: About how long will it take to get the stratification data? 3 4 DR. BURSTIN: I'm not sure they would 5 actually have enough data if children's hospitals aren't reporting it. So, CMS may not be the best 6 source to find that out. 7 8 CHAIR ANTONELLI: Yes, because what I 9 am grappling with is the inactive endorsement and reserve status with the NQF. Because if that 10 11 decision was made on adult-only data -- okay. 12 Okay. 13 Would you like to make a motion? 14 MEMBER BENIN: Sure. I move that we suggest adding this, you know, for CMS's 15 16 consideration, to add this metric to the panel. 17 CHAIR ANTONELLI: Is there a second? 18 (No response.) 19 I don't see a second. I'll give 20 people another minute or so, since Helen is 21 distracting us. 22 (Laughter.)

Is there a second? Was that a hand? 1 2 If you could speak, please. I'll second, yes. 3 MEMBER GREINER: 4 CHAIR ANTONELLI: Okay. So, the 5 motion has been made to recommend 1659 be advanced to be part of the child core set, and it 6 has been seconded. 7 Comments or questions before we 8 9 proceed to a vote? 10 Amy? 11 MEMBER RICHARDSON: So, if I 12 understand, the previous question is we don't have baseline data to know to what extent this is 13 14 a problem we're trying to solve. Is that 15 correct? Or pediatric data? 16 CHAIR ANTONELLI: We're trying to 17 confirm that. That's what Andrea's belief is, 18 and the staff is going to see if they can pull 19 that up for us. 20 We could put this one on pause, go to 21 the next one, and come back. I'm assuming we are 22 talking minutes and not days. Yes.

Ĩ	2.
1	So, Andrea, is that okay with you?
2	Let's hold this motion on 1659. Let's move on to
3	the next question. We'll come back to this one,
4	and the staff will let us know the affirmation of
5	Andrea's observation.
6	Okay. So, the next one is 2800.
7	MS. GORHAM: So, actually, I think our
8	Chair we're telling people about using the
9	mic, and then, I don't turn mine on.
10	Actually, our Chair Rich and Kim are
11	our lead discussants for this measure.
12	CHAIR ANTONELLI: So, 2800 is NQF
13	endorsement about screening for children and
14	adolescents newly on antipsychotics. The measure
15	steward is NCQA.
16	The description, I'll read it quickly.
17	Percentage of children and adolescents 1 to 17
18	who have had two or more antipsychotic
19	prescriptions and had metabolic testing.
20	The denominator is ongoing treatment,
21	at least two prescriptions for these medications.
22	There's no exclusions. It is administrative

1 claims data.

4

And we wanted to bring this forward
for discussion in this group.

Kim?

DR. ELLIOTT: I think that 5 I agree. this is an area, since we have been increasing 6 our use of behavioral health medications, we have 7 8 been really putting a lot more emphasis from a 9 measurement perspective on behavioral health services in general. I think that this is an 10 11 area from the future for these children to really 12 do a better job of monitoring their metabolic 13 conditions.

14 And it's an easy one to measure. It's prescription-based. Kids are already diagnosed, 15 16 and it just should not be a challenging one. Ι 17 think it would have a huge benefit to make sure 18 those kids that are not having those things 19 monitored actually have them monitored, so that 20 we can make sure the long-term consequences of 21 these medications don't impact their lives. 22 MEMBER ADIRIM: Yes, I was going to

say I support that this is a really important thing to improve on. And I see where, down to the clinical level, I know people have mentioned that before. Like how can the states use this to improve care? So, I definitely could see how this would be useful for that.

7 And I think, as pediatricians are more 8 and more prescribing these medications and may 9 not have the experience or education or training, 10 or whatever, for these meds, that it would be 11 important.

12 I think what I would want to know, 13 because, again, to the theme of real estate, not 14 that that's as big of an issue for me, but how many children would this affect and, within each 15 16 state, what would be the number of children? 17 Because for the diagnoses that children would 18 require antipsychotics, it is like 1 percent of 19 the population, you know, like bipolar with 20 psychotic breaks. Schizophrenia doesn't exist in 21 young children. So, yes, I would want to get an idea of the numbers of children affected before 22

> Neal R. Gross and Co., Inc. Washington DC

1

2

3

4

5

6

1

making a decision.

-	
2	CHAIR ANTONELLI: Do you have an
3	answer? And also, is the measure developer on
4	the line, if we need him or her? Do we know?
5	They're not on? Okay.
6	Rachel?
7	MEMBER LA CROIX: I believe we had our
8	plans report it last year. So, I am trying to
9	pull up the file it's just taking a minute
10	so that I can tell you how many folks we had
11	eligible for the measure. But, once I have it,
12	I'll let you know.
13	MEMBER POOLE-YAEGER: I can just give
14	my gut concept. I don't have any numbers in
15	front of me. But, in Medicaid, especially in
16	foster care, the use of antipsychotics is quite a
17	bit higher than in the overall population. So, I
18	think this would be one of those things that
19	would be disproportionately high in Medicaid
20	probably.
21	DR. ELLIOTT: And also in the
22	disability population.

	22
1	MEMBER POOLE-YAEGER: Correct,
2	correct.
3	CHAIR ANTONELLI: Terry?
4	MEMBER ADIRIM: Yes, but my concern
5	within the foster care population would be about
6	appropriate use of antipsychotics. So, that, I
7	think, is the issue with that population. I
8	think the appropriate use, you want to make sure
9	that there's appropriate monitoring and all of
10	that.
11	So, I'm really conflicted about this
12	measure because I see its importance. I'm just
13	concerned that the numbers would be small, that
14	it wouldn't affect as large a population as some
15	of the other measures.
16	DR. MATSUOKA: So, to Terry's point
17	I'm curious to know Rachel's numbers, too. But
18	while we're waiting, to Terry's point, we do have
19	two antipsychotic medication-related measures
20	already in the child core set. One is looking at
21	the use of multiple concurrent antipsychotics to
22	get to the sense of utilization and

Neal R. Gross and Co., Inc. Washington DC 226

appropriateness. The other one is first-line
psychosocial care for children who are using
these medications for a certain period of time,
to try to get at, you know, is it an
inappropriate substitution of medication for
psychosocial care? So, we have those two in the
core set.

We do have an affinity group that we 8 9 have been running with around eight states looking at the issue in general, but, also, 10 11 around the measurement of the issue. I am going 12 to ask Renee to see -- we have some preliminary 13 data from NCQA just from the plans that they are -- the core measure, like what the rate is of 14 even just the utilization piece. And that might 15 16 help to back into, of the subset for whom this might be appropriate, is there some metabolic 17 18 monitoring going on?

19 MEMBER ADIRIM: And didn't somebody 20 say -- this was maybe two years ago we had that 21 person from Louisiana come and say that 40 22 percent of the boys in her state on Medicaid were

on antipsychotics? Am I like hallucinating? 1 But 2 it was some really ridiculous --3 DR. ELLIOTT: I wasn't there, but, yes, I think that that is true. 4 MEMBER ADIRIM: Right, and that's why 5 we put these measures on there, because it's 6 7 inappropriate use of antipsychotics. It is really a huge issue. 8 9 MEMBER POOLE-YAEGER: Rachel has her 10 numbers? 11 MEMBER LA CROIX: I do, and we 12 required last year our plans to report on the use 13 of multiple concurrent, and we also have them 14 report on the metabolic monitoring. So, for the 15 use of multiple concurrent antipsychotics -- and, 16 of course, this is an inverse measure; we want 17 rates to be low for this -- but across all of our 18 plans we had 10,300 eligible members for the 19 measure. And the weighted rate across our plans 20 was 1.77 percent, so a relatively low rate, which 21 is what we want. 22 And then, for the metabolic monitoring

for children and adolescents on antipsychotics, 1 2 the total rate -- so, this is bringing together the three different age bands that are reported 3 4 -- it was a total of 13,732 eligible members 5 across the plans met the criteria for the measure. And our weighted rate across our plans 6 7 was 37.77 percent. So, yes. 8 CHAIR ANTONELLI: Any other 9 discussion? 10 Yes, go ahead. DR. FOX: Well, I can just explain a 11 12 little bit about the affinity group. As Karen 13 said, we have our two measures, one of which is 14 NOF-endorsed and the other one is not. 15 We had eight states, and many states 16 actually use the whole HEDIS bundle, which is 17 three measures. And so, there were several 18 states that chose to look at metabolic monitoring 19 because there's a disconnect. Either it's the 20 subspecialty provider who does the prescription 21 and, then, the PCP does the followup. There is a 22 question about getting the labs back. Also, it's

hard to get people to go from a doctor's office 1 2 to a lab to get blood drawn. They get lost in And so, there were multiple challenges, 3 between. 4 but they have chosen to work on that. 5 And California found they had a wide 6 range of numbers of people; plus, they also had, if they only looked at blood glucose instead of 7 8 lipids, there were many more people who got 9 their --10 MEMBER ADIRIM: So there's room for 11 improvement? 12 DR. FOX: There is definitely room for 13 improvement. I think the numbers -- that our 14 NCOA friends are here now. 15 If we can ask you to CHAIR ANTONELLI: 16 come up to the microphone, identify yourself? 17 We can come back to the -- terrific. 18 If you can identify yourself and, then, jump in 19 for the question? 20 MS. BYRON: Sure. Hi. I'm Sepheen 21 Byron. I'm the Assistant Vice President, Performance Measurement at NCQA, and worked on 22

230

1 the Center of Excellence that developed these 2 measures that we eventually adopted into the HEDIS health plan measure set. 3 And I apologize, I got here a few 4 5 minutes ago, and I may have missed what the actual questions were. So, if you don't mind 6 7 repeating? 8 CHAIR ANTONELLI: So, I think that 9 we're riffing on the questions that Terry had raised about population size, potential room for 10 11 improvement. But I think that we've actually had 12 that data. So, I'm going to pause. 13 Task Force Members, do you need 14 anything else to inform your thinking on 2800? And please don't leave that seat 15 16 because we will pull you back in for a different 17 question. 18 (Laughter.) 19 But, focusing on 2800, any other 20 question for the measure developer? 21 Otherwise, I am going to make a 22 request for a motion.

1	(No response.)
2	Okay. Kim?
3	DR. ELLIOTT: I'd like to move that
4	this measure I forget the number right now
5	be added to the child core measure set.
6	CHAIR ANTONELLI: Is there a second?
7	MEMBER ADIRIM: I second.
8	CHAIR ANTONELLI: Okay.
9	MS. GORHAM: So, just as a reminder,
10	because we have folks on the phone, we can hear
11	you in the room, but they can't hear you if you
12	don't use your mic. So, just a reminder to speak
13	into your mic, please.
14	CHAIR ANTONELLI: Miranda?
15	MS. KUWAHARA: So, if we are ready to
16	vote on Measure No. 2800, we will go back to
17	trying to use the clickers. We believe we have
18	resolved the issue. But, just to ensure that the
19	clickers are working properly, if you could
20	please use the test question, "Did you have
21	coffee with your breakfast this morning?" And
22	please direct your clickers in this direction.

	⊿
1	We're still waiting on a few
2	responses.
3	A new one coming down.
4	All right, we just got the 13th vote.
5	All right, we should be good to go.
6	Again, this is Measure No. 2800,
7	metabolic monitoring for children and adolescents
8	on antipsychotics.
9	Should this measure be added to the
10	core set? If you support, please press 1; if
11	not, press 3.
12	Eighty-five percent of the 13 voting
13	members voted to support this measure.
14	CHAIR ANTONELLI: All right. So,
15	let's go back to the motion that's still on the
16	table for 1659. I think we have an update to the
17	questions that were raised about the influenza
18	vaccine. But, I think, with the presence of NCQA
19	in the room now, Andrea, would you like to just
20	give us a quick summary, so that she can weigh-
21	in?
22	MEMBER BENIN: I don't think it's an
_	

1 NQCA measure, but I'm happy to. It's a Joint 2 Commission measure. I mean it is an ORYX CMS 3 measure, yes. 4 CHAIR ANTONELLI: Mine says NCQA. 5 Okay. Okay. DR. BURSTIN: If 1659 was the one we 6 7 were talking about, which is inpatient influenza 8 screening, which is not NCQA. That's CMS. 9 CHAIR ANTONELLI: Okay. So, it's a 10 typo on the slide then? Okay. 11 DR. BURSTIN: They do the outpatient 12 one by survey. 13 CHAIR ANTONELLI: Okay. Use the 14 microphone, please. 15 So, the HEDIS measure, MS. BYRON: 16 childhood immunization status, does have flu in it. 17 That's for up to age 2. 18 CHAIR ANTONELLI: Right. Okay. Okay. 19 Debjani, you have something, I think, 20 to report on, and then, I'm going to call for a 21 vote on 1659. 22 MS. MUKHERJEE: So, it is a facility-

level measure, and it does include children and 1 2 older individuals, adults, but it's facility level, so we don't have stratification, 3 4 stratified data that was submitted to us. So, if 5 you're a children's hospital, you will be submitting that data, but we don't have the sort 6 7 of parsing. 8 MEMBER BENIN: But children's 9 hospitals do not submit to the IQR. Adult hospitals with children's units would submit, but 10 11 children's hospitals would not be submitting. 12 CHAIR ANTONELLI: Right, right. DR. BURSTIN: She checked with the 13 14 people who led the project as well as the 15 submission form, and it only indicates 16 disparities by race/ethnicity. 17 CHAIR ANTONELLI: Yes. 18 DR. BURSTIN: Nothing at all by age. 19 And I think probably because they just don't have 20 the data. 21 CHAIR ANTONELLI: Right. Okay. 22 So, the motion has already been made

and seconded on 1659. 1 2 Any further discussion before Miranda calls for a vote? 3 4 (No response.) Go ahead. 5 Hearing none, we will 6 MS. KUWAHARA: take it to a vote. Again, this is Measure No. 7 8 1659, influenza immunization. 9 If you would like to support this measure for inclusion in the core set, please 10 select 1; if not, please select 3. 11 12 We are still waiting on one response. 13 Eighty-five percent of the 13 voting 14 members voted not to support this measure. 15 CHAIR ANTONELLI: Okav. 16 MS. GORHAM: Okay. Measure 3154, 17 informed coverage, is a CHOP measure, and I do 18 believe they are on the line. 19 But we can continue. So, Andrea 20 recommended this measure, and this measure is 21 currently undergoing evaluation. So, this metric gets 22 MEMBER BENIN:

back to the issue that I really believe to be 1 2 critically important right now, which is around And anything that we can to understand 3 access. access in this environment and in this population 4 5 is essential. And I think it is also essential that we position ourselves to be able to look at 6 7 it over time. And this is another metric that 8 can get us at that.

9 This metric is a little bit different 10 in that -- and I believe that Jeff Silber is on 11 the phone. So, I am going to let him actually 12 explain it. But at its highest level, the idea 13 here is that the denominator is patients who 14 would be eligible for services, and then, the 15 numerator is ones who actually get into coverage.

And so, this is a different type of metric than the other access metrics that we have. The other access metrics that we have are truly, I think, metrics of, once you have coverage, do you get services? And that is substantially relevant, but this metric may actually may become increasingly relevant as the

1

opportunities to cover children go down.

2 And while this metric may still have some kinks that are being worked out, especially 3 given some of the lag issues and what happens 4 over the next year or so, I think it's critically 5 important to give the states the opportunity to 6 7 be able to take a look at it and figure out if 8 they can mount it, and what that would look like. 9 And I don't think that delaying is in the best interest of the children that we serve here. 10 11 But I would like just to have, Jeff, 12 if you don't mind explaining the metric in a little bit more detail, because I think this is a 13 14 really critically important issue. 15 CHAIR ANTONELLI: Actually, Jeff, I 16 don't know whether you're on mute or not, but 17 we're not hearing anything. 18 But let me ask the Task Force members 19 that are in the room, are you getting in the 20 queue for after Jeff presents or do you have 21 questions? 22 Deborah, do you have a question that

	2
1	you would like to put out there for possibly Jeff
2	before he goes?
3	MEMBER KILSTEIN: Not a question, just
4	a comment.
5	CHAIR ANTONELLI: A comment? Do you
6	want to do that before you hear his presentation?
7	MEMBER KILSTEIN: I am fine either
8	way. I can either do it before or after.
9	CHAIR ANTONELLI: Okay. So, why don't
10	we have you put that down?
11	Jeff, are you there?
12	(No response.)
13	Are you on mute?
14	(No response.)
15	He is? Okay.
16	MEMBER BENIN: Maybe there is someone
17	from AHRQ who could take the discussion. I think
18	Kamila is not here, but I don't know. Who has
19	the I think the bottom line here is that the
20	denominator is the patients who are eligible and
21	the numerator is the patients who actually get
22	coverage in the time period.

i	2
1	There are some nuances that they use,
2	an appendicitis rate, to kind of adjust and
3	double-check the metric. I was hoping that they
4	could explain that part of it, but it is a way to
5	pick a disease that has a similar you're going
6	to show up for appendicitis. And so, whether you
7	have coverage or not, you're probably going to
8	show up. And so, how do you use the rate of
9	coverage amongst those patients to double-check
10	and to adjust for the overall rate that you're
11	ending up with. So, it is a nuanced way to
12	tackle this, but I do understand it to be
13	feasible.
14	So, it would be good if there's
15	anybody else who wants to jump in.
16	CHAIR ANTONELLI: Yes.
17	MS. GORHAM: All right. So, we have a
18	representative from CHOP, not Jeff. But can you
19	introduce yourself, please?
20	MS. SHAH: Hi. I'm Shivani Shah. I
21	am a research assistant for Jeff Silber. He
22	should be on the line, too, but I can try to

answer as many questions in the meantime. 1 2 CHAIR ANTONELLI: Is he for sure going to be joining, because I would rather not have to 3 4 repeat a set of questions. 5 MS. SHAH: Okay. Let me just -- like give me one minute. 6 7 Okay. CHAIR ANTONELLI: 8 I'll go get him. MS. SHAH: 9 CHAIR ANTONELLI: Okay. You go ahead 10 and do that. 11 MS. SHAH: Okay. 12 CHAIR ANTONELLI: And, Deborah, go 13 ahead. 14 MS. SHAH: Okay, okay. Hi. Oh, yes. 15 Here, here, here. 16 MEMBER KILSTEIN: I was just going to 17 make a comment in terms of the importance of 18 continuity of care as a quality issue --19 Hi. This is Jeff Silber. MR. SILBER: 20 MEMBER KILSTEIN: -- and also as an 21 efficiency issue. 22 MR. SILBER: Can anyone hear me?

I	24
1	CHAIR ANTONELLI: Jeff, stand by for a
2	moment, please.
3	MR. SILBER: Okay.
4	MEMBER KILSTEIN: Based on some data
5	that we have looked at, per-member per-month
6	costs go down the longer someone's enrolled
7	because of the benefits of the ongoing access to
8	primary preventive care.
9	And there is an efficiency aspect of
10	this as well, because if someone loses
11	eligibility and, then, has to go back through the
12	enrollment process, there is an administrative
13	cost to re-enroll them.
14	So, we think that churn is an ongoing
15	problem in Medicaid and CHIP, and is critical
16	when you are looking at care for kids. And so,
17	this was an important measure from our
18	perspective.
19	CHAIR ANTONELLI: Thank you.
20	MR. SILBER: Can you hear me now?
21	This is Jeff Silber.
22	CHAIR ANTONELLI: We can and the floor

1	
1	is yours. Just give us a 20-second introduction,
2	Jeff, and then, please go.
3	MR. SILBER: Okay. I'm sorry?
4	CHAIR ANTONELLI: Just introduce
5	yourself and please give us your schtick.
6	MR. SILBER: Oh, okay. Okay. I'm
7	Jeff Silber, the developer of the metric, the
8	Director of the Center for Outcomes Research at
9	Children's Hospital.
10	I've been on the conference call the
11	whole time, but did not put my phone on mute.
12	But, for whatever reason, I couldn't be heard.
13	But I'm on a different phone now and apologize
14	for your inconvenience.
15	Shall I go forward with the metric?
16	CHAIR ANTONELLI: Yes.
17	MR. SILBER: Okay.
18	CHAIR ANTONELLI: We would like a
19	succinct description of the metric
20	MR. SILBER: Okay.
21	CHAIR ANTONELLI: so that the Child
22	Task Force members can be in a position to ask

1 questions --2 MR. SILBER: Right. 3 CHAIR ANTONELLI: -- as we proceed to 4 deliberation. 5 The metric-MR. SILBER: Sure. 6 informed coverage uses appendicitis, a random 7 event that isn't related to primary care or other 8 health conditions, to help estimate the fraction 9 of patients who are covered, or have insurance, divided by those who are eligible, which is often 10 11 also referred to as the participation rate. 12 Informed coverage uses appendicitis 13 patients because, if you develop appendicitis, 14 you're going to be hospitalized. If you were 15 eligible for insurance, we would see you in the 16 MAX data. If you were not eligible, MAX data 17 wouldn't pick you up. It is a claims-based 18 measure. 19 And the development of the metric is based on claims data with the states that have 20 21 adequate claims data in MAX to be able to be

analyzed. And what we have developed is a way to

Neal R. Gross and Co., Inc. Washington DC

22

-	n
1	scan the data and look for adequate data and,
2	then, be able to make this estimate.
3	We compare our measure to the current
4	metrics that are out there now, which, No. 1,
5	duration, which is looking at children who have
6	been insured, then drop off the rolls, and then,
7	when they come back, duration starts at time zero
8	and sees how long they stay on the rolls.
9	The problem with that metric and
10	we've talked to stakeholders about this is
11	that kids that are always enrolled during a time
12	period don't show up in the duration metric. So,
13	that's a major problem of duration.
14	The other measure is the participation
15	ratio by COO. That metric has a problem in that
16	it assumes that, if you have ever had insurance
17	during a period, you're always eligible and,
18	therefore, that is the rate that they give. And
19	it also doesn't do many adjustments for aging out
20	or for partial time periods in the time period of
21	analysis.
22	So, we developed this metric based on

The big advantage is that it looks 1 appendicitis. 2 at everyone who could possibly be eligible because they would be ending up being 3 4 hospitalized for a random event of appendicitis. 5 And then, we look to see whether they did have insurance before they developed their 6 7 appendicitis. In this way, we are not having 8 those gaps that the other measures have. 9 Furthermore, what we have done is utilized this and developed the package with a 10 way to look at the statistics around it, so that 11 12 it is easy for the states to get their variances and their confidence intervals and do the 13 14 statistics that they need to compare themselves to the rest of the states or to other individual 15 16 states. 17 I'll stop there and address any 18 questions you might have. 19 Actually, I just want to mention one 20 other thing, which is we use as a gold standard 21 for validation the American Community Survey. 22

And that survey, our measure is better

correlated, and that is in the documents that we have provided. It is better correlated than any of the other two metrics, be it the continuity ratio or the duration metric.

5 So, one of the strong aspects of our 6 measure is that it is better correlated with 7 actual survey data, which would get at that 8 missing population. And secondly, the error 9 rates are lower in our measure versus the survey 10 than the other two measures. So, I just wanted 11 to point that out, too, and I will stop now.

12 CHAIR ANTONELLI: Okay. Comments or 13 questions?

14 DR. BURSTIN: At this point, it is still going through the evaluation of the 15 16 Pediatric Standing Committee. It went through. 17 It was heavily reviewed for everything except 18 there was a lack of consensus around reliability 19 of the measure. In fact, one of the major 20 concerns was this question of whether it might be 21 a great self-assessment tool for states to 22 improve coverage rates. The question was, is it

> Neal R. Gross and Co., Inc. Washington DC

1

2

3

4

an appropriate measure for accountability? 1 2 Again, this is a state-level discussion, so take 3 that as it may. 4 And I think there was some concern 5 about -- and since you have states here -- the 6 ability of states to accurately calculate the 7 measure, since it was pretty complex. So, 8 experience with using it for this discussion 9 might be helpful. Is it NQF-endorsed? 10 MEMBER ADIRIM: 11 DR. BURSTIN: It's in process. 12 Comment period closes May 31st. There is a postcomment call with the Pediatrics Committee on May 13 14 So, it's still in process. 31st. I wrote an in-depth 15 MR. SILBER: response to the concerns. One of the concerns 16 17 was that poorer states might have a different 18 measure than richer states, and I showed that 19 that wasn't something that would throw off our 20 measure. Secondly, there was a concern that a 21 lot of states were clustered. And what we showed 22

was that there is a distribution of states in 1 2 terms of their informed coverage, and we outlined that in the new documents that were sent out, 3 4 such that we can identify large clusters of states that are way below average and others that 5 are above average, and many in the middle. 6 7 So, we can differentiate states as 8 groups, but, also, state-by-state. About two-9 thirds of the states can be distinguished from other states, but it just so happens that some 10 11 states have very similar informed coverage, but 12 There's enough variability, such many don't. 13 that you can compare state-by-state and you can 14 also compare states to the group or states to any 15 segment of the state populations. 16 CHAIR ANTONELLI: Jeff, this is Rich 17 Antonelli. I'm the Chair of this group, but I'm 18 stepping out of the Chair to ask this technical 19 question. 20 So, for hospitals that are near 21 boundaries, borders, state borders, if you will, 22 -- and I'm thinking about CHOP, but it could

apply pretty much anywhere -- if the child gets 1 2 admitted for that emergent event, like in appendicitis, does that do anything to the data? 3 4 MR. SILBER: Yes, the data is based on 5 what the individual states submit to the federal government. So, it is based on MAX data. 6 So, 7 when you do a state analysis, you are looking at 8 patients who were insured in that state. So, the 9 bills can come back to that state if they were 10 seen out of state, say a New Jersey patient seen 11 at CHOP, but it is dependent on the quality of 12 the state data. 13 CHAIR ANTONELLI: Thank you. 14 Terry? 15 MEMBER ADIRIM: To Andrea's point, I 16 really think this addresses a very critical 17 concern, child health insurance coverage, 18 continuity of child health insurance coverage. 19 But I think I have a little bit of trepidation 20 about it not being quite ready yet for being put 21 on the core set. 22 I mean, my thinking is I would

advocate for it being looked at next year to be 1 2 put on the core set. I'm sort of -- something like that, because, you know, I think it needs a 3 little more work before we --4 5 DR. SIBLER: Could I ask in what way? 6 Because we might have addressed it in the memos 7 that we -- I don't know if you've got the memos 8 that we were addressing --9 MEMBER ADIRIM: Sure. Well, it's --10 DR. SIBLER: Yes? 11 MEMBER ADIRIM: Yes. No, it just 12 doesn't seem like all the testing and the considerations and all that have been done yet. 13 14 I think it's a great measure. I think it is an 15 important --16 DR. SIBLER: I think they work, but 17 I --18 MEMBER ADIRIM: Yes, well, I'm not 19 going to argue with you, but --20 DR. SIBLER: Well, it's just, right now, I don't hear a reason. So, it would be nice 21 to hear a reason. 22

1	MS. GORHAM: So, just to think about
2	just to state history, we discussed this measure
3	last year as well. So, this was a consideration.
4	But you all deliberated and decided not to
5	recommend the measure. If you decide to
6	recommend this year, you can recommend with
7	conditional support pending NQF endorsement.
8	Again, CMS is in the room. They are
9	listening to the conversation. It is up to them
10	whether or not they want to add it to the core
11	set now or later.
12	But, just a matter of history, we did
13	discuss it last year. We decided, as Terry said,
14	to wait. You all decided to wait until it went
15	through NQF endorsement. It is still going
16	through NQF endorsement. If you would like to
17	join the post-comment call on May 31st, you're
18	welcome to do that as a public member, just to
19	listen, and then, you also can, you know, respond
20	during the public comment period.
21	CHAIR ANTONELLI: Roanne?
22	MEMBER OSBORNE-GASKIN: So, I would
1	just like to clarify, because this is an
----	--
2	important thing that we are trying to look at,
3	coverage for kids. But the coverage, the limits
4	you are going to use appendicitis, if I got it
5	right, but the limit is 2 to 16, whereas you're
6	trying to look at coverage from zero to 18,
7	right?
8	So, I'm trying to figure out if using
9	that population and maybe I'm not getting it
10	right but I assume that you are using that
11	population to sort of base your measurement on,
12	but it is still not it is going to leave out a
13	couple of years before and after. I mean, are we
14	okay with that?
15	DR. SIBLER: May I explain or may I
16	explain?
17	CHAIR ANTONELLI: Yes, Jeff, go ahead.
18	DR. SIBLER: It doesn't, the
19	appendicitis metric uses 2 to 16 because, first
20	of all, appendicitis doesn't happen in the
21	earlier group and, secondly, that we didn't want
22	to have the states worry about survival

statistics by going up to the edge of 18. 1 2 But the metric uses, in its data it uses all kids for all diagnoses, not just 3 appendicitis. It only uses the appendicitis to 4 weight the two assumptions about the populations, 5 whether they were presumed to be eligible or 6 7 presumed to be ineligible. So, the appendicitis 8 metric itself is used as a way to inform the 9 entire population's coverage or participation. It's not only using the data from 10 11 appendicitis. It uses the data from all the 12 kids, but it weights all the kids based on what 13 we get from the appendicitis sample, which is a 14 very random sample over that population. So, it's not only using the kids with appendicitis to 15 16 come up with that result or any of the 17 subanalyses that we put into the report. 18 So, we make two main assumptions. You 19 can either be saying that the kids are almost all 20 presumed eligible or presumed ineligible. We still get the rates of their coverage in those 21 two groups. Then, we weight that by the 22

appendicitis sample, but we are using the whole 1 2 population in describing the state. And all the numbers from all the kids are used in getting 3 4 that overall coverage, informed coverage rate. So, it uses appendicitis, but it's not just based 5 on appendicitis. 6 7 CHAIR ANTONELLI: Thank you. DR. SIBLER: And it is far better 8 9 correlated than the other measures with the gold standard of the community survey. 10 11 CHAIR ANTONELLI: Amy, on my left? 12 MEMBER RICHARDSON: Thank you. 13 So, I'm curious, as a newcomer, from a 14 CMS perspective and from an NQF perspective. This is an important public policy issue. 15 16 Everything else we have talked about reflects 17 some dimension of quality of medical care, not 18 extent of insurance coverage. Those two may be 19 related, but they're not the same. 20 So, I'm curious about the notion of 21 including this public policy measure in the core 22 set. So, maybe I need to understand how it would

i	∠ 1
1	be used if it ends up in the core set.
2	CHAIR ANTONELLI: Karen?
3	DR. SIBLER: Do you want me to
4	CHAIR ANTONELLI: No, Jeff. I think,
5	Jeff, as the Chair, I'll call when we need you to
6	weigh-in, okay?
7	DR. SIBLER: Okay. Thank you. Thank
8	you.
9	DR. MATSUOKA: So, I'm trying to call
10	up the actual statutory language. I want to say,
11	though I will confirm this, that there is some
12	language in CHIPRA that alludes to the importance
13	of continuity of coverage as an important
14	indicator of how we're doing as a program.
15	So, it's true that most of the core
16	set measures deal with quality of care, but, you
17	know, as we've talked about before, we also think
18	about access as an important dimension of quality
19	of care. You can't get good quality of care if
20	you don't have access to that. And one way to
21	think of this might be that continuity of
22	coverage is an important driver of access.

	4
1	So, how we would use this would be in
2	the same way that we would use every other core
3	set measure, which is it would be voluntary.
4	States could either report it or not. We would
5	do some technical assistance with the states to
6	ensure some consistency between the states that
7	are reporting the measure and, then, publicly
8	report the information.
9	And then, to the extent that there's
10	interest, we might do some targeted technical
11	assistance like we have done with the
12	antipsychotic medication stuff. But, in general,
13	that's kind of how we use the measures.
14	CHAIR ANTONELLI: Amy?
15	MEMBER POOLE-YAEGER: Hi. Jeff, this
16	is Amy Poole-Yaeger. I'm with Centene, which is
17	a large managed care organization.
18	And I'm just curious. Just to make
19	sure I understand the concept of this message.
20	So, you're going to get at the people because
21	somebody had asked, well, can't we get that
22	information? But I can look at people that I

know are eligible, you know, that have had at 1 2 least one month of eligibility, and see how they have had gaps. But this is going to look at 3 maybe somebody that -- this is going to tell you 4 5 who should have had eligibility in certain months, right, and then, did they have it? 6 And sort of give a look outside of what we could see 7 8 just in our data, is that correct? 9 DR. SIBLER: Right. It uses, it's a point in time to estimate the overall time over a 10 11 time period that someone was participating when 12 they were eligible. But it's a point in time. 13 So, we are saying, at the point right before they 14 developed appendicitis, was that child 15 participating with coverage? We knew they were 16 eligible because we wouldn't have seen their 17 records for their appendectomy in Medicaid unless 18 Medicaid paid it, meaning they were covered. 19 At that point in time we show is 20 proportional to or equals the number of months 21 someone is on or off during a given time interval. So, it is talking about a 22

participation rate over a time interval. 1 It is 2 based on a point-in-time estimate for all the kids in the state that are developing 3 appendicitis and, then, for all the kids in the 4 5 state that did or did not have appendicitis. So, it is telling us whether someone's 6 participating and in the system when they are 7 8 eligible. If they are often not in the system 9 and not participating, then the point-in-time estimate would be lower. If they are often 10 participating when they are eligible, then we 11 would have a higher estimate for our coverage 12 13 rate. 14 CHAIR ANTONELLI: Okay. So, I want to follow on the paradigm that we had yesterday and 15 16 continued. I want to ask the Task Force, does 17 anybody want to submit a condition? 18 No? Again, I apologize because of the 19 Has this been motioned and approved? qaps. Yes. 20 So, why don't we go ahead and do that? Make your 21 motion. 22 MEMBER BENIN: All right. So, I move

	2
1	that we suggest including this in the panel, this
2	metric in the panel.
3	CHAIR ANTONELLI: Okay. Is there a
4	second?
5	MEMBER KILSTEIN: I'll second.
6	CHAIR ANTONELLI: Second. Okay.
7	Any further conversation about the
8	motion? Is that a yes?
9	MEMBER BENIN: Can I make one more
10	comment? Or you don't want to? You want to move
11	on?
12	CHAIR ANTONELLI: Well, I was actually
13	going to revisit, now that the motion has been
14	officially made and seconded, I want to come back
15	to the question about whether people would like
16	to consider a condition attached to it, so that
17	this way, we know whether we are voting on it up
18	or down.
19	But do you want to go ahead?
20	MEMBER BENIN: I mean, I would just
21	make two additional comments. One is that this
22	is a PQMP metric. You know, we have a couple

more of the PQMP metrics coming up, but the premise of the PQMP program was to generate metrics that we could use for children and for pediatrics. And this is one of those, and it has been pretty robustly developed, although it is still going through the process, obviously.

7 I would also say that, I think it was 8 Karen, you know, just outlined a process by which 9 using this metric could be very practical, in that adding it to the panel, allowing the states 10 that could muster it to pick it up, and then, 11 12 next year we would be here and we would have more 13 information, or two years from now we would have 14 more information. I mean, the problem is we 15 won't have any more information for two years 16 from now. And so, it would take a couple of 17 years for us to get that information. 18 CHAIR ANTONELLI: Okay. 19 MEMBER BENIN: So, getting it into the 20 cycle now enables us to have that information a 21 little bit sooner.

22

1

2

3

4

5

6

CHAIR ANTONELLI: Okay.

1 MEMBER BENIN: So, that was my 2 additional comment. CHAIR ANTONELLI: 3 Okay. Thank you. 4 So, Deborah? Yes, I would suggest 5 MEMBER KILSTEIN: conditional support, just because it is pending 6 NQF endorsement. 7 8 CHAIR ANTONELLI: Okay. And what 9 would the condition be? NOF endorsement, period? 10 MEMBER KILSTEIN: Yes. 11 CHAIR ANTONELLI: Okay. So, can you 12 state that motion, please? 13 MEMBER KILSTEIN: Yes. I would place 14 conditional support pending NQF endorsement. CHAIR ANTONELLI: Is there a second to 15 16 that motion? 17 MEMBER ADIRIM: Second. 18 CHAIR ANTONELLI: Okay. I will allow 19 one minute to discuss, if people want to speak 20 about the condition and, then, we are going to 21 move to a vote. 22 Any issue? I'm talking about the

condition now. Yes, okay.

2	MEMBER ADIRIM: No, and the reason why
3	I support that is that, unlike other measures
4	because I don't think to be on the measure set
5	you have to be NQF-endorsed. But this is a new
6	measure, and I think having it looked at to make
7	sure that it is measuring what we want it to
8	measure and that it is reliable, I think would be
9	important.
10	I think it is, I agree with Andrea
11	this is a very critical concept, but I would like
12	to see it, before we let it take up the real
13	estate, I would like to see it fully endorsed.
14	CHAIR ANTONELLI: Okay. Thank you.
15	So, let's proceed. And, Miranda,
16	thank you for anticipating this slide.
17	So, the vote is there. So, walk us
18	through, please.
19	MS. KUWAHARA: We are voting on
20	Measure No. 3154, informed coverage. We are
21	asking if this measure should be added to the
22	core set. You have two options, conditional

1	28
1	support, the condition being NQF endorsement.
2	If that is your choice, please select
3	2; if not, please select 3.
4	(Voting.)
5	Eight percent of the 13 voting members
6	voted to support this measure; 54 percent voted
7	to conditionally support this measure, and 38
8	percent voted not to support this measure. But,
9	because it rolls up, it is conditionally
10	supported.
11	CHAIR ANTONELLI: Okay. So, we're all
12	set?
13	Did you want to weigh-in?
14	MS. GORHAM: It's fine.
15	CHAIR ANTONELLI: You're okay?
16	MS. GORHAM: Yes.
17	CHAIR ANTONELLI: Okay. Right. Jeff,
18	thank you for being available.
19	All right. Let's move on, please.
20	MS. GORHAM: Okay. So now, we're at
21	Measure 3166, Antibiotic Prophylactics Among
22	Children With Sickle Cell Anemia.

	26
1	I'm sorry. This is horrible. I'll
2	start over.
3	Measure 3166, Antibiotic Prophylactics
4	Among Children With Sickle Cell Anemia, was
5	recommended by Rich and Terry. So, I will turn
6	the floor over to you. Again, we have 3166, the
7	specifications as well as the algorithm on your
8	screen.
9	CHAIR ANTONELLI: Terry, why don't you
10	go first? Okay, I'm happy to do it. Yes, take a
11	cleansing breath. I can do it.
12	MEMBER ADIRIM: This measure is a
13	fairly recently-endorsed measure. It is a key
14	metric measure, and it covers children age three
15	months to five years, prescribed antibiotic
16	prophylaxis for 300 days out of a year.
17	And the reason why I thought this
18	would be a good measure is that sickle cell
19	disease was identified as one of the gap areas.
20	I know we recommended the transdoppler one last
21	year. But, since then, I've talked to our hema
22	docs regarding this. And this is, you know,

within our population, we probably have a higher than an average than in the commercial plan population.

4 Antibiotic prophylaxis has been shown 5 very clearly to reduce, to eliminate the incidence of infection and sepsis. And so, even 6 with vaccination, it is still considered 7 8 recommended, according to the CDC Practice 9 Guideline from 2014. So, I thought that this would be a measure that we should consider for 10 recommending to go into the core set. 11 12 MS. GORHAM: Can I make one 13 correction? So, the measure is not yet endorsed. It is not finalized. It will not be finalized 14

15 until June. So, the Standing Committee 16 recommended endorsement, but it has not finalized 17 that.

MEMBER ADIRIM: Okay, but a previous one was, right? And this was a change or something? No?

21 CHAIR ANTONELLI: This is the second 22 measure, the transcranial ultrasound last year.

> Neal R. Gross and Co., Inc. Washington DC

1

2

Y
•

1	So, those are some of the reasons that
2	I wanted to bring this forward as well.
3	We can talk at length and/or I can
4	have the measure developer step in.
5	There is an evidence base for this
6	that antibiotic prophylaxis has a very beneficial
7	impact on this at-risk population.
8	Are there any comments from the Task
9	Force before I ask for a motion?
10	Amy?
11	MEMBER POOLE-YAEGER: I just had a
12	question. And again, I think it is a great
13	measure. I am worried a little bit about the
14	denominator size in the states, either because,
15	as you look at how many sickle cell patients you
16	have, and now you are taking away the three to
17	five year-olds, you know, whether you're going to
18	get to such a small number in many of the states
19	that it is not going to be relevant.
20	I can just tell you, from our
21	perspective, we have trouble with that, even
22	looking across 23 states, although it is just a

I

portion of the population, not the whole state population. So, I just wanted to bring that up as a question for the states and if that would be 4 a barrier to using this one.

CHAIR ANTONELLI: Okay. Okay. 5 Would our CMS folks like -- is there something that you 6 can add to that point? I don't want to put you 7 on the spot. But, to the degree that you've got 8 9 a federal view of an important condition that may have a small-ish denominator, does that generate 10 11 any concern from your perspective?

12 DR. MATSUOKA: So, for the 13 transcranial doppler, it is one of the ones that 14 was recommended last year, but we didn't accept. 15 One is, of course, parsimony, the overarching 16 thing. So, if we are going to measure something, 17 you know, what comes out in exchange? I think 18 that, factored into the ones that we took versus 19 the ones that we didn't.

But this issue of small "N's" did come 20 21 up as part of that discussion, as well as the 22 geographical variation. So, you know, our ideal

> Neal R. Gross and Co., Inc. Washington DC

1

2

would be that the states that report on this measure -- you know, as many states as possible report on the measure. That, then, also, the implicit assumption is that, you know, the prevalence of any given condition is somewhat uniform across the states. So that all 50 states and territories might want to report on it.

8 And so, we weren't sure about absolute 9 numbers in general, but, then, also, just the geographic spread state by state. It is one of 10 11 the reasons why we are really interested to see 12 what you guys come up with as part of the PQMP 13 phase two grant. Because one of the things we 14 want to think about is, what is the impact of potential small "N's"? Given that this is an 15 16 area that is important to measure, what do we do 17 about the fact that there are potentially small 18 "N's," that the "N's" might vary state-by-state? 19 And what does that mean for measuring it at the state level? 20 21 CHAIR ANTONELLI: Thank you.

22

So, is your card still up? Okay.

Terry?

2	MEMBER ADIRIM: Yes. No, just Amy and
3	I were talking about this before. So, I was very
4	surprised at how small the denominator, the "N"
5	was, maybe because I practice in a children's
6	hospital in a very urban area. I don't know.
7	So, we see a lot of sickle cell.
8	So, that is something to consider, and
9	I think we need to weigh the importance of this
10	measure and being a priority condition. I think
11	we should think about that.
12	But I think, also, additionally, based
13	on conversation that we have had over the last
14	two days, I mean, it sounds like states really
15	want measures where they can make an impact and
16	where there can be quality improvement. And I
17	think this is one of those areas. But, anyway
18	CHAIR ANTONELLI: So, is there a
19	motion?
20	Ann, did you have a comment?
21	MEMBER GREINER: A question. So, I
22	know we started off with 27 measures in the core

set for children. And I'm just wondering where 1 2 we are now in terms of our count. I don't know if it is easy to find in terms of what we've 3 4 added and what we've taken away. MS. MUKHERJEE: So, we are still at 27 5 because we make recommendations. Until CMS/HHS 6 7 takes and makes changes, we will still be at 27. 8 MEMBER GREINER: Right. No, I do 9 understand that distinction. So, I wasn't clear. 10 I meant in terms of what we're recommending. 11 Obviously, then, CMS makes their decision. 12 MS. GORHAM: We're at four right now. 13 MEMBER GREINER: Four --14 MS. GORHAM: Four recommended, but we also removed, and what we will be sure to do at 15 16 the end, once we make all of the recommendations, 17 is put a slide up. 18 MEMBER GREINER: Yes. 19 MS. GORHAM: Because what we will, 20 then, ask the Task Force members to do is 21 prioritize and rank, so that we can say to CMS that the Task Force made these recommendations 22

and they think they are important in this order. 1 2 MEMBER GREINER: Yes. I guess it's just a comment that, you know, these are really 3 important discussions. And after a while -- and 4 5 I'll speak for myself -- you do begin to get lost 6 in how many are we recommending that are added 7 and removed. And just thinking holistically 8 about the number that practitioners are 9 reporting. 10 CHAIR ANTONELLI: Does anybody want to 11 make a motion? 12 MEMBER ADIRIM: I guess you're looking 13 at me. Yes. I move that we recommend this 14 measure, whatever number it is, 3166, to add to 15 the child core set. CHAIR ANTONELLI: Is there a second? 16 I'll second. 17 18 Any conditions that somebody would 19 like to propose to the motion on the floor for 3166? 20 21 And remember, it is not NQF-endorsed 22 yet. So, I'll go ahead and put in a condition

1

pending NQF endorsement.

-	penaing ngr enderbement.
2	Is there a second to that motion?
3	MEMBER GREINER: Second.
4	CHAIR ANTONELLI: Okay. All right.
5	So, Miranda, we have 3166, if you can take us
6	through that, and be mindful that conditional
7	support, do not support. You can vote for
8	support, but there is a condition attached. So,
9	really, you're voting for either number 2 or
10	number 3. Okay?
11	MS. KUWAHARA: That's right. So, we
12	are voting to recommend No. 3166, antibiotic
13	prophylaxis among children with sickle cell
14	anemia to the child core set.
15	Please select 2 if you would like to
16	conditionally support this measure for inclusion
17	with the condition that it receives NQF
18	endorsement. If you would like to not support
19	this measure, please select 3.
20	(Voting.)
21	Fifty-four percent selected to not
22	support this measure, and 46 percent selected to

conditionally support this measure. We had all 1 2 13 respondents, that's correct. CHAIR ANTONELLI: Okay. 3 Thank you. 4 We're moving forward. If you can 5 advance us maybe when you get a chance? This is not an NOF measure that we're 6 7 looking at. So, there is no number attached. 8 It's emergency department visits potentially 9 treatable in primary care. The measure steward is the New 10 11 Hampshire Department of Health and Human 12 Services. I presume that somebody from New 13 Hampshire is on the line. 14 MS. STEWART: Yes, Andrea Stewart is 15 on. 16 CHAIR ANTONELLI: Okay. All right. 17 So, we want to bring this up for 18 discussion. The description here is ambulatory 19 emergency department visits for conditions 20 potentially preventable and treatable in primary 21 care settings per thousand member months by age Administrative claims, the data source. 22 group.

There's no exclusions, and it is being used right 1 2 now in New Hampshire. And we wanted to bring it to the Task Force for this discussion. 3 If there are no immediate comments or 4 5 questions, I'm going to hand it off to Dr. or Ms. Stewart to tee this up a little bit more. 6 7 So, seeing no -- oh, I do see a card. 8 No, I don't see a card. 9 So, why don't you go ahead and Okay. describe the measure a little bit. Be as 10 succinct as possible, please, so that the Child 11 12 Task Force can formulate its questions. 13 MS. STEWART: All right. Essentially, 14 we use this to assess inappropriate ED utilization. We're able to easily use this 15 16 compare across our managed care plans, across age 17 groups, across geography, different breakouts. 18 We are also using it as part of our delivery 19 system transformation waiver. We are using it to 20 assess in determining incentive payments for that 21 particular program. In terms of the background on this, 22

1 for New Hampshire, it is basically six times more 2 likely for a Medicaid member to inappropriately 3 use the ED than it is for a commercial insurance 4 patient. 5 We do have the diagnoses. There is a 6 bit of an elution on the diagnoses that we use

for this. We started with the algorithm that NYU
Wagner developed that helps to classify ED
utilization. We, then, for about the last 10
years, have been looking at our own claim data
and comparing inpatient utilization versus
primary care for those diagnoses.

Also, Dr. Watts, who is not able to be
on the call today, is our chief medical officer.
And she's got 10 years as an ED doctor and was
able to do a clinical assessment of what we
utilized for this measure.

We also even took the step of removing some diagnoses from the list, basically those where a member might go to the ED with a perceived problem that by the time they are discharged has been discovered not to be the

The examples of those would include 1 case. 2 anxiety, chest pain, stomach pain, things like that. 3 4 CHAIR ANTONELLI: Okay. Thank you. 5 Open up for any comments or questions. Deborah? 6 MEMBER KILSTEIN: 7 Just a question. Ι 8 know a number of states have been looking at this 9 issue, but I assume they have all developed individualized measures on how they are using it. 10 11 Some are actually using it for payment or pay-12 for-performance. And I don't know, by choosing 13 one measure over the other, if it is going to 14 cause issues for states that are using a measure. 15 CHAIR ANTONELLI: Karen? 16 MEMBER KILSTEIN: Can any of the state 17 help? 18 DR. MATSUOKA: Yes, I was hoping that 19 Rachel would be here to answer, and maybe we will make sure to ask her when she comes back. 20 21 But I want to say that the process by which we arrived at this measure was that we 22

reached out to the Medicaid Medical Directors 1 2 Network to say, first, what do you think are the measure gaps, and some of you have identified a 3 measure gap; how would you propose to fill it? 4 And this is the measure that they put 5 6 So, at some level, the Medicaid Medical forward. Directors, their representatives, if they had a 7 concern with it, they didn't voice it. 8 9 But now that Rachel is here --MEMBER LA CROIX: 10 Yes. 11 DR. MATSUOKA: So, the question on the 12 table is, one of the Medicaid Medical Directors 13 from New Hampshire -- well, we reached out to the whole network of Medicaid Medical Directors to 14 15 say, what do you think the measure gaps are and, 16 if there are gaps, what would you put forward to fill it? 17 18 This is what that network put forward, 19 which is the preventable ER visit measure that 20 they are using in New Hampshire. So, the 21 question that Deborah put forward is, you know, 22 we know that this measure is probably used by

many states, but may be defined in different ways 1 2 by different states. And so, if we were to adopt this particular specification, what would that do 3 to other states? And so, I gave my input, but, 4 really, I want to hear what you have to say. 5 MEMBER LA CROIX: No, I'm looking at 6 7 preventable events in general, not just emergency 8 department, as something that has become a 9 priority for Florida Medicaid at least. We've started looking at it using the 3M software. 10 And 11 so, we have been using those algorithms and 12 running it through those, rather than having a 13 separate measure like this. 14 And through that, we have been looking at emergency department admissions, readmissions, 15 16 and ancillary care. So, we have been starting to 17 try to look at a few different things like that 18 as kind of outcome measures. 19 So, we definitely would agree with the 20 importance of this kind of measure, but I would 21 have to look in more detail at the specifics 22 around it to see whether that would be something

that would work well with some of the other ways we're looking at this data.

MEMBER POOLE-YAEGER: Hi. This is a 3 4 question for the measure steward. You mentioned 5 looking at the NYU algorithm and, then, changing. I had looked at the NYU algorithm as well from a 6 7 pediatric perspective. A lot of those algorithms 8 are based on adult ED visits. And so, when you 9 look at PD conditions on there, it didn't make a 10 lot of sense to me. 11 So, can you just explain a little bit 12 Like was it pediatric-based when you more? 13 looked at those diagnosis codes? And, you know, 14 explain that a little bit more. I think one thing that 15 MS. STEWART: 16 we need to point out with this measure is that we 17 actually do use it across adults and children. 18 So, we realize that this has been selected for 19 discussion for the child core set, but it really 20 does apply to both. 21 MEMBER POOLE-YAEGER: Thanks. Yes, I 22 think, again, from my perspective, the devil's in

> Neal R. Gross and Co., Inc. Washington DC

1

1	the details, in the codes that you pick. At
2	least from my perspective I don't know; Terry
3	may have some comments but it's different in
4	kids sometimes than adults. And so, I would love
5	to have a pediatric-specific one, if we were
6	going to use in the child set.
7	MEMBER ADIRIM: Yes, I think your
8	point is well-taken. I think we might have a
9	different set of conditions or a different bar
10	for emergency department visits than in an adult
11	world.
12	I think this measure gets somewhat
13	indirectly to access. You know, so it would be
14	like one of those measures measuring access to
15	care to primary care, but maybe not, because,
16	supposedly, now we have more access to primary
17	care; we have Patient-Centered Medical Home. And
18	yet, ED visits go up.
19	So, I'm sort of hesitant to want any
20	measure around ED visits at all for that reason,
21	because it is a tough measure because, then, it
22	is often, as somebody mentioned, applied for

value-based purchasing programs and incentives, and things like that. So, yes, that's all I would say about that.

4 MEMBER BEATTIE: So, I am just 5 reiterating with an emphasis from Washington 6 state what Amy was saying. I worked on a task force when I was there with our Medicaid 7 8 department, trying to establish a metric just 9 like this just for the state, where we, then, would track each of the healthcare systems and 10 11 adjust their reimbursement based on their ability 12 to achieve this. And the devil is truly in the 13 details.

14 Before I could endorse a measure like 15 this, I would have to be able to look at the exact list of what is on the list. And I am not 16 17 familiar with the NYU criteria. But I can say, 18 when we tried to get to that, we actually settled 19 on something in the state that didn't involve 20 this specific type of a metric, because it was 21 just too hard to say that, based on a code, you should or shouldn't be seen in a particular 22

> Neal R. Gross and Co., Inc. Washington DC

1

2

setting because there are so many other factors. And it just depends, and especially in kids it depends.

And I think that when you move towards more and more of our patients being under a managed care model with a per-member per-month, you know, ACO-type model, that indirectly addresses this because the systems are incentivized to direct the patients to get the care at the appropriate location.

11 MEMBER ADIRIM: Yes, I was just going 12 to add, I support what you are saying. In our 13 health system, people insisted -- and I was 14 neutral on it -- but they insisted on including a 15 measure, and it is not a real measure, but just, 16 basically, how many kids had ESI 1 or 2 coded, 17 and that those were assumed to be ambulatory 18 care-sensitive kind of visits. 19 So, there's all different viewpoints. 20 There's all different ways that you can measure

22 really looking at this, but there's a lot of

this. And I know people who are payers are

Neal R. Gross and Co., Inc. Washington DC

21

1

2

issues around child visits to emergency
 departments.

This is Andrea Stewart 3 MS. STEWART: We did submit the list of ICD-10 codes 4 again. 5 that we utilized for this measure when we sent 6 the information to May back in April. And I don't know if anyone has access to that list. 7 8 To whom did you CHAIR ANTONELLI: 9 submit the codes? 10 MS. STEWART: It was part of the 11 document that we emailed to May when we sent the 12 NQF MAP Measure Form. It was the last section of 13 that document. It starts on page three and goes 14 for about seven pages. 15 MS. GORHAM: Can you speak to the 16 child-specific codes? We are looking for the 17 document that you're referring to now. 18 MS. STEWART: Okay. We have, let's 19 see, we've got conjunctivitis. We've got a whole 20 slew of ear-related diagnoses. Oh, we've got the 21 sinusitis. We've got tonsillitis. We've got 22 other respiratory conditions. We've got nausea

and vomiting, a number of pain-related diagnoses. 1 2 I'm just trying to think kind in general highlevel groups. Asthma. Diaper dermatitis is one 3 of the very specific ones. 4 Do you want me to go 5 MEMBER BEATTIE: So, a number of those diagnoses that you 6 ahead? are mentioning have a very broad range of 7 presentation and would appropriately -- for any 8 9 one of those, I could give a scenario where that may be the diagnosis, but would be appropriate 10 for a kid to be in the ED. 11 12 Specifically, tonsillitis, I recently 13 had a patient whose primary diagnosis was 14 tonsillitis, but ended up expiring from sepsis 15 within 36 hours. So, had that kid presented to 16 the ED instead of an ambulatory setting, there might have been a different management on the 17 18 initial presentation. 19 So, I'm just going to have a real 20 challenge in using this as a quality metric. Ι 21 think there are just way too many variables, and 22 there is a better way for Medicaid systems to get

at the outcome they are trying to get, which is appropriate destination care.

MEMBER POOLE-YAEGER: 3 And I'm just 4 going to comment that I completely get -- I mean, 5 again, we struggle with this. I know it is the number one measure that the Medicaid Directors 6 7 ask for. We are all trying to get at the answer 8 to this question, but I think probably every 9 state has a different way of doing it, because it is so hard to figure out. 10

And I will give another example. You 11 know, upper respiratory infection in a 10 year-12 13 old may not be bad, but in a two month-old it is. 14 And so, I have never seen an algorithm that kind of does enough in pediatrics to make me feel 15 16 comfortable from a clinician perspective that it 17 is getting at the right thing. So, if that 18 helps --

19 MEMBER ADIRIM: Right. And just very 20 briefly, I agree with everything that is being 21 said here. I think the problem I have with this 22 is that I just don't see interventions to change.

> Neal R. Gross and Co., Inc. Washington DC

1

You know, I work in an emergency department. 1 Ι 2 still work shifts every month. And 80 percent Medicaid, and you can teach them, you can talk to 3 4 them; it won't change anything. In fact, they 5 don't know the difference between the ER, their primary care doctor, and the urgent care. 6 7 So, I just don't see interventions 8 that are necessarily going to change this. ACA 9 was supposed to be the intervention to reduce 10 emergency department visits, and they went up. 11 So, I think it is important that we 12 follow this and that we look at this and people research this, but I'm not convinced that there 13 14 is a lot of state -- well, anyway, sorry. So, I would like to 15 CHAIR ANTONELLI: 16 call the question. Does somebody want to make a 17 motion? 18 Amy? Mic, please. 19 MEMBER RICHARDSON: I move that we not 20 adopt this, recommend this measure for addition 21 to the child core. CHAIR ANTONELLI: Is there a second? 22
i	ے ا
1	MEMBER BEATTIE: I'll second that.
2	MS. GORHAM: So, there is no need to
3	vote on this measure then.
4	CHAIR ANTONELLI: Yes.
5	MS. GORHAM: We can move to the next
6	one. The next set of measures are actually the
7	FECC measures, the measures, that family
8	experience with coordination of care measures.
9	The measure steward is the Seattle Children's
10	Research Institute.
11	And so, the lead discussant for this
12	measure is Terry. I know that Rich wanted to say
13	a few words first.
14	CHAIR ANTONELLI: Thank you.
15	So, first, a disclosure. I was on the
16	Delphi panel that led to the formation of the
17	FECC. But, just to be clear, we weren't putting
18	the questions or measures together. The Delphi
19	panel was basically asked, what does care
20	coordination look and feel like? So that they
21	could eventually lead to that. So, that is my
22	disclosure.

And then, I also want to really do
some ground rules here. The National Quality
Forum doesn't endorse surveys. What it does is
it puts forward measures. So, there are a lot of
questions, all of which roll up into the FECC.
And what I am going to ask Terry to do
is to talk about them really and, if you will, en
masse. And then, we will get people to react to
them, okay, just for the sake of time management.
MEMBER ADIRIM: Okay.
CHAIR ANTONELLI: All right. Terry,
take it away.
MEMBER ADIRIM: I get it. Good. I'm
an ED doc. I'll talk in bullets.
So, the reason why I recommended this
set be considered by us for inclusion in the core
set, there's several reasons. This measure set
came to mind when looking over the high-priority
gap areas. This fits several of those high-
priority gap areas, including care coordination,
social services coordination, care coordination
for conditions requiring community linkages,

targeting people with chronic needs, patient reported outcome measures.

So, I really thought that this hit a 3 number of the high-priority gaps. It is a PQMP 4 measure from one of their Centers of Excellence -5 - the Centers of Excellence which create measures 6 for us to consider for the child core set. 7 8 The set of measures are 10 measures. 9 It is based on a survey of families. It is family experience with care coordination. 10 The 11 denominator is elucidated by a pediatric 12 medically-complex algorithm which is an evidence-13 based tool to identify medically-complex 14 children. So, the target population is 15 16 medically-complex children, which for state 17 Medicaid agencies, as you know, are high-cost 18 populations. So, it targets that population. 19 And of the 10 measures that went up 20 for endorsement, 8 of them were endorsed. And 21 you can see it yourself under the list of measures, but it hits multiple areas for care 22

> Neal R. Gross and Co., Inc. Washington DC

291

coordination for children with special needs or medically-complex children.

So, I really think it is important 3 4 that we do consider parsimony, but you need to 5 balance that with generating stretch goals. And somebody else used that term. I think Lindsay 6 7 mentioned that term. So, having some stretch goals, looking at our core set, are we addressing 8 9 all the needs of this population? And 10 considering a measure set that may be more measures than you would like, but I think really 11 12 hits areas that we have been talking about for 13 the last several years that we would like to 14 I will say that this measure set is an have. evidenced-based, very well-done measure set. 15 16 So, I know that one of the 17 representatives of the measure developers is on 18 the phone who could probably speak better about 19 what the measures specifically are. I believe 20 her name is Layla, is on the phone, in case you

22

21

1

2

So, I just wanted us to consider this.

Neal R. Gross and Co., Inc. Washington DC

(202) 234-4433

have questions.

www.nealrgross.com

1	CHAIR ANTONELLI: Okay. Open for
2	comments and questions.
3	Deborah?
4	MEMBER KILSTEIN: Yes, my question is
5	the child core set already includes CAHPS, which
6	is a fairly extensive survey. So, this would be
7	adding another, a second survey, which is pretty
8	intensive. Is there no way that some of this
9	can't be put into CAHPS as an additional CAHPS
10	question versus a separate survey?
11	MEMBER ADIRIM: This is a completely
12	different survey, hits a different population.
13	The CAHPS survey, my understanding and you
14	guys correct me if I'm wrong is for all
15	children, as opposed to this particular measure
16	set that identifies medically-complex children
17	within Medicaid. So, it is a different measure
18	set.
19	I don't know if somebody more
20	MEMBER KILSTEIN: Isn't there a way
21	that we could do a subset like a and
22	additional CAHPS questions that would where

I	2
1	we, for the subset, ask a question
2	MEMBER ADIRIM: That would, then, take
3	I mean, I would imagine that they would have
4	to redo it all, and it is already NQF-endorsed,
5	the measures the way they are.
6	I don't know. Somebody else might
7	CHAIR ANTONELLI: Do we have somebody
8	from Seattle on the line?
9	MS. PARAST: Layla Parast is here.
10	I'm from RAND, but representing Seattle. I was
11	the statistician on the project. I can comment
12	on that, if it would be helpful.
13	CHAIR ANTONELLI: Yes. In fact, keep
14	your comments as circumscribed as possible,
15	please.
16	MS. PARAST: Yes. Okay. So, I didn't
17	hear what was just said. I think it was a little
18	bit far away from the microphone.
19	But, in terms of adding to CAHPS, they
20	are certainly different surveys and very
21	different populations. But I know that other
22	CAHPS surveys have the opportunity to add

supplemental questions as long as they are at the 1 2 end of the core CAHPS questions. So, that could be considered for the questions that would be 3 It would need to be 4 needed for these measures. 5 identified such that only kids that should be receiving these questions receive the survey with 6 7 the supplemental questions, but that is certainly 8 done in other CAHPS settings to tailor the 9 surveys like that. 10 CHAIR ANTONELLI: Okay. So, your 11 response to Deborah Kilstein's question is that 12 it is possible? 13 MS. PARAST: Yes. 14 CHAIR ANTONELLI: Okay. Thank you. 15 Roanne? 16 MEMBER OSBORNE-GASKIN: So, I just had 17 a question about any idea of the percentage of 18 medically-complex children who would be excluded 19 because their caregivers don't speak English or 20 Spanish. I think there is a need for care 21 coordination especially in that population, and I 22 notice that they are the ones who would be

So, do we have any idea how many or a 1 excluded. 2 percentage? Or I'm just curious about that. MEMBER ADIRIM: I don't know. 3 I'm not 4 the measure developer. So, I will let them 5 answer that question. CHAIR ANTONELLI: Could you hear the 6 7 question. 8 MEMBER ADIRIM: But it is in English 9 and in Spanish. Yes, I did hear the 10 MS. PARAST: Yes. 11 question. And, yes, the survey is available in 12 English and Spanish, but you're correct that 13 families who may not speak English or Spanish 14 would not be covered by the survey. It currently is not translated into other languages, but could 15 16 be. 17 I don't have numbers on the proportion 18 that were ineligible due to a language barrier. 19 I seem to remember it was quite small. But we 20 tested in the Medicaid population in Washington 21 and Minnesota. So, I think even any percentage I 22 gave you, of course, wouldn't be representative

1

of the whole country.

2	So, that would certainly be a concern,
3	but it is something that could be addressed with
4	further translations, just like the CAHPS surveys
5	are certainly translated over time in multiple
6	languages, as you identify what populations are
7	not being targeted.
8	CHAIR ANTONELLI: Andrea?
9	MEMBER BENIN: Just a comment on the
10	CAHPS. There is a CAHPS chronic care module that
11	can be added onto the end of CAHPS. We've looked
12	at it up against the FECC questions. The module
13	is extremely long. It is like quite weighty,
14	like all of the CAHPS modules.
15	And the brilliance in the development
16	of the FECC questions is that they are
17	independently-validated. So, the questions stand
18	alone. They don't have to be in contrast,
19	when you do a survey, you know, the survey
20	validity depends on the survey being administered
21	in the way that it was designed. And the FECC
22	survey questions, to my understanding, are

validated independently. So, they can be used 1 2 and they don't have to be used a whole. And so, that gives you a little bit more flexibility in 3 4 the survey burden. In contrast if you were to 5 use the CAHPS chronic care, you have to add that entire module onto an entire CAHPS thing. 6 So, that's my understanding of that. 7 8 CHAIR ANTONELLI: Helen? 9 DR. BURSTIN: Just some historical 10 I think over the years we have seen context. newer surveys come forward, and, eventually, we 11 12 have seen some surveys come together. 13 I will say this was particularly different. 14 The developers were charged with doing work on care coordination, which is the 15 16 biggest gap across everything we do in all health 17 care. We have almost no decent measures on care 18 coordination. They tried to do a targeted 19 They tried to do claims. review. They tried to 20 And truly, the only way to really do e-measures. 21 get at care coordination with this complex 22 population was asking parents. There is almost

nothing in the current CAHPS survey that really 1 2 gets at care coordination. So, I just want to remind us, again, I 3 4 agree it is patient self-report, which is 5 certainly a burden, but it is the only one that actually gets at the unique and special issue for 6 7 kids with special healthcare needs around care 8 coordination, which was the intent. 9 MEMBER ADIRIM: And I think it also 10 gets at those things that we have been talking 11 about with regard to outside of the medical 12 I mean, coordinating with social sphere. 13 services and the like. So, I think that is what 14 makes it unique. So, does somebody 15 CHAIR ANTONELLI: 16 want to make a motion? 17 MEMBER ADIRIM: I move that we 18 recommend including the FECC measure set in the 19 child core set. 20 CHAIR ANTONELLI: To get the language 21 precise, it would be the NQF numbers that are in this, as opposed to the FECC itself, right. 22

	30
1	MEMBER ADIRIM: Okay.
2	CHAIR ANTONELLI: Yes.
3	MEMBER ADIRIM: So, the 2842, 43, 44,
4	45, 46, 47, 49, 50, the eight measures that were
5	NQF-endorsed.
6	CHAIR ANTONELLI: Yes. Okay. Is
7	there a second? Did somebody second?
8	MEMBER GREINER: I'll second.
9	CHAIR ANTONELLI: Okay. So, it's been
10	seconded.
11	Any discussion?
12	Amy looked perplexed. You look
13	perplexed.
14	MEMBER RICHARDSON: I am.
15	CHAIR ANTONELLI: Microphone, please.
16	MEMBER RICHARDSON: Perplexed, just
17	trying to envision how we anticipate this will be
18	done. This will by the states? This will be
19	done by health plans? Who will do this at what
20	cost?
21	CHAIR ANTONELLI: Renee or Karen?
22	DR. MATSUOKA: So, this is a little

bit of an unusual situation because all the core 1 2 sets are voluntary. And so, if we were to hypothetically put these on the core set, I'm 3 guessing what we would do is the technical 4 5 specifications would just be the survey questions. And then, I think it would be up to 6 the states to determine how they're going to go 7 8 about administering those questions. 9 DR. FOX: And I guess this isn't so 10 much a question, but a comment. It is that, if 11 you were going to choose one of these eight, is 12 there one that gets to most of the question? 13 CHAIR ANTONELLI: Boy, at the risk of 14 opening that Pandora's box, I will exercise the 15 Chair's prerogative and ask the developer that 16 question, if that's okay with you. And everybody 17 keep your fingers crossed because there is a 18 holiday on Monday. 19 So, measure developer team, Dr. Fox 20 has a question for you. Did you hear it? 21 MS. PARAST: I did. I did hear it. 22 CHAIR ANTONELLI: Okay.

1	MS. PARAST: Of course, we would say
2	that we certainly think these measures are best
3	used together because we think they provide
4	complementary information to each other.
5	I think that they certainly could be
6	used individually. We did, as was mentioned,
7	validate them individually, so that different
8	states or entities, whoever is interested in
9	this, can pick and choose. It is hard to just
10	pick one because it depends what you're
11	interested in and what you might know is a gap
12	maybe in your specific state or plan.
13	So, I think a lot depends on what you
14	might already know about your particular
15	population. I don't think that there is a single
16	one that captures everything because, I mean, if
17	you just look at them, they cover such a large
18	range of components of care coordination. But I
19	think it would be possible to pick one, depending
20	on what is most important to your population.
21	CHAIR ANTONELLI: So, I'm just going
22	to come back to you. So, based on the experience

in Minnesota and in Washington, do you have data 1 2 that would directionally suggest any kind of a hierarchy and, if so, at what level, at the 3 state, at the region, at the level of a hospital, 4 at the level of a practice? 5 A hierarchy, you mean in 6 MS. PARAST: 7 terms of the measures? 8 CHAIR ANTONELLI: Yes. I know you 9 gave an answer to Dr. Fox. But I'm sort of 10 putting myself in the position; I'm a Medicaid director and I'm going to choose one of these 11 12 things. What is the guidance that would give me 13 a sense of where to begin the process? 14 So, one way to think MS. PARAST: about it would be that in part of our validation 15 16 work we looked at how these measures are 17 associated with a caregiver's overall rating of 18 their provider and their overall rating of access 19 to care. And so, we identified measures that 20 were key drivers, like really key drivers of 21 provider rating, and suggested that if you were only to target a certain subset, that perhaps 22

1 these would be the ones you would want to target. 2 And we found that, basically, having a designated care coordinator and a shared care plan were the 3 4 strongest ones associated with provider rating. 5 So, those are the two I would put at the top of my list. 6 CHAIR ANTONELLI: Okay. All right. 7 Thank you. 8 9 Roanne, unless you've got something burning, I think I am going to bring this to a 10 Is that okay? 11 vote. Okay. 12 All right. And then, following our 13 pathway so far, does anybody want to suggest a 14 condition? Otherwise, it's an up/down without a 15 condition. 16 (No audible response.) 17 Okay. No conditions. 18 All right. Miranda? 19 And are we going to have to vote for 20 each one individually since they are NQF 21 measures? 22 DR. BURSTIN: No.

	ۍ ۱
1	CHAIR ANTONELLI: So, all of them
2	together? Okay.
3	MS. KUWAHARA: So, again, we are
4	voting for the measure set, not the eight
5	individual measures previously recited. So, we
6	are voting to add the family experiences with
7	coordination-of-care measure set to the child
8	core set.
9	If you would like to support this
10	measure please select 1; if not, please select 3.
11	Let's try it now.
12	(Voting.)
13	There we go.
14	We are waiting on one more response.
15	There we go.
16	Fifty-four percent of the 13 voting
17	members voted to support this measure, and 46
18	percent voted not to support this measure. So,
19	we will not be recommending this measure for
20	inclusion in the core set.
21	DR. BURSTIN: So, there was one other
22	measure from Seattle Children's from that same

set that just came through our process, and I 1 2 don't want to add it initially for today, but just to point it out to you. There is a 3 4 continuity of primary care for children with 5 medical complexity that is a new measure that is claims-based. I don't know that anybody has seen 6 7 it yet. 8 We could certainly pass people on 9 information about that to follow. But it is claims-based, intended at the level of the health 10 plan, specifically using -- you guys probably 11 12 know more about this -- a Bice-Boxerman 13 Continuity of Care Index over a 12-month period. 14 So, it is a brand-new measure going through our process. It should be endorsed in 15 16 June. 17 CHAIR ANTONELLI: Thank you. 18 DR. BURSTIN: It's 3153. 19 CHAIR ANTONELLI: All right. So, I 20 think we have gone through the list. Yes? 21 DR. BURSTIN: I think you did. 22 CHAIR ANTONELLI: Yes. So, I'm going

to hand it over to Shaconna to tell us what is 1 2 next. 3 MS. GORHAM: So, we are going to go to 4 public comment before we rank within the room, 5 because I know that some members have to leave, and that is very important that we stick our 6 stickers where we need to. But we want to go to 7 8 public comment first. 9 So, Operator, can you open the line up 10 please? 11 **OPERATOR:** Ladies and gentlemen, if you would like to make a public comment, please 12 13 press *1 on your telephone keypad. Again, that's 14 *1 for a public comment. 15 (No audible response.) 16 And currently, we have no public 17 comments at this time. 18 MS. GORHAM: Thank you so much. 19 So, for the members in the room, we 20 are going to rank. So, the adults did it 21 yesterday. But we are going to put the slide up of all of the measures that you have recommended 22

for inclusion thus far. They are also written
behind you, one directly behind me and one to the
left of me.

4 We have four measures that were 5 recommended. And we have 1800 as the medication We have the 2903, contraceptive care, 6 ratio. 7 most or moderate effective measure or method. 8 That is with condition. And we have the 2800, 9 metabolic screening. We have the 0418, screening for clinical depression and followup. And then, 10 we have the 3154, informed coverage, and that is 11 12 also conditional support.

13 So, you have four dots. The colors 14 mean nothing at all. You put your dots where you would like to see the measures ranked. 15 So, we 16 will ask CSM for addition of these members. But, 17 when we put them in the report, we will say that 18 the Child Task Force recommended these measures, 19 and we will put them in order of importance.

20 You can do however you want. If you 21 think that you want to put all four dots on one 22 measure because that measure is that important,

	د ا
1	you can do that. So, you can put your dots
2	wherever. You only have four, but we have five
3	measures that are recommended. So, that way, it
4	will help us rank.
5	Let's do that now.
6	MS. MUKHERJEE: So, if we can just
7	quickly come back? We're almost done. Our
8	ranking is over.
9	And so, 2903 and 1800, the
10	contraceptive care measure as well as the asthma
11	measure, those two got the most ranking votes at
12	14.
13	And then, we have 3154, which is
14	informed coverage, the third highest one with 10
15	votes.
16	And then, we have 0418, screening,
17	with 9 votes.
18	And the lowest vote was No. 2800 with
19	5 votes.
20	So, we have our top three. Our top
21	three would be 2903 and 1800 being one, and then,
22	two being 3154, and then, 0418 being No. 3.

With that, we go into our second 1 2 activity of the afternoon, which is looking at And with respect to gaps, what we wanted 3 qaps. to do is be, again, not necessarily strategic, 4 5 but parsimonious and look through all the gaps, which you will see are on the sidewalls and 6 7 stickies. 8 And we wanted to go through another 9 prioritization exercise with the gaps because we know a lot of these gaps have existed and will 10 exist, and the list will live. But, if we want 11 12 it to be truly parsimonious and give CMS some 13 concrete direction, we wanted to be able to 14 triage them and provide them with sort of the top 15 five gaps. 16 And so, we'll take part in another 17 exercise now where you will get dots. And then, 18 the gaps, as you can see, are on the sidewall. 19 And we ask you to be thought about sort of 20 ranking them and, again, giving your dots to the 21 different topic areas that you think are sort of 22 most important. And that doesn't mean the rest

of the gap areas will go away, but it will add 1 2 sort of an additional level of analysis, as sort of here are the top five gap areas. 3 4 MEMBER RICHARDSON: Sorry. For each 5 of your gap areas, do we know that there are existing measures? 6 7 MS. MUKHERJEE: No, no. 8 MEMBER RICHARDSON: Okay. 9 DR. BURSTIN: So, I'll just mention, 10 for the adult group, and for some of you who were with us the first day, we also shared with this 11 12 group the new prioritization criteria NQF has put forward across all of our work. And so, this 13 14 might just be informative as you think and look 15 towards this. 16 So, there's four criteria: The first is we prefer measures to be 17 18 outcomes-focused, either outcomes or closely 19 related to outcomes. The second is we would like them to be 20 21 improvable and actionable, something that came up 22 a lot through the course of this discussion over

1 the last several days.

2	The third is we would like the results
3	to be meaningful to patients and caregivers, that
4	those results would be understandable and they
5	would know what to do with them.
6	And the fourth, I think really
7	importantly for a population like kids, in
8	particular, is we would like to see measures that
9	increasingly reflect an integrated view of care.
10	So not measures necessarily that are so site-
11	specific or provider-specific, but more reflect
12	the integrated or a systemic view of care.
13	So, if that is helpful for you, as you
14	look through those, we will be building that into
15	all of our work going forward. So, this is a bit
16	of a preview for you, but I think it is a helpful
17	way to think.
18	Thanks.
19	MEMBER SAKALA: Did you want us to
20	vote on the domains or the subdomains?
21	MS. MUKHERJEE: So, I think the
22	domains because we will keep the subdomains. So,

1 if you really thought you wanted to promote one 2 subdomain, feel free to give it a dot, and we will just highlight as something under the 3 4 domain. But, if you say one of the domains, like 5 the cost measures, are the most important, we will say these were the two subdomains with it. 6 7 But it is completely up to you. If you think one 8 of the subdomains is more important than sort of 9 the big criteria, feel free to vote either way. DR. BURSTIN: And shall we also allow 10 them to add a measure, add a gap, as we did for 11 12 the adult side? But, unfortunately, they were 13 tougher than I would have been. You have to use 14 a dot if you put a new one up. But feel free to add one as well. We probably should do that 15 16 first before everybody goes up. 17 MS. MUKHERJEE: So, on this side, we 18 will have an "add your gap," and you will lose a 19 dot. 20 (Laughter.) 21 Just for parity, because adults did that, the adult group, and they had to like 22

provide a dot for the new category that they 1 2 added. DR. BURSTIN: And the added dot got 3 4 more votes than anything else on the screen. So, 5 don't feel bad about adding a dot. So, I have an issue 6 MEMBER SAKALA: with overuse because I think that often is paired 7 8 with underuse. Like, if you are not going to do 9 -- so, here's an example -- electronic fetal monitoring, you had better do intermittent 10 auscultation. And so, it is not only about -- or 11 12 there's a lot of beneficial practices that are 13 not part of the culture, whatever. 14 So, can I pair that with overuse because I think it goes with it? Or does that 15 16 become an extra one? 17 MS. MUKHERJEE: It's not on; it will 18 be a new one. 19 MEMBER SAKALA: Okay. 20 MS. MUKHERJEE: You can put it on the 21 blank sheet over here as sort of a new and say it is pairing with that, but you will still lose a 22

1 dot. 2 MEMBER SAKALA: Uh-hum. It's okay. 3 MS. MUKHERJEE: You can 4 add it. 5 MEMBER SAKALA: Thank you. Yes. MS. MUKHERJEE: And we're ready. 6 We 7 have all of that up there on the sides. You all 8 have your dots. So, feel free to sort of get up, 9 move around, add your dots. And the blank sheet is up as well with a marker there. So, we're all 10 11 set. 12 No, go ahead. 13 MEMBER OSBORNE-GASKIN: I just have a 14 question about the durable medical equipment. 15 Was there a specific concern about that or was 16 that a cost thing? 17 MS. MUKHERJEE: An access issue with 18 that and sort of supply, and things like that. 19 (Pause.) 20 CHAIR ANTONELLI: We are all set. So, 21 do we --22 MS. MUKHERJEE: We have the data right there.

1

2	CHAIR ANTONELLI: Oh, there it is.
3	There it is. All right. This is you, isn't it?
4	MS. MUKHERJEE: So, hello, everybody.
5	I am just going to sit back here, so I can see
6	the dots.
7	And so, the top ones seem to be
8	substance abuse; mental health, and with mental
9	health, we have also the subcategories of ED use
10	for behavioral health, coordination, access,
11	things like that. We also overuse, medically-
12	unnecessary care.
13	And a point was brought up that, with
14	overuse, we should always pair underuse. Because
15	if you are overusing something, you're underusing
16	something that's more appropriate. So, we might
17	add that and make that modification.
18	And the others that sort of fell out
19	in the top five were coverage; that was the other
20	one, duration of insurance coverage. And then,
21	we also have a subcategory that was added to
22	that. So, we will capture that.

(202) 234-4433

i	ن ۱
1	We have mental health, which I think
2	I've already covered.
3	So, we have substance abuse, one;
4	mental health, two; coverage, and then, we have
5	cost of measures. And then, the final one I
6	can't even read my own handwriting is care
7	coordination. Care coordination is huge. That
8	was the other one. That's on the top five.
9	So, we will roll it up. So, when we
10	talk about the measure, we will say care
11	coordination and, then, we will call out all of
12	these, but, then, highlight the ones that got
13	dots.
14	It is care integration. Care
15	integration has two yellow, one red. Care
16	coordination for conditions requiring community
17	linkage has one yellow. Cross-sector measures
18	has one yellow. Social services coordination,
19	one red. And then, care coordination all
20	together has one, two, three, four, five, six,
21	seven, eight. Eight dots.
22	And with that, we have ranked our

measures. We will keep this. We will add them 1 2 up and add it to the report. And then, with that, I will turn it 3 4 over, because we are coming to the final stages 5 of our last day of meeting. So, we are going to open 6 MS. GORHAM: 7 it up for public comment one more time. 8 Operator, can you open the lines, 9 please? 10 **OPERATOR:** Ladies and gentlemen, if 11 you would like to make a public comment, please 12 press *, then 1, on your telephone keypad. Again, *1 for a public comment. 13 14 (Pause.) And currently, we have no public 15 16 comments. 17 MS. GORHAM: Thank you. So, on your screen, for the folks in 18 19 the room, all of the measures that you ranked, we have them listed: 20 21 2903, contraceptive care, and 1800, 22 asthma medication ratio, I will rank No. 1. They

tied. 1 2 3154, informed coverage, was No. 2. 0418, screening for clinical 3 depression and followup, ranked No. 3. 4 5 And then, No. 4, 2800, metabolic screening for children and adolescents, ranked 6 7 No. 4. 8 So, with that, if there are no Okay. 9 questions or comments on the measures that will be recommended to CMS -- Andrea? 10 11 MEMBER BENIN: I just have a comment 12 But are you doing that next? about gap. No? 13 MS. GORHAM: No. You can now. Now is fine. 14 15 MEMBER BENIN: Okay. 16 MS. GORHAM: As long as there are no 17 comments on the recommended measures, we 18 definitely can floor and take comments for gaps, 19 or whatever else. 20 MEMBER BENIN: Okay. I just want to 21 really echo what Kathryn said earlier about the mental health issues, particularly the mental 22

health issues in the emergency department. 1 2 There's an absolute crisis right now in the emergency departments around mental health. 3 And I think whether that is related to the Netflix 4 5 television activity and the other things that have been going on, it is untenable what is going 6 on in our emergency departments. And that is 7 8 consistent through -- it is not just --9 Connecticut is a disaster, but it is consistent throughout children's hospitals that emergency 10 11 departments are filled -- filled -- with children 12 who are suicidal, and there are no beds for them. 13 We get in our emergency department 30 14 new psych patients a day. And at any given time, 15 we have patients who have been in our emergency 16 department for 20 or more days. So, it is a 17 substantial -- substantial -- problem, and it 18 doesn't just impact those poor children, but it 19 impacts the other septic babies who come in and 20 all those other people who can't access the 21 emergency department because we are running a 22 psych ward in a way that is not the best for

those children. They shouldn't be getting their
mental health care in an emergency department.
That's not ideal for them.

So, this is a substantial crisis that I cannot possibly imagine that we, as a sort of field, you know, can't figure out how to measure better, so that we can explain it better in a way that we can make change. Because what's going on out there is really horrifying.

10 CHAIR ANTONELLI: So, I'm going to 11 react to that. And then, Kathryn, I will pick 12 you up.

I'm not sure that the answer is necessarily measuring better. Because what you just said actually is universal is for pediatrics; it's adults. EDs are basically, they are holding tanks.

In Massachusetts, anywhere between 20 and 40 percent of every emergency department bed in the entire Commonwealth is taken up by a patient with acute psych needs, and there is no disposition.

1	And so, I want to sort of challenge
2	that notion. So, I think we have got measures
3	that show that the system, as it is currently
4	functioning, is really, really inefficient,
5	ineffective, and, in fact, undignifying.
6	But are there interventions that
7	would, then, call the need for better measures?
8	I don't mind. I put a lot of those yellow
9	stickers over there that link to the community.
10	So, going upstream for pediatrics as well as
11	adults in the behavioral health space is better.
12	So, I do want us to think, yes, this
13	is the National Quality Forum. We are all about
14	measurement. But I also think that we already
15	know just how horrible this problem is. So, that
16	was my editorial comment.
17	Kathryn, to you, please.
18	MEMBER BEATTIE: So, I am just going
19	to add to what Andrea was saying on two fronts.
20	One, I do think putting a quality metric is a way
21	of communicating with our states' Medicaids.
22	And in the states that I have been an

administrator in as a pediatrician, one of the 1 2 major issues has been access for Medicaid patients because we will have the inpatient 3 4 facilities are not expanding. Either they don't 5 have enough staff for the beds they have or they are not expanding their beds because they can't 6 7 afford to, because the reimbursement is so low. 8 Then, we have the challenge of whether 9 or not they will even approve an appropriate So, it is very unlikely that, when you 10 stay. 11 change a medication for a kid, that a seven-day 12 stay is going to be long enough, but that is all 13 they want. They want them to come in for 14 inpatient psych care in seven days. So, I do think somehow getting to the 15 16 quality is linked to the appropriate location of 17 care by the appropriate providers that are 18 trained to manage these complex mental health 19 concerns of the children that we are dealing 20 with. 21 The second piece that I want to speak 22 to is actual safety. So, yes, the kids are

coming to the emergency department. If we admit them into the hospital, then they lose their standing for appropriate placement. And so, they go on the bottom of the list for the inpatient facility. But it is really unsafe to keep them in the ER, and it is often unsafe to admit them.

7 The place where I work now, we just 8 had Joint Commission there, and probably 50 9 percent of their time was talking about risk to our mental health patients, ligature risks. 10 So, if you know what a normal patient room looks 11 12 like, there are wires and cords all over. You 13 know, it is the pull cord in the bathroom. Ι 14 have had an adolescent patient, when they are walking one-to-one with a sitter, run into a 15 16 public bathroom and pull a plastic bag over their 17 head.

And so now, we have to not just think about the individual room and how we make that room safe, but how we make all the public areas safe. Because these aren't facilities that are designed to care for these patients.

> Neal R. Gross and Co., Inc. Washington DC

1

2

3

4

5

6
1	
1	And when you have an adult mental
2	health patient who is sitting, waiting for
3	appropriate placement, they are not kids. Kids,
4	you can't just lock them in a room and put the
5	lights off and give them some meds to sedate
6	them, and that's enough. I mean, we have to do
7	something to create a schedule and activities for
8	these kids, and it is just so unsafe when they
9	are not in an environment that is designed to be
10	safe for them.
11	So, I'm off my soapbox, but it is a
12	very complex issue and we really need Medicaid's
13	help, at least in every state that I have been
14	in.
15	CHAIR ANTONELLI: Terry?
16	MEMBER ADIRIM: No, and I can't repeat
17	enough, I agree with both of them. As somebody
18	who works in a peds emergency department, this is
19	a big issue.
20	So, if we have to have an emergency
21	department measure, this would be a good one
22	because I think there are things that the state

can do with regard to their managed care 1 2 contractors to improve these issues. I mean, kids do not belong in the 3 4 emergency department with mental health issues 5 unless they are going to be making it soon to an 6 inpatient facility, and that is just not 7 happening anywhere. 8 CHAIR ANTONELLI: Helen? 9 DR. BURSTIN: This brings an issue to me, and I'm not sure this is the case. 10 But I 11 also just wonder whether it would be useful to 12 look to see whether there are some existing adult 13 measures that actually could be specified for kids. 14 I was just trying to find on my 15 16 computer, which I couldn't. For example, there 17 are ED throughput measures --18 CHAIR ANTONELLI: Right. 19 DR. BURSTIN: Admit time, decision 20 time, things like that, that I don't know that 21 they're only adults. Or could they be looked at? 22 It might be an easier lift, for example, for the

Pediatric Centers of Excellence to take existing 1 2 measures and think about whether there might be some early modifications to some of those --3 CHAIR ANTONELLI: Right. 4 DR. BURSTIN: -- to get at issues like 5 boarding. 6 I know psychiatric patients stratified 7 8 intentionally. So, it might be really 9 interesting data. We would be happy to share 10 that with you guys, just to sort of see if we 11 could find the original specs and see if there is 12 an opportunity there, because this is, obviously, 13 untenable. 14 CHAIR ANTONELLI: And don't forget to 15 measure the gap, right? So, in Massachusetts, we 16 actually have legislation to drive ED boarding. 17 My wife does quality measurement for surgery at 18 Mass General. So, for them, it is boarding for 19 everything surgical. But, when I talk about it, 20 it is exactly what you are just saying, 20-plus 21 days sitting in the ED for a given patient. 22 So, I don't mean to say we don't need

additional measures. What I am saying is I think
that we have got boarding measures that we could
be thinking about.

But the gap area for me is the capacity, right? Why are those patients sitting in the ED? It is because they are not going to where it would be a higher-value setting.

8 So, if we think broadly and outside 9 of, let's call it, the traditional brick-and-10 mortar medical system, of which the ED is the 11 default repository, we should be looking at other 12 measures of acute psychiatric care and high-13 value, high-safety environments.

The number of states that I'm aware of 14 that are reducing inpatient beds, while the 15 16 country's pandemic of behavioral -- so, there is 17 something wrong with that, and we should be 18 thinking about those. And that is actually something that could happen, could and should be 19 20 happening at the level of states. Terry, you had something? 21

MEMBER ADIRIM: You know, I was going

Neal R. Gross and Co., Inc. Washington DC

22

1	to say I agree with that. And one of the things
2	and this is, again, anecdotal as an ED
3	practitioner but what I hear over and over
4	again from the social worker who is trying to
5	find a bed is they don't take Medicare or they
6	don't take this insurance.
7	So, I think there is something that
8	the state could do to move these kids to places.
9	And it is a bed issue, too. I mean, a lot of
10	times the beds are full and there's not enough
11	practitioners, and so on. But I think all of
12	this should be looked at and measured.
13	MEMBER KILSTEIN: I just want to say
14	that, for adults, there are different policy
15	issues and levers than for kids, and it has to do
16	with the Institution for Mental Diseases
17	restrictions that do not apply to kids under 21,
18	but do apply to a facility for more than 16 beds
19	for an adult.
20	CHAIR ANTONELLI: Amy?
21	MEMBER RICHARDSON: So, I don't
22	disagree with anything that has been said. But

we haven't talked about ownership of the problem, 1 2 and I think the states can only go so far until we have sufficient child and adolescent 3 4 psychiatrists. I don't hear anything happening 5 around workforce. All I do is have a drink with friends who bemoan the fact that there aren't 6 7 enough of them and don't see any progress on the workforce, and don't understand why some of this 8 9 isn't under the ownership of big health systems, 10 not the state, but big health systems who want to 11 build the beds that are gravy, right, have a big 12 margin, and don't want to build the beds that are 13 really hard and low-margin. And so, I think 14 there is a lot of ownership, that this doesn't 15 necessarily just belong to the states. 16 MEMBER ADIRIM: How do health systems 17 -- I'm sorry, I'm not sure I understand. Because 18 states and the federal government pay GME. So, 19 they would have a capacity to increase --20 MEMBER RICHARDSON: If you look at how 21 health systems billed -- I invite you to go to Cleveland and watch the arms race in hospital-22

building, right? And it's all about the high-1 2 margin beds. What kinds of beds, what kinds of services can we build that gives us the biggest 3 4 margin. And psych beds have a little, tiny 5 margin. Right. There is that, 6 MEMBER ADIRIM: 7 but we just don't have enough practitioners who 8 are willing to practice. 9 MEMBER RICHARDSON: Right. So, I would ask the psychiatrists and the child and 10 11 adolescent psychiatrists about workforce 12 development. 13 I'm not saying the states and all of 14 us don't have a role in this. I'm saying that we could task the states with fixing this. 15 And 16 until there's workforce and beds built, then it 17 is not going to get solved. It is not just tell 18 the states to fix it. 19 MEMBER BEATTIE: So, I am specifically 20 referring more to child and adolescent access to 21 care. And with that, we oftentimes don't have the continuum of care that we do in the adult 22

1	world, and that hasn't been acknowledged by
2	states to even develop a reimbursement model.
3	So, a great example is partial
4	hospitalization. A lot of the kids who end up in
5	the ED are somewhere below needing an inpatient,
6	but above being okay with seeing their
7	psychiatrist once a month and a counselor once a
8	week or so.
9	And most states today do not have a
10	reimbursement structure established for either
11	intensive outpatient, where the kid goes to
12	school all day and, then, goes into a therapy
13	setting for two or three hours after school every
14	day or a PHP, where they go to PHP all day and,
15	then, get to go home and sleep at night.
16	We are actually working very
17	aggressively in my team to get that reimbursement
18	structure developed with our Medicaid team. They
19	have reimbursement under Medicare for those
20	facilities, but those are all adults. And they
21	just don't have anything. You know, it is not a
22	code you can ask for.

ĺ	د. ا
1	So, there needs to be some
2	acknowledgment of this is a crisis for children
3	and adolescents. We need to develop the
4	reimbursement structure, so that you can even put
5	the program in place.
6	We are not even looking to make money
7	on psych. We're not. We just want to be able to
8	break even or use a moderate amount of foundation
9	money to support care for these kids.
10	But there needs to be some
11	acknowledgment that those are resources that need
12	to be available in our states.
13	CHAIR ANTONELLI: So, if I try to
14	string together the pearls that I have heard in
15	the last 12 minutes or so, what I'm hearing is
16	that it is a pandemic problem and there's lots of
17	opportunity for collaboration, right? So, I
18	agree with you about high-margin beds. There's a
19	reason why people build, you know, cardiac
20	surgery hospitals, right?
21	But, that said, so the delivery system
22	has ownership. The financial incentives, the

types of care models that you are referring to,
for which in some cases there's already evidence,
and just because there's no code, you can't
implement them.
So, this is a shared responsibility.
And frankly, I can't think of any other way of
going after the behavioral health crisis in this
country without everybody sort of stepping up.
So, next steps.
Yes, go ahead. You did this so well
yesterday.
(Laughter.)
MS. KUWAHARA: So, between now and
July 7th, the project staff will diligently to
capture the recommendations and sentiments from
the Adult and Child Task Forces. And then, we
will go out for public comment on those drafter
parts, July 7th through August 6th. Then, the
final reports will be submitted to HHS August
31st.
The MAP Coordinating Committee will
meet to be determined, August-September time.

sort
sort
sort
5
:
e is
1
1
),
x you
sort
ping

	3. I
1	sort of guide us through two days of intense
2	discussion. We wouldn't be able to do it
3	(Applause.)
4	As well as the NQF leadership, Helen
5	sort of being here and helping out in a pinch.
6	And also, the staff. We wouldn't be
7	able to do what we do without the team.
8	(Applause.)
9	DR. BURSTIN: And just lastly, we know
10	this is a volunteer gig for all of you. This is
11	our job. And so, thank you, especially for so
12	many of you who spent three days with us. That
13	is a huge commitment both from our federal
14	partners as well as those of you in the private
15	sector. So, thank you.
16	MS. GORHAM: And I just want to say
17	thank you to CMS. Renee and Gigi work so well
18	with us behind the scenes. And so, we really
19	appreciate it. We definitely could not pull this
20	off without you.
21	And then, I'm going to tell on Rich.
22	I know he doesn't want me to, but I am anyway.

This is actually his first year as Chair. 1 And 2 when we approached him about the position, the first thing he said, "Oh, I would love to do it." 3 4 He was like, "Give me all of the meetings because my schedule is full, and this is so important, I 5 want to make sure that I have time." So, I just 6 7 wanted to say thank you. 8 CHAIR ANTONELLI: Thank you. 9 (Applause.) DR. FOX: Yes, and from the CMS side, 10 we want to thank the staff, and Rich 11 particularly, because he is just really very 12 13 helpful, and Helen. And thank you to the Task 14 Force members because you did give your time and 15 your expertise. 16 CHAIR ANTONELLI: I certainly don't 17 deserve the last word. So, somebody from the 18 staff is going to have the last word. 19 But I just basically want to revisit 20 the comment that I ended with yesterday. When 21 you consider what's happening outside these walls politically, and yet, inside the walls the amount 22

1	of really intense, good work, multidisciplinary,
2	cross-stakeholder, cross-sectoral, discussions
3	around value, transparency, and all of that, if
4	anything, we have redoubled our efforts to get
5	measurement in place and to pull together
6	traditionally or non-traditional bedfellows, so
7	to speak, around alignment. For me, this is
8	actually very sustaining.
9	And we are going to endure. The
10	families for whom we provide care are really
11	depending on us, especially the ones that are
12	already vulnerable.
13	So, thank you. Thank you for the
14	federal partners. And in particular, I know it
15	is tough for you right now. We've got your back.
16	(Whereupon, at 3:49 p.m., the meeting
17	was adjourned.)
18	
19	
20	
21	
22	
•	

achieved 192:5 Α achievement 41:19 **a.m** 1:9 5:2 104:13,14 ACIP 218:1 **AAP** 92:4 acknowledge 60:12 **AAP's** 127:20 128:3 77:8 105:10 165:19 abandon 73:21 acknowledged 332:1 **ability** 24:1,22 80:20 acknowledging 6:19 123:9 149:3 197:11 acknowledgment 333:2 248:6 283:11 333:11 able 9:3 28:3 48:6,15 ACO-type 284:7 63:14,22,22 64:7 65:1 ACOG 130:18 131:3 68:12,14,18,19 77:4 178:11 83:10 94:4 97:9,14 act 171:19 100:11 101:5,6 action 182:18 103:15 105:11 108:22 actionable 311:21 115:5 121:11 148:18 actively 38:16 42:14 150:10 155:18 161:5 activities 162:19 325:7 197:5,14 218:19 activity 100:17 145:5 237:6 238:7 244:21 310:2 320:5 245:2 276:15 277:13 actual 36:14 56:14 277:16 283:15 310:13 92:18 125:13 147:13 333:7 336:2.7 219:6 231:6 247:7 absolute 270:8 320:2 256:10 323:22 absolutely 90:15 95:18 acute 203:19 321:21 95:20 179:8 328:12 abuse 316:8 317:3 adapt 69:2.17 ACA 172:14 288:8 add 6:13 65:1 76:16 Accelerator 46:6 95:10 111:20 139:5 accept 29:13 269:14 139:10 149:5 179:4 acceptable 180:12 181:2 204:7 210:11 access 11:8 14:13 220:16 252:10 269:7 20:18 21:14 22:1,10 273:14 284:12 294:22 22:13 27:5 30:9 40:8 298:5 305:6 306:2 43:19 44:2,17,19 51:8 311:1 313:11,11,15 72:15 76:10 77:1 313:18 315:4,9 89:18 112:17 114:11 316:17 318:1,2 116:3,13 134:19,22 322:19 135:1,22 136:4 added 11:13,16,20 192:16 193:7,10,13 12:17,18 38:4,11 194:1,16 195:14,15 110:2 172:14 184:6 195:22 196:1,3,17,18 187:15 207:21 232:5 196:22 197:9 198:11 233:9 263:21 272:4 198:16,17,21 199:8 273:6 297:11 314:2,3 210:7,13 237:3,4,17 316:21 237:18 242:7 256:18 adding 220:15 261:10 256:20,22 282:13,14 293:7 294:19 314:5 282:16 285:7 303:18 addition 10:19,21 315:17 316:10 320:20 125:19 203:5,12 323:2 331:20 206:1 288:20 308:16 accessing 92:1 additional 7:11 64:21 account 61:2 145:7 75:5 77:4 135:16 accountability 248:1 186:3 214:3,6,12 accountable 212:16 260:21 262:2 293:9 accreditation 126:21 293:22 311:2 328:1 126:22 additionally 271:12 accumulate 159:5 address 19:9 24:3 25:4 accurately 94:4 248:6 40:7 46:4 73:2 90:13 achieve 87:1 156:10 168:17 210:5 246:17 283:12

addressed 30:8 193:21 251:6 297:3 addresses 89:11 206:13 250:16 284:8 335:12 addressing 19:19 251:8 292:8 adequate 184:12 244:21 245:1 ADHD 76:11 adherence 116:19 117:7 ADIRIM 1:12 28:9 29:6 86:19 122:14 123:16 127:16 138:22 170:1 187:14,20 189:11 191:8 195:21 213:6 213:11,14 214:2 223:22 226:4 227:19 228:5 230:10 232:7 248:10 250:15 251:9 251:11,18 262:17 263:2 265:12 266:18 267:1 271:2 273:12 282:7 284:11 287:19 290:10.13 293:11 294:2 296:3.8 299:9 299:17 300:1,3 325:16 328:22 330:16 331:6 adjacent 128:9 Adjourn 4:18 adjourned 338:17 adjudicate 120:13 adjust 240:2,10 283:11 adjusted 159:9 adjusting 44:12 adjustments 245:19 admin 127:10 administered 147:10 297:20 administering 217:3 301:8 Administration 1:17 administrative 13:7 55:11 121:22 127:1 222:22 242:12 275:22 administratively 103:6 administrator 89:3 323:1 admission 164:12 admissions 117:2,9 210:6 280:15 admit 324:1,6 326:19 admitted 250:2 ado 5:7 adolescence 11:21 112:17

adolescent 13:21 15:21 74:20 95:3 109:19 115:2,6,10 117:20 134:19 135:7,8,22 136:4 137:3 138:2 191:15 193:7,22 196:3,8 324:14 330:3 331:11,20 adolescents 11:8,19 12:2 22:1,8 95:11,12 114:22 115:11,12,17 116:5,7,11 118:2,5 138:7 184:10 193:22 195:7 198:13 208:10 214:20 222:14,17 229:1 233:7 319:6 333:3 adolescents' 199:8 adopt 29:12 280:2 288:20 adopted 10:22 171:16 231:2 adopting 41:12 adult 5:9,22 10:3 11:16 18:19 29:10 59:13 60:2 64:8 73:13 90:17 92:10.18 131:13 170:8,12 171:16 172:14 173:7.8 176:12 179:21,22 181:4 182:11,19 210:20,22 216:18 235:9 281:8 282:10 311:10 313:12,22 325:1 326:12 329:19 331:22 334:16 adult-only 220:11 adults 61:22 90:20 92:17 235:2 281:17 282:4 307:20 313:21 321:16 322:11 326:21 329:14 332:20 advance 78:2 84:14 105:11,12 109:12 202:11 275:5 advanced 17:18 221:6 advancement 8:15 advantage 246:1 Advisory 2:2 12:4 advocate 197:7,17 251:1 advocating 72:18 125:19 Aetna 1:20 Affairs 1:12 affect 135:17 173:22 212:22 224:15 226:14 Affiliated 1:16

affinity 117:18 227:8 229:12 affirm 178:5 affirmation 222:4 affirming 8:19 afford 323:7 afraid 180:19 after-the-fact 89:11 afternoon 6:11 7:9 201:4 310:2 age 12:6 23:8 30:15,20 31:4,7,9 45:8,9 50:1 53:4 61:4 66:5 92:17 101:5 115:4 138:7 180:1 181:3 184:7 190:19 191:3 194:21 214:19 229:3 234:17 235:18 265:14 275:21 276:16 agencies 291:17 agency 1:17 47:11 ages 21:13 35:19 49:22 56:12 aggregate 114:20 aggressively 332:17 aging 245:19 ago 27:9 78:20 102:12 159:9 227:20 231:5 Agrawal 6:20 agree 20:13 73:17 74:17,18,19 91:5,16 121:2 127:20 128:3 128:22 141:22 157:13 160:6 196:7 223:5 263:10 280:19 287:20 299:4 325:17 329:1 333:18 ahead 75:8 93:6 101:18 104:9 111:18 112:13 123:1 134:17 182:2,8 229:10 236:5 241:9 241:13 253:17 259:20 260:19 273:22 276:9 286:6 315:12 334:10 AHIP 168:5 178:10 AHRQ 204:13 239:17 aim 38:21 130:13 aimed 60:9 alarming 167:1 Albany 82:3 111:6 algorithm 206:16,17 209:3 265:7 277:7 281:5,6 287:14 291:12 algorithms 280:11 281:7 align 78:11,11,12 127:4 127:5

aligned 151:11 aligning 132:7 alignment 11:16 13:5 78:15,19 79:10,19 168:4,7,8 171:10 178:4,20 338:7 all-encompassing 20:22 allergy 131:22 Alliance 130:14 allow 53:3,5 103:17 218:13 262:18 313:10 allowable 195:12 allowed 143:12 150:22 allowing 139:6 144:5 261:10 alludes 172:11 256:12 ambulatory 275:18 284:17 286:16 amendment 144:9 America 177:11 America's 89:5 American 50:22 178:9 246:21 amount 155:20 333:8 337:22 AMR 9:9 amuck 128:8 Amy 1:19,20 98:16 119:14 127:14 143:15 150:20 157:6 160:5 169:22 174:18 176:2 179:15 180:13 187:2 194:7 196:13 198:4 221:10 255:11 257:14 257:16 268:10 271:2 283:6 288:18 300:12 329:20 analysis 17:2 28:17 206:15 245:21 250:7 311:2 Analyst 2:17 analytics 159:8 analyzed 206:5 244:22 anchor 84:18 anchored 85:9 ancillary 280:16 and/or 49:5 268:3 Andrea 1:13 3:16 96:1 152:5 189:2 196:13 209:14 222:1 233:19 236:19 263:10 275:14 285:3 297:8 319:10 322:19 Andrea's 221:17 222:5 250:15 anecdotal 329:2 anemia 208:3,13

264:22 265:4 274:14 animation 75:4 Ann 1:15 16:22 153:1 271:20 Ann's 154:20 annual 6:20 12:11 335:1 answer 67:13 95:1 103:22 114:9 118:6 154:18 166:18 167:3 167:18 212:16 217:11 219:2 225:3 241:1 267:19 278:19 287:7 296:5 303:9 321:13 answered 118:7 219:9 answers 86:17 117:15 antibiotic 208:12 264:21 265:3.15 266:4 268:6 274:12 antibiotics 203:15 anticipate 300:17 anticipating 263:16 antipsychotic 222:18 226:19 257:12 antipsychotics 208:11 222:14 224:18 225:16 226:6,21 228:1,7,15 229:1 233:8 anxiety 278:2 anybody 8:9 27:7 50:14 111:19 119:7 167:18 176:4 187:10 192:15 200:15 240:15 259:17 273:10 304:13 306:6 anymore 80:21 133:5 167:1 anyway 50:11 219:12 271:17 288:14 336:22 AP 184:6 apart 117:22 apologize 67:1 70:20 188:8 231:4 243:13 259:18 appear 106:3 append 143:18 appendectomy 258:17 appendicitis 240:2,6 244:6,12,13 246:1,4,7 250:3 253:4,19,20 254:4,4,7,11,13,15 255:1,5,6 258:14 259:4,5 Applause 336:3,8 337:9 Applegate 7:5 **apples** 25:18,18 application 1:3 78:7 applied 282:22 **apply** 250:1 281:20

329:17,18 applying 71:14,19 appointment 70:5 appreciate 78:9 84:16 336:19 approach 6:9 42:19,21 47:13,13 48:9 58:15 79:5 86:6 approached 337:2 appropriate 128:12 138:20 184:10 203:14 226:6,8,9 227:17 248:1 284:10 286:10 287:2 316:16 323:9 323:16,17 324:3 325:3 appropriately 286:8 appropriateness 227:1 **approve** 143:7 323:9 approved 259:19 April 285:6 area 48:20 59:8,12 73:1 91:14 206:13 223:6 223:11 267:12 270:16 271:6 328:4 areas 4:14 6:10.12 12:15 72:5,14 197:20 207:10 209:21 265:19 271:17 290:19,20 291:22 292:12 310:21 311:1,3,5 324:20 argue 124:13 251:19 arguing 98:20 99:4 185:7 argument 99:6 arm 190:8 arms 330:22 arrangement 98:15 arrangements 77:19 array 162:7 arrived 278:22 articulate 143:4 articulating 84:22 artifact 95:7 asked 18:19 47:7 51:18 65:15 95:18 112:4 165:17 166:16 257:21 289:19 asking 9:1 17:6 20:12 22:15 23:18 26:1 29:16 67:12 70:4 100:2 263:21 298:22 asks 60:13 aspect 242:9 aspects 45:1 247:5 aspirational 60:10 76:18 100:21 assess 14:12 102:7

188:21 206:18 276:14 276:20 assessed 31:9 189:13 189:14 assessing 190:4 204:19 assessment 7:18 13:22 68:15,22 69:9 76:12 91:20 95:4 100:6 109:15,21 110:19 137:4 138:3 188:1 190:20 191:1,17 277:16 Assessments 8:18 assistance 25:11,22 118:4 139:20 257:5 257:11 assistant 1:12 230:21 240:21 associated 14:6 303:17 304:4 Association 1:13,16 178:10 Association's 51:1 assume 54:22 253:10 278:9 assumed 284:17 **assumes** 245:16 assuming 70:21 101:17 221:21 assumption 270:4 assumptions 254:5,18 Assurance 3:2 assured 8:12,13 asterisk 207:11 208:17 asthma 12:22 13:14 116:16,17,20 117:2,4 117:10,13 131:22 203:15 286:3 309:10 318:22 at-risk 268:7 attach 143:2 163:1 attached 43:5 57:22 151:14 260:16 274:8 275:7 attempt 17:11 217:11 attempts 189:21 attend 75:18 attention 41:16 45:5 51:9 52:2 166:20 audible 304:16 307:15 auditing 127:1 August 334:18,19 335:14,16,17 August-September 334:22 auscultation 314:11 autism 132:1

availability 202:9 203:21 available 58:12 66:12 73:7 74:13 108:3 110:11 122:1 131:17 155:19 202:15 203:17 211:16 264:18 296:11 333:12 average 61:20 249:5,6 266:2 **avoidable** 117:1,10 avoiding 170:4 aware 42:3 328:14 awesome 21:18 В b 120:4 212:21 **babies** 120:1 130:3 320:19 **back** 5:4 8:19 18:7 48:12 65:13 69:13 70:19 74:3.9 78:21 80:9 82:22 83:10 88:22 90:19 91:22 92:2 93:15 94:18 97:9 104:13 107:17 119:7 119:11 132:21 134:18 144:8 145:3 151:22 155:22 161:4.14 163:14 180:13 181:19 182:10 185:17 187:3 201:2,3,7,8,21 213:4 215:8 221:21 222:3 227:16 229:22 230:17 231:16 232:16 233:15 237:1 242:11 245:7 250:9 260:14 278:20 285:6 302:22 309:7 316:5 338:15 backed 72:12 backfill 47:20 background 63:10 276:22 backing 73:6 bad 28:10 36:4 45:11 140:3,7 160:7 287:13 314:5 bag 324:16 Baker 160:20 balance 292:5 bands 229:3 bar 282:9 barrier 32:15 269:4 296:18 base 253:11 268:5 based 26:21 27:21 44:12 77:3 78:8 159:15 217:22 242:4

244:20 245:22 250:4 250:6 254:12 255:5 259:2 271:12 281:8 283:11,21 291:9,13 302:22 baseline 38:8,10 39:2 39:11 221:13 basically 145:22 151:2 175:13 277:1,19 284:16 289:19 304:2 321:16 337:19 basis 30:9 170:5 bathroom 324:13,16 bearing 335:19 beast 83:18 **BEATTIE** 1:14 89:2 92:4 95:9 163:20 164:2 181:15,17 182:4 184:5 185:9,14 188:11 190:2 283:4 286:5 289:1 322:18 331:19 beautiful 43:6 **becoming** 142:10 **bed** 321:19 329:5,9 bedfellows 338:6 beds 89:19 90:4 320:12 323:5,6 328:15 329:10,18 330:11,12 331:2,2,4,16 333:18 beginning 14:7 38:1 53:2 56:11 87:14 172:21 beaun 204:14 behalf 154:20 159:10 behavior 166:20 167:2 behavioral 7:18 8:17 68:15 76:11 90:18 91:7 101:13 109:14 110:19 111:5 185:17 202:20 223:7,9 316:10 322:11 328:16 334:7 belief 221:17 believe 28:21 147:17 155:2 169:10 182:19 188:14 204:2 209:9 212:2 218:13 225:7 232:17 236:18 237:1 237:10 292:19 belong 326:3 330:15 bemoan 330:6 benchmark 18:4 158:12 158:14 169:1 211:4 beneficial 268:6 314:12 benefit 36:3 58:11 62:15 197:10 214:3,6 214:12 223:17

benefits 242:7 Benin 1:13 9:20 50:6,13 53:19 54:4 96:2 120:9 152:6 189:3,8 196:15 209:17 211:21 214:15 218:18 219:10 220:14 233:22 235:8 236:22 239:16 259:22 260:9 260:20 261:19 262:1 297:9 319:11,15,20 bennies 163:6 best 46:2 66:11,15 72:2 72:12 74:12 75:10,11 79:9 94:12 131:16 133:9 144:6 157:14 209:6 216:12 220:6 238:9 302:2 320:22 best-performing 18:13 50:1 better 16:7 26:8,16 27:11,12 44:18 46:15 47:10 55:19 58:10 83:15 98:8 120:4 130:11 142:15 146:5 159:17 170:8 212:1 223:12 246:22 247:2 247:6 255:8 286:22 292:18 314:10 321:7 321:7,14 322:7,11 beyond 48:4 125:13 126:5 169:19 182:22 Bice-Boxerman 306:12 big 52:21 60:9 77:6,17 77:22 100:3,20 138:19 151:18 164:5 164:16 224:14 246:1 313:9 325:19 330:9 330:10,11 bigger 76:7 biggest 298:16 331:3 **bill** 128:20 billed 330:21 billing 128:16 bills 250:9 bipolar 224:19 birth 67:11 108:13 109:1 119:19 121:3 130:15 159:12,13 births 15:12 158:20 bit 5:19,21 9:11 16:7 24:6,18,20 29:20 32:21 33:18 35:2,6 41:5 49:4 57:13 60:4 62:13,19 64:10 65:6 66:1 69:2,18 70:2 83:11 86:11,17 87:18 88:6,11,14,16 90:11 91:22 93:8,11 96:3,8

96:9.19 105:9 107:2 145:10 149:6 161:17 214:22 217:9,18 225:17 229:12 237:9 238:13 250:19 261:21 268:13 276:6,10 277:6 281:11,14 294:18 298:3 301:1 312:15 blank 96:18 314:21 315:9 blessing 177:21 **blood** 230:2,7 bloodstream 14:6 blue 35:20 **board** 25:18 211:2 boarding 327:6,16,18 328:2 **body** 8:14 **boost** 118:4 borders 249:21,21 **born** 32:2 bottom 36:16 40:15,17 61:18 62:3 192:12 239:19 324:4 boundaries 249:21 **box** 301:14 boy 129:15 301:13 **boys** 227:22 brand-new 306:14 Bravo 84:12 break 101:16 104:7 124:14 132:18 190:8 200:19 201:1 333:8 breakdown 13:2 202:17 breakfast 232:21 breakouts 276:17 breaks 224:20 breath 265:11 brick-and- 328:9 brief 13:10 60:7,22 87:3 briefly 202:4 287:20 briefs 18:14 57:9 brilliance 297:15 bring 19:8 24:12 57:7 63:3 67:16 68:11 80:9 97:9 115:20 119:6 120:18 127:13 132:16 134:6 155:21 177:13 185:22 205:8 223:2 267:9 268:2 269:2 275:17 276:2 304:10 bringing 8:17 32:14 160:22 229:2 brings 326:9 broad 132:5 162:7 286:7 broadly 328:8

broken 43:21 brought 7:12 70:17,22 316:13 bucketed 15:2 bucketing 137:12 budget 68:9 108:1 **build** 82:9 103:16 142:20 330:11,12 331:3 333:19 building 42:8,8 312:14 331:1 **built** 102:19 331:16 **bulk** 79:15 **bullet** 45:5 217:14 bullets 290:14 bundle 130:15 175:12 229:16 **bundled** 49:8 burden 23:19 52:21 79:21 298:4 299:5 **Bureau** 3:3 **burn** 178:1 burning 118:15,16 304:10 Burstin 2:13 146:20 147:1 148:5.7.12 155:4,11 156:15 160:19 176:9,20 178:7,15 182:13 183:15 185:16,20 186:2 192:7,10 219:5 220:4 234:6,11 235:13,18 247:14 248:11 298:9 304:22 305:21 306:18.21 311:9 313:10 314:3 326:9,19 327:5 336:9 **Business** 129:14 button 209:8 Byron 3:2 230:20,21 234:15 С **C-section** 157:14.17.18 157:20 164:15 165:2 165:7,16 175:4,7,11 175:14 C-sections 120:1 165:6 165:11 170:4 Caesarian 108:13 119:19 121:3 125:22 129:10,12 130:5,6 158:21,22 159:12 Caesarian-born 131:20 Caesarian-related

129:11

Caesarians 130:20

159:20 160:7 169:5

169:17 **CAHPS** 215:17,21 216:15,15,17,18 293:5,9,9,13,22 294:19,22 295:2,8 297:4,10,10,11,14 298:5,6 299:1 calculate 108:8,9 248:6 calculation 108:2 110:10 California 158:14,17 230:5 call 4:2 32:17 39:13 45:4 66:7 83:18 191:6 234:20 243:10 248:13 252:17 256:5,9 277:14 288:16 317:11 322:7 328:9 called 6:21 46:22 47:1 72:16 calling 72:22 133:12 145:20 146:21 calls 133:6 236:3 **CAMI** 148:4,6,8 campaign 58:8 canal 51:19.20 candidate 112:2 candidates 136:15 capacity 65:10 328:5 330:19 capture 55:22 115:16 144:6 316:22 334:15 captured 215:4 captures 302:16 capturing 8:22 103:4 car 115:16 **card** 101:17 134:12 175:22 179:1 188:9 270:22 276:7,8 cardiac 333:19 cards 16:20 49:3 care-for-all 62:22 care-sensitive 284:18 careful 139:4,17 140:8 carefully 126:11 caregiver's 303:17 caregivers 295:19 312:3 caries 13:20 38:3 Carol 1:21 8:16 127:14 129:7 157:7 160:4 168:12 177:12 Carol's 168:3 carve 55:10 carved 55:1 carveout 55:3 carveouts 55:8,9,9 carving 90:18

case 51:17 130:9 167:9 170:21 192:15 201:11 278:1 292:20 326:10 cases 128:14 157:21 334:2 casual 169:9 categories 106:14 207:4 categorized 12:15 category 314:1 cause 278:14 caution 74:5 146:17 cavalry 146:22 caveat 75:8 81:15 165:17 caveats 141:5 CCSQ 162:21 168:5 CDC 266:8 CDC's 14:9 ceiling 52:8 cell 29:19 30:4 88:12,14 88:15,17 203:2 208:3 208:13 264:22 265:4 265:18 267:11 268:15 271:7 274:13 **Centene** 1:19 257:16 center 162:13 231:1 243:8 centers 2:7 3:5,6,8,9,10 68:20 204:14 291:5,6 327:1 central 213:1 central-line- 14:5 CEO 6:19 certain 42:17 44:13 62:6 87:8 98:10 135:10,12 169:19 193:15 227:3 258:5 303:22 certainly 112:6,22 173:5 174:5 185:16 185:21 212:11 294:20 295:7 297:2,5 299:5 302:2,5 306:8 337:16 certainty 166:18 certificate 109:1 certified 128:6 cetera 52:13,20 151:10 151:10 CHA 90:5 Chair's 7:19 301:15 challenge 48:12,13 50:21 52:16 72:16 73:1,11 90:8,16 94:22 286:20 322:1 323:8 challenges 25:20 56:18 80:12 84:20 230:3 challenging 28:7 51:22

60:5 64:17 223:16 chance 141:11 275:5 change 48:6 76:19 155:15 167:2 266:19 287:22 288:4,8 321:8 323:11 changes 14:19 84:21 129:20 165:8 166:19 197:13 272:7 changing 77:16 100:3 123:14 281:5 channel 7:4 characteristics 13:8 44:13 charge 95:21 charged 298:14 chart 17:15 18:17 145:4 148:2 168:20 chase 127:11 **chat** 200:13 **check** 36:14 144:11,16 151:17 219:5 checked 235:13 **checkup** 36:13 checkups 52:7,11 chest 278:2 chief 2:13 277:14 child's 47:5 173:11 174:5 child-specific 285:16 childcare 193:20 childhood 14:15 30:14 31:3 140:10,12 214:18 234:16 children 13:20 38:3,22 45:9 49:22 61:1,2,7 61:10,17,22 62:2,11 62:16 71:18 73:10,15 75:22 82:11,20 88:3,5 88:21 90:22 91:20 94:21 101:4 103:15 131:20 159:3 164:16 188:19 193:11 195:3 195:6 208:10.12 210:8 215:3 218:21 219:3,3 222:13,17 223:11 224:15,16,17 224:21,22 227:2 229:1 233:7 235:1 238:1,10 245:5 261:3 264:22 265:4,14 272:1 274:13 281:17 291:14,16 292:1,2 293:15,16 295:18 306:4 319:6 320:11 320:18 321:1 323:19 333:2 children's 1:13,14 3:12

3:14 14:13 48:15 51:13 53:8 89:3 90:8 90:21 147:5 211:3,4 214:10 219:10,18 220:5 235:5,8,10,11 243:9 271:5 289:9 305:22 320:10 CHIP 44:9 204:21 242:15 CHIPRA 202:7 256:12 chlamydia 74:21 98:21 99:12 100:6,16 101:1 choice 264:2 choose 96:18 301:11 302:9 303:11 choosing 278:12 CHOP 236:17 240:18 249:22 250:11 chose 229:18 chosen 230:4 chronic 62:12 131:21 203:19 214:21 215:1 291:1 297:10 298:5 **churn** 242:14 **circle** 197:3 circumscribed 294:14 CIS 213:19 city 61:5 82:2 **CLABSI** 14:8 claim 277:10 claims 13:7 121:13 183:7 198:8 215:16 215:22 223:1 244:20 244:21 275:22 298:19 claims-based 15:6 244:17 306:6,10 clamoring 169:8 clarification 29:7 170:15 190:3 clarify 112:5 146:12 150:16 253:1 clarifying 180:4 classify 277:8 cleaning 36:10 45:12 cleanings 52:11 cleansing 265:11 clear 60:11 98:7 103:3 125:18 147:13 156:17 177:3 189:15 211:14 272:9 289:17 clearly 30:4 177:4 266:5 **Cleveland** 330:22 click 209:5 clickers 152:11 154:12 232:17,19,22 clinical 47:9,13 48:10 116:19 130:17 186:17

203:18 224:3 277:16 308:10 319:3 clinically 218:12,14 **clinician** 287:16 clinicians 46:13 47:16 clock 118:15,16 close 27:2 44:5 63:5 97:5,8 98:8 closely 94:8,11 97:5 311:18 closeness 97:16 closer 15:3 84:1 164:1 closes 248:12 closing 44:3,14 80:18 101:12 clue 128:11 clustered 248:22 clusters 249:4 CMS 6:4 8:13 10:9 11:18 26:13 27:13 28:19 29:13 33:17,22 41:3 51:7 56:1 59:14 97:16 104:10 107:18 113:11,14,21 114:11 118:13 123:22 125:15 141:7 145:5.20 151:22 155:12 161:4 162:10,20 170:17 177:21 178:8,11 184:3,9 204:13 207:21 219:1 220:6 234:2,8 252:8 255:14 269:6 272:11,21 310:12 319:10 335:1 335:16 336:17 337:10 CMS' 10:3 CMS's 220:15 CMS-AHIP 131:10 CMS/HHS 272:6 CMS/State 4:5,7 co-chairs 185:20 **COBL** 31:1 code 103:6,8 108:4 122:1,2 128:17,19 169:9 190:7 197:21 283:21 332:22 334:3 coded 129:3 284:16 coder 128:6 codes 26:10 49:6 121:12,16 128:7 197:22 281:13 282:1 285:4,9,16 coding 142:1,13 147:21 COEs 204:15 coffee 152:8 153:17 232:21 **Cogan** 3:3 4:7 57:3 58:18 59:2,4 85:21

87:20 90:15 92:15 93:19 96:21 99:7 102:9 165:14 166:17 167:13 168:1 collaboration 46:6 82:1 333:17 collaborative 1:15 168:6 colleague 6:6 25:3 colleagues 8:13 61:15 170:3 175:2 collect 49:17 65:2 70:11 82:17 120:13 147:14 168:19 **collected** 64:3 157:12 170:21 177:8,11 183:7 collecting 68:19 131:9 136:14 160:13 162:10 162:11 collection 13:4 64:19 205:2 color 18:20 colors 308:13 **combine** 143:13 combined 12:2.3 combining 212:13 combo 213:10,19,21 combos 213:13,22 come 24:2 25:3 52:19 58:18 70:18 71:9 72:8 75:14 76:6 79:8.18 80:6 82:8 83:10 102:13 103:16 121:15 132:21 142:19 144:8 147:5 163:1,6,18 166:8 181:19 187:2 189:20 221:21 222:3 227:21 230:16,17 245:7 250:9 254:16 260:14 269:20 270:12 298:11,12 302:22 309:7 320:19 323:13 comes 8:7,14 30:3 36:18 71:13 76:8 119:11 147:21 269:17 278:20 comfortable 138:18 154:1,11,12,14 287:16 coming 6:4 9:4 64:15 68:10 91:1 104:1 130:1 134:22 145:6 151:21 156:19 163:14 233:3 261:1 318:4 324:1 comment 4:10,12,15 8:2 31:12 87:3,4,12

95:19 121:17 122:15 139:1 151:12,21 155:4 168:13 172:7 174:20 176:9 182:1,3 182:5 188:12 200:4,6 200:8,16 211:20 239:4,5 241:17 248:12,13 252:20 260:10 262:2 271:20 273:3 287:4 294:11 297:9 301:10 307:4,8 307:12,14 318:7,11 318:13 319:11 322:16 334:17 337:20 commentary 8:13 150:18 151:4,7,19 156:16 184:2 185:12 193:5 comments 16:19 84:17 85:9 121:1 126:18 178:22 188:8 189:6 194:6 200:11 221:8 247:12 260:21 268:8 276:4 278:5 282:3 293:2 294:14 307:17 318:16 319:9.17.18 commercial 44:7 99:15 159:12 162:3 164:6 166:5,7,11 195:2 266:2 277:3 Commission 119:20 120:3 131:7 157:10 160:10,17,21 161:2 161:22 171:1 177:9 178:9 234:2 324:8 Commissioned 159:8 commitment 336:13 **committee** 3:2 6:22 12:4 28:1 131:2 150:4 185:18 217:20 218:9 247:16 248:13 266:15 334:21 335:15 common 69:9 Commonwealth 321:20 communicating 322:21 **community** 1:16 90:10 128:19 246:21 255:10 290:22 317:16 322:9 community-based 58:9 company 127:1 compare 17:13 23:14 34:3 245:3 246:14 249:13,14 276:16 compared 45:7 62:5 comparing 25:9 277:11 comparison 130:5 competitive 43:12 complement 61:14

114:5 complementary 302:4 **complete** 190:10 completely 127:20 128:3 287:4 293:11 313:7 complex 90:22 248:7 298:21 323:18 325:12 complexity 306:5 compliant 69:14 complicate 55:12 complicated 53:22 127:12 complicates 55:20 components 302:18 composite 77:11 composites 86:12 comprehensive 109:5 comprised 64:3 compromised 196:19 computer 326:16 concept 140:16 225:14 257:19 263:11 concepts 96:8 concern 142:4 216:10 226:4 248:4.21 250:17 269:11 279:8 297:2 315:15 concerned 119:3 133:2 226:13 concerns 93:14 247:20 248:16,16 323:19 conclusion 16:11 concrete 310:13 concurrent 226:21 228:13.15 condition 95:15 106:18 141:12 143:2,7,15,20 144:16 145:1,3,5,17 145:18,19,21 146:2,8 150:18 151:5 155:3 179:4 180:8 181:5 208:1 259:17 260:16 262:9,20 263:1 264:1 269:9 270:5 271:10 273:22 274:8,17 304:14,15 308:8 conditional 7:17 9:8 27:20 97:13 106:15 138:9 140:22 142:10 142:14 144:1 145:10 146:13,15 171:17,18 207:6 252:7 262:6,14 263:22 274:6 308:12 conditionality 180:11 180:15 conditionally 11:1 106:17 133:9 143:7

Neal R. Gross and Co., Inc.

Washington DC

264:7,9 274:16 275:1 conditions 62:12 66:6 90:22 131:21 199:2,4 203:19,19 223:13 244:8 273:18 275:19 281:9 282:9 285:22 290:22 304:17 317:16 conducted 69:10 conference 1:8 90:5 243:10 confidence 246:13 confirm 92:22 182:10 215:9 221:17 256:11 conflicted 226:11 conformed 26:7 confusion 112:4 conjunction 116:1 conjunctivitis 285:19 Connecticut 40:3 320:9 consensus 178:16 247:18 consensus-driven 202:14 consequences 223:20 consider 92:14 112:7 118:20 122:11 134:4 136:12 138:15 176:3 218:6 260:16 266:10 271:8 291:7 292:4,22 337:21 consideration 6:13 29:5 111:2 118:12,13 122:17 123:10 134:14 136:17 149:4 184:8 185:12 206:12 220:16 252:3 considerations 141:6 251:13 considered 132:15 171:18 266:7 290:16 295:3 considering 112:19 188:14 292:10 consistency 184:19 257:6 consistent 108:7 320:8 320:9 consistently 94:5 110:7 constantly 80:5 82:22 constraints 108:1 constructive 145:22 contact 84:8 93:2 335:6 335:10 content 114:14 138:20 CONTENTS 4:1 context 6:8 33:20 48:18 138:20 149:6 165:21 166:13 171:20 219:21

220:1 298:10 contexts 169:17 continue 39:9 40:5 48:2 82:8 92:22 105:15 109:8 133:11 167:11 236:19 continued 63:5 259:16 continuing 35:15 83:15 continuity 89:22 241:18 247:3 250:18 256:13 256:21 306:4,13 continuous 31:16 195:10 continuously-enrolled 61:17 continuum 89:12,15 331:22 contraception 97:4 contraceptive 9:6 11:15 308:6 309:10 318:21 contract 57:21 contracting 41:14 contractors 326:2 contracts 129:19 contrast 23:15 297:18 298:4 contributed 104:5 contribution 56:21 contributions 26:6 control 144:15 160:16 controlled 103:13 convenience 175:3 conversation 7:9 27:9 93:1 105:16 120:12 132:16 139:8 149:19 155:12 176:6 182:11 193:1 252:9 260:7 271:13 conversations 91:2 138:17 convinced 288:13 COO 245:15 coordinating 299:12 334:21 335:15 coordination 6:22 101:11 159:17 203:3 209:11 289:8,20 290:20,21,21 291:10 292:1 295:21 298:15 298:18,21 299:2,8 302:18 316:10 317:7 317:7,11,16,18,19 coordination-of-care 305:7 coordinator 304:3 cord 324:13 cords 324:12

Corporation 1:19 3:9 correct 125:5 143:5 147:11 167:20 221:15 226:1,2 258:8 275:2 293:14 296:12 correction 266:13 correctly 128:20 correlate 94:11 correlated 247:1.2.6 255:9 cost 61:15,20 62:4,7 64:22 79:21 130:2 132:10 139:11 168:18 242:13 300:20 313:5 315:16 317:5 costly 62:2 68:8 166:19 costs 159:9 166:19 242:6 counseling 68:22 69:22 100:16 101:2,2,3 counselor 332:7 count 36:12 69:5 84:3 103:7,8 154:17 184:16 272:2 counting 56:21 70:19 75:11 country 49:11,13 70:12 139:14 297:1 334:8 country's 151:15 328:16 counts 70:20 75:12 84:3 couple 27:9 77:21 102:12 103:14 121:2 121:21 253:13 260:22 261:16 course 23:11 39:10 92:5 164:18 167:16 228:16 269:15 296:22 302:1 311:22 cover 62:15 238:1 302:17 coverage 43:17 203:15 203:21 208:11 236:17 237:15,20 239:22 240:7,9 244:6,12 247:22 249:2,11 250:17,18 253:3,3,6 254:9,21 255:4,4,18 256:13,22 258:15 259:12 263:20 308:11 309:14 316:19,20 317:4 319:2 covered 30:6 50:9,19 51:12,16 55:4 129:18 244:9 258:18 296:14 317:2 covers 265:14

CPHQ 2:2 **CPT** 108:4 197:22 cracked 102:11 create 291:6 325:7 created 79:1 crisis 91:12 320:2 321:4 333:2 334:7 criteria 10:13 111:11 206:10 229:5 283:17 311:12,16 313:9 critical 81:19 122:18 123:20 140:13 177:19 197:13 242:15 250:16 263:11 critically 8:15 178:6 237:2 238:5,14 Crohn's 132:1 CROIX 1:17 33:8 121:1 164:20 225:7 228:11 279:10 280:6 cross 29:10 cross-sector 81:22 317:17 cross-sectoral 338:2 cross-stakeholder 338:2 crossed 301:17 crosswalking 193:18 crunch 37:17 CSM 308:16 culture 314:13 curative 267:20 curiosity 123:4 curious 22:17 23:5 93:17 135:2 214:3,11 226:17 255:13,20 257:18 296:2 current 72:13 107:10 123:7,8 149:2 204:4 245:3 299:1 currently 28:22 73:7 81:17 89:10 179:22 184:22 192:10 200:10 202:19 203:13 205:15 208:18 218:16 236:21 296:14 307:16 318:15 322:3 customary 51:5,6 cut 54:12 92:17 113:16 118:14 cutting 78:21 cycle 27:22 63:14 261:20 D **D.C** 1:9 dabbling 86:16

damaged 159:2 dashboards 43:6 data 9:1 10:10 13:4,7 14:7,8 24:7 25:5,9,13 25:16 26:2,6,7,14,21 27:3,21 28:3,12,17 32:2,8,14 35:13 36:19 37:15,16 49:17 50:8 51:2 58:16 64:16,19 65:10,11,17 76:8 82:15 108:1,10,19 109:1,3 110:9 121:5,6 121:8,20 126:7 128:20 147:14 160:22 161:1,10 164:10 176:17 177:1,7,13 198:8,8 205:2,3 219:12,14 220:3,5,11 221:13,15 223:1 227:13 231:12 235:4 235:6,20 242:4 244:16,16,20,21 245:1,1 247:7 250:3,4 250:6,12 254:2,10,11 258:8 275:22 277:10 281:2 303:1 315:22 327:9 database 26:11 databases 26:2 date 202:18 dated 18:15 **David** 160:19 day 5:8,21 7:13 15:19 83:3 179:21 207:1,13 311:11 318:5 320:14 332:12,14,14 days 10:14 110:15 125:12 176:13 221:22 265:16 271:14 312:1 320:16 323:14 327:21 335:19 336:1,12 deadline 39:6 deal 151:18 169:16 256:16 dealing 47:3 323:19 dearth 48:14 Deb 182:3,7 Debjani 2:18 5:5 7:9 156:20 183:15 200:21 234:19 Debjani's 151:3 Deborah 1:16 54:14,19 85:10 133:1 140:19 196:14 198:9 238:22 241:12 262:4 278:6 279:21 293:3 295:11 decent 298:17 decide 26:18 106:16

252:5 decided 5:22 18:21 22:3 27:4 110:19 114:18 115:6 252:4 252:13,14 deciding 65:1 decision 85:4 106:14 183:14 207:4 220:11 225:1 272:11 326:19 decisions 8:6 129:4 138:19 deck 57:17 105:21 113:7 decreased 15:13 108:16 deeper 18:8 88:6,16 94:19 100:12 default 328:11 Defense 1:12 define 124:12 184:9 205:3 defined 280:1 definitely 25:15 50:4 110:17 113:3 125:20 126:1 137:17 218:6 224:5 230:12 280:19 319:18 336:19 definitively 267:20 degree 151:7 269:8 degrees 32:7 delaying 238:9 deliberate 111:9 deliberated 252:4 deliberating 125:16 218:4 deliberation 244:4 delineated 97:3 deliver 9:4 47:17 164:19 delivered 69:16 deliveries 165:7 delivering 45:1 delivery 116:10,20 130:8 165:15 166:21 168:16 169:12 175:14 276:18 333:21 **Delphi** 289:16,18 demographic 44:13 demonstrate 72:10 demonstration 111:6 denominator 56:22 188:18 191:2 222:20 237:13 239:20 268:14 269:10 271:4 291:11 denotes 207:12 dental 13:19 14:2,14 19:3,9,12,15,17 20:1 20:8,19 21:1,9 22:13

Neal R. Gross and Co., Inc. Washington DC

Dakota 40:16,16

22:19.21 23:1 35:15 35:19 36:7 37:2,11,15 39:1 40:8 42:1 44:9 45:10 46:13,17 47:17 49:6 50:22 52:3,11 54:22 55:5,9,15,20 56:7 73:18 85:17 dentist 20:7 50:14 55:5 56:4.5.6.8 dentist's 35:21 45:16 dentists 20:20 43:12 50:15 department 3:3,16 59:5 208:14 275:8,11,19 280:8,15 282:10 283:8 288:1,10 320:1 320:13,16,21 321:2 321:19 324:1 325:18 325:21 326:4 departments 285:2 320:3,7,11 dependent 250:11 depending 42:13 51:6 302:19 338:11 depends 284:2,3 297:20 302:10.13 deploved 58:7 depressant 95:4 depression 91:21 92:5 92:11 95:10 100:15 138:6 182:16.16 183:17 186:17 189:13 308:10 319:4 depressive 13:21 15:21 95:14 109:20 137:4 138:3 188:17 190:20 191:4,16 dermatitis 286:3 describe 71:17 276:10 described 79:5 describes 172:15 describing 255:2 description 190:17 222:16 243:19 275:18 deserve 337:17 design 48:8 designated 304:2 designed 46:7,12 58:7 74:16 75:19 76:5 78:10 297:21 324:22 325:9 destination 287:2 detail 35:2 161:17 207:14 208:8 238:13 280:21 detailed 16:4 details 184:17 214:16 282:1 283:13

determine 301:7 determined 334:22 determining 276:20 develop 26:10 27:12,14 47:12 67:14 97:7 244:13 332:2 333:3 developed 74:10 133:10 147:8 168:3 202:5 204:12,15 231:1 244:22 245:22 246:6,10 258:14 261:5 277:8 278:9 332:18 developer 27:21 28:2 97:17 107:6 123:5,11 140:4 144:18,20 147:7 148:22 149:9 150:3 225:3 231:20 243:7 267:6,8 268:4 296:4 301:15,19 developers 149:14,15 292:17 298:14 developing 71:7 131:8 131:20 259:3 development 48:20 89:22 123:19 159:1 202:12 203:8 204:2.3 212:1,18 244:19 297:15 331:12 developmental 24:14 26:19 27:1,10 82:5,14 85:18 101:22 107:3 121:18 122:15 127:21 128:4 133:3 139:3,19 140:12 147:22 152:15 devil 283:12 devil's 281:22 diabetes 131:22 diagnosed 91:20 223:15 diagnoses 101:14 224:17 254:3 277:5,6 277:12,19 285:20 286:1.6 diagnosis 188:18 190:7 190:19 191:3 281:13 286:10,13 diamine 47:2 53:14 **Diaper** 286:3 dichotomous 141:10 199:3 dies 175:7 difference 44:11 115:18 167:9 184:20 288:5 differences 115:15 different 23:21 29:9,11 31:2 46:10 59:16 66:19 77:21 114:13

116:8,15 117:5,11 129:11 147:16 148:3 162:8,9 168:10 171:10 172:12,12 197:1,20 210:17 214:4,5 215:20 219:4 229:3 231:16 237:9 237:16 243:13 248:17 276:17 280:1,2,17 282:3,9,9 284:19,20 286:17 287:9 293:12 293:12,17 294:20,21 298:14 302:7 310:21 329:14 differentiate 126:14 249:7 differs 62:9 difficult 64:12 105:9 121:8 158:5 176:17 difficulties 121:20 193:17 difficulty 135:14 diq 100:11 diligence 179:17 diligently 334:14 dimension 50:19 116:15 255:17 256:18 dimensions 50:18 direct 29:12 232:22 284:9 direction 127:8 131:6 232:22 310:13 directionally 111:13 303:2 directions 200:19 directly 67:4 170:9 308:2 director 2:18 59:7 243:8 303:11 directors 88:15 279:1,7 279:12,14 287:6 disability 225:22 disagree 329:22 disaster 320:9 discarding 162:12 discharge 209:20 discharged 216:9 277:22 disclosure 289:15.22 disconnect 229:19 discovered 277:22 discuss 106:4 110:18 134:7 207:3 209:5 252:13 262:19 discussant 206:7 209:16 289:11 discussants 222:11 discussed 10:8 13:1

15:19 96:9 106:10.13 108:1 109:11 110:18 179:21 182:12 196:16 203:4 206:9,15 210:15 252:2 discussing 125:17 207:1 discussion 6:16 22:2 23:18 59:1 84:14 95:3 95:5 96:6 109:21 112:20 113:1,10,14 114:6 119:9,18 120:19 125:14 126:14 137:20 141:2,5 142:19 155:13 157:4 158:4 181:21 182:14 183:16 184:15 187:11 189:3 201:20,22 207:14 208:22 209:1 209:7 217:6,13 219:22 223:3 229:9 236:2 239:17 248:2,8 269:21 275:18 276:3 281:19 300:11 311:22 336:2 discussions 13:14 26:4 126:10 183:8 273:4 335:21 338:2 disease 30:4 47:4,4 53:16 132:1 240:5 265:19 267:11 Diseases 329:16 disincentive 57:22 disorder 13:22 15:21 95:4.14 109:20 132:1 137:4 138:3 188:17 190:20 191:4,16 disparate 24:21 78:4 267:13 disparities 30:8 235:16 displayed 43:20 disposition 321:22 disproportionately 30:5 225:19 dissertation 99:10 distance 193:15 distinction 272:9 distinguished 249:9 distinguishes 128:11 distracting 220:21 distribution 211:10 249:1 distributions 61:4 dive 18:8 32:22 88:16 diverse 61:6 88:5 divided 244:10 diving 88:6 **Division** 3:4,6,7 59:7

108:20 doc 290:14 docket 92:20 docs 265:22 doctor 277:15 288:6 doctor's 128:16 230:1 document 285:11,13,17 documentation 128:13 documented 129:2 documents 247:1 249:3 doing 17:19 18:17 19:18,20 34:2 35:3 44:14 45:22 46:1,18 46:18,19,20,21 55:19 56:1 57:14 59:15 69:19 77:20 79:9 80:22 85:14 90:12 95:22 114:20,21 115:5 116:4,5 117:7 128:12 145:18 168:7 175:4 178:2 256:14 287:9 298:15 319:12 dollars 155:19 domain 86:6 87:10 122:18 313:4 domains 71:22 72:7 86:3 87:8 98:21 312:20,22 313:4 door 151:18 doppler 269:13 **dot** 313:2,14,19 314:1,3 314:5 315:1 dots 308:13,14,21 309:1 310:17,20 315:8,9 316:6 317:13 317:21 double 164:14 166:5 double-check 240:3,9 doubt 119:21 doubting 192:15 downside 210:14 downstream 120:2 **DPO** 55:1.6 drafter 334:17 drawn 230:2 drill 66:14 94:19 drink 330:5 drive 89:21 93:16 128:8 139:7 166:19 167:11 184:19 327:16 driven 93:12 driver 256:22 drivers 62:7 303:20,20 driving 45:22 46:2,9 75:2 175:19 drop 129:16 245:6 drops 70:7 **DTPs** 31:5

due 179:16 296:18 335:16 dump 37:17 duplication 171:11 duplications 187:9 duplicative 79:20 durable 315:14 duration 203:20 245:5 245:7,12,13 247:4 316:20 dying 189:19 dynamic 124:17

Е e-measures 298:20 ear-related 285:20 earlier 28:21 36:20 40:18 63:18 107:3,5 109:22 162:1 206:10 253:21 319:21 early 5:11 82:3 101:14 130:8 165:15 166:21 327:3 easier 326:22 easiest 209:9 easily 96:15 158:7 276:15 easy 219:9 223:14 246:12 272:3 EBP 79:1 echo 319:21 **ED** 276:14 277:3,8,15 277:20 281:8 282:18 282:20 286:11,16 290:14 316:9 326:17 327:16,21 328:6,10 329:2 332:5 edge 254:1 editorial 151:12 322:16 EDs 321:16 educate 128:18 education 53:12 58:8 87:10 224:9 effect 36:15 effective 9:7 175:19 308:7 effectively 43:3 efficiency 164:19 241:21 242:9 effort 34:10 79:21 142:5 158:18 171:11 efforts 34:14 40:20,21 41:1 338:4 eight 192:3 203:2 227:9 229:15 264:5 300:4 301:11 305:4 317:21 317:21 Eighty-five 233:12

236:13 either 45:12 49:5 65:20 70:5 76:15 85:5 97:16 99:15 133:16 146:15 148:1 178:8 180:21 229:19 239:7,8 254:19 257:4 268:14 274:9 311:18 313:9 323:4 332:10 elaborate 204:3 elect 113:21 elective 130:8 165:7,10 165:15 166:21 168:15 169:5,12 electronic 64:16,19 67:22 110:9 314:9 element 90:14 110:9 elements 72:1 108:2 elephant 151:16 elevated 13:20 117:9 eligibility 31:17 242:11 258:2,5 eligible 31:22 225:11 228:18 229:4 237:14 239:20 244:10.15.16 245:17 246:2 254:6 254:20 258:1.12.16 259:8,11 eligibles 14:1 eliminate 266:5 Elisa 2:14 148:13 ELLIOTT 2:2 55:21 56:13,17 93:7 134:1 168:13 223:5 225:21 228:3 232:3 eloquent 177:16 elucidated 291:11 elution 277:6 email 335:12 emailed 285:11 **embedded** 133:14 eMeasure 8:20 131:8 emergency 91:9,12 140:10 208:13 275:8 275:19 280:7,15 282:10 285:1 288:1 288:10 320:1,3,7,10 320:13,15,21 321:2 321:19 324:1 325:18 325:20 326:4 emergent 250:2 emerging 202:13 emphasis 178:8 223:8 283:5 emphasize 170:2 employed 165:15 employer-based 44:8 **EMRs** 8:22

en 290:7 enables 261:20 encompassing 179:12 encounter 188:22 190:5 encounters 15:7 121:13 190:11 encourage 34:21 encouraged 28:2 150:2 encouraging 49:20 end-game 151:8 end-users 139:15 ended 286:14 337:20 endorse 183:4 283:14 290:3 endorsed 13:5 28:5 92:19 97:12 107:5,7,8 145:8 150:12 192:21 202:18,20 218:9 263:13 266:13 291:20 306:15 endorsement 11:2 12:9 12:11,21 13:3,10 27:3 27:16,20 29:2 80:7 97:18 124:8,20 125:5 140:2 144:2,13,18 148:17,21 150:1,8,12 203:13 208:17 220:9 222:13 252:7,15,16 262:7,9,14 264:1 266:16 274:1,18 291:20 endorsements 13:11 ends 256:1 endure 338:9 energy 186:8 engage 40:22 51:9 81:13 engagement 5:16 46:21 53:13 58:6 England 40:6 English 295:19 296:8 296:12,13 enrolled 61:8 242:6 245:11 enrollee 62:4 enrollees 61:3 79:14 enrollment 43:17 195:10 203:20 242:12 ensure 108:6 232:18 257:6 ensuring 73:2 81:19 entertain 118:11 entire 67:12 174:7 254:9 298:6,6 321:20 entirely 215:4 entities 302:8 environment 196:18

197:12 237:4 325:9 environments 328:13 envision 300:17 Epi 153:14 EPSDT 23:5,11 24:9 25:9 26:21 36:19 37:15 38:17 49:18 51:15 56:4 85:17 equally 86:8 equals 258:20 equipment 315:14 ER 189:20 279:19 288:5 324:6 err 134:16 error 247:8 **ESI** 284:16 especially 159:5 165:2 165:18 197:9 225:15 238:3 284:2 295:21 336:11 338:11 essential 89:5 237:5,5 essentially 19:2 44:11 147:4 180:15 276:13 establish 283:8 established 202:7 332:10 estate 178:1 224:13 263:13 esteemed 146:20 estimate 244:8 245:2 258:10 259:2.10.12 et 52:12,20 151:10,10 ethnic 43:22 44:1,2 ethnicity 219:8 ethos 151:15 evaluated 210:9 evaluating 66:19 evaluation 3:3 236:21 247:15 event 244:7 246:4 250:2 events 280:7 eventually 79:22 82:7 231:2 289:21 298:11 everybody 5:3,15 96:15 130:10 200:2 201:9 204:13 212:8,14 215:5 301:16 313:16 316:4 334:8 everybody's 212:22 evidence 28:12 94:6 217:22 268:5 334:2 evidence-77:2 291:12 evidence-based 20:5 45:20 46:19 73:3,22 116:21 131:4 202:14 evidenced-based 292:15

exact 207:10 283:16 exactly 24:1 106:12 113:18 124:11 190:3 190:12 327:20 examinations 198:2 example 45:6,21 49:9 53:3 67:4 81:9,11 98:21 116:2,16 125:22 161:22 162:16 164:3 169:20 198:12 287:11 314:9 326:16 326:22 332:3 examples 278:1 exams 36:12 Excellence 204:14 231:1 291:5,6 327:1 **exception** 169:10 exchange 158:15 269:17 excited 59:22 60:1 exciting 60:4 excluded 63:4 295:18 296:1 exclusion 211:9 exclusions 191:4 222:22 276:1 executive 128:7 160:20 exercise 192:17 301:14 310:9,17 exist 224:20 310:11 existed 310:10 existence 267:18 existing 64:9 180:6 311:6 326:12 327:1 expand 63:3 96:8 202:9 expanded 96:3 212:7 expanding 323:4,6 expansion 63:7 expect 48:13 expectation 164:8 expected 68:20 expects 12:10 expenses 55:13 expensive 168:18 170:3 experience 9:12 20:18 84:18 224:9 248:8 289:8 291:10 302:22 experienced 15:11 experiences 203:2 305:6 experiment 42:20 47:8 expert 19:9 expertise 137:18 337:15 experts 2:1 217:19 expiring 286:14 explain 27:19 229:11

237:12 240:4 253:15 253:16 281:11,14 321:7 explaining 238:12 exploded 79:2 explore 205:17 **explored** 177:14 exploring 162:14 extended 164:13 extension 39:8 extensive 184:15 293:6 extent 116:19 117:1 130:11 221:13 255:18 257:9 extra 314:16 extract 67:15 102:20 extraction 51:21 extremely 61:6 297:13 **eye** 63:5 93:2 98:12 183:20 F **FAAFP** 1:18 **FAAP** 2:7 face 48:13 98:4 159:4 facilitate 84:21 122:21 facilities 162:6 163:5 169:3 210:22 323:4 324:21 332:20 facility 163:11 235:2 324:5 326:6 329:18 facility-234:22 fact 65:15 71:11 81:15 96:3 125:3 133:4 135:6 151:12.13 154:11 170:11 171:9 173:13 180:3 182:14 185:21 247:19 270:17 288:4 294:13 322:5 330:6 factor 168:18 factored 269:18 factors 284:1 facts 180:1 fairest 130:4 fairly 117:8 210:21 265:13 293:6 fall 70:13,14 75:7 150:4 203:14 218:5 falls 119:17 198:3 familiar 25:11 52:5 71:21 207:5 211:12 283:17 families 1:22 58:11 86:4 291:9 296:13 338:10 family 46:20 53:13 203:2 289:7 291:10

305:6 far 79:16 88:8 106:13 108:1 119:2 120:3 169:5 218:8 255:8 294:18 304:13 308:1 330:2 fare 17:4 fashion 162:20 fast 129:16 favor 192:3,4 feasibility 122:16 125:21 126:5,12 204:19 210:18 217:10 217:15 feasible 48:2 146:4 240:13 FECC 208:20 289:7,17 290:5 297:12,16,21 299:18,22 federal 2:4 13:4,15 117:17 154:6 167:21 168:10 173:5 174:5 209:21 210:2 250:5 269:9 330:18 336:13 338:14 fee 51:3 fee-for-service 51:3 55:12 61:9 217:2 feedback 85:3 206:10 feeding 83:18 feel 20:3 65:11 80:12 81:18 84:6,9 129:9 131:11,13 146:13 187:10 287:15 289:20 313:2,9,14 314:5 315:8 335:7 feelings 119:8 feels 176:20 fell 129:19 316:18 felt 102:17 female 11:19 females 12:5 fetal 130:19 314:9 fewer 98:20 99:4 106:5 fewest 15:16 field 71:9 124:1 130:12 131:5 202:16 205:1 321:6 fifties 70:8 Fifty-four 274:21 305:16 figure 46:14 47:12 48:10 103:11,12 135:15 177:21 238:7 253:8 287:10 321:6 figured 47:10 147:15 file 225:9 fill 96:18 279:4,17

filled 320:11.11 final 155:9 317:5 318:4 334:19 335:13,18 finalized 266:14,14,16 finally 159:7 financial 65:12 333:22 find 26:3 30:17 87:16 124:14 150:10,13 155:18 197:6 209:9 220:7 272:3 326:15 327:11 329:5 finding 19:19 20:20 47:15 126:7 fine 80:16 81:3 119:10 239:7 264:14 319:14 fingers 301:17 finish 120:11 148:14 192:18 first 13:18 31:20 34:2 38:6 40:1 62:22 69:4 71:9 74:11 82:5,15 85:10 101:22 107:4 114:4 121:2 123:19 125:12 131:11 138:15 152:16 158:11.20 166:9 182:7 188:10 208:7.8 209:4.10 213:10 214:7 253:19 265:10 279:2 289:13 289:15 307:8 311:11 311:17 313:16 337:1 337:3 first-line 227:1 first-time 157:19 fiscal 13:16,17 14:5,8 14:12,19 15:5,11,18 fit 72:4 fits 290:19 five 10:18,20 265:15 268:17 309:2 310:15 311:3 316:19 317:8 317:20 five-star 86:2 fix 331:18 fixing 331:15 flag 163:1 flagging 182:2 flatlined 154:12 flatlining 153:12,19 flavor 64:11 74:15 fleshing 197:3 flexibility 298:3 floor 1:8 52:9 119:7 132:20 133:22 134:8 134:10 178:22 188:5 242:22 265:6 273:19 319:18 Florida 1:17 39:13,16

40:10 41:18 57:7,17 57:18 280:9 flows 24:7 **flu** 209:19,19 210:9 215:14,16,18 216:1,6 216:7,11 234:16 fluoride 36:11 45:12 47:2 52:12,20 53:15 focus 19:1 52:2 72:1 130:12 focuses 25:14 focusing 40:19,21 110:5 132:8 141:19 231:19 folks 50:9 56:9,22 136:12 196:18 201:20 206:6 225:10 232:10 269:6 318:18 follow 72:11 77:5 84:9 92:12 105:11 122:15 141:9 151:3 183:5 259:15 288:12 306:9 followed 69:11 70:4 99:2 following 63:16 197:10 304:12 followup 70:13,14 75:6 76:11 98:19 99:2,21 99:22 100:19 101:7 150:5 182:17,22 183:1,11 184:12,13 186:17 229:21 308:10 319:4 food 200:20 for-performance 42:19 278:12 force 1:3,8 5:10 6:1,4 8:8 9:13 10:16 11:3,7 11:9 16:19 84:17 111:19 113:21 119:3 122:10 137:17 141:11 156:4,12,21 177:3,20 179:21,22 182:15 203:5 207:21 231:13 238:18 243:22 259:16 268:9 272:20,22 276:3,12 283:7 308:18 337:14 Forces 5:9 334:16 forefront 91:1 foregoing 104:12 201:5 forget 79:11 187:5 232:4 327:14 forgetting 147:20 forgive 142:22 forgot 213:2 form 4:4 162:20 219:6 235:15 285:12

formation 289:16 formulate 276:12 formulated 143:15 formulating 143:1 forth 71:5 83:1 89:1 97:12 108:11 109:5 110:12 123:13 fortune 98:19 Forty-eight 109:22 **Forum** 1:1,8 290:3 322:13 forward 5:17 7:10 9:8 25:1,15,21 85:2,6 103:2 111:10 120:19 136:17 185:2 206:19 206:22 223:2 243:15 267:10 268:2 275:4 279:6,16,18,21 290:4 298:11 311:13 312:15 foster 225:16 226:5 fostering 81:22 found 28:10 55:21 69:8 100:17 122:3 230:5 304:2 foundation 129:6 333:8 foundational 132:3 foundations 47:20 four 15:15 39:14 52:19 53:5 106:5,20 137:14 138:15 147:10 194:22 202:20 217:15 272:12 272:13,14 308:4,13 308:21 309:2 311:16 317:20 fourth 312:6 **Fox** 3:4 18:12 19:5,10 23:9 25:2 26:22 27:19 28:14,16 29:9,22 30:3 30:18,21 31:10 147:17 148:6,11,15 150:2 204:9 229:11 230:12 301:9,19 303:9 337:10 fraction 244:8 fragmented 76:4 83:16 83:17 framed 146:20 framework 72:11 frankly 334:6 fraud 128:14,15 free 84:6,9 313:2,9,14 315:8 335:7 frequencies 52:6,8,9 53:8 frequency 7:15 8:11 11:5 frequent 46:20 52:22 frequently 14:11 15:9

37:10.13 41:20 frequently- 17:11 frequently-reported 17:3 friends 230:14 330:6 front 62:14 107:9,9 207:5 225:15 frontlines 8:1 fronts 322:19 frozen 105:10 frustrations 85:1 full 103:20 177:21 329:10 337:5 fully 169:5 263:13 functioning 106:3 322:4 Fund 61:16 funding 204:13 further 27:21 28:12 38:2 81:5 140:6 217:6 236:2 260:7 297:4 Furthermore 246:9 future 60:20 92:14 144:22 159:4 173:20 183:21 223:11 FY2012 108:15 FY2013 108:15 FY2015 106:3,22 107:16 110:2 G gaining 8:21 gap 4:14 6:10,12 71:13 87:16 88:19,19,19 114:22 206:13 207:10 211:10,10 218:5,12 265:19 267:12 279:4 290:19,20 298:16 302:11 311:1,3,5 313:11,18 319:12 327:15 328:4 gaps 23:15 44:2,15 66:17 71:11 94:20 189:4 195:12 207:12 207:12,14,15 218:14 246:8 258:3 259:19 279:3,15,16 291:4 310:3,3,5,9,10,15,18 319:18 gateway 78:5 gather 67:21 68:13 82:17 177:1 gathered 219:19 gender 66:5 general 17:7 111:17 139:1 140:11 165:6 176:9 198:2 206:4 210:19 223:10 227:10

257:12 270:9 280:7 286:2 327:18 generalized 92:11 generally 202:9 generate 261:2 269:10 generating 292:5 gentlemen 200:5 307:11 318:10 geo-193:12 geographic 270:10 geographical 269:22 geography 276:17 gestalt 146:9 getting 18:6 20:22 21:1 30:22 45:2,18 47:5,18 48:12 49:2 56:12 58:10 59:20 70:19 75:18 76:22 77:2 80:15 85:16 87:20 91:10 100:8 114:15 115:3 116:13 131:3 142:15 143:9 157:11 157:12 159:18 166:3 166:14 193:20 196:10 198:13,14 210:17 229:22 238:19 253:9 255:3 261:19 287:17 321:1 323:15 **gig** 336:10 Giqi 3:10 336:17 qive 6:7 13:9 18:20 21:5 21:16 28:3 31:11 33:17 51:13 60:17 62:10 75:5 81:20 100:5 136:12 141:11 180:21 197:8,11 200:18 201:17 209:11 220:19 225:13 233:20 238:6 241:6 243:1,5 245:18 258:7 286:9 287:11 303:12 310:12 313:2 325:5 337:4,14 given 17:9 27:20 31:19 39:7 61:3,14,18 64:11 74:15 91:18 96:2 102:21 154:11 162:13 170:20 238:4 258:21 270:5,15 320:14 327:21 gives 10:9 21:13 23:14 94:12 194:2 298:3 331:3 giving 169:9 310:20 global 57:6 globally 219:20 **glucose** 230:7 **GME** 330:18 goal 34:9 39:4,10,12,15

58:1.4 96:15 132:14 goals 10:3 41:17,18,20 42:17 60:10,16 77:17 204:18 205:4 292:5,8 gold 246:20 255:9 GORHAM 2:16 95:1 105:7 112:21 113:18 113:20 118:22 123:2 124:4 125:6 137:5 144:11 148:20 156:11 179:20 204:5 205:21 217:8 222:7 232:9 236:16 240:17 252:1 264:14,16,20 266:12 267:5 272:12,14,19 285:15 289:2,5 307:3 307:18 318:6,17 319:13,16 336:16 gotten 68:6 73:8 government 2:4 250:6 330:18 grab 192:19 grams 15:13 grant 59:19 88:13 97:6 270:13 grantees 205:15,17 graph 15:4 39:17 grappling 220:9 gravy 330:11 gray 209:7 greater 15:5 156:13 green 36:16 169:14 Greiner 1:15 17:1,8,21 18:11 153:1 221:3 271:21 272:8,13,18 273:2 274:3 300:8 ground 79:7 290:2 group 2:2 45:8,10 50:1 84:14 88:5,7 120:20 129:14 148:3 150:13 157:22 161:20 223:3 227:8 229:12 249:14 249:17 253:21 275:22 311:10,12 313:22 groupings 115:4 groups 23:8 43:22 44:1 44:2 80:6 117:19 249:8 254:22 276:17 286:3 guess 7:4 33:16 95:21 115:8 124:12 195:14 267:8 273:2,12 301:9 guessing 67:19 301:4 guidance 108:5 120:10 303:12 quide 6:16 137:20 209:1,7 217:13 336:1 Guideline 266:9

guidelines 123:13 127:20 128:19 guiding 71:8 140:14 gut 225:14 н half 36:2,4 215:20 hallucinating 228:1 halt 53:16 halting 47:4 hammer 66:3 71:15 Hampshire 3:16 40:4 275:11,13 276:2 277:1 279:13,20 hand 9:10 153:20 154:1 154:13,14,15 155:1 186:18 191:19 192:1 192:2 199:12,15 221:1 276:5 307:1 handle 40:7 handles 59:8,12 handout 16:5 106:13 hands 154:16 155:6,8 186:10,19 191:20 199:13.16 hands-on 34:16 40:20 handwriting 317:6 hang 94:9 hanging 40:17 happen 5:20 20:6 145:11 167:8 169:11 175:8 253:20 328:19 335:14,17 happened 35:22 99:22 148:14 212:10 happening 23:15 102:18 158:1 169:17 326:7 328:20 330:4 337:21 happens 23:11 90:2 127:8 139:9 197:12 238:4 249:10 happy 36:21 101:16 155:16 234:1 265:10 327:9 hard 78:21 81:16 82:16 93:3 121:7 126:1 139:11 177:12 188:4 192:12 216:4 230:1 283:21 287:10 302:9 330:13 harder 122:8 harm 210:6 Harold 185:20 hat 82:16,18 126:16 127:19 128:5,6 146:22 147:2 hazards 159:1,5

HCAHPS 203:8 205:13 head 34:4,12 39:21 40:1 46:16 177:5 214:8 324:17 head-down 157:20 headstart 41:11 healthcare 14:9 71:2,18 81:12,13,18 88:4 160:2 162:6 164:17 173:8 202:11 214:9 283:10 299:7 healthy 61:22 73:11 158:13 169:2 hear 18:7 75:17 86:20 91:13 93:10 125:20 139:19 149:17 158:6 161:14,20,20 170:2 170:16 173:4 175:2 232:10,11 239:6 241:22 242:20 251:21 251:22 280:5 294:17 296:6,10 301:20,21 329:3 330:4 heard 6:18 7:22 64:6 73:18 114:9 126:1 149:22 155:13 156:17 206:10 213:16 243:12 333:14 hearing 236:6 238:17 333:15 heart 24:15 124:14 heavier 45:17 86:8 heavily 247:17 heavy 111:5 **HEDIS** 64:3 109:4 126:22 127:10,12 142:7 229:16 231:3 234:15 held 40:13 126:20 Helen 2:13 71:4 149:19 156:19 160:18 161:18 220:20 298:8 326:8 336:4 337:13 hello 10:1 316:4 help 58:4 66:14 84:21 89:21 97:6 119:1,4 124:1 127:6 155:20 161:3 227:16 244:8 278:17 309:4 325:13 helped 169:15 helpful 26:8 86:20 96:20 125:15 126:4 161:10 176:10 248:9 294:12 312:13,16 337:13 helping 335:22 336:5 helps 43:12 277:8 287:18

hema 265:21 hesitant 282:19 Hey 32:12 97:22 HHS 334:19 hi 5:3 9:15 30:11 33:4 50:6 89:2 230:20 240:20 241:14,19 257:15 281:3 hierarchy 303:3,6 high 11:10 15:2,3 53:3 60:9 62:7,7 157:17,22 159:20 210:21 211:1 218:11,20,22 225:19 high- 286:2 290:19 328:12 331:1 high-cost 291:17 high-impact 189:18 high-margin 333:18 high-performers 57:10 132:6 high-priority 267:11 290:18 291:4 high-reported 137:13 high-safety 328:13 high-volume 67:9 82:2 higher 53:7 62:13 98:8 100:13 119:22 159:11 164:12 225:17 259:12 266:1 higher-cost 87:15 higher-value 328:7 highest 237:12 309:14 highlight 57:9,11 110:16 194:17 217:9 313:3 317:12 highlighted 217:12,13 highlights 7:13 14:21 highly 70:10 131:5 151:11 hint 123:22.22 historical 298:9 history 62:20 172:10,18 252:2,12 hit 75:3 84:6 96:17 291:3 hits 291:22 292:12 293:12 hold 134:10 222:2 holding 212:15 321:17 holiday 301:18 holistically 273:7 home 60:9 66:4 71:15 87:6,7,11 90:17 162:6 198:1 282:17 332:15 homes 90:21 hone-in 88:2 honor 40:13 188:9 hope 34:11 144:7 177:2

197:9 hopefully 5:10 83:10 103:15 158:5 163:14 hoping 205:6 240:3 278:18 Hopkins 147:8 horizontal 14:21 horrible 265:1 322:15 horrifying 321:9 hospital 1:13,14 3:12 3:14 61:16 89:3 91:10 117:2,9 120:6 126:2 157:10 162:18 175:4 177:11 178:10 205:19 210:8 211:14 212:20 212:21 216:4,6,9 235:5 243:9 271:6 303:4 324:2 hospital- 330:22 hospital-based 176:14 178:17 hospitalist 89:4 hospitalization 72:17 332:4 hospitalizations 89:8 90:1 hospitalized 244:14 246:4 hospitals 89:5 90:3,8 90:10 108:22 109:3 158:17 162:5 175:10 210:20 211:3,5 214:10,22 219:1,11 219:18 220:5 235:9 235:10,11 249:20 320:10 333:20 hour 104:8 hours 286:15 332:13 housed 121:5 housekeeping 134:11 hovering 49:21 HPV 11:18 12:1,7 117:20 HRSA 147:9,9 huge 20:19 50:4 76:18 77:8 80:19 90:16 91:5 101:8 130:2 132:9 169:2 223:17 228:8 317:7 336:13 huh 192:12 human 3:17 132:2 275:11 hundreds 149:15 hybrid 127:2,11 147:22 hygiene 56:8 hypothesis 195:20 hypothetically 52:17 301:3

I ICD-10 121:11 285:4 idea 7:21 10:9 36:20 169:8 175:10 224:22 237:12 295:17 296:1 ideal 96:10 269:22 321:3 ideally 26:13 99:17 ideas 134:17 ideations 189:21 identification 82:6 identified 70:1 95:13 188:20 207:11 218:5 265:19 279:3 295:5 303:19 identifies 293:16 identify 184:12 218:19 230:16,18 249:4 291:13 297:6 idiosyncracies 211:22 illustrates 14:3,17 illustration 15:1 imagine 163:4 294:3 321:5 immediate 276:4 immunization 12:4 30:14 31:4 32:5,7 118:4 208:9 210:12 213:19,20 214:18 234:16 236:8 immunizations 11:21 12:2 14:15 31:3,19 115:10,17 116:6 135:8 193:21 210:4 impact 55:19 164:5,16 188:15 189:1 223:21 267:19 268:7 270:14 271:15 320:18 impactful 53:8 impacts 54:5 320:19 **implement** 102:17 123:22 146:4 213:7 334:4 implementation 103:10 122:17,21 124:2 139:7,21 173:3 implemented 52:7,13 130:16 implementing 204:16 implications 80:10 implicit 210:1 270:4 implies 151:9 import 178:17 importance 126:12 226:12 241:17 256:12 271:9 280:20 308:19 important 7:21 8:1,8,10 8:11,15 9:2,3 24:16

27:7 29:8 66:4.21 73:21 74:8,20,21 78:13 82:19 98:12 111:7 112:10 114:4 121:4,19 126:9 128:22 130:7 131:14 133:4 140:16,16 141:22 151:13 156:16 158:13 161:19 170:5 172:21 173:10,14 174:3 176:16 177:6 177:20 178:6 184:21 210:7 216:12 224:1 224:11 237:2 238:6 238:14 242:17 251:15 253:2 255:15 256:13 256:18,22 263:9 269:9 270:16 273:1.4 288:11 292:3 302:20 307:6 308:22 310:22 313:5,8 337:5 importantly 312:7 impossible 32:13 improvable 311:21 improve 26:15 34:8 43:13 110:5 202:8 224:2,5 247:22 326:2 improved 39:5 improvement 2:6 11:11 16:12 22:7 34:14,17 34:22 38:9 39:12,15 40:20,21 41:1,17,17 41:19 42:5,6,9,14,15 50:5 57:19,20 65:18 65:19,21 66:14 67:5 87:1 129:22 132:9 140:15 183:19 205:1 205:4 230:11,13 231:11 271:16 improvements 43:22 121:11 improving 42:17 in-depth 248:15 inactive 220:9 inappropriate 227:5 228:7 276:14 inappropriately 277:2 incentive 165:3 276:20 incentives 41:18 42:16 65:12 164:22 283:1 333:22 incentivized 284:9 incentivizing 82:4 incidence 266:6 inclination 166:9 include 18:21 42:10 72:19 98:14 99:5 107:20 108:19 177:17

181:13 199:21 235:1 278:1 included 141:5 164:21 184:18 213:8 includes 13:17 54:22 101:12 131:22 180:1 214:13 293:5 including 43:10 55:8 96:13 203:17 207:17 207:18 255:21 260:1 284:14 290:20 299:18 inclusion 111:11 180:9 184:8 186:13,16 236:10 274:16 290:16 305:20 308:1 Inconsistencies 108:10 inconvenience 243:14 incorrect 90:1 increase 10:4,5,6 15:11 38:21 43:18,19 107:13 131:19 164:11 202:13 330:19 increased 108:14 159:3 increasing 223:6 increasingly 237:22 312:9 incredible 66:21 incredibly 68:2,8 71:6 82:16 88:4 176:16 incremental 79:4 independently 298:1 independently-valida... 297:17 Index 306:13 Indiana 49:11 indicated 184:13 indicates 235:15 **indicator** 256:14 indirectly 282:13 284:7 individual 25:20 76:4 82:12 85:15 94:18 131:15 208:22 246:15 250:5 305:5 324:19 individualized 278:10 individually 302:6,7 304:20 335:8 individuals 235:2 inductions 169:16 ineffective 322:5 inefficient 322:4 ineligible 254:7,20 296:18 inexpensive 267:14 infant 215:10 infants 213:20 infection 14:6 266:6 287:12 influence 85:4

influenced 167:14 influenza 208:9 214:1 214:14 233:17 234:7 236:8 inform 231:14 254:8 information 16:4,6 18:6 18:15 43:20 64:7,22 66:12 67:15,21 68:2,6 68:13 70:11 71:5 84:8 102:20 108:20 117:17 118:1 121:12 162:10 162:11,19 217:18 257:8,22 261:13,14 261:15,17,20 285:6 302:4 306:9 335:6,10 informative 311:14 informed 208:11 236:17 244:6,12 249:2,11 255:4 263:20 308:11 309:14 319:2 initial 48:4 69:5 183:1 286:18 initially 8:20 169:7 172:13 306:2 Initiative 33:1 38:19 90:17 initiatives 77:21 innovation 46:6 130:14 202:12 inpatient 89:18 161:7 170:22 234:7 277:11 323:3,14 324:4 326:6 328:15 332:5 inpatients 209:18 **input** 280:4 inquiry 161:14 inside 111:6 337:22 insight 211:1 insisted 284:13,14 instance 34:2 instances 34:15 Institute 51:1 289:10 Institution 329:16 instructions 102:20 instruments 122:2 **insurance** 44:7,8,8 203:15 244:9,15 245:16 246:6 250:17 250:18 255:18 277:3 316:20 329:6 insured 245:6 250:8 **integrated** 312:9,12 integrating 91:6 integration 317:14,15 intelligence 76:15 intend 78:16 143:1 intended 8:20 71:17

98:1 130:15 202:8 306:10 intense 336:1 338:1 intensive 46:18 293:8 332:11 intent 146:3 299:8 intention 141:8 intentionally 327:8 interaction 111:3 114:10 interest 80:6 238:10 257:10 interested 18:1 21:2 61:19 88:15 149:21 175:17 270:11 302:8 302:11 interesting 50:7 54:2 57:11 115:21,22 117:6 147:3 211:6 327:9 interim 46:22 intermittent 314:10 internally 26:13 114:10 161:5,9 162:21 168:7 interpret 50:18 interpretation 103:1 interval 258:22 259:1 intervals 246:13 intervention 20:6 32:12 36:15 45:20 53:16 82:3 116:10 120:3 170:4 267:14 288:9 interventions 46:22 49:15 50:2 287:22 288:7 322:6 intrapartum 159:19 intrauterine 159:1 intriguing 211:10 introduce 32:22 58:22 240:19 243:4 introduction 78:22 243:1 inverse 228:16 invest 70:12 invested 8:4 invite 25:2 58:17 330:21 involve 283:19 involved 58:9 210:16 212:17 **IQR** 161:6,6 177:9 219:1 235:9 iron 25:12 isometric 197:5 issue 20:19 46:4 51:11 87:20 89:9 91:6 105:6 124:6,12,15 130:2 133:12 146:19 159:1

176:13 177:3 224:14 226:7 227:10,11 228:8 232:18 237:1 238:14 241:18,21 255:15 262:22 267:21 269:20 278:9 299:6 314:6 315:17 325:12 325:19 326:9 329:9 335:1 issued 130:22 issues 55:2 57:1 93:14 103:10 125:21 139:17 168:4 197:3 210:14 238:4 278:14 285:1 319:22 320:1 323:2 326:2,4 327:5 329:15 item 23:1 J jargon 101:11 JD 1:16 3:7 Jeff 3:14 237:10 238:11 238:15,20 239:1,11 240:18,21 241:19 242:1,21 243:2,7 249:16 253:17 256:4 256:5 257:15 264:17 Jersey 250:10 **job** 19:18,20 44:14 45:22 46:1 55:19 58:10 84:22 223:12 336:11 ioq 114:7 **Johns** 147:8 ioin 49:12 252:17 joined 6:6 joining 241:3 Joint 119:20 120:3 131:7 157:9 160:10 160:17,21 161:2,21 171:1 177:8 178:9 234:1 324:8 jointly 5:22 judge 216:1 juices 43:11 **July** 334:14,18 jump 188:10 230:18 240:15 June 266:15 306:16 justification 52:18 Κ Kamila 239:18 Karen 3:6 8:12 111:20

Neal R. Gross and Co., Inc. Washington DC 113:6,22 125:9 135:5

151:22 155:17 161:16

172:7 177:4 204:9

229:12 256:2 261:8

278:15 300:21 Karen's 124:17 Kathryn 1:14 160:5 163:17,19 182:1 319:21 321:11 322:17 keep 22:4,15 29:15 51:7 85:8 91:16 94:9,16 95:18 98:11 114:3,19 115:5,6,19 124:4,20 129:10 144:5 294:13 301:17 312:22 318:1 324:5 keeping 22:11 63:4 80:17 111:10 115:2 183:8 192:4 key 4:4 28:18 71:22 204:18 265:13 303:20 303:20 keypad 200:7 307:13 318:12 kid 44:7 45:18 51:19,20 52:22 286:11,15 323:11 332:11 kids 19:19,21 20:6 21:1 32:9 36:3 40:8 45:14 45:15.19 46:15.17 47:17 49:15 53:3.4 55:17 56:11 85:16,16 85:20 89:9,16 90:2 91:4,8 116:20 164:15 193:20 198:15 223:15 223:18 242:16 245:11 253:3 254:3,12,12,15 254:19 255:3 259:3,4 282:4 284:2,16 295:5 299:7 312:7 323:22 325:3,3,8 326:3,14 329:8,15,17 332:4 333:9 **KILSTEIN** 1:16 54:20 85:12 119:5 133:2,15 133:20 140:20 141:14 141:17 145:2 182:9 184:1 198:10 239:3,7 241:16,20 242:4 260:5 262:5,10,13 278:7,16 293:4,20 329:13 Kilstein's 295:11 Kim 2:2 54:14 93:6 101:17 168:12 222:10 223:4 232:2 Kimberly 3:9 25:3 kindergarten 82:7 83:7 85:13 87:4,9 94:1,5 102:2,7 kinds 54:1 59:16 74:22 84:5 86:7 103:9

159:18 189:4 331:2.2 kinks 238:3 knew 27:3 258:15 knowing 20:1 124:5 143:8 174:3 known 63:1 73:15 95:13 96:11 knows 130:10 177:12 211:22 KUWAHARA 2:17 152:10,21 153:1,5,9 153:16 154:2,7,18 155:7 156:5 186:14 191:14 192:8 199:7 200:14 232:15 236:6 263:19 274:11 305:3 334:13 335:5 L LA 1:17 33:8 121:1 164:20 225:7 228:11 279:10 280:6 lab 230:2 labor 175:5 labor-intensive 68:3 70:10 labs 229:22 lack 247:18 Ladies 200:5 307:11 318:10 lag 121:6 238:4 land 173:21 landed 172:15,19 173:1 173:20 language 256:10,12 296:18 299:20 languages 296:15 297:6 large 79:17 114:20 226:14 249:4 257:17 302:17 largely 64:2 lastly 336:9 late 59:15 74:3 130:10 166:7 335:2 lately 165:18 latest 49:21 Laughter 23:2 33:14 40:12 93:5 152:9,13 153:13,15 167:6 177:22 179:2 187:13 220:22 231:18 313:20 334:12 launch 59:1 launched 46:5 launching 81:11 Laurie 3:7 4:6 22:12 32:17,21 49:1 54:11

lavalier 205:16 law 37:14 Layla 3:9 292:20 294:9 LCSW 3:10 lead 151:3 206:7 209:15 222:11 289:11,21 leadership 118:14 144:12 336:4 leading 44:18 130:16 139:13 lean 127:22 163:22 learn 83:12 learning 53:7 leave 83:14 119:6,9 179:1 181:7,9 231:15 253:12 307:5 leaving 197:17 led 129:19 235:14 289:16 left 84:8 152:20 183:20 255:11 308:3 lefthand 43:21 legacy 212:9 legislation 327:16 length 164:13 268:3 let's 7:2 25:9 26:18 33:12 65:6 79:11 80:9 104:15 120:16,17 132:14 151:18 157:6 169:21 170:21 181:6 181:9.20 182:7 200:22 201:1 222:2.2 233:15 263:15 264:19 285:18 305:11 309:5 328:9 level 34:21 42:13,15 49:5 64:13 77:12,13 94:19 100:12,13 103:22 117:9,17 118:17 120:6 121:9 147:15 157:10 160:9 161:10 163:2,21 164:3 165:4 166:13 167:21 168:19 171:9 173:5 174:5 177:14 204:17 205:9 211:17 224:3 235:1,3 237:12 270:20 279:6 286:3 303:3,4,5 306:10 311:2 328:20 levels 15:4 21:14 59:9 106:21,21 205:11 leverage 64:1 leverageable 24:21 leveraging 79:7 81:12 levers 329:15 lie 85:1 life 31:20 82:6,15 102:1

107:4 152:16 213:10 lifelong 132:4 lifespan 173:16 174:7 lift 45:18 111:5 326:22 ligature 324:10 light 140:14 169:14 lights 80:18 325:5 liked 111:3 likelihood 131:20 limb 72:21 limit 253:5 limitations 24:9 limited 18:9 limiter 53:5 limiting 94:17 limits 253:3 Lindsay 3:3 4:7 27:8 54:14 57:2 58:18,21 59:4 84:18 96:2 111:4 165:13 292:6 Lindsay's 54:15 line 14:21 34:5,5,12,13 35:14,20 36:7,10,16 36:21 39:21,21 40:1 40:10 56:3.9 71:1 121:14 146:21 172:2 195:1 200:3 210:6 212:5 225:4 236:18 239:19 240:22 275:13 294:8 307:9 lines 22:12 195:2 318:8 link 61:18 89:7 160:13 173:11,13 322:9 linkage 126:3 317:17 linkages 290:22 linked 323:16 lipids 230:8 list 109:5 119:16 136:22 137:6 168:9 208:5 277:19 283:16,16 285:4,7 291:21 304:6 306:20 310:11 324:4 listed 63:16 64:9 203:7 203:11 318:20 335:11 listen 105:15 252:19 listening 92:8 169:6 252:9 literally 163:13 little 5:19,21 9:11 11:11 16:7 17:18 18:15,20 24:6,18,20 29:20 32:21 33:18 35:1,6 40:6 41:5 49:4 57:13 60:4 62:19 64:10 65:6 66:1 69:2,17 73:8 83:11 86:11,17 87:18 88:6,11,14,16 90:11 91:22 93:8,11,17 96:3

96:8.9.19 107:2 109:21 130:10 135:14 140:17 145:10 149:6 158:7 161:17 163:22 170:12 197:15 208:8 209:11 211:1 214:22 216:10 217:9,18 229:12 237:9 238:13 250:19 251:4 261:21 268:13 276:6,10 281:11,14 294:17 298:3 300:22 331:4 live 15:12 67:11 178:15 310:11 lively 22:2 lives 223:21 location 284:10 323:16 **lock** 325:4 locus 160:16 logic 109:2 182:18 logical 47:21 logistics 157:11 long 22:18,20 36:5 81:1 117:14 118:6 215:22 220:2 245:8 295:1 297:13 319:16 323:12 long-term 163:7 223:20 long-winded 142:13 longer 28:5 40:11 107:5 143:8 242:6 longstanding 25:10 **look** 15:3 17:2,11,12 20:22 23:8 26:16 30:17 32:1,8 46:9 59:10,11 74:1,6 75:8 81:5 83:6 86:4,5 88:18 91:4 93:16 97:18 99:18 100:22 101:1,2,3,10 113:9 115:12,13,14 121:8 122:8 123:21 159:14 164:10 165:6 173:20 193:19 194:15 204:15 204:17 205:18,22 210:10 229:18 237:6 238:7,8 245:1 246:5 246:11 253:2,6 257:22 258:3,7 267:22 268:15 280:17 280:21 281:9 283:15 288:12 289:20 300:12 302:17 310:5 311:14 312:14 326:12 330:20 looked 18:12 44:22 45:6 88:11 99:10 102:13 116:1 169:6 215:16 219:20 230:7 242:5 251:1 263:6

(202) 234-4433

281:6.13 297:11 300:12 303:16 326:21 329:12 looking 5:17 23:7 24:10 25:8,18 26:13 59:18 61:17,19 63:3 64:18 66:6 78:2,21 79:8 81:8 82:10 83:19 85:14,15,18,19,20 86:13 88:13 89:10,21 90:21 93:3 116:18 117:3,21 122:7 146:5 161:11 163:13 165:1 166:1 172:1 173:6,15 174:22 181:13 182:13 183:18,21 194:1 199:5 226:20 227:10 242:16 245:5 250:7 268:22 273:12 275:7 277:10 278:8 280:6 280:10,14 281:2,5 284:22 285:16 290:18 292:8 310:2 328:11 333:6 looks 50:8 91:17 153:18 195:19 209:22 211:2 219:2 246:1 324:11 **loop** 101:12 loosen 53:6 lose 81:4 87:22 124:7 313:18 314:22 324:2 loses 242:10 losing 29:2 80:14,19 loss 151:9 lost 13:11 125:4 148:21 150:1 230:2 273:5 lot 6:18 7:6 8:2 22:7 32:9 47:19 59:12 65:13,15,19 67:20 68:6 71:11 75:17 85:21 88:1 91:13 96:21 104:9 105:19 114:6 126:17 129:21 130:22 139:9 146:13 163:9 165:18 166:4,6 168:16 182:14 183:11 184:2 189:20 210:21 215:1,14 223:8 248:22 271:7 281:7 281:10 284:22 288:14 290:4 302:13 310:10 311:22 314:12 322:8 329:9 330:14 332:4 lots 169:3 333:16 loud 156:17 Louisiana 227:21 love 24:1 27:8,10,11

84:7 178:20 282:4 337:3 **low** 15:3,18 106:21 110:3,16 117:21 165:22 166:3 228:17 228:20 323:7 low- 63:18 112:1 136:22 low-cost 47:2 62:1 73:11 low-impact 47:3 low-margin 330:13 low-performers 57:12 low-performing 40:22 low-reported 113:8 137:6 low-reporting 137:14 lower 70:7 166:14,14 188:22 247:9 259:10 lowest 15:22 106:21 309:18 lowest- 40:15 lowest-performing 40:11 Lucretia 97:6 172:17 173:16 Luke's 1:14 lunch 192:14,19 200:19 201:2,4,6 Μ magic 37:21 main 63:21 65:8 71:7 114:3,18 142:4 254:18 maintain 22:9 107:7 123:6 144:19 149:1 149:10 167:11 199:1 maintaining 123:12 125:2 149:21 150:7,9 maintenance 12:11 151:10 major 13:21 15:21 95:3 109:20 137:3 138:2 188:17 190:19 191:3 191:16 245:13 247:19 323:2 majority 13:6 188:19 making 93:2 125:8 137:2 165:7 167:9 175:12 225:1 326:5 males 12:5 manage 323:18 managed 31:14 41:13 42:1,4,13 54:21 55:4 55:9 61:8 62:20 63:4 63:6 64:4,13 65:13,18 65:20 82:1 90:19 126:16 127:3 128:7

135:1 139:9 257:17 276:16 284:6 326:1 managed- 62:21 management 12:21 84:16 120:5 186:6 203:18 286:17 290:9 Manager 2:16,19 managing 57:12 mandated 58:2 mandatory 23:14 51:14 mania 79:1,1 manic 79:1 MAP 29:11,14,19 203:9 207:18 285:12 334:21 mapping 72:6 maps 18:16 margin 330:12 331:2,4 331:5 mark 36:2 marker 315:10 market 32:5 Marsha 2:7 9:15,17,18 9:19 161:15 marvelous 84:22 **Mary** 7:4 Mary's 67:18 Mass 327:18 Massachusetts 321:18 327:15 masse 290:8 massive 212:3 match 121:7 material 109:6 materials 4:4 6:3,16 maternal 7:14 13:13 130:14 207:17 Maternal- 130:18 maternal/newborn 159:10 maternity 130:9 160:1 167:19,20 168:2,21 MATSUOKA 3:6 111:22 114:2 115:20 124:9 125:10 161:11,21 167:22 168:2 170:19 172:9 216:17,22 226:16 256:9 269:12 278:18 279:11 300:22 matter 2:1 104:12 185:21 201:5 252:12 **MAX** 244:16,16,21 250:6 **MBA** 1:16,18,20 MCOs 109:3 110:11 126:19 **MD** 1:11,12,13,14,18,19 1:20 2:7,13 3:4,14 **MDwise** 1:18

Neal R. Gross and Co., Inc.

			35
mean 26:20 113:4	159:12 162:3 163:8	10:16 16:20 122:10	232:12,13 288:18
119:10 124:9 133:8	164:5 165:22 166:6	186:21 194:20 203:5	Michigan 88:12
137:7 145:11,13	166:10 171:8 178:18	228:18 229:4 231:13	microbiome 132:3
146:14 150:8 170:2	195:2 196:19 204:20	233:13 236:14 238:18	microphone 28:8 128:
173:3 175:16 178:3	206:21 215:3,13	243:22 264:5 272:20	137:22 230:16 234:1
187:16 189:14,19	220:1 225:15,19	305:17 307:5,19	294:18 300:15
190:8 193:10 196:5	227:22 242:15 258:17	-	
		308:16 337:14	midday 132:18 middle 249:6
198:11,16,19 211:21	258:18 277:2 279:1,6	memo 267:4	
215:10 218:6 234:2	279:12,14 280:9	memory 114:7	middle-aged 93:4
250:22 253:13 260:20	283:7 286:22 287:6	memos 251:6,7	mileage 193:15
261:14 270:19 271:14	288:3 291:17 293:17	meningococcal 12:7	miles 135:13
287:4 294:3 299:12	296:20 303:10 323:2	mental 92:1 202:21	milestone 36:1
302:16 303:6 308:14	332:18	316:8,8 317:1,4	million 37:7
310:22 325:6 326:3	Medicaid's 325:12	319:22,22 320:3	mind 7:8 31:13 118:15
327:22 329:9	Medicaid-specific	321:2 323:18 324:10	179:15 231:6 238:12
meaning 258:18	126:8	325:1 326:4 329:16	290:18 322:8
meaningful 122:4 172:3	medicaid.gov 17:17	mention 67:3 246:19	mindful 111:9 143:16
312:3	Medicaid/Medicare	311:9	274:6
means 38:6 170:19	168:8	mentioned 24:19 40:18	minds 178:13
198:17	Medicaids 322:21	88:3 224:3 281:4	mine 153:11 222:9
meant 19:18 272:10	medical 1:20 49:13	282:22 292:7 302:6	234:4
measure-by-measure	55:15,15 67:10,12,16	mentioning 286:7	minimum 155:20
104:19	69:8 88:14 90:2	mentions 67:1	Minnesota 296:21
measure-focused	102:12 108:3 116:18	merits 211:17	303:1
72:14	122:6 142:2,11	mess 128:8	minute 39:17 136:13
Measure-Specific 4:8	255:17 277:14 279:1	message 58:11 140:15	201:14 220:20 225:9
measure-to- 106:1	279:6,12,14 282:17	257:19	241:6 262:19
measured 139:14,16	299:11 306:5 315:14	messaging 8:7	minutes 21:6 101:15
329:12	328:10	met 1:8 33:5 58:1 150:4	221:22 231:5 333:15
measurement 2:15 3:3	medically- 316:11	229:5	Miranda 2:17 191:12
59:6,8,9,10,16,21	medically-complex	metabolic 208:10	199:5 200:13 232:14
71:10 74:12 76:20	291:12,13,16 292:2	222:19 223:12 227:17	236:2 263:15 274:5
79:5,6,19,21 80:14	293:16 295:18	228:14,22 229:18	304:18
82:16 85:7 87:16	Medicare 2:8 3:5,6,8,9	233:7 308:9 319:5	missed 67:18 231:5
100:4,22 101:11	3:10 29:11,13,13	method 13:4 121:22	267:4
128:8 195:5,8,9 223:9	162:2,13 163:7	308:7	missing 247:8
227:11 230:22 253:11	170:22 171:3,4	methods 9:7	Mistry 204:2
322:14 327:17 338:5	177:10 329:5 332:19	metric 197:10,18	model 81:12 284:6,7
measurements 85:6	medication 12:21 117:7	209:17,18,20 210:5	332:2
measuring 7:22 30:9	203:22 227:5 257:12	210:20,22 211:4,19	models 48:4 334:1
37:2 75:12,13 84:2,4	308:5 318:22 323:11	212:1 219:18 220:16	moderate 308:7 333:8
87:21 93:13 103:4	medication-related	236:22 237:7,9,17,21	moderately 9:7
114:12,14 116:14	226:19	238:2,12 240:3 243:7	modification 42:22
117:5 135:3,4 171:6	medications 222:21	243:15,19 244:19	171:14 316:17
214:13 263:7 270:19	223:7,21 224:8 227:3	245:9,12,15,22 247:4	modifications 327:3
282:14 321:14	medicine 130:19 198:1	253:19 254:2,8 260:2	modify 170:16 171:12
meat 63:11	198:2	260:22 261:9 265:14	module 297:10,12
mechanism 162:22	medium 15:2	283:8,20 286:20	298:6
177:1 211:6 219:13	medium- 137:13	322:20	modules 297:14
Medicaid 1:3 2:8 3:5,7	meds 224:10 325:5	metric- 244:5	moment 242:2
3:8,10,11 5:8 20:19	meet 31:7 57:19 58:4	metrics 50:10 54:5,6	moms 119:22 157:19
20:20 21:1 23:13 24:9	334:22	71:2 96:4,10,13,17	Monday 301:18
30:5,6 44:8 47:11	meeting 4:4 6:21 70:21	164:14 196:16 197:1	money 43:5 53:21
53:21 59:12 61:1,3	107:19 111:11 178:13	197:8 210:12 214:16	129:5 333:6,9
	182:12 318:5 335:15	214:20 237:17,18,19	monitor 34:19
		245:4 247:3 261:1,3	monitored 223:19,19
62:20 63:1,7 65:12 71:19 76:1 2 78:3	338.16		
71:19 76:1,2 78:3	338:16 meetings 337:4		
	338:16 meetings 337:4 members 1:10 2:4 9:13	MHS 3:2 mic 205:17 222:9	monitoring 22:10 204:22 208:10 223:1

226:9 227:18 228:14 228:22 229:18 233:7 314:10 month 258:2 288:2 332:7 month-old 287:13 months 27:9 183:2 194:20 195:4,4 212:8 258:6.20 265:15 275:21 morning 5:4,14 6:2 9:18 33:3 232:21 mortar 328:10 mother 170:6 mother's 174:4 mothers 130:3 169:7 motion 118:17,21 120:17 124:22 125:8 132:13,22 133:14,16 133:18,21 134:21 135:18,20 136:3 137:2,8,22 138:9 143:12 151:1 152:4 170:16 171:13,22 174:11,12,17 176:3,5 177:18 178:21 180:5 180:5,14,19 181:10 181:19 185:7,10 186:9 187:5 188:5 189:9 193:4,8 220:13 221:5 222:2 231:22 233:15 235:22 259:21 260:8,13 262:12,16 268:9 271:19 273:11 273:19 274:2 288:17 299:16 motioned 259:19 motions 113:2 132:20 134:7,10 motivate 41:15 42:15 motivated 39:16 70:18 motivation 43:4 motivations 55:14 mount 238:8 mouth 47:5 move 26:6 54:15 60:3 73:19 78:15 102:4 104:17 105:17 106:11 120:7 138:2,14 143:6 152:14 153:20 160:10 166:22 171:16 176:6 181:2 183:17 187:12 206:19,22 220:14 222:2 232:3 259:22 260:10 262:21 264:19 273:13 284:4 288:19 289:5 299:17 315:9 329:8

moved 9:8 40:1.14 118:12 147:7,20 movement 167:15 moving 7:10 44:19 93:9 111:12 157:4 171:17 185:1 202:19 275:4 **MPH** 1:12 2:7,18,19 **MSPH** 1:21 **MUKHERJEE** 2:18 5:3 141:1 145:9 182:21 190:16 194:19 197:19 200:22 234:22 272:5 309:6 311:7 312:21 313:17 314:17,20 315:3,6,17,22 316:4 335:3,13 multidimensional 197:16 multidisciplinary 338:1 multilevel 205:4 multiple 59:9 85:14 131:9 226:21 228:13 228:15 230:3 291:22 297:5 MUNTHALI 2:14 149:5 150:6 MUP 1:15 muster 261:11 mute 238:16 239:13 243:11 mutually-exclusive 13:8 mystery 37:4,12 myth 50:11 Ν N 271:4 N's 269:20 270:15,18 270:18 **N.W** 1:9 NACION 2:19 10:1 157:2 202:3 **NAIR** 2:6 naive 213:7 name 5:5 59:4 93:3 147:20 158:15 292:20 names 335:6 narrowing 218:11,13 narrowly-defined 36:9 nation 40:11 national 1:1,8,21 3:2 14:9 39:10 62:9,14 130:16 147:5 158:11 159:9 169:6 290:2 322:13 Nationally 39:3 nausea 285:22 NCQA 12:9 126:20,21

222:15 227:13 230:14 230:22 233:18 234:4 234:8 near 249:20 necessarily 44:17 46:1 72:8,18,20 81:9 100:9 117:13 125:10 137:7 139:7 145:16 151:15 155:15 173:22 183:13 187:22 189:14 193:10 194:3 195:22 288:8 310:4 312:10 321:14 330:15 necessary 100:18 108:2 110:10 need 8:5 19:19 20:1 37:2 52:19,22 54:6 62:7 65:7 66:19 70:12 72:19,21 75:2,20 76:19 77:1,4,14 79:22 80:1,2,7,8 81:2 82:21 83:22 88:9,19,20,20 100:9 101:6 103:20 106:17 111:9 114:8 118:3 123:21 130:21 139:4.16.19.20 140:7 140:14 143:9 144:11 144:16 151:22 152:8 154:17,19 155:21 159:21 160:1 177:4 184:16,17 187:11 198:18 207:3 216:8 225:4 231:13 246:14 255:22 256:5 267:21 271:9 281:16 289:2 292:4 295:4,20 307:7 322:7 325:12 327:22 333:3,11 needed 28:17 45:15 77:3 99:21 100:14 101:7 295:4 needing 209:18 332:5 needle 160:11 needs 7:6 19:20 51:16 51:19,20 52:19 85:2 87:18 88:4,7 96:15 135:15 150:9 151:7 169:10 177:14 251:3 291:1 292:1,9 299:7 321:21 333:1,10 negative 186:8 neighbors 18:3 Neither 23:16 net 79:15 **Netflix** 320:4 network 14:10 165:1 279:2,14,18 networks 164:7

neutral 284:14 never 68:18 71:17 83:20,21 94:4 147:13 287:14 nevertheless 117:8 171:5 new 3:3,16 6:6 12:8 13:18 15:22 22:10,16 38:11 39:22 40:3,6 46:21 54:18 58:18 59:5 61:1,5 62:13,21 63:12 64:22 77:17 79:17 81:2 84:18 88:20 89:15 91:13 95:8 101:21 102:8 104:11 121:14,19 130:12 166:1 169:18 202:12 205:2 207:12 233:3 249:3 250:10 263:5 275:10,12 276:2 277:1 279:13 279:20 306:5 311:12 313:14 314:1,18,21 320:14 newborn 164:17 newcomer 255:13 newer 146:5 298:11 newly 222:14 newly-identified 207:12 news 35:14,14 36:4 43:16 44:4 219:14.20 news/bad 35:13 nice 33:10 100:10 251:21 NICU 164:11 night 332:15 nine 169:1 nineties 63:2 no-surgery 47:3 nominating 201:11 non- 69:10 non-compliant 32:1 non-dental 49:7 non-HEDIS 64:14 non-medically-indica... 165:10 non-traditional 338:6 NON-VOTING 2:4 normal 46:16 324:11 Norris 3:7 4:6 19:11 20:16 21:3,8,12,16 32:17,19 33:2,10,15 49:10 50:12,17 54:3,9 55:7 56:3,16,20 57:16 North 40:16 167:8 not-endorsed 142:8 notable 85:6 note 11:14 12:20 112:1

120:16 123:4 125:21 148:20 noted 11:9 90:6 notes 67:22 notice 28:21 295:22 noticeable 114:22 noticed 101:20 noting 62:17 notion 7:1 255:20 322:2 NQCA 234:1 NQF 2:11 6:21 11:2 12:8 17:22 28:5 80:7 97:17 124:7,14,19 125:4 140:1,2 142:8 144:2,22 145:8 150:7 150:11 181:2 191:15 220:10 222:12 252:7 252:15,16 255:14 262:7,9,14 264:1 274:1,17 275:6 285:12 299:21 304:20 311:12 336:4 NQF- 192:20 202:19 NQF-endorsed 28:20 29:1 133:6 143:8 151:8 152:1 229:14 248:10 263:5 273:21 294:4 300:5 nuanced 240:11 nuances 184:8 240:1 number 10:5,6 14:3,18 15:16,16 17:9 34:16 40:19 42:17 55:8 78:22 107:16 108:13 126:8 135:13 136:1 153:18 163:2 171:5 179:14,15 187:5 192:21 197:1 224:16 232:4 258:20 268:18 273:8,14 274:9,10 275:7 278:8 286:1,6 287:6 291:4 328:14 number- 37:16 numbers 44:5 49:20,21 73:14 157:21 224:22 225:14 226:13,17 228:10 230:6,13 255:3 270:9 296:17 299:21 numerator 190:22 237:15 239:21 nursing 162:5 163:5,10 nutrition 100:16 101:3 NYU 277:7 281:5,6 283:17 Ο **OB** 175:1,2

OB/GYN 168:9 OB/GYNs 165:2 observation 101:20 222:5 observe 33:19 observed 35:2 46:13 obtain 158:5 obtained 14:9 obvious 156:2 obviously 49:6 123:16 261:6 272:11 327:12 oddly 177:9 off-microphone 166:16 offer 65:12 89:16 117:19 offered 216:6 offering 164:22 office 1:12 2:6 20:7 23:11 35:21 45:18,19 45:21 50:2 56:2 108:21 128:16 197:22 216:8 230:1 officer 2:13 277:14 officially 260:14 offline 127:10 oftentimes 163:6 176:15 331:21 Ohio 40:17 old 13:20 287:13 older 92:6 180:2 212:8 235:2 once 75:3 225:11 237:19 272:16 332:7 332:7 one-to-one 324:15 ones 18:21 22:16 63:17 77:22 112:16 127:11 237:15 269:13,18,19 286:4 295:22 304:1,4 316:7 317:12 338:11 ongoing 7:16 11:5 205:8 222:20 242:7 242:14 open 16:18 102:11 111:18 178:22 181:20 193:1,5 200:3 209:1 211:7 278:5 293:1 307:9 318:6.8 opened 6:20 opening 4:3 185:5 301:14 operates 52:4 operating 55:18 Operator 200:3,5 307:9 307:11 318:8,10 operatory 55:17 **Opinion** 131:2 opportunities 7:11

24:19 50:5 159:15 238:1 **opportunity** 4:10,12,15 7:7 11:11 35:8 60:3 94:12 132:9 176:21 178:12 210:3 238:6 294:22 327:12 333:17 opposed 89:12 171:11 183:18 193:22 293:15 299:22 optics 8:6 options 263:22 oral 33:1,20 35:3,7 37:9 38:18 41:5,16 48:15 49:14 51:13 53:8,11 58:2,8 208:1 order 4:2 77:17 112:2 115:4 136:19 142:2 143:10 180:21 206:17 213:2 273:1 308:19 Oregon 42:20 147:8,20 148:3,3,13 organization 55:11 105:22 184:14 194:22 257:17 organizations 31:1 58:9 organized 113:7 origin 172:12 original 35:17 39:6 134:19 327:11 originally 148:2 orphan 145:12,13 orthopedist 190:9,9 **ORYX** 219:18 234:2 **OSBORNE-GASKIN** 1:18 30:11,19 101:19 112:14 113:15,19 115:8 134:18 135:21 136:20 138:11 193:6 252:22 295:16 315:13 outcome 44:20 73:9,17 73:18,20 74:1,7 83:8 86:16 93:17 94:8,11 99:6 156:4 183:19 203:1 280:18 287:1 291:2 outcomes 3:5,6,8 46:9 46:15 47:10,22 48:11 48:14 66:20 73:15 93:10,12,13,22 94:21 130:2 160:14 164:18 173:12 175:8 203:20 243:8 267:13 311:18 311:19 outcomes-focused 311:18 outline 71:22

outlined 10:21 12:16 13:13 218:15 249:2 261:8 outpatient 64:2 89:17 91:11 197:22 234:11 332:11 outside 258:7 299:11 328:8 337:21 overall 11:10 16:12 116:11 138:6 157:17 176:11 189:1 218:22 225:17 240:10 255:4 258:10 303:17,18 overarching 269:15 overlap 24:20,21 26:3 189:17 overlapping 23:10 overrided 98:2 overuse 314:7,14 316:11,14 overused 130:21 overusing 316:15 overview 4:4 10:3,12 13:15 60:7,18 206:4 owned 148:12 ownership 330:1,9,14 333:22 oxygen 103:6 164:12 Ρ P-R-O-C-E-E-D-I-N-G-S 5.1 **p.m** 201:6,7 338:16 **Pacific** 129:14 pack 17:15 package 62:15 246:10 packs 18:17 page 16:9 285:13 335:10 pages 285:14 paid 50:15,20 52:15 258:18 pain 278:2,2 pain-related 286:1 paint 25:6 pair 314:14 316:14 paired 314:7 pairing 314:22 pandemic 328:16 333:16 Pandora's 301:14 panel 4:5,7 210:4 220:16 260:1,2 261:10 289:16,19 paper 71:6 paradigm 141:9 199:1

259:15

parallel 35:1

Parast 3:9 294:9.9.16 295:13 296:10 301:21 302:1 303:6,14 parent 44:13 148:8 parent-report 44:12 parents 82:4 298:22 parity 313:21 parsimonious 310:5,12 parsimony 6:17 7:7 24:22 30:1 78:19 111:12 167:16 178:3 269:15 292:4 parsing 235:7 part 22:4 42:10 49:18 51:14 55:1 59:17,18 72:10 99:9 102:2 114:9 129:17 131:7 136:2 147:9 148:9 149:18 164:4 193:9 203:10 221:6 240:4 269:21 270:12 276:18 285:10 303:15 310:16 314:13 partial 245:20 332:3 participated 71:5 participating 258:11,15 259:7,9,11 participation 16:13 244:11 245:14 254:9 259:1 particular 8:2 72:5 73:1 83:1 87:17 97:3 123:5 139:17 170:21 172:19 212:1 276:21 280:3 283:22 293:15 302:14 312:8 338:14 particularly 8:16 22:8 147:14 155:18 298:13 319:22 337:12 particulars 109:17 partner 47:9 partners 6:1 336:14 338:14 partnership 1:3,21 48:9 63:1 parts 162:9 334:18 pass 306:8 patchwork 76:6 path 60:11 74:2 147:13 pathway 147:16 304:13 patient 72:15 162:18 163:7,8 190:18,22 204:21 250:10 277:4 286:13 299:4 321:21 324:11,14 325:2 327:21 patient- 183:18 203:19 291:1

patient-centered 1:15 211:19 282:17 patient-level 161:1 patient-reported 203:1 patients 20:20,21 24:8 50:16 162:3,3,4,7 163:10 171:3 180:1 190:18 191:2,2 193:11 194:3 210:7 237:13 239:20,21 240:9 244:9,13 250:8 268:15 284:5,9 312:3 320:14,15 323:3 324:10,22 327:7 328:5 pause 105:5 132:12 200:9 201:15 209:13 221:20 231:12 315:19 318:14 pay 41:15 51:2,9 53:5 77:16 96:12 124:1 166:22 330:18 pay- 42:18 278:11 pay-for- 96:22 pay-for-performance 97:11 98:7 164:4.7 165:3 pay-for-reporting 97:1 98:11 payer 162:8 163:1,2 176:18 payer-level 177:13 payers 59:11 78:15 79:11,18 284:21 paying 42:16 46:10 48:1 55:16 82:11 165:6 175:10 payment 46:5 47:12 48:9 78:8,10,17,18 81:12 96:4 98:1,3 129:15 165:4,19 174:22 278:11 payments 77:19 159:10 175:12 276:20 PC 162:17 171:2 **PC-02** 108:12 **PCP** 56:2 114:15 194:12,21 195:5,8 229:21 **PCP's** 56:2 PD 281:9 PDENT 21:9 38:15,17 41:8 45:7 49:6 56:20 96:16 PDIs 72:19 pearls 333:14 pediatric 4:11 28:1 82:2 127:19 147:18 148:16

150:3 201:18 202:6 202:10,15 208:1 221:15 247:16 281:7 291:11 327:1 pediatric-based 281:12 pediatric-specific 282:5 pediatrician 89:4 140:11 175:1 323:1 pediatricians 31:18 224:7 pediatrics 248:13 261:4 287:15 321:16 322:10 peds 325:18 peers 43:9 208:6 penalties 41:19 pending 144:2 208:17 252:7 262:6,14 274:1 people 6:17 12:21 23:12 31:21 49:2 53:10 66:15 70:1 76:22 80:5 103:20 120:18 132:15 134:6 134:13 136:16 139:9 151:6 153:22 154:9 158:13 166:8 167:1 169:2,8,9,15 176:15 179:17 187:21 188:7 189:19 193:4 205:12 210:16 219:15 220:20 222:8 224:3 230:1,6,8 235:14 257:20,22 260:15 262:19 267:9 284:13,21 288:12 290:8 291:1 306:8 320:20 333:19 per-member 242:5 284:6 per-month 242:5 284:6 perceived 277:21 percent 39:3,4 45:9,14 49:22 51:5,6 56:11,15 61:2,5,11,21 69:20 77:18 90:6 96:14.15 98:9 155:14 156:2,7 156:10,14 166:2 167:8 186:20 224:18 227:22 228:20 229:7 233:12 236:13 264:5 264:6,8 274:21,22 288:2 305:16,18 321:19 324:9 percentage 14:1,13 38:21 39:5 190:18 194:20 222:17 295:17 296:2,21 percentage-point 57:19 percentages 195:1

percolate 75:15 perfect 21:19 23:16 183:13 197:4 199:19 perfectly 194:10 perform 18:2,3 28:16 performance 11:10 17:3 24:7 26:21 42:4 42:6,9 50:10 51:10 65:21 75:19 84:2 96:10 97:1 204:22 205:3 210:20 212:22 218:10,11,14,20,22 230:22 **performers** 40:4,5,6 performing 40:16 43:8 perinatal 7:14 13:13 203:17 period 29:4 164:17 188:4 227:3 239:22 245:12,17,20 248:12 252:20 258:11 262:9 306:13 periodicity 52:2,10 periods 245:20 permissible 171:13 perplexed 300:12.13.16 Perrault 3:9 25:3.4 person 33:9 213:1 227:21 personally 158:2 personnel 49:8 perspective 4:5,7 6:5 20:21 24:7 33:17 58:19 158:4 160:8 166:15 173:16 189:20 216:14 223:9 242:18 255:14,14 268:21 269:11 281:7,22 282:2 287:16 perspectives 173:4 phase 12:12 73:5 74:11 79:6 118:13 159:19 204:12,14 270:13 phased 10:18,21 phased-in 79:4 **PhD** 1:17,21 2:2 3:6 Philadelphia 3:13,15 phone 9:13,19 33:6 105:1.2 172:17 177:5 232:10 237:11 243:11 243:13 267:6,8 292:18,20 PHP 332:14,14 PHQ-2 184:11 **PHQ-9** 183:6 184:10,15 184:21 **PHQA** 184:11 physical 91:6 100:17

404.0		
101:2	134:11,12 135:20	216:20 217:4 225:13
physician 55:3 69:11	137:22 143:21 152:18	226:1 228:9 257:15
140:11	154:22 156:4 172:8	257:16 268:11 281:3
physicians 23:12	186:17 190:15 191:13	281:21 287:3
175:11	191:19,22 192:22	poor 19:20 89:18
pick 121:11 149:16	198:6 199:11,15	320:18
159:16 216:13 240:5	200:4,6 202:2 211:20	poorer 248:17
244:17 261:11 282:1	221:2 231:15 232:13	population 30:6 61:5,6
302:9,10,19 321:11	232:20,22 233:10	61:14 63:7 87:17,21
picked 164:6	234:14 236:10,11	88:11 115:13 123:20
picking 103:6	240:19 242:2 243:2,5	135:13 166:1 171:8
picks 144:20	262:12 263:18 264:2	188:13 211:12,17
picture 21:13 25:7	264:3,19 274:15,19	215:15 216:2 224:19
62:10 76:7 77:6 99:18	276:11 288:18 294:15	225:17,22 226:5,7,14
pie 197:15,16	300:15 305:10,10	231:10 237:4 247:8
piece 53:13 115:3	307:10,12 318:9,11	253:9,11 254:14
123:20 140:17 156:16	322:17	255:2 266:1,3 267:12
177:6 227:15 323:21	pleased 38:13 48:6	268:7 269:1,2 291:15
pieces 82:12 139:7	plow 192:13	291:18 292:9 293:12
pilot 46:8 81:11 83:7	plus 230:6	295:21 296:20 298:22
87:5 102:1,10 103:11	PMP 1:17 2:16	302:15,20 312:7
129:15	PMQP 203:12,16	population's 254:9
pinch 336:5	pneumococcal 267:18	population-based
Pincus 185:20	point 35:13,17 70:10	82:19
PIP 58:2	82:9 84:10 101:20	populations 62:6 63:4
pivot 201:10	111:21 112:3 113:6	66:7,8,11,16,20 74:19
place 40:13 50:4 68:12		
	115:21 116:10 124:17	83:20,21 87:15
76:9 78:14 90:3 129:1	126:4 127:13 145:11	193:16 204:21 219:7
172:5 177:2 183:20	162:1 168:3 169:1,19	249:15 254:5 291:18
194:17 203:9 219:19	172:12 197:8 210:8	294:21 297:6
262:13 324:7 333:5	215:9 217:14 226:16	portal 67:14,17
338:5	226:18 247:11,14	portfolio 202:14
placement 324:3 325:3	250:15 258:10,12,13	portion 269:1
places 329:8	258:19 269:7 281:16	posing 99:7
plan 41:14 55:1,4 58:1	282:8 306:3 316:13	position 120:4 185:6
63:1 86:1 121:9	point-in-time 259:2,9	237:6 243:22 303:10
168:19 204:17 216:18	pointed 178:10	337:2
231:3 266:2 302:12	points 4:4 29:7 38:22	positive 70:1 82:6
304:3 306:11	39:5 71:7 85:3 158:10	99:13 100:18 184:17
plans 1:16 22:11 34:19	206:16	possibility 99:17
34:20 41:15 42:5,6,13	policies 165:9	160:22 165:5
57:21 58:3,4 64:4	policy 2:17 51:1 82:18	possible 161:6,15
65:13,20 82:1 86:2	97:15 165:8,11	162:11 165:3 270:2
108:9 121:21 135:2	255:15,21 329:14	276:11 294:14 295:12
135:10,11 164:22	policymakers 18:1	302:19
165:8 193:13 215:14	politically 337:22	possibly 239:1 246:2
216:22 225:8 227:13	Poole-Yaeger 1:19	321:5
228:12,18,19 229:5,6	18:18 19:2,7 20:10,17	post- 248:12
276:16 300:19	21:7,11,15,18 22:14	post-comment 252:17
planting 201:11	22:20 23:3,17 27:15	postpartum 11:15
plastic 324:16	28:6,15 29:15 30:2	potential 22:10 55:13
plateaued 129:13	31:8,11 126:15 136:9	106:8 128:14 134:14
players 215:2,2	138:1 141:21 143:5	206:1 231:10 270:15
playing 86:10	143:22 157:8 174:19	potentially 53:20
plays 81:19 96:11,19	179:3,7,10 180:16	179:18 180:9,14
please 28:8 33:1 84:9	181:1,8,11 187:4,7	208:14 270:17 275:8
	101.1,0,11.10/.4,/	
	101.8 105.12 106.6	275.20
104:18 105:15,17 109:12 124:14 128:1	194:8 195:13 196:6 213:9,12,18 215:12	275:20 potentials 145:4

power 5:11 87:22 powering 335:20 PQI-15 116:22 **PQMP** 202:4,5,7,20 203:9 260:22 261:1,2 270:12 291:4 practical 261:9 practice 49:16 266:8 271:5 303:5 331:8 practice-based 59:20 practices 12:5 131:4 314:12 practitioner 196:2,4 329:3 practitioners 11:9 22:2 112:18 134:20 135:22 136:5 193:7,12 199:9 273:8 329:11 331:7 precise 299:21 prefer 110:7 311:17 preference 150:11 pregnancies 159:4 pregnant 7:18 9:2 68:15 preliminary 206:15 227:12 premise 261:2 prenatal 7:16,16 8:10 8:11 11:5 24:16 67:6 68:20 preparation 6:4 65:16 72:9 prepared 95:2 prerogative 7:20 180:22 192:17 211:8 301:15 prescribed 265:15 prescribing 224:8 prescription 229:20 prescription-based 223:15 prescriptions 222:19 222:21 presence 233:18 present 1:10 2:4 3:1,21 16:3 58:18 presentation 54:16,18 65:16 67:19 72:9 73:19 86:19 87:14 104:21 239:6 286:8 286:18 presentations 90:7 presented 10:13,20 26:16 286:15 presenting 21:6 presents 238:20 President 2:14 160:21 230:21

359

н

presiding 1:9 press 200:7 233:10,11 307:13 318:12 presumably 188:19 presume 275:12 presumed 254:6,7,20 254:20 pretty 43:14 57:3 97:4 106:3 119:17 156:2 159:4 166:3 177:3 192:12 211:1 212:3 248:7 250:1 261:5 293:7 prevalence 270:5 prevent 90:1 preventable 72:17 210:5,6 275:20 279:19 280:7 prevental 89:8 preventative 56:1 89:12 203:18 prevention 19:21 46:18 46:19 52:1 267:15 preventive 21:9 36:7,15 37:11 39:1 45:6,10 72:14 116:14 182:15 198:1 242:8 preview 17:18 312:16 previewed 38:20 previous 10:14 221:12 266:18 previously 10:8 95:13 107:8 196:15 205:7 210:15 305:5 previously-endorsed 149:1 primarily 13:7 15:7 primary 1:15 11:8 14:13 15:7 22:1 49:9,14 50:2 52:4 56:9,22 78:2 95:15 112:17 128:10 130:6 134:20 135:12,22 136:4 192:16 193:7,12,14 194:2,12 196:1,1,3 199:9 208:15 242:8 244:7 275:9,20 277:12 282:15,16 286:13 288:6 306:4 principle 71:8 prior 141:10 195:8 priorities 18:8 204:4 prioritization 310:9 311:12 prioritize 272:21 prioritizing 4:13,14 6:10 priority 66:7 271:10

280:9 290:20 private 202:11 336:14 privilege 6:19 153:22 probably 5:6 41:20 67:20 71:4 143:6 148:13 157:14,20 174:11 175:15 196:22 215:20 225:20 235:19 240:7 266:1 279:22 287:8 292:18 306:11 313:15 324:8 problem 31:13 51:21 166:10,11 197:2 198:16,17 218:20 221:14 242:15 245:9 245:13,15 261:14 277:21 287:21 320:17 322:15 330:1 333:16 problematic 19:16 **problems** 198:19 proceed 74:5 111:18 118:19 201:19 202:2 221:9 244:3 263:15 process 13:6 17:17,19 18:6 25:10 35:1 37:16 58:6 66:20 73:10 74:6 85:4 93:8.20.21 94:7 94:10 111:1 145:19 146:9,16 150:16 210:11 242:12 248:11 248:14 261:6.8 278:21 303:13 306:1 306:15 process-of-care 73:22 processes 93:13.16 produced 48:16 producing 47:22 product 195:1,2 production 211:10 productive 20:4 professional 130:17 program 4:11 13:4 46:7 62:20 78:4 87:6,12 131:4 161:8 164:4 170:20 171:1 201:18 202:7 219:11 256:14 261:2 276:21 333:5 programs 54:1 66:19 87:7 132:8 168:10 210:2,16 283:1 progress 39:9 47:4 71:3 330:7 project 2:16,19 42:9 46:5,7,11 47:8 48:18 65:21 68:5,9,17 82:9 111:7 130:13 149:7 208:18 217:17,19 235:14 294:11 334:14

335:5.10.10 projects 42:5,7 46:8 64:9 promise 132:21 promote 7:2 180:9 313:1 promoting 129:5 179:19 181:21 promptly 104:8 propagate 83:15 properly 129:2,2,2 232:19 Prophylactics 264:21 265:3 prophylaxis 208:12 265:16 266:4 268:6 274:13 proportion 38:22 61:10 62:1 296:17 proportional 258:20 **propose** 75:9 142:9 273:19 279:4 proposing 118:11 pros 207:2 proud 38:5 proven 159:7 provide 25:12,22 26:11 42:18 48:2 79:13,15 102:10 166:12 179:14 219:22 302:3 310:14 314:1 338:10 provided 97:19 107:18 108:5 247:2 provider 42:15 43:4 50:20 52:21 55:22 59:20 69:11.12 128:18 135:12 204:17 216:8 229:20 303:18 303:21 304:4 provider-based 64:15 provider-level 164:21 176:17 provider-specific 312:11 providers 42:16 43:7,7 49:13,14 53:12 56:2 67:5,9,15 79:13,15,18 80:13,18 82:2 108:3,6 128:10 130:7 157:17 162:6 165:1 171:3,4 173:9 193:15 194:2,4 214:9 323:17 providing 49:14 210:4 provisional 27:20 proxy 210:13 pruning 7:11 201:10 psych 90:4 320:14,22 321:21 323:14 331:4

333:7 psychiatric 89:9 95:15 327:7 328:12 psychiatrist 332:7 psychiatrists 330:4 331:10,11 psychosocial 68:21 227:2,6 psychotic 224:20 **public** 4:10,12,15 38:8 108:20 200:4,6,8,10 200:16 202:10 252:18 252:20 255:15,21 307:4,8,12,14,16 318:7,11,13,15 324:16,20 334:17 public/private 168:4,6 publication 34:11 publicly 14:22 38:7 65:10 257:7 published 18:13 pull 29:16 57:12 81:10 122:4 161:9 180:5 190:14 221:18 225:9 231:16 324:13,16 336:19 338:5 pulled 31:15 91:2 167:7 pulling 121:20 purchasers 202:11 purchasing 283:1 purposes 15:1 74:11 96:4 pursuing 25:1 **push** 79:9 83:10 pushback 97:21 pushed 81:4 83:3 pushing 76:17 77:18 80:13 83:8 put 41:10 49:3 57:18 66:17 67:2 68:13,18 71:5 72:21 76:5,15 82:15,18 97:12 98:10 103:19 128:6 132:19 134:12 136:17 137:13 137:22 141:2 149:13 165:21 178:8 179:17 192:20,22 213:2 219:15 221:20 228:6 239:1,10 243:11 250:20 251:2 254:17 269:7 272:17 273:22 279:5,16,18,21 293:9 301:3 304:5 307:21 308:14,17,19,21 309:1 311:12 313:14 314:20 322:8 325:4 333:4 **puts** 290:4

147:12 178:22 194:5 205:13 216:21 217:10 217:12 221:8 231:6,9 233:17 238:21 241:1 241:4 244:1 246:18 247:13 276:5,12 278:5 289:18 290:5	rate 37:9 57:20 72:17 117:21 130:4,5 157:18 169:4 174:3 191:1 216:2 227:14 228:19,20 229:2,6	243:12 251:21,22 263:2 265:17 282:20 290:15 333:19 reasoning 119:1 reasons 13:12 15:18
205:13 216:21 217:10 217:12 221:8 231:6,9 233:17 238:21 241:1 241:4 244:1 246:18 247:13 276:5,12 278:5 289:18 290:5	117:21 130:4,5 157:18 169:4 174:3 191:1 216:2 227:14 228:19,20 229:2,6	263:2 265:17 282:20 290:15 333:19 reasoning 119:1
217:12 221:8 231:6,9 233:17 238:21 241:1 241:4 244:1 246:18 247:13 276:5,12 278:5 289:18 290:5	157:18 169:4 174:3 191:1 216:2 227:14 228:19,20 229:2,6	290:15 333:19 reasoning 119:1
233:17 238:21 241:1 241:4 244:1 246:18 247:13 276:5,12 278:5 289:18 290:5	191:1 216:2 227:14 228:19,20 229:2,6	reasoning 119:1
241:4 244:1 246:18 247:13 276:5,12 278:5 289:18 290:5	228:19,20 229:2,6	
247:13 276:5,12 278:5 289:18 290:5		
278:5 289:18 290:5	· · · · · · · · · · · · · · · · · · ·	22:5 63:21 106:8
	240:2,8,10 244:11 245:18 255:4 259:1	
202.24 202.2 22		107:17,20,22 108:19
292:21 293:2,22	259:13	110:4 112:6 124:18
295:1,2,3,6,7 297:12	rates 50:21 56:14 57:7	125:4 268:1 270:11
297:16,17,22 301:6,8	93:15 108:22 118:5	290:17
		recall 219:7
-		receipt 14:15
		receive 12:6 14:2 38:2
		68:21 295:6
		received 6:3,15 11:2
		14:16 17:15,16
		receives 274:17
222:16 309:7	308:6 318:22	receiving 25:16 26:14
uite 16:13 39:7 62:12	rationale 134:21 193:9	93:15 188:20 209:19
70:2 117:7,21 135:3	rationalizing 173:21	295:6
225:16 250:20 296:19	RD 2:6	recently-endorsed
297:13	re- 148:16	265:13
uorum 154:19	re-endorsement 28:4	recipient 88:13 97:6
-	re-enroll 242:13	recited 305:5
R	reach 83:21 160:19	recognize 17:8 26:5
ace 61:4 66:5 219:8	335:8	30:4
330:22	reached 36:2 279:1,13	recognized 130:1
ace/ethnicity 235:16		172:20
		recognizing 25:19 26:
		158:4 185:5
		recollection 184:2
		194:10
		recommend 72:20
		113:1,3,5,11 122:19
		221:5 252:5,6,6
		273:13 274:12 288:2
		299:18
		recommendation 9:5
		12:5,16,18 85:5 92:5
		97:2,10 98:6 113:12
		119:2 121:3 128:4
		146:18 171:16 184:7
		203:10 212:7
		recommendations 4:8
-		6:12 7:15 29:14 60:1
		97:15,19 113:14
		130:22 207:20 218:1
		272:6,16,22 334:15
anges 70:2	-	recommended 10:18
	realize 100:20 101:8	11:4,6,13 19:14 21:2
309:4 318:22	105:8 281:18	29:18 52:6 112:16,22
anked 308:15 317:22	realm 100:8	113:4,16,20 186:12
318:19 319:4,6	reason 8:21 19:13 22:9	192:7,8 199:22 203:
anking 309:8,11	29:2,3 46:12 50:13	206:6,8 207:19,21
310:20	69:7 106:17 110:3	208:6,20 236:20
ankings 335:20	111:14 112:9 114:1,3	265:5,20 266:8,16
are 162:2 169:10	114:15,18 160:12	269:14 272:14 290:1
atched-up 58:5	188:14 194:13 213:3	307:22 308:5,18
	uite 16:13 39:7 62:12 70:2 117:7,21 135:3 225:16 250:20 296:19 297:13 uorum 154:19 ace 61:4 66:5 219:8 330:22 ace/ethnicity 235:16 achel 1:17 8:1 33:5 57:3 112:13 120:22 163:17 175:21 225:6 228:9 278:19 279:9 achel's 226:17 acial 43:21 44:1,2 aise 95:20 111:19 154:22 186:17 191:19 191:22 199:11,15 aised 127:15 231:10 233:17 267:17 aising 118:21 AND 3:9 294:10 andom 244:6 246:4 254:14 ANEY 3:10 17:5,14 18:5,22 19:8 21:20 28:18 ange 30:16 51:4 230:6 286:7 302:18 anges 70:2 ank 272:21 307:4,20 309:4 318:22 anked 308:15 317:22 318:19 319:4,6 anking 309:8,11 310:20 ankings 335:20 are 162:2 169:10	ueue 16:21 95:7 164:12 165:2 166:2 238:20 164:12 165:2 166:2 uick 10:2 30:12 215:15,19 228:17 136:21 233:20 rating 86:1,2 303:17,18 uickly 16:8 57:18 303:21 304:4 87:22 119:17 197:20 222:16 309:7 222:16 309:7 308:6 318:22 ratio 245:15 247:4 308:6 318:22 70:2 117:7,21 135:3 rationale 134:21 193:9 225:16 250:20 296:19 re-148:16 297:13 re-encol 242:13 uorum 154:19 reached 36:2 279:1,13 reached 36:2 279:1,13 reached 36:2 279:1,13 reached 36:2 279:1

309:3 319:10,17 recommending 156:12 212:14 266:11 272:10 273:6 305:19 reconciliation 203:22 record 67:13,16,22 69:8 104:13,14 122:6 142:3,12 185:15 190:7 201:6,7 216:6 recording 15:16 records 67:11 68:4,16 102:12 108:3 110:10 122:7 126:3 258:17 red 10:21 12:16 14:20 36:7 317:15,19 redo 294:4 redoubled 338:4 reduce 79:20 174:3 187:9 266:5 288:9 reduced 165:2 reducing 328:15 **redundant** 170:18 refer 107:17 112:15 reference 109:6 164:9 referral 68:22 69:22 182:17 referrals 82:6 159:17 referred 70:4 244:11 referring 95:10 285:17 331:20 334:1 refinement 205:2 reflect 12:4 15:15 107:11 312:9,11 reflected 14:7 102:17 reflective 15:7 reflects 155:12 255:16 reform 129:15 174:22 reformed 47:16 reformulate 180:14 reformulation 174:8 regard 22:8 86:22 87:14 114:22 116:10 139:2 139:5,18 214:11 299:11 326:1 regarding 265:22 regardless 35:21 145:8 **region** 303:4 registry 32:5,7 regularly 66:9 reimburse 49:13 reimbursed 47:19 50:9 reimbursement 50:21 53:11,14 283:11 323:7 332:2,10,17,19 333:4 reimbursing 165:9 reiterating 283:5 related 85:7 116:12

121:17 131:5 132:2 134:9 244:7 255:19 311:19 320:4 relates 67:5 relationship 159:6 relative 43:8,9 159:13 relatively 116:3 165:22 228:20 relevance 62:11 164:9 relevant 71:7 162:12 237:21,22 268:19 reliability 247:18 reliable 128:21 263:8 religiously 34:3 reluctant 53:13 remain 137:10 191:22 199:15,17,22 Remaining 4:14 remains 35:13 Remarks 4:3 **remember** 132:14 150:20 212:4 213:22 273:21 296:19 remembering 214:16 215:11 remind 151:6 193:3 299:3 reminder 16:20 28:18 232:9,12 **remission** 101:13 183:18.21 removal 7:15 11:4,7,14 21:22 106:9 111:2 112:3.16 113:10 122:12 124:19 125:19 132:15 133:8 134:15 136:17 138:16 139:2 142:10 146:15 174:13 174:14 176:3 188:14 192:9 207:19 removals 146:13,14 remove 7:17 11:18 109:16 110:20 114:16 133:22 134:21 136:3 137:2,7,8 140:21 141:4 145:18 146:1,2 156:6,7,8,12 177:18 178:22 180:15 181:4 187:5,16 188:6 189:10 191:15 193:8 199:8,20 removed 7:1 11:14 12:22 19:3 27:16 109:9 113:22 120:8 133:16,18 137:11,19 138:4 140:3 144:13 144:18 152:18 154:22 177:17 191:19 192:6

199:11 272:15 273:7 removing 29:3 85:5 112:7 136:22 146:16 146:17 179:18 192:3 197:8 277:18 Renee 3:4 24:19 204:6 204:7 227:12 300:21 336:17 renewed 147:19 repeat 125:11 187:4 241:4 325:16 repeatedly 185:11 repeating 231:7 replace 74:6 179:4,11 180:6 replaced 19:6,12 replacing 138:5 report 23:12 37:9 38:5 38:6,12 63:14,15,22 64:1,7,13 65:6,10 68:14 69:3,3 71:3,22 72:8 82:17 94:5 98:13 101:21 104:3 107:16 108:18 109:22 122:5 126:7,20 141:3 148:9 159:8 163:11.15 168:14 176:11 177:2 205:15 216:8 219:14 219:21 225:8 228:12 228:14 234:20 254:17 257:4,8 270:1,3,7 308:17 318:2 335:16 **reported** 10:6 14:11,22 15:5,9,22 16:4,10,14 17:12 21:4 37:10.13 56:14 106:2,5 107:13 107:14 110:6 112:2 137:14,15 183:19 195:3 203:20 215:21 229:3 291:2 reporters 63:19 reporting 10:5 13:16,18 14:4,18,19 15:4,10,18 15:19 16:1 17:7 23:6 23:19,19 25:8 26:8 37:15,18,19 38:13,17 49:4,18 56:4 58:16 59:13 63:12,14 64:2 68:14 102:5 106:21 108:14 110:3,6,17 112:8 126:18,19 137:1 161:8 162:18 163:9 168:10 171:2 192:11 205:2 209:21 210:2,18 217:1 220:6 257:7 273:9 reports 146:6 157:10 194:22 334:19

repository 328:11 represent 83:17 representative 72:4 240:18 296:22 representatives 279:7 292:17 represented 30:5 representing 89:5 294:10 request 89:8 190:12 231:22 require 108:8 122:6 224:18 required 23:12 28:19 37:14 42:4,6 77:3 109:4 110:11 122:2 128:13 148:17,18 228:12 requirement 57:18 97:13 requirements 195:11 requires 108:19 126:3 182:15 requiring 290:22 317:16 research 28:12 66:18 240:21 243:8 288:13 289:10 reserve 218:9 220:10 **resolve** 177:4 resolved 232:18 resource 107:17 resources 8:3 18:9 34:10 65:1 68:18 70:13 107:6 123:6 140:5 148:22 149:10 151:14 159:16,22 333:11 respect 58:19 310:3 respectful 8:4 138:16 respiratory 285:22 287:12 respond 252:19 respondents 275:2 response 86:14 136:18 163:20 176:7 200:17 220:18 232:1 236:4 236:12 239:12,14 248:16 295:11 304:16 305:14 307:15 responses 233:2 responsibility 334:5 responsible 211:15 rest 201:4 246:15 310:22 restate 143:20 193:3 restorations 47:1 restrictions 329:17

result 165:21 254:16 results 21:17 47:6 76:17 102:10 103:2 103:21 209:2 216:16 312:2.4 retired 11:20 12:1 14:1 **review** 4:4 5:21 6:2 9:12 22:11 104:20 106:2 108:3 122:6 128:15 131:16 142:3,12 148:2 168:20 202:4 203:13 205:22 206:3 298:19 reviewed 7:14 105:20 149:7 217:16 247:17 reviews 69:9 131:18 revised 47:16 revisit 260:13 337:19 revisiting 138:18 **rich** 5:13 68:5,7 110:14 110:21 222:10 249:16 265:5 289:12 336:21 337:11 **Richard** 1:9,11 RICHARDSON 1:20 98:18 119:15 127:18 128:2 160:6 170:14 171:12 172:4 174:10 174:14 198:5 221:11 255:12 288:19 300:14 300:16 311:4.8 329:21 330:20 331:9 richer 248:18 rid 93:21 115:3 ridiculous 228:2 riffing 231:9 righthand 40:10 rings 124:17 ripe 91:15 rise 118:17 129:13 risk 7:18 8:17 13:20,22 38:3 53:3 54:1 68:15 68:21 69:9 76:12 80:13,19 95:4 109:14 109:20 110:19 137:4 138:3 167:4 185:4 188:1 189:14 190:21 191:16 212:12 267:13 301:13 324:9 risks 165:20 324:10 **RN** 1:16 Roanne 1:18 30:10 101:18 112:4,12 118:22 196:7 252:21 295:15 304:9 robust 26:15 43:14 **robustly** 261:5 role 58:22 81:19 159:22

331:14 roll 63:6 127:7 290:5 317:9 rolling 86:3 rolls 56:13 245:6,8 264:9 room 1:8 8:9 16:12 22:7 24:15 31:18 55:18 91:9.12 105:8.15 149:20 151:17 153:2 154:9 186:8,21 200:16 230:10,12 231:10 232:11 233:19 238:19 252:8 307:4 307:19 318:19 324:11 324:19,20 325:4 root 51:19,20 168:16 rose 129:16.18 round 210:3,11 routine 12:6 215:4,7 218:1 routinely 177:7 rules 28:5 124:15 290:2 run 53:10 324:15 running 227:9 280:12 320:21 S **sadly** 40:9 safe 324:20,21 325:10 safety 14:9 72:15 323:22 safety- 79:14 **SAKALA** 1:21 129:8 158:9 168:21 312:19 314:6,19 315:2,5 sake 75:13 84:4,15 105:13,22 179:16

186:6 290:9

255:1

save 189:5

78:5 98:14

sample 67:10 68:3,16

122:7 254:13,14

sat 176:12 217:20

satisfaction 14:16

saying 22:13 28:9

72:21 75:1 80:15

100:5 101:4 123:11

124:21 125:1 140:7

173:6 196:7 211:14

254:19 258:13 283:6

328:1 331:13,14

says 24:16 51:19

284:12 322:19 327:20

142:14 145:17 150:17

savings 42:21 55:14

saw 45:8 114:22 163:18

scarred 159:2 scars 159:5 scattered 44:22 scenario 286:9 scenes 336:18 schedule 31:4 32:18 52:3 215:7 325:7 337:5 schedules 51:3 215:5 Schizophrenia 224:20 school 81:13,16,19 162:5 332:12,13 schools 82:3 schtick 243:5 science 151:16 Scientific 2:13 scope 49:16 **score** 184:16,16 scoring 92:12 screen 69:18,19 74:22 98:22 99:9 105:10 108:6 183:4 192:22 218:17 265:8 314:4 318:18 screened 74:21 99:11 99:12,20 100:14,15 209:18 screening 19:3 24:15 26:19 27:2,10,17 68:22 75:5 76:12 82:5 82:14 83:9 85:17,18 91:19 92:6,12 95:11 95:12,14 98:22 99:1,3 99:5,19 100:5 101:1 101:22 103:7 107:3 111:6 121:18 122:16 127:21 128:4 133:3 138:6 139:3,19 140:12 147:22 152:15 182:16,17 186:16 222:13 234:8 308:9,9 309:16 319:3.6 scroll 217:9 **SEAL** 41:7,8 42:22 sealant 19:6,13 20:4,13 36:11 38:2 41:9 45:7 45:12,15,16 49:5 sealants 13:19 20:5 searching 160:15 seat 231:15 seats 16:6 Seattle 289:9 294:8,10 305:22 second 31:20 87:13 113:2 120:9 132:12 132:22 133:22 134:1

151:14 192:11 234:4

scan 245:1

134:2 136:9 138:10 138:11,12 143:13 152:3,6 158:20 180:19 181:12,14,15 181:16 195:6 220:17 220:19 221:1,3 232:6 232:7 260:4,5,6 262:15,17 266:21 273:16,17 274:2,3 288:22 289:1 293:7 300:7,7,8 310:1 311:20 323:21 secondary 267:15 seconded 113:2 118:18 120:16 150:21 181:19 185:8 221:7 236:1 260:14 300:10 seconding 182:4 185:10 secondly 247:8 248:21 253:21 seconds 7:20 58:22 136:8 152:5 Secretary 1:12 section 67:22 104:16 126:1 285:12 sector 81:13 336:15 sectors 81:18 sedate 325:5 seeing 25:7 43:13,22 44:1,9,17 117:8 120:17 162:2,7 183:19 276:7 332:6 seen 37:7 42:12 43:17 43:18 115:18 194:3 198:15 250:10,10 258:16 283:22 287:14 298:10,12 306:6 sees 245:8 segment 88:10 98:17 249:15 seize 211:8 select 48:8 152:18 236:11,11 264:2,3 274:15,19 305:10,10 selected 72:3 274:21 274:22 281:18 selection 10:13 141:13 206:10 selective 34:9 self 80:8 self-148:8 self-assessment 247:21 self-motivate 34:13 self-motivated 46:14 self-report 299:4 send 37:14 43:5 140:15

Senior 2:16.18 sense 9:1 43:12 68:7 186:7 226:22 281:10 303:13 sent 81:1 107:18 128:14 161:13 249:3 285:5,11 sentiments 334:15 separate 23:8,10 55:14 180:11 187:19 188:4 194:22 280:13 293:10 separately 195:3 separating 126:11 Sepheen 3:2 230:20 sepsis 266:6 286:14 septic 320:19 sequentially 132:16 series 131:21 171:2 213:20 serve 135:14 150:18 151:5 193:16 238:10 service 35:16,19 39:1 45:10 49:9 51:13 55:3 55:5 70:6 85:20 130:7 services 2:2,8 3:5,7,8 3:10,11,17 14:2,14 21:10 36:8,17 37:11 41:16 42:1,18 44:10 49:8 51:14,15 55:11 56:1,8,12 72:15 82:7 82:20 90:19 182:15 196:18 198:1,1 203:18,21 223:10 237:14,20 275:12 290:21 299:13 317:18 331:3 session 111:4 sets 23:19 31:1,2 65:3 78:19 79:10 90:14 150:12 167:16,17 171:10 172:11,12 301:2 335:2 setting 162:2 284:1 286:16 328:7 332:13 settings 162:4 169:15 275:21 295:8 settled 283:18 seven 156:1 285:14 317:21 323:14 seven-day 323:11 **severe** 159:4 **Shaconna** 2:16 104:20 149:9 218:18 307:1 **Shah** 3:12 240:20,20 241:5,8,11,14 shaking 177:4 share 158:10 169:20 213:4 327:9

shared 35:11 42:21 78:5 98:14 304:3 311:11 334:5 SharePoint 335:7,11 sharing 134:16 sheet 314:21 315:9 shifted 61:15 shifts 288:2 Shivani 3:12 240:20 short 77:10,17 143:10 **short-term** 142:12 157:12 shortages 212:4 shot 81:20 shots 210:9 **show** 12:14 39:17 154:15,16 155:6,8 186:19 191:20 192:2 199:13,16 240:6,8 245:12 258:19 322:3 **showed** 29:17 44:10 63:17 248:18,22 showing 37:8 44:21 91:12 131:19 shown 266:4 **shows** 15:4 106:8.12 shrink 44:3 shrinking 94:15 **SIBLER** 251:5,10,16,20 253:15,18 255:8 256:3.7 258:9 **sick** 194:14 195:18 196:4,5 198:14,18 sickle 29:19 30:4 88:12 88:14,15,17 203:1 208:2,12 264:22 265:4,18 267:11 268:15 271:7 274:13 side 27:13 29:13 40:10 43:21 55:16,20 116:20 134:16 220:1 313:12,17 337:10 sides 315:7 sidewall 310:18 sidewalls 310:6 sight 172:2 signal 27:7 78:12 171:10 significant 84:20 115:15 218:12,14 267:19 significantly 267:13 Signs 71:2 77:9 Silber 3:14 237:10 240:21 241:19,19,22 242:3,20,21 243:3,6,7 243:17,20 244:2,5 248:15 250:4

silent 130:19 silver 47:1 53:14 **SIM** 59:19 similar 22:12 23:20 24:16 34:22 64:5 168:15 240:5 249:11 simple 53:15 172:20 simply 137:12 single 34:11 39:11 52:22 190:5 302:15 sinusitis 285:21 sit 316:5 site 47:9 48:10 335:11 site- 312:10 **sites** 48:4 sits 170:17 171:9 sitter 324:15 sitting 175:4 325:2 327:21 328:5 situation 53:20 89:14 103:14 149:13 301:1 situations 96:22 six 183:2 203:12 212:8 277:1 317:20 size 231:10 268:14 skilled 163:5 skip 152:11 slated 95:5 sleep 332:15 slew 285:20 slice 126:7 197:15 slide 10:15 12:20 14:3 14:17 28:21 29:17 35:10,12,14 37:5,7 38:14 39:19,22 41:2 43:15,17,20 44:16,21 45:5 46:3 48:21 57:16 60:6,21 61:13 62:18 63:9,20 65:4 66:22 68:12 70:16 73:4 74:14 75:4,16 77:15 81:6,21 83:13 95:2 98:18 104:17 105:17 105:18,21 106:7,8,19 107:1 109:12,18 110:13 112:15,18 119:19 203:7 206:2 206:14 207:8,16,17 208:4,5,19 234:10 263:16 272:17 307:21 335:9 slides 12:13 16:3 33:13 35:4 62:3 63:18 105:12,20 106:4 207:9,10 slight 42:22 **slightly** 23:21 114:13 116:4,5,8,14 117:5,11

slope 35:15 small 34:16 40:19 46:8 61:10 62:1 68:3,16 73:14 81:11 87:21 102:9 103:11.13 171:5 188:13,15 226:13 268:18 269:20 270:15,17 271:4 296:19 small-ish 269:10 Smith 2:7 9:15,15 105:1 105:2 154:5 161:13 snapshot 60:22 So-and-So 141:3 soapbox 325:11 social 69:10 290:21 299:12 317:18 329:4 societies 130:17 **Society** 130:18 **software** 127:1 280:10 **solicit** 143:13 solid 129:6 solution 64:19 83:2.5 102:14 103:17 104:2 178:16 solve 221:14 solved 331:17 **solving** 105:6 somebody 27:11 51:19 128:15 144:4 149:20 150:20 152:3.19 155:18 158:5 175:5 178:2 189:12 211:22 216:7 227:19 257:21 258:4 273:18 275:12 282:22 288:16 292:6 293:19 294:6,7 299:15 300:7 325:17 337:17 someone's 242:6 259:6 somewhat 270:5 282:12 soon 326:5 sooner 261:21 sorry 22:15 29:15 67:18 128:2 136:21 156:6 192:8 205:16 213:18 243:3 265:1 288:14 311:4 330:17 sort 18:13 22:15 23:21 23:22 34:9,15,22 36:1 40:20 43:11,16 44:19 44:22 46:21 51:17 52:6 60:19 61:14 63:17,18 65:8 66:14 66:18 71:22 72:16 74:6,15 78:14 79:8,18 80:10 81:4 82:14,20

86:1 90:14,18,22 91:17,22 94:17,19 96:6,12,22 97:16 98:6 98:20 100:3 101:10 102:6,11 116:18 119:17 124:12 141:6 146:2,6,9,10 165:20 170:10 172:15 193:18 197:21 205:8 211:11 212:9 219:19 235:6 251:2 253:11 258:7 282:19 303:9 310:14 310:19,21 311:2,2 313:8 314:21 315:8 315:18 316:18 321:5 322:1 327:10 334:8 335:3,19 336:1,5 souls 151:17 sound 145:21 sounds 138:8 140:1 155:11,21 271:14 source 44:6 163:1 198:7 220:7 275:22 sources 25:6 26:3,7 64:16 162:8 219:17 South 40:16 167:8 **space** 7:7 8:3 44:20,20 47:9 48:13,15 51:18 52:1,4 59:6 60:4 61:7 66:14 73:12,13 85:22 86:5,16 90:17 91:16 91:18 99:15 165:19 166:4,7 322:11 **spaces** 59:16 70:15 80:14 Spanish 295:20 296:9 296:12,13 speak 49:4 62:14 70:19 87:18 96:19 114:1 126:16 211:13 221:2 232:12 262:19 273:5 285:15 292:18 295:19 296:13 323:21 338:7 speaker's 162:1 speaking 19:10 118:14 **spec** 31:13,14 special 33:4 88:3 148:9 292:1 299:6,7 specialized 83:19 specific 16:10 17:6 18:22 30:16,20 41:17 74:10,17,19 85:6 91:19 95:19 139:3 188:12 205:12 206:20 283:20 286:4 302:12 312:11 315:15 specifically 7:10 25:8 36:8 59:11 115:14

189:7.8 190:10 286:12 292:19 306:11 331:19 specification 12:8 43:1 108:7 109:2 144:3 280:3 specifications 127:2 145:6 184:18 185:1,6 265:7 301:5 specifics 100:11 280:21 specified 326:13 **specs** 23:21 30:15 31:16 69:4 102:21 107:9 142:6,15 144:5 190:15 194:9,19 209:2 327:11 spectrum 76:21 82:11 132:1 spend 7:20 41:4 61:22 78:6 105:19 111:15 120:17 129:4 spending 45:2 spent 336:12 sphere 299:12 spirit 178:5 spite 125:3 split 61:9 156:1 187:19 **spot** 167:5 208:21 269:8 **spread** 48:3 57:15 270:10 spreadsheet 198:7 squeeze 24:22 **SSI** 61:11 62:5,6 St 1:14 staff 2:11 4:4 9:11 17:2 95:18 113:7 120:11 123:3 140:2 153:5 156:3 177:16 179:14 180:7 182:10 200:18 201:12,21 206:17 221:18 222:4 323:5 334:14 335:5 336:6 337:11,18 stages 318:4 stakeholder 58:5 stakeholders 245:10 stampede 169:14 stand 242:1 297:17 standard 53:9 142:11 246:20 255:10 standardization 143:9 standardize 102:7 standardized 68:1 184:9 standards 67:6 107:10 123:7,8,13 126:21

135:10 149:2 158:16 standing 6:22 203:10 217:20 247:16 266:15 324:3 stands 123:7 start 86:18 104:8 157:6 163:1 181:20 265:2 started 5:8 41:7 58:10 75:14 90:16.20 104:16 105:8 271:22 277:7 280:10 starting 12:6 42:20 53:6 53:17 78:14 86:4 91:8 163:6,13 280:16 starts 245:7 285:13 state's 26:10 80:6 state- 161:9 state-by-state 249:8,13 270:18 state-level 129:3 248:2 state-reporting 205:19 **state-side** 166:15 stated 107:5 110:4 185:11 statement 24:5 57:6 177:19 states' 22:10 124:2 322:21 statewide 58:7.8 64:18 83:2,4 102:14 103:16 103:22 104:2 166:2 statistician 294:11 statistics 108:21 121:6 246:11.14 254:1 stats 26:10 status 13:3 27:16 30:14 218:10 220:10 234:16 statutory 256:10 stay 105:14 164:13 245:8 323:10,12 stayed 182:19 staying 36:21 steady 36:21 steep 129:13 stems 212:2 step 48:19 77:10,14 92:2 104:21 162:21 213:4 268:4 277:18 stepped 153:2 stepping 249:18 334:8 steps 4:16 35:6 334:9 steward 11:20 12:10 140:4 144:3 145:13 222:15 275:10 281:4 289:9 stewardship 151:9 Stewart 3:16 275:14,14 276:6,13 281:15

285:3,3,10,18 stick 76:3 307:6 stickers 307:7 322:9 stickies 310:7 stillbirth 159:3 stomach 278:2 stop 69:18 99:19 118:7 176:5 188:4 246:17 247:11 stopped 77:9 129:12 story 62:9 64:5 116:8 148:14 straight 152:14 strange 172:10 177:10 strategic 7:9 310:4 strategies 42:11 98:5 205:5 stratification 66:2 88:1 220:3 235:3 stratified 176:18 235:4 327:7 stratify 219:6 stratifying 66:4 streaming 105:9 streamline 25:15 Street 1:9 strengthen 202:8 strengthening 4:9 6:9 strengths-based 58:15 stretch 60:15 292:5,7 strikes 170:7 string 333:14 strong 16:13 40:5,6 41:15 64:1 94:6 119:8 150:11 247:5 strongest 304:4 strongly 65:11 81:18 129:9 197:7,17 structure 5:20 332:10 332:18 333:4 structured 146:7 struggle 20:21 76:7 82:22 88:22 98:4 287:5 struggled 27:1 215:22 stuck 105:21 170:10 studies 44:22 131:15 131:17 study 44:10 61:16 65:22 stuff 36:13 47:19 142:1 159:21 160:7 257:12 subanalyses 254:17 subcategories 316:9 subcategory 316:21 subcriteria 206:20 subdomain 313:2 subdomains 312:20,22

313:6.8 SUBJECT 2:1 submission 219:6 235:15 submit 28:4,17 109:4 110:11 148:15 150:3 235:9,10 250:5 259:17 285:4,9 submitted 12:8 52:18 144:14,17,22 161:7 162:20 206:5 235:4 334:19 submitting 153:6 219:11 235:6,11 subsequent 69:12 subset 163:12 187:8 188:13,15 189:17 227:16 293:21 294:1 303:22 subspecialty 229:20 substance 316:8 317:3 substance-abuse-type 202:21 substantial 320:17,17 321:4 substantially 237:21 substitution 227:5 successes 85:1,7 succinct 243:19 276:11 **succinctly** 135:20 sucking 159:21 suddenly 131:3 sufficient 118:10,20 183:9 330:3 suggest 141:12 220:15 260:1 262:5 303:2 304:13 suggested 201:20 209:14 303:21 suggesting 122:12 137:16 150:17 suggestion 145:20 146:18 151:3 156:21 186:4 suicidal 320:12 suicide 13:22 91:19 95:4,12 100:6 109:20 137:4 138:3 188:1,2 189:15,18,21,21 190:10,20 191:1,16 **SUMA** 2:6 Summarize 4:16 summary 233:20 sunsetting 24:14 super 38:5 41:14 44:4 supervision 56:5,7 supplant 140:9 supplemental 295:1,7

supplementation 164:13 supply 212:12 213:1 315:18 support 7:17 28:13 34:8,16 73:17 92:3 106:14,15,15,16 124:2 133:9 145:5 146:21 165:8 185:10 186:16,21 204:22 207:6,6,7 224:1 233:10,13 236:9,14 252:7 262:6,14 263:3 264:1,6,7,8 274:7,7,8 274:16,18,22 275:1 284:12 305:9,17,18 308:12 333:9 supported 10:17 11:1 133:5 264:10 supporting 89:22 supports 9:8 **suppose** 58:3 supposed 33:17 51:16 139:13 190:9 288:9 supposedly 282:16 surgery 327:17 333:20 surgical 327:19 surprise 33:11 63:17 surprised 129:9 271:4 surprisingly 15:20 surround 138:19 survey 147:5,9,9 148:9 215:17,21 216:15 234:12 246:21,22 247:7,9 255:10 291:9 293:6,7,10,12,13 295:6 296:11,14 297:19,19,20,22 298:4 299:1 301:5 surveys 169:7 290:3 294:20,22 295:9 297:4 298:11,12 survival 253:22 suspect 212:9 sustain 48:11 sustainability 68:9 sustainable 47:14 sustaining 338:8 swing 119:10 synergy 178:4 system 26:11 64:2 71:18 75:19 76:2 83:17 84:2 153:6 160:1,2 164:5 188:9 259:7,8 276:19 284:13 322:3 328:10 333:21 systematic 131:16,18

systemic 312:12 systems 26:14 59:18 283:10 284:8 286:22 330:9,10,16,21 Т TA 26:11 tab 209:7 table 233:16 279:12 tabs 115:5 tackle 48:18 91:8 240:12 tactical 26:18 tail 34:5,13 39:21 40:9 tailor 295:8 taken 71:16 116:7 171:15 185:12 210:9 272:4 321:20 takes 272:7 talk 5:19 7:10,20 9:11 24:6,13,18 29:20 31:15 32:21 33:16 51:10 60:1,2,8 63:11 65:6 70:16 71:10 83:11 86:22 89:7 90:11 92:1,15 93:11 125:1 145:9 178:20 217:15 268:3 288:3 290:7,14 317:10 327:19 talked 54:21 66:1 82:13 87:15 107:2 111:14 116:17 173:16 183:3 245:10 255:16 256:17 265:21 330:1 talking 33:6 45:17 56:10 78:6 80:17 93:7 94:14 102:1 136:13 138:5 170:22 214:7 221:22 234:7 258:22 262:22 271:3 292:12 299:10 324:9 talks 134:22 tangent 80:4 tanks 321:17 target 66:15 96:15,18 202:19 291:15 303:22 304:1 targeted 65:21 118:3 257:10 297:7 298:18 targeting 173:8 291:1 targets 291:18 task 1:3,8 5:9,10 6:1,4 8:7 9:13 10:16 11:3,7 11:9 16:19 84:17 111:18 113:21 119:3 122:10 137:17 141:11 156:4,11,21 177:2,20

179:21,22 182:15 203:4 207:20 231:13 238:18 243:22 259:16 268:8 272:20,22 276:3,12 283:6 308:18 331:15 334:16 337:13 tate 108:7 **Tdap** 12:7 **Tdaps** 31:6 teach 288:3 team 155:17 301:19 332:17,18 336:7 teasing 126:11 139:17 technical 25:11,22 105:6 118:3 125:4 139:6,20 249:18 257:5,10 301:4 technically 182:22 183:10 technology-intensive 159:20 tee 186:9 201:22 276:6 teeing 201:13 teenagers 189:22 194:13 195:16 teleconference 3:21 telephone 200:7 307:13 318:12 television 320:5 tell 17:5 18:17 35:1 43:7 65:8 76:16 77:13 78:11 99:13 116:8 119:1 128:13 156:3 198:6 200:21 215:19 225:10 258:4 268:20 307:1 331:17 336:21 telling 23:22 222:8 259:6 tells 117:10 198:12 tend 15:6 26:8 tended 219:8 tends 51:17 52:7 Tennessee 43:3 tent 16:20 tenure 71:9 term 120:1 157:19 292:6.7 terms 25:5,7 51:12 55:2 116:6 125:15 133:8 145:6 173:2 202:17 241:17 249:2 272:2,3 272:10 276:22 294:19 303:7 terrific 36:4 230:17 territories 270:7 **Terry** 1:12 85:11 95:6 122:13 127:15 134:9

138:21 169:21 191:7 213:5 215:9 226:3 231:9 250:14 252:13 265:5.9 271:1 282:2 289:12 290:6,11 325:15 328:21 **Terry's** 126:4 226:16,18 test 48:7,8 107:6 123:6 123:9 130:9 148:22 149:3 184:9 205:4 232:20 tested 99:12 123:17 296:20 testing 124:1 140:6 148:18,19 155:20 204:16 205:1 222:19 251:12 Texas 40:1 53:3 thank 5:16 8:16 16:17 18:11 20:10 21:19 33:2,8,10 48:22 49:1 54:8 58:14,15 59:2 84:12 104:4 105:3,16 109:13 110:22 112:11 119:12,13,15 122:9 127:18 136:6 138:22 140:18 141:14.17 142:17 153:7 156:19 156:20 160:3 163:16 178:20 187:1 198:8 200:2.12 204:9 205:16 242:19 250:13 255:7,12 256:7,7 262:3 263:14,16 264:18 270:21 275:3 278:4 289:14 295:14 304:8 306:17 307:18 315:5 318:17 335:18 335:22 336:11,15,17 337:7,8,11,13 338:13 338:13 thanks 29:6,8 50:6,22 104:10,10 126:15 156:21 158:8 160:4 168:11 185:3,15 281:21 312:18 theme 73:7 224:13 themes 6:18 84:19 85:9 theoretically 51:15 theory 48:5,6 132:2 therapeutic 47:1 therapy 332:12 things 8:1 23:10 26:9 29:5 36:10 53:17,22 58:13 60:13 75:1 82:4 89:6 98:22 118:17 127:2 138:17 159:16 159:18 162:12 165:11

166:21,22 167:10 168:15 172:10 174:21 183:2 184:22 189:4 201:13 223:18 225:18 270:13 278:2 280:17 283:2 299:10 303:12 315:18 316:11 320:5 325:22 326:20 329:1 third 5:8 40:14 45:5 61:21 309:14 312:2 thirds 249:9 thought 23:5 30:7 62:17 114:4,16 115:2 138:4 145:19 146:3,9 146:16 163:17 213:15 214:7 215:10 265:17 266:9 267:3 291:3 310:19 313:1 335:14 335:18 thoughtful 134:13 thoughts 21:21 93:18 thousand 103:14 275:21 three 13:11 31:5 33:7 36:9 39:8 58:13 63:16 65:8.9 82:5.15 107:4 123:19 129:10.12 136:12,14 145:4 152:16 156:22 158:9 207:10 217:15 229:3 229:17 265:14 268:16 285:13 309:20.21 317:20 332:13 336:12 three-way 141:13 threshold 192:5 thrilled 20:7 184:6 throughput 326:17 throw 74:6,7 189:22 248:19 throwing 93:8 99:16 THURSDAY 1:5 tie 41:18 65:13 86:15 tied 138:17 319:1 ties 54:7 94:8 timeframe 191:8 timeliness 7:16 8:10 times 37:8 52:19 53:6 277:1 329:10 tiny 331:4 today 5:9,18,20 7:8,12 9:14,20 24:13 35:5 59:3 63:12 70:18 71:15 75:5,9,21 77:13 83:14 84:11 92:16,20 95:17 104:5 109:22 119:18 203:4 277:14 306:2 332:9 told 65:5

tonsillitis 285:21 286:12,14 tool 42:2 94:3 165:14 203:8 247:21 291:13 toolkit 158:18 tools 108:6 top 7:8 35:20 58:13 76:17 104:8 304:5 309:20,20 310:14 311:3 316:7,19 317:8 topic 12:15 310:21 topics 203:14 topping 168:22 toss 175:16 tossing 175:15,17 total 130:5 203:16 229:2,4 totally 73:16 141:21 tough 102:21 282:21 338:15 tougher 313:13 track 19:16 34:3 35:18 36:17 49:19 51:7.8 75:6 135:16 283:10 tracked 135:9 167:10 tracking 21:13 50:3 55:13 traction 8:21 53:17 73:13 traditional 328:9 traditionally 338:6 trained 323:18 training 224:9 transcranial 266:22 269:13 transdoppler 265:20 transfer 37:20 transformation 276:19 transition 67:2 translated 296:15 297:5 translations 297:4 transparency 65:11 338:3 treatable 208:14 275:9 275:20 treated 99:13 treatment 14:2 19:12 19:15,17 20:2,8 36:11 36:17 37:3 45:13 46:22 51:18 99:2 222:20 treatments 52:12,20 trenches 6:7 trend 167:1,12 trepidation 250:19 triage 310:14 triangulating 197:1 trichotomous 199:3

tricky 64:15 80:22 102:22 tried 283:18 298:18,19 298:19 tripped 176:15 trouble 170:12 268:21 true 27:17 44:6 90:9 96:7 124:17 135:1 228:4 256:15 truly 145:13 177:12 188:16 196:17 210:5 214:18 237:19 283:12 298:20 310:12 truth 162:15 try 25:6,12 40:22 85:8 88:2 91:8 94:4 103:10 103:12 121:22 149:8 157:16 161:9 219:9 227:4 240:22 280:17 305:11 333:13 trying 25:15 29:16 30:17 32:11 52:1 78:11,13 79:20 83:7 85:22 86:11,15,22 88:16 94:13 103:5 110:5 114:6 135:15 150:16 168:17 175:2 211:16 221:14,16 225:8 232:17 253:2,6 253:8 256:9 283:8 286:2 287:1,7 300:17 326:15 329:4 turn 5:12 31:22 110:14 209:15 222:9 265:5 318:3 turned 46:16 turns 162:9 tweak 185:6 Twenty-seven 107:15 Twenty-three 169:1 **two** 7:13 10:17 11:12 12:3 13:18 23:19 30:18 37:8 38:12 44:12 48:7 50:18 52:11,11,12 69:5 101:15 115:11 125:12 128:7,11 134:4,7,9 172:11 187:19 188:4 188:7 195:1 202:22 204:18 207:2 208:16 210:1 213:10 214:19 217:14 222:18,21 226:19 227:6,20 229:13 247:3,10 254:5,18,22 255:18 260:21 261:13,15 263:22 270:13 271:14 287:13 304:5 309:11

309:22 313:6 317:4 317:15,20 322:19 332:13 335:19 336:1 two- 249:8 two-year 31:21 tying 66:20 129:15 type 13:3 78:22 131:22 211:19 217:11 237:16 283:20 types 26:1 55:22 64:12 97:14 334:1 typical 52:10 56:6 142:7 typically 149:12 173:15 typo 234:10 U U.S 182:15 219:14,20 Uh-hum 315:2 ultimate 34:9 ultimately 48:3 125:16 ultrasound 266:22 unable 27:22 28:3,16 unavailable 108:10 **uncouple** 180:10 **uncoupled** 187:17 undergoing 203:13 236:21 underlies 128:21 underlving 151:16 underneath 100:10 underscore 125:13 understand 34:1 66:10 66:15,16 94:20 98:20 135:5 190:3 196:22 197:13,15 221:12 237:3 240:12 255:22 257:19 272:9 330:8 330:17 understandable 312:4 understanding 66:18 190:12 196:17 197:2 197:9 214:17 218:21 293:13 297:22 298:7 understood 184:4 underuse 314:8 316:14 underusing 316:15 undignifying 322:5 unendorse 103:18 unfortunately 313:12 uniform 81:17 270:6 uniformity 26:12 unique 25:20 299:6,14 United 61:16 units 235:10 **universal** 321:15 unnecessary 119:22 160:7 316:12

unobtainable 60:14 unsafe 324:5,6 325:8 untenable 320:6 327:13 unusual 46:12 301:1 up-to-date 144:5 up/down 76:12 144:8 145:16 150:18 151:4 199:6 304:14 update 4:11 10:22 12:11 13:10 201:17 233:16 335:1 updated 67:6 107:11 updates 12:10 13:10 upfront 60:12 upper 287:12 upstream 322:10 upward 35:15 urban 50:11 271:6 urgent 288:6 **usability** 204:19 use 14:14 16:20 22:10 25:6 26:6 33:22 34:1 34:7,18,19,20 38:18 41:5,12,13 42:1,8,14 43:14 44:9 58:12 65:16 66:11,13 68:19 80:16 81:3 92:11 94:3 97:10 121:22 122:2 128:17 135:11 164:12 173:3,15 202:10 203:14 205:3 218:17 223:7 224:4 225:16 226:6,8,21 228:7,12 228:15 229:16 232:12 232:17,20 234:13 240:1,8 246:20 253:4 257:1,2,13 261:3 276:14,15 277:3,6 281:17 282:6 298:5 313:13 316:9 333:8 useful 157:18 185:1 204:18 205:10 224:6 326:11 uses 10:9 33:18 41:3 65:7,8 244:6,12 253:19 254:2,3,4,11 255:5 258:9 **USPTF** 183:3 **usual** 51:5,6 usually 60:2 123:2 usurp 101:17 uterus 159:2 utilization 19:16 44:19 226:22 227:15 276:15 277:9,11 utilized 246:10 277:17 285:5

V vaccinated 32:9 vaccination 11:19 12:7 117:21 214:5 215:4 215:15 216:1,7,11 266:7 vaccinations 215:16 218:2 vaccine 209:19,19 211:9,17 212:15,20 213:7 214:1 215:18 216:7 233:18 267:19 vaccines 211:15 214:14 vaginal 130:15 159:13 175:12,13 **valid** 122:2 124:5.10 validate 108:22 302:7 validated 298:1 validation 246:21 303:15 validity 297:20 value 46:9 48:16 125:2 178:5 328:13 338:3 value-78:7 159:14 value-based 46:5 47:12 48:8 77:19 81:12 129:22 165:19 283:1 variability 22:6 249:12 variables 286:21 variances 246:12 variation 132:5 169:3 269:22 variations 135:6 varied 103:1 variety 43:10 various 25:6 45:1 205:10 vary 26:4 270:18 varying 32:6,7 vastly 215:20 **VBAC** 164:15 VDAC 129:16 **verify** 109:3 Vermont 40:4 version 149:1 versus 23:5 64:22 127:11 160:9 164:15 175:4 184:11 247:9 269:18 277:11 293:10 Vice 2:14 160:20 230:21 view 6:7 269:9 312:9,12 viewed 130:4 viewpoints 284:19 virtually 32:13 vis-a-vis 18:3 visit 69:4,12 99:2 114:5 114:8,13,15,17

115:10 135:8 194:11 194:12,21 195:5,7 196:8 279:19 visiting 87:6,7,11 193:11 visits 14:14 23:4,6 46:20 69:6 116:5 118:1 190:18,22 193:20 196:5,10 198:14,14 208:14 275:8,19 281:8 282:10,18,20 284:18 285:1 288:10 vital 71:1 77:9 108:21 121:6 126:3 vitally 9:3 voice 161:18 279:8 **voluntary** 257:3 301:2 volunteer 336:10 vomiting 286:1 vote 120:12 125:14 132:17 140:20 141:13 143:2,14,17 144:8,10 145:16 146:3 151:4 152:20,22 153:10,20 153:22 154:1,9,10,13 154:15 155:7 157:4 174:1,2,16 180:8,20 187:12 191:13,15 199:1,4,17 207:1 217:7 221:9 232:16 233:4 234:21 236:3.7 262:21 263:17 274:7 289:3 304:11.19 309:18 312:20 313:9 **voted** 11:6 109:7,8,15 141:4 156:6,6,7 186:21 187:22 199:20 199:21 233:13 236:14 264:6,6,8 305:17,18 votes 153:3 180:11 187:19 188:4 309:11 309:15,17,19 314:4 voting 2:1 145:10,17 146:1,7,8 154:5,20 186:20 199:7,20 207:2 233:12 236:13 260:17 263:19 264:4 264:5 274:9,12,20 305:4,6,12,16 vulnerable 66:7 338:12 w Wagner 277:8

wagner 277:8 wait 169:16,19 252:14 252:14 waiting 161:14 169:13 175:5 212:4 226:18

233:1 236:12 305:14 325:2 waiver 59:17 63:1 78:3 276:19 waivers 62:15 walk 263:17 walked 57:4 walking 178:19 324:15 walls 337:21,22 wanted 22:9 41:4 62:10 67:3 70:9 111:22 112:15 114:3 119:6 122:14 157:9 170:1 184:3 185:14 204:12 217:8 223:2 247:10 267:9 268:2 269:2 276:2 289:12 292:22 310:3,8,13 313:1 337:7 wants 240:15 ward 320:22 Washington 1:9 40:3 164:3 283:5 296:20 303:1 wasn't 8:20 22:16 27:7 28:3.10.11 97:22 99:1 99:14 102:15.16 111:7 128:15 129:17 147:19 228:3 248:19 272:9 watch 197:11 330:22 Watts 277:13 way 9:12 20:1 23:14 36:5 37:2 38:2 41:15 41:21 42:7 43:13 46:10,12,16 47:16 48:1,3 51:5 55:21 68:1,8,8 69:3 70:22 71:19 77:16,20 81:17 82:20 88:20 91:21 97:12,13 100:3 102:6 122:4 126:6,7 137:16 137:20 142:13 143:10 145:10 146:6 158:6 174:1 195:21 196:5 196:21 209:9 211:3 213:21 214:4,5 239:8 240:4,11 244:22 246:7,11 249:5 251:5 254:8 256:20 257:2 260:17 286:21,22 287:9 293:8,20 294:5 297:21 298:20 303:14 309:3 312:17 313:9 320:22 321:7 322:20 334:6 ways 47:3 131:9 210:17 280:1 281:1 284:20

website 18:14 week 332:8 weeks 169:13,19 201:21 weigh 64:21 271:9 weigh- 233:20 267:8 weigh-in 6:5 125:9,11 256:6 264:13 weighing 15:12 weighs 86:7 weight 100:16 101:1 254:5,22 weight- 86:8 weighted 228:19 229:6 weights 254:12 weighty 297:13 welcome 5:4 91:15 92:3 201:8 252:18 Well-Being 149:7 217:17,19 218:8 well-child 14:14 23:4,6 well-conducted 131:16 well-done 292:15 well-taken 282:8 went 8:19 70:5 104:12 104:13 153:11 163:18 188:9 201:5.6 214:8 247:16 252:14 288:10 291:19 weren't 126:18 148:18 198:18 270:8 289:17 white 146:22 whoa 80:8,9 wide 51:4 88:4 230:5 widely 130:1 wife 327:17 willing 331:8 win 37:20 175:6 winner 39:22 wires 324:12 Wisconsin 40:15 wish 36:22 37:1 withdraw 174:11,12 withdrawing 27:4 withdrawn 27:4 176:2 withdrew 123:9 149:4 woman 129:12 170:9 women 1:22 7:18 68:16 68:21 74:20,22 99:11 129:18 158:20 159:21 wonder 326:11 wonderful 104:6 wondering 17:1 158:3 272:1 word 6:17 29:22 337:17 337:18 words 180:10 289:13 work 5:18 6:11 7:8 8:2

47:11 48:14 59:6,19 65:19 85:22 87:11 88:12 91:15 97:5 99:10 104:9 110:8 137:18 139:20 142:14 143:9 149:8,14,15 150:14 155:16 157:16 162:21 166:6 178:18 186:3 201:21 205:7,8 210:21 215:14 230:4 251:4,16 281:1 288:1 288:2 298:15 303:16 311:13 312:15 324:7 336:17 338:1 worked 142:1,13 230:22 238:3 283:6 worker 69:10 329:4 workforce 330:5,8 331:11,16 working 25:16 39:18 42:14 57:14 67:4,9 74:2 87:5 89:4 105:13 168:5 192:14 201:2,4 201:13 232:19 332:16 works 194:11 325:18 world 29:10 32:15 41:10 96:11 130:1 135:1 178:16 219:14 219:21 282:11 332:1 worms 185:5 worried 103:2 268:13 worry 173:19 216:3 253:22 worth 25:1 62:17 99:3 wouldn't 114:16 118:2 212:21 219:12 226:14 244:17 258:16 296:22 336:2,6 written 308:1 wrong 147:11 293:14 328:17 wrote 71:3 248:15 Х **X** 96:18 x-rays 36:12 γ year 11:1 13:16,17,18 14:5,8,12,20 15:5,11 15:18 19:11 21:22 22:3 27:1,2,22 31:17 31:20 35:12 37:20 38:4,6,11,21 39:8 49:12 52:11.12.12.19 53:6 62:4 63:2 90:6 112:22 113:4,13,16

26:10 34:10.15 46:7

113:21 114:6 119:2 122:5 131:2 149:8 150:1 163:14 166:14 183:2 195:5,8,8,9 212:12 215:6 225:8 228:12 238:5 251:1 252:3,6,13 261:12 265:16,21 266:22 269:14 337:1 year's 11:9 year-287:12 year-olds 268:17 years 17:22 33:7 40:14 43:18 48:8 73:16 78:20 82:5,15 101:22 102:12 107:4 110:7 123:19 147:10 152:16 159:8 190:19 191:3 194:21 195:4,6,7 212:3,7,10,11 213:10 227:20 253:13 261:13 261:15,17 265:15 277:10,15 292:13 298:10 yellow 317:15,17,18 322:8 yes/no 125:14 141:10 yesterday 5:17,22 6:18 6:20 7:5 10:9 11:6 13:1,14 18:19 66:2 67:19 96:9 104:5 105:21 106:10,13 109:7,11 112:4 116:18 119:18 141:9 152:11 160:20 163:13 173:17 199:2 206:3,5 206:16 259:15 307:21 334:11 337:20 vield 65:1 York 3:3 6:6 54:18 58:18 59:5 61:1,5 62:13,21 63:12 77:17 79:17 84:18 89:15 91:13 101:21 102:8 104:11 121:20 166:1 young 224:21 Ζ zero 26:19 96:14 245:7 253:6 zillion 98:22 0 **0038** 30:21 215:9,10 **0418** 179:17 181:2,13 181:21 186:12.16.21 308:9 309:16,22 319:3

0471 108:12 132:13	234:6,21 236:1,8	27 271:22 272:5,7	45 300:4
157:2,3 176:3	17 13:5 108:15 190:19	2797 208:2	46 274:22 300:4 305:17
1	191:3 222:17	28 15:14	47 300:4
·	1799 12:22 13:12	2800 208:9 222:6,12	49 300:4
1.77 228:20	18 253:6 254:1	231:14,19 232:16	5
1:00 201:3	1800 308:5 309:9,21	233:6 308:8 309:18	
1:10 201:7	318:21	319:5	5 4:2 31:2 49:22 53:4
10 4:4 28:22 38:21	19 16:14 194:21 195:7	2842 300:3	56:12 61:11 156:6
49:22 56:11 158:21		29 15:13	192:3 309:19
200:22 213:21 277:9	2	2903 308:6 309:9,21	5- 20:14
277:15 287:12 291:8	2 31:2,4,7,9,22 152:18	318:21	5-ish 214:19
291:19 309:14	204:14 213:21 234:17	3	50 270:6 300:4 324:8
10- 57:18	253:5,19 264:3 274:9		50- 56:14
10-percentage-point	274:15 284:16 319:2	3 26:19 31:2 213:21	50-percent 36:2 159:11
39:12,14 57:20	20 35:19 107:14 320:16	233:11 236:11 264:3	52 39:4
10,300 228:18	321:18	274:10,19 305:10	54 156:7 264:6
10:46 104:13	20-percent 131:19	309:22 319:4	57 4:7 45:9
100 70:3 96:14 98:8	20-plus 327:20	3- 20:14	6
158:17 186:20	20-second 243:1	3:49 338:16	
1030 1:8	200 4:10	30 7:20 58:21 90:6	6 20:16,17 38:3 92:13
104 4:8	2000 130:19	184:21 320:13	155:10 156:1,6
11 12:6 195:6	2009 67:7	300 265:16	184:16,20 190:19
11:02 104:14	201 4:11	307 4:12,13 105:18	191:3 195:4
1115 59:17 78:3	2011 39:2,3	309 4:14	6- 13:19
12 12:6 92:6,17,19	2012 8:19 14:8	310 106:19	6-to-9 45:8,9
108:14 138:7 180:2	2013 14:20 63:13	312 119:20	6-year-olds 20:14
181:3 184:7 186:20	107:15	3153 306:18	60 61:5 155:14 156:2,10
194:20 195:4,7	2014 15:14 44:5 61:17	3154 236:16 263:20	156:13
199:21 333:15	107:15 108:16 130:22	308:11 309:13,22	60-percent 192:5
12-month 306:13	266:9	319:2	69 70:2
12:45 201:6	2015 13:16,16,17 14:5	3166 208:11 264:21	6th 334:18
13 166:2 167:8 233:12	14:12,20,22 15:6,9,12	265:3,6 273:14,20	7
236:13 264:5 275:2	15:14,18 16:1 17:15	274:5,12 318 4:15	
305:16 13,732 229:4	27:2 36:2 39:5,15,22		7 4:3 155:10 156:5
1354 208:11	39:22 45:8 61:12 107:12 108:17 204:1	31st 248:12,14 252:17 334:20	195:6
1365 136:21 138:10		333 207:16	7th 334:14,18
178:21 187:6,7,11	207:11,20 2016 10:16,17 11:3	334 4:16	8
		338 4:18	
188:5,12 189:10 191:13,15	12:16,18 149:8 207:11,20 218:5	34 4:5 108:18	8 291:20 80 51:6 77:18 288:2
1391 7:15 13:11	2017 1:6 10:19,22 11:12	36 41:22 54:21 286:15	81 69:20
13th 233:4	12:14,17 335:2	37 61:21	81 09.20
14 166:2 309:12	2018 39:8	37.77 229:7	9
1407 11:22	2020 77:18 158:13	38 264:7	9 20:16,17 38:3 154:19
1448 107:2 111:15	169:2	39 169:13,19	158:21 184:16,21
133:19,22 141:19	21 329:17	3M 280:10	309:17
142:19 143:3,16	21 323.17 22 15:17 106:5 107:12	U 200.10	9-year- 13:19
144:10 152:15 154:22	23 32:6 63:15 215:13	4	9:00 1:9
15 108:16	268:22	4 31:2 39:5 213:21	9:08 5:2
15-minute 201:1,1	2393 208:1	319:5,7	90 203:16
15-year-old 190:6	24 13:17 16:14 195:4	4- 20:14	90/10 61:9
1517 13:12	204:1	40 15:5,10 227:21	96110 128:9 148:1
15th 1:8	25 1:6 14:22 16:15	321:19	96111 128:9
16 45:14 79:7 108:16	195:4	400 102:12	9th 1:8
202:19 253:5,19	2500 15:13	416 56:1	
329:18	252 112:15,18	42 39:3	
1659 208:9 209:5,10	26 15:10 38:5 51:4	43 61:2 300:3	
	63:15	44 300:3	1

CERTIFICATE

This is to certify that the foregoing transcript

In the matter of: Measure Application Partnership Medicaid Child Task Force

Before: NQF

Date: 05-25-17

Place: Washington, DC

was duly recorded and accurately transcribed under my direction; further, that said transcript is a true and accurate record of the proceedings.

near Rans &

Court Reporter

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS 1323 RHODE ISLAND AVE., N.W. WASHINGTON, D.C. 20005-3701

www.nealrgross.com

371

(202) 234-4433